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Dysregulation of intramuscular triglyceride (IMTG) turnover in human skeletal muscle 
in sedentary and obese states leads to accumulation of lipid metabolites that 
contribute to skeletal muscle insulin resistance and ultimately progression to type 2 
diabetes (T2D). People with T2D display low levels of IMTG turnover in comparison 
to insulin sensitive and trained individuals. IMTG stores are used as an energy 
substrate during 1 h of moderate-intensity exercise in trained individuals only and can 
be increased by consumption of a high fat, high calorie (HFHC) diet in sedentary and 
trained states. This thesis explores the metabolic and molecular regulation of proteins 
that regulate IMTG turnover, specifically focusing on the effects of 1) a HFHC diet 
and 2) a moderate-intensity exercise bout and 3) IMTG stores in different diseases 
states (lean, obese and T2D). Chapter 2 determined there were no sex-specific 
differences or main effects in functional outcomes of cardiovascular (arterial stiffness) 
and metabolic health (glucose tolerance and metabolic flexibility) in response to 7 
days HFHC diet. Chapter 3 provides novel evidence that 7 days HFHC diet induces 
fibre type specific increases in IMTG stores primarily underpinned by an increase in 
perilipin-3 (PLIN3) protein expression and a redistribution of perilipin-2 (PLIN2) to lipid 
droplets (LD) storing IMTG. This occurred with no impairments in skeletal muscle 
insulin signalling and it is therefore proposed that increases in IMTG content assisted 
by PLIN2 and PLIN3 minimise the accumulation of lipid metabolites known to disrupt 
the insulin signalling cascade. Chapter 4 revealed that hormone sensitive lipase 
(HSL) preferentially redistributes to LD associated with perilipin-5 (PLIN5) following 1 
h of moderate-intensity exercise. Chapter 5 developed a PLIN5 immunoprecipitation 
mass spectrometry protocol which identified phospholipase A2- group II, subgroup A 
(PA2GA) as a novel protein associated to PLIN5 in muscle from lean sedentary 
humans. In conclusion, this thesis presents novel data on key proteins that regulate 
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Chapter 1. General Introduction 
  
2 
1.1 Defining the normal human phenotype 
In the late-Palaeolithic era (50,000 – 10,000 BC) food sources were not always readily 
available and food consumption would rely on the capacity to perform high levels of 
physical activity to hunt and gather food (Diamond, 2003). Due to seasonal changes 
and often a low abundance of food sources, humans would cycle between periods of 
famine and feast. In 1962, Neel (1962) proposed that these environmental pressures 
would have led to the evolution of a ‘thrifty’ human genotype, making humans 
exceptionally efficient at storing and utilising energy sources. In particular, humans 
are capable of digesting, storing and utilising two main fuel sources, carbohydrates 
and fats (glycogen and triglyceride), and switching between these two sources 
depending on energy intake and energy expenditure (Chakravarthy & Booth, 2004). 
Furthermore, the ‘thrifty’ human genotype is better equipped to tolerate fluctuating 
periods of feast and famine and physical activity and rest (Neel, 1999; Booth et al., 
2002). The human genotype has remained largely the same for the past 10,000 years 
(Eaton et al., 1988). However, unlike our hunter-gatherer ancestors, humans in 
modern day western civilization are now confronted with readily available poor quality, 
energy-dense food sources mirrored by increasingly sedentary daily living, and this 
has had catastrophic metabolic consequences. In the UK, 60% of people’s total 
waking hours is occupied by sedentary behaviour (Townsend et al., 2012) and 39% 
of the UK population do not meet current physical activity guidelines of 150 min/week 
of moderate intensity exercise (British Heart Foundation, 2017), thus minimising 
habitual energy expenditure. If this is not matched with a decrease in energy intake, 
positive energy balance and weight gain will ensue. It is proposed that high-fat foods 
often contribute to this positive energy balance due to being palatable yet very energy 
dense (Rolls, 2000). 
This westernised lifestyle has led to an increase of the prevalence of obesity and type 
2 diabetes (T2D). In 2016, the World Health Organisation estimated that 1.9 billion 
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adults, equivalent to 39% of the adult population worldwide, were overweight (body 
mass index (BMI) ≥ 25 kg.m-2). Of these, 650 million adults, equivalent to 13% of the 
world adult population were classified as obese (BMI ≥ kg.m-2). These most recent 
estimates imply that worldwide obesity prevalence has almost tripled since 1975 
(World Health Organisation, 2017). In 2017 nearly 3.7 million people were diagnosed 
with diabetes in the UK (Diabetes UK, 2017).  However, the actual number of people 
living with diabetes in the UK is expected to be considerably larger due to 
undiagnosed cases. Of the diagnosed cases, approximately 90% had T2D and about 
10% type I diabetes.  
This introduction will first outline the regulation of healthy glucose and lipid 
metabolism in human skeletal muscle. This will be followed by perturbations in lipid 
metabolism that are seen in sedentary and obese individuals and that can lead to the 
development of skeletal muscle insulin resistance and, therefore, loss of glucose 
homeostasis contributing to the development of T2D.  
1.1.1 Insulin Sensitivity 
Fasting blood glucose concentration is typically <5.5 mmol.L-1 in healthy insulin 
sensitive individuals (American Diabetes, 2015). Following meal ingestion 
carbohydrates are digested in the gut and released into circulation as glucose. Post-
prandial elevations in plasma glucose are followed by secretion of insulin from the 
pancreas into circulation (Wilcox, 2005). Meal-induced increases in plasma insulin 
accelerate the arterial blood supply  to skeletal muscle (Keske et al., 2016)  due to an 
increased recruitment of microvascular units. This allows an increase in the delivery 
of insulin, glucose, fatty acids, lipids and amino acids (Wagenmakers et al., 2016). 
Insulin-sensitive tissues such as skeletal muscle, adipose tissue and liver have insulin 
receptors to which insulin binds to in order to stimulate glucose uptake from the blood 
(Wilcox, 2005).  During this post-prandial period, there is concomitant suppression of 
4 
hepatic glucose production, thus synergistically minimising large elevations in blood 
glucose levels (Edgerton et al., 2017).   
1.1.1.1 Skeletal Muscle Insulin Sensitivity  
Various tissues have the ability to uptake glucose from the circulation including; 
adipose, skeletal muscle, liver and brain. Skeletal muscle is the largest of these 
tissues and is estimated to account for 80% of glucose removal during a 
hyperinsulinaemic euglycemic (HE) clamp in lean healthy individuals (DeFronzo et 
al., 1981) and up to 50% of glucose uptake following a mixed meal in older individuals 
(Capaldo et al., 1999).  Of the tissues linked to T2D, skeletal muscle is recognised for 
its high plasticity to adapt or mal-adapt to increased or decreased physical activity 
and different nutritional challenges (Brook et al., 2016; Hoppeler, 2016), which can 
impact skeletal muscle insulin sensitivity. Due to its capacity to store and/or oxidise 
glucose, maintaining skeletal muscle insulin sensitivity is paramount in preventing the 
development of T2D (Petersen et al., 2007; DeFronzo & Tripathy, 2009). Whilst it is 
accepted that control of the microvascular system is important in mediating insulin-
stimulated glucose uptake at the muscle, this thesis will primarily focus on the 
intramuscular factors that regulate and impact insulin-stimulated muscle glucose 
uptake. 
1.1.1.2 Metabolic Flexibility 
Metabolic flexibility is defined as the capacity to switch from lipid oxidation in fasting 
conditions to increased glucose uptake, oxidation and/or storage with supressed lipid 
oxidation following insulin-stimulated conditions such as a HE clamp (Kelley & 
Mandarino, 2000). An ability for muscle to prioritise lipid oxidation during an overnight 
fast or when fatty acid supply to the muscle is increased such as during high-fat diets 
or exercise is also an important facet of metabolic flexibility (Galgani et al., 2008b; 
Corpeleijn et al., 2009). Metabolic flexibility is important to meet the varying demands 
of nutrient availability and energy expenditure throughout habitual living. The ability 
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to prioritise fat oxidation during fasting conditions serves as an inherent mechanism 
to preserve glucose for glucose-dependent organs such as the brain.  During fasted 
conditions, fatty acids (FA) constitute the primary fuel source resulting in a low 
respiratory quotient (RQ). Fasting RQ is often elevated in skeletal muscle of obese 
insulin-resistant individuals (0.90 vs 0.83 in lean individuals) (Kelley et al., 1999) or 
T2D adults (0.85 vs 0.77 in non T2D subjects) (Kelley & Simoneau, 1994) resulting in 
persistently high rates of carbohydrate oxidation. Individuals with visceral obesity 
display a reduced fasting fatty acid uptake into skeletal muscle (Colberg et al., 1995). 
During fasting conditions and during exercise, obese T2D individuals show reduced 
oxidation of plasma-derived fatty acids compared to obese controls (Blaak et al., 
2000). A decreased capacity for mitochondrial beta-oxidation and impaired oxidative 
activity are also believed to contribute to impairments in fatty acid oxidation during 
fasting, allowing glucose oxidation to take precedent (reviewed more thoroughly by 
Corpeleijn (2009)). Elevated fasting RQ in metabolically inflexible individuals may 
therefore be a consequence of an impaired ability to uptake and oxidise fatty acids, 
in addition to the chronic hyperglycaemia. However, it is important to note that a study 
has also reported a higher fasting RQ in lean subjects compared to obese individuals 
(Blaak et al., 2006). Given these equivocal findings, more research needs to be 
conducted to address whether a low fasting RQ or an elevated fasting RQ is indicative 
of impaired metabolic health. 
Whilst the amount of fat that can be stored in adipose tissue is extremely large, 
glucose storage as glycogen in the liver and muscle is comparatively limited. 
Following carbohydrate ingestion, it is not only essential to take up glucose from the 
blood to maintain euglycaemia but to also increase carbohydrate oxidation, 
particularly when glycogen stores are full. To prioritise glucose oxidation there needs 
to be concomitant suppression of fatty acid uptake and oxidation during insulin-
stimulated conditions. Metabolic flexibility to insulin-stimulated conditions is 
6 
traditionally measured during a HE clamp, where the difference from fasting RQ to 
peak RQ during the clamp is denoted as ∆RQ. During the clamp, various studies have 
shown a positive association between insulin sensitivity and ∆RQ (Kelley et al., 1999; 
Wohl et al., 2004; Ukropcova et al., 2007). Obese subjects show a diminished 
capacity to suppress fat oxidation during a HE clamp compared to lean controls 
(Kelley et al., 1999). Impairments in ∆RQ during a HE clamp in T2D individuals 
compared to non-diabetic subjects were no longer observed after adjusting for 
glucose disposal rates (Galgani et al., 2008a) suggesting glucose entering the cells 
is likely to be directed towards oxidation rather than storage. Similar findings of 
impaired substrate switching have also been observed in response to a meal in 
individuals with T2D and in individuals with impaired glucose tolerance (Kelley & 
Simoneau, 1994; Corpeleijn et al., 2008). Impairments in substrate oxidation are 
believed to be linked to impairments in substrate uptake, however, these two 
aberrations do not always occur in parallel and can be independently impeded 
(Corpeleijn et al., 2009). Importantly impairments in metabolic flexibility can exist in 
people with a pre-diabetic state of impaired glucose tolerance (Mensink et al., 2001; 
Faerch & Vaag, 2011) suggesting impairments in substrate switching may have an 
early role in the development of T2D.  
1.1.2 Sex differences in metabolic flexibility and insulin sensitivity 
Prevalence rates of T2D is higher in males compared to females (Wild et al., 2004) 
and pre-menopausal females have a lower cardiovascular risk compared to males 
(Groban et al., 2016). Large cross-sectional studies have confirmed that males have 
a higher prevalence of impaired fasting glucose in comparison to females (Kuhl et al., 
2005; Munguia-Miranda et al., 2009) and a reduced blood glucose clearance capacity 
following an intravenous glucose tolerance test (Clausen et al., 1996). Smaller clinical 
trials (n  30) investigating insulin sensitivity in BMI and age-matched males and 
females using a HE clamp have established that females exhibit a similar or higher 
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glucose infusion rate per kilogram of body mass when compared to males (Yki-
Jarvinen, 1984; Nuutila et al., 1995; Donahue et al., 1996; Rattarasarn et al., 2004; 
Borissova et al., 2005), and a markedly higher glucose infusion rate when adjusted 
per kilogram of lean mass (Yki-Jarvinen, 1984; Donahue et al., 1996). In the post-
prandial state females have shown greater metabolic flexibility by favouring 
carbohydrate oxidation (Uranga et al., 2005), which may be indicative of increased 
glucose uptake and subsequent oxidation in insulin sensitive tissue. Despite females 
displaying a lower risk of metabolic and cardiovascular complications, they have 
notably higher adipose tissue mass (a known risk factor for T2D), in comparison to 
BMI-matched males yet also display greater insulin sensitivity (Clausen et al., 1996). 
This may be partly due to females favouring deposition of fat in the lower regions of 
the body which has a lower risk of metabolic complications (Janjic, 1996).  
Differences in insulin sensitivity between sexes appear to be largely influenced by sex 
hormones. A longitudinal study using a HE clamp examined insulin sensitivity 
(expressed relative to lean body mass) in adolescents between the ages of 11 and 
19 years and showed divergent changes in insulin sensitivity between the sexes 
through puberty (Moran et al., 2008). Males displayed a reduction in insulin sensitivity 
whereas females increased insulin sensitivity culminating in a significantly higher 
insulin sensitivity for females compared to males at the age of 19 (Moran et al., 2008). 
The cessation of female sex hormone production during menopause results in an 
increased risk of cardiovascular disease and T2D (Polotsky & Polotsky, 2010), 
indicating female sex hormones exert a protective effect whilst females are pre-
menopausal. When post-menopausal females received a venous 2.5mg estrogen 
bolus during a HE clamp, plasma estradiol levels increased acutely by ~200% and 
insulin action on glucose disposal rate increased by 20% compared to the saline 
control (Van Pelt et al., 2003). Female sex hormones undergo large fluctuations 
during each menstrual cycle however there has been confounding data on how this 
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impacts insulin sensitivity. When estradiol and progesterone levels are higher in the 
luteal phase some studies have shown a reduction in insulin sensitivity in healthy  
eumenorrheic females (Valdes & Elkind-Hirsch, 1991; Escalante Pulido & Alpizar 
Salazar, 1999), whereas other have shown no changes between different phases of 
the menstrual cycle or between menstrual cycles  (Bingley et al., 2008). Despite the 
known reduced risk of T2D and cardiovascular disease in pre-menopausal females 
compared to males there is surprisingly little research investigating the mechanisms 
underpinning this protection. Furthermore, the pathology of insulin resistance and 
T2D is largely understudied in females with very few studies directly comparing sexes.  
1.2 Insulin-mediated skeletal muscle glucose uptake 
Transendothelial transport of glucose from the lumen of skeletal muscle capillaries 
into the interstitial fluid surrounding the skeletal muscle fibres is mediated by the 
insulin independent glucose transporter-1 (GLUT-1). Transendothelial transport of 
glucose occurs via facilitated diffusion and depends on the existence of a downward 
glucose concentration gradient between the lumen of the capillaries and the muscle 
interstitium (Wagenmakers et al., 2016). Insulin-stimulated glucose uptake in skeletal 
muscle occurs through activation of the insulin signalling cascade resulting in the 
translocation of glucose transporter-4 (GLUT-4)  from intracellular storage vesicles in 
the muscle fibres into the plasma membrane (Watson et al., 2004; Bradley et al., 
2015). Glucose uptake in skeletal muscle also occurs via facilitated diffusion and 
depends on the existence of a downward glucose concentration gradient between the 
interstitial fluid and the cytosol of the muscle fibres.  
The initiation of the insulin signalling cascade in skeletal muscle commences when 
insulin binds to domains on the extracellular - subunit of the insulin receptor. This 
causes a conformational change in the insulin receptor resulting in trans-
autophosphorylation of the tyrosine kinase domain in the transmembrane -subunit. 
Insulin receptor tyrosine phosphorylation results in recruitment and tyrosine 
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phosphorylation of the insulin receptor substrate proteins (IRS1-4) and the Shc 
adapter protein isoforms, signal regulatory protein family members, Gab-1, Cbl, and 
adaptor protein with pleckstrin homology and Src homology (APS) (Pessin & Saltiel, 
2000). Activation of the insulin receptor results in activation of two divergent yet 
complimentary insulin signalling pathways that both appear crucial in regulating 
glucose uptake from the blood. The first, and more well-established pathway, is the 
IRS-PI3-K signalling cascade. The second pathway is the APS/CAP/Cbl pathway. 
Highlighting the importance of the IRS-PI3-K pathway is the finding that inhibition of 
phosphoinositide 3-kinase (PI3-K) with wortmannin, or overexpression of a dominant 
interfering mutant of the p85 regulatory subunit of PI3-K, reduces GLUT-4 
translocation and glucose uptake (Cheatham et al., 1994; Okada et al., 1994). 
Pharmacological activation of intermediates of the IRS-PI3-K pathway, however, 
does not completely account for GLUT-4 translocation to the plasma membrane and 
glucose uptake (Egawa et al., 2002; Konrad et al., 2002) suggesting the secondary 
pathway also needs to function in concert with the IRS-PI3-K pathway (Figure 1.1) 
1.2.1 IRS-PI3-K Insulin signalling pathway 
Several tyrosine phosphorylation sites exist on IRS-1 (White & Kahn, 1994b), but 
specific phosphorylation of Tyr612 and Tyr632 are considered pivotal for downstream 
PI3-K activation and GLUT-4 translocation (Esposito et al., 2001). These 
phosphorylation sites reside on the C-terminus of IRS-1, which when phosphorylated 
reveals Src homology (SH2)-domain binding sites (White & Kahn, 1994b). PI3-K is a 
hetero-dimer consisting of a p85 regulatory subunit containing two SH2 domains that 
bind to the tyrosine phosphorylation sites of IRS-1 (Myers et al., 1992) and a p110 
catalytic subunit. Upon activation, PI3-K is then targeted to the inositol ring where it 
phosphorylates PI to produce phosphatidylinositol-3-phosphates. The formation of 
phosphatidylinositol-3,4,5-triphosphate (PIP3) is particularly important because it 
attracts downstream targets phosphoinositide-dependent kinase 1 (PDK1) and Akt 
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(also known as protein kinase B) to the plasma membrane via their pleckstrin 
homology (PH) domain. Once PDK1 and Akt are colocalised, PDK1 phosphorylates 
Akt at Thr308 and Ser473 resulting in complete kinase activity (Alessi et al., 1996). 
Downstream Akt targets include glycogen synthase kinase-3 (GSK-3) and Akt 
substrate of 160 kDa (AS160), also known as TBC 1 domain family, member 4 
(TBC1D4). Akt phosphorylates and inactivates GSK-3 at Ser9 which reduces 
inhibition of glycogen synthase thus increasing its activity and promoting glycogen 
synthesis. AS160 contains a Rab-GAP (GTPase-activating protein) domain and 
several Akt phospho-motifs (Miinea et al., 2005). Rab proteins are small G proteins 
implicated in vesicle trafficking and exocytosis of glucose transporters. Under basal 
conditions Rab-GAP retains Rab proteins in a GDP-loaded state. Upon AS160 
phosphorylation by Akt on the Akt phospo-motifs, Rab-GAP is inhibited, allowing GTP 
loading which subsequently enables the translocation of GLUT-4 to the plasma 
membrane (Figure 1.1).  
1.2.2 APS/CAP/Cbl complex pathway  
The APS/CAP/Cbl pathway is proposed to originate from lipid raft microdomains 
located at the plasma membrane that are enriched with cholesterol. Caveolin binds 
to cholesterol in a subset of these microdomains forming caveolae which are small 
invaginations of the plasma membrane enriched in signalling proteins including the 
insulin receptor (Gustavsson et al., 1999). Another substrate for insulin receptor 
kinase is APS, an adaptor protein with a PH and SH2 domain. The SH2 domain of 
APS forms a homodimer which binds to different subunits of the insulin receptor 
heterodimer. Association and phosphorylation of APS with the insulin receptor 
provides a binding site for the SH2 domain of Cbl. Cbl has multiple tyrosine residues 
which can be phosphorylated by the insulin receptor but requires the association of 
Cbl adaptor proteins, mainly CAP (Cbl-associated protein) (Baumann et al., 2000). 
The SH3 domains in the C-terminus of CAP bind to the proline rich domain of Cbl 
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whereas the Sorbin homology (SoHo) domain in the N-terminus of CAP binds to 
flotillin which recruits and incorporates CAP/Cbl complex into the lipid raft. Tyrosine 
phosphorylation of Cbl further recruits the adaptor protein CrkII and guanine 
nucleotide exchange factor CG3 to the lipid rafts activating TC10, a Rho family small 














































Figure 1.1. Insulin-mediated glucose uptake into skeletal muscle. APS, adaptor protein with a PH and SH2 domain; AS160, Akt substrate 
of 160 kD; CAP, Cbl-associated proteain; GLUT4, glucose transporter 4; IR, insulin receptor; IRS-1, insulin receptor substrate-1; PDK, 
phosphoinositide-dependent kinase 1; PI3-K phosphoinositide 3-kinase; Rab-GDP, Rab guanosine disphosphate; Rab-GDP, Rab guanosine 
triphosphate;  SNAP23, synaptosomal associated protein; VAMP2, v-SNARE vesicle associated membrane protein-2.  
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1.2.3 GLUT-4 translocation 
GLUT-4 translocation to the plasma membrane can occur by either polymerized 
microtubules or actin cytoskeleton pathways (Fletcher et al., 2000; Lopez et al., 
2009). Actin polymerization is likely mediated by PI3-K and atypical protein kinase C 
(PKC) isoforms following insulin stimulation (Liu et al., 2006b). The quantity of GLUT-
4 at the cell surface is a balance between endocytosis to intracellular storage vesicles 
and exocytosis embedment into the plasma membrane. Invagination of the plasma 
membrane forms t-tubules protruding into the cell, which can increase surface area 
for GLUT-4 exocytosis and glucose diffusion into the cell. Evidence from cell culture 
studies suggests that under basal conditions approximately 2-5% of GLUT-4 is 
located at the cell surface (Kanzaki, 2006). Following insulin stimulation GLUT-4 
exocytosis to the plasma membrane at the cell surface and at t-tubules increases 
allowing for larger uptake of glucose to the cell (Cushman & Wardzala, 1980; 
Lauritzen et al., 2006; Fazakerley et al., 2010). More recently, the increase in GLUT-
4 at the plasma membrane has been confirmed in human skeletal muscle following 
glucose feeding (75g) with the use of confocal immunofluorescence microscopy 
(Bradley et al., 2015). 
1.2.4 GLUT-4 tethering and fusion 
Once translocated to the plasma membrane, GLUT-4 requires tethering and fusion to 
the plasma membrane facilitated by soluble N-ethylmaleimide sensitive factor (NSF) 
attachment protein receptor (SNARE) proteins. Target SNAREs (tSNAREs) located 
on the plasma membrane interact with vesicle SNAREs (vSNAREs) on the GLUT-4 
vesicle. SNARE proteins facilitate numerous exocytosis processes however the 
SNARE proteins implicated primarily in GLUT-4 docking are the v-SNARE vesicle 
associated membrane protein-2 (VAMP2) and t-SNAREs; synaptosomal associated 
protein 23 (SNAP23) and syntaxin 4 (Figure 1.1).  For SNARE proteins to become 
activated and form a SNARE complex they require a conformational change in shape 
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fuelled by NSF and alpha SNAP (soluble NSF associated protein) (Sollner et al., 
1993). Formation of a SNARE complex brings together the plasma membrane and 
GLUT-4 into close proximity allowing their lipid bilayers to fuse.  APS/CAP/Cbl 
mediated activation of TC10 results in translocation and activation of Exo70 to lipid 
raft microdomains where it binds to Snapin (Figure 1.1). The binding of Snapin with 
Exo70 activates SNAP23 (Bao et al., 2008), a SNARE protein that appears crucial in 
GLUT-4 tethering and insulin-stimulated glucose uptake. In vitro studies that have 
transfected adipocytes with an inactive mutant of SNAP23 or microinjected an 
antibody to SNAP23 have shown reduced GLUT-4 translocation and docking to the 
plasma membrane (Foster et al., 1999; Kawanishi et al., 2000) and reduced glucose 
transport (Foster et al., 1999). In addition to this important role SNAP23 has more 
recently been implicated in fusion of lipid droplets (LD) (discussed in section 1.6.3.3). 
The formation of a SNARE complex is also initiated by insulin-mediated 
phosphorylation of the insulin receptor leading to Munc18c phosphorylation. This 
reduces Munc18c association to t-SNARE syntaxin 4, thus increasing syntaxin 4 
availability to form SNARE-complexes (Jewell et al., 2011). v-SNARE VAMP2 on the 
GLUT-4 vesicle binds with syntaxin 4 at the plasma membrane (Watson et al., 2004). 
Once GLUT-4 is tethered and fused to the plasma membrane glucose is able to enter 
the muscle via a diffusion gradient. 
1.2.5 Carbohydrate metabolism 
Once glucose is transported into the muscle, it is phosphorylated to glucose-6-
phosphate (G6P) by hexokinase (Ureta, 1982). This reaction is important in keeping 
intracellular glucose levels low and maintaining a diffusion gradient for glucose uptake 
into the muscle. G6P is subsequently converted to fructose-6-phosphate before being 
phosphorylated to fructose-1, 6 bisphosphate by the key glycolytic enzyme 
phosphofructokinase (PFK) (Wegener & Krause, 2002). Following several 
subsequent catalytic reactions two 3 carbon pyruvate molecules are formed leading 
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to the next important step in glycolysis. Pyruvate is converted to acetyl-CoA by 
pyruvate dehydrogenase (PDH) which requires the inactivation of PDH kinase, which 
is regulated by intrinsic factors within the muscle and substrate availability (Bhagavan 
& Ha, 2011). Acetyl-CoA then enters the tricarboxylic acid cycle in the mitochondria.  
Instead of being converted to pyruvate, G6P can undergo glycogen synthesis by the 
action of the enzyme glycogen synthase (GS). Glycogen synthase activity can be 
increased by insulin and allosteric activation by G6P (reviewed  in (Jensen & Lai, 
2009)). Dephosphorylation of glycogen synthase occurs via insulin-stimulated Akt-
mediated phosphorylation of GSK3 (Cohen, 1999). The phosphorylation of GSK3 
decreases its kinase activity thus decreasing phosphorylation of GS and therefore 
increasing GS fractional activity (Jensen & Lai, 2009). An accumulation of G6P 
through glycolytic flux can also increase GS activity independent of phosphorylation 
status (Jensen & Lai, 2009). During post-prandial periods when insulin levels are 
elevated there is an increase in glucose uptake and an increase in glucose oxidation 
and/or glycogen storage.  
During increased energetic demands of skeletal muscle such as high intensity 
exercise, glycogenolysis occurs to release glucose-1-phosphate via the 
phosphorylation of glycogen which can be converted to G6P and continue down the 
glycolytic pathway towards the mitochondria (Blanco & Blanco, 2017). Glycogen 
phosphorylase is responsible for glycogenolysis and is regulated by muscle 
contraction, substrate availability and hormonal regulation (Blanco & Blanco, 2017).  
1.3 Skeletal muscle lipid metabolism 
1.3.1 Adipose tissue storage 
Adipose tissue is the principal organ responsible for buffering the flux of FA in the 
circulation during the postprandial period. Most FA are packaged and stored as 
triglyceride (TAG) in adipose tissue equating to total fat mass of 18kg for males and 
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25kg for females when BMI is approximately 25 kg.m-2 (Heymsfield et al., 2002). 
Following ingestion of a mixed meal, digested fat is directed to chylomicron-TAG 
synthesis in the small intestine. Increases in insulin following carbohydrate or mixed 
meal ingestion suppresses hormone sensitive lipase (HSL) activity in adipose tissue 
therefore reducing FA release into the circulation. Insulin also activates lipoprotein 
lipase (LPL) on the capillaries of adipose tissue, stimulating the hydrolysis of 
chylomicron-TAG into FA for subsequent uptake into adipocytes for storage as TAG. 
Although adipose tissue is the primary site for TAG storage, ectopic lipid accumulation 
can occur in the cells of many tissues including skeletal muscle, liver and heart (Ryysy 
et al., 2000; Goodpaster et al., 2001; Schulze, 2009). The focus of this thesis will be 
on how TAG is stored and used in skeletal muscle.  
1.3.2 IMTG metabolism 
Muscle has the capability to oxidise both carbohydrates and lipids (see 1.1.1.2). In 
addition to glucose uptake, healthy skeletal muscle is capable of trafficking FA from 
the circulation into the muscle facilitated by various FA transporter proteins. Once 
transported into the muscle FA are converted to fatty acyl-CoA by fatty acyl-CoA 
synthetase (Coleman et al., 2000) and consequently are either esterified into 
intramuscular triglyceride (IMTG) stores or directed to the mitochondria for β- 
oxidation. Although most FA are packaged and stored as triglyceride in adipose tissue 
in the body, a small (200g) (van Loon, 2004) yet significant proportion is capable of 
being stored in skeletal muscle as IMTG (1-2% of total fat stores). Furthermore, IMTG 
is now recognised as an important source of ATP production during moderate-
intensity exercise. During moderate-intensity exercise IMTG contribute to 50% to 
total fat oxidation with the remaining 50% attributable to plasma FA (van Loon et al., 
2001). Tracer studies in human skeletal muscle have demonstrated that a significant 
proportion of plasma derived-FA are trafficked into the IMTG stores (Kanaley et al., 
2009). Pharmacological blockers of lipases with radiolabelled FA in cultured 
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myotubes showed increase radioactivity in the IMTG pool further demonstrating that 
a large proportion of plasma derived FA are first trafficked towards IMTG before being 
oxidised (Meex et al., 2015). The quantity of IMTG within the muscle reflects the 
balance between the rate of IMTG synthesis and IMTG lipolysis 
1.3.2.1 IMTG synthesis  
In healthy individuals at rest IMTG synthesis rates are 3.4%/h resulting in complete 
IMTG turnover in 29 h (Capaldo et al., 1999). If fatty-acyl CoA are directed to IMTG 
synthesis via acyl-CoA synthetase isotypes (Teodoro et al., 2017), they undertake 
acylation to a glycerol-3-phosphate in a stepwise progression (Figure 1.2). The 
acylation of the first fatty-acyl CoA generates lysophosphatidic acid which is catalysed 
by glycerol-3- phosphate acyltransferase (GPAT). An additional fatty acyl-CoA is 
acylated to lysophosphatidic acid to form phosphatidic acid by 1-acyl-glycerol-3-
phosphate-O-acyltransferase (AGPAT). Following removal of a phosphate group by 
phosphatidate phosphatase-1, lipin-1 diacylglycerol (DAG) is formed. DAG can also 
be produced by acylation of fatty acyl-CoA to MAG by monoacylglycerol 
acyltransferase (MGAT). An additional FA-CoA is acylated to DAG by diacylglycerol 
acyltransferase (DGAT) forming IMTG.  
(i) Glycerol-3-Phosphate Acyltransferase (GPAT) 
GPAT is considered the rate-limiting enzyme in the IMTG synthesis pathway because 
it exhibits the lowest enzyme activity (Coleman & Lee, 2004). There are 4 known 
GPAT isoforms; GPAT1 and 2 are located at the mitochondria whereas GPAT3 and 
4 are located at the endoplasmic reticulum (ER) membrane (microsomal) (Gimeno & 
Cao, 2008). Approximately 10% of total GPAT activity is attributable to mitochondrial 
GPAT in most tissues (Takeuchi & Reue, 2009). Despite this, mitochondrial GPAT1 
is the most-extensively studied of all the isoforms. Biochemical assays reveal that 
GPAT1 has a two-fold higher preference for saturated compared to unsaturated fatty-
acyl CoAs (Vancura & Haldar, 1994). GPAT1 is regulated both transcriptionally and 
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post-transcriptionally. For example, GPAT1 mRNA levels in mouse liver increase by 
20-fold upon high-carbohydrate diet after fasting, which stimulates hepatic 
lipogenesis (Shin et al., 1991). The increase in GPAT1 mRNA is reduced by 70% 
when rats were also supplemented with dibutyryl 3’, 5’-cyclic adenonsine 
monophosphate (cAMP), identifying adenylate cyclase and increased cAMP levels as 
a negative regulator of GPAT1 gene expression (Shin et al., 1991).  Contrastingly 
GPAT1 protein and activity decreases by more than 30% following 48 h fasting in liver 
and adipose tissue in rats (Lewin et al., 2001). The importance of GPAT1 in TAG 
synthesis has been exemplified in mice through GPAT1 overexpression by 
adenovirus resulting in increased TAG and DAG content by 12-fold and 7-fold, 
respectively (Linden et al., 2006). GPAT1-KO mice exhibit lower, but not completely 
diminished, hepatic TAG and lower plasma TAG and VLDL-TAG concentrations 
(Hammond et al., 2002), thus indicating other GPAT isoforms may serve a functional 
role upon ablation of GPAT1. GPAT1 content has been identified in human skeletal 
muscle by western blot (Schenk & Horowitz, 2007; Newsom et al., 2011), but the 
understanding of the regulation of GPAT1 in this tissue is limited. If lysophosphatidic 
acid is produced at the mitochondria by GPAT it may require transportation to the ER 
where the majority of other IMTG-synthesising enzymes are located. In the liver this 
occurs by liver-fatty acid binding protein (Gonzalez-Baro et al., 2007), but how this 
process occurs in skeletal muscle is still unknown. Elevations in DAG and TAG 
synthesis occur in soleus muscle in vitro in response to insulin (Dyck et al., 2001) 
suggesting that both GPAT and DGAT activity is increased by feeding. Inhibition of 
PI3-K reduces FA esterification, further indicating insulin-stimulated IMTG synthesis 
occurs via a PI3-K pathway (Muoio et al., 1999; Dyck et al., 2001).  
(ii) 1-acyl-glycerol-3-phosphate-O-acylytransferase (AGAPT) 
Phosphatidic acid is produced from the acylation of a fatty acyl-CoA to 
lysophosphatidic acid catalysed by AGPAT. There are 10 AGPAT isoforms reported 
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thus far in the literature, with AGPAT1 and AGPAT2 being the most well-established 
(Takeuchi & Reue, 2009). Expression of AGPAT1 and AGPAT2 is more pronounced 
in adipose tissue, but they are also expressed in skeletal muscle (Yamashita et al., 
2014).  The location and activity of AGPAT is largely at the ER (Takeuchi & Reue, 
2009) but also at the mitochondria (Bursten et al., 1991). AGPAT1 plays a key role in 
TAG synthesis because in 3T3-L1 adipocytes and C2C12 myotubes overexpression 
of AGPAT1 increased [3H]oleate incorporation into TAG (Ruan & Pownall, 2001). The 
importance of AGPAT2 in adipocyte TAG synthesis has been illustrated by studies 
showing defects in the AGPAT2 gene resulting in congenital generalized 
lipodystrophy, which results in a lack of adipose tissue (Agarwal et al., 2002). 
(iii) Phosphatidate phosphatase (PAP)/ Lipin-1 
Phosphatidate phosphatases (PAP) are Mg2+-dependent and inactivated by N-
ethylmaleimide (Martin et al., 1987). Lipin-1, -2 and -3 have been identified as the 
proteins responsible for PAP activity during the process of TAG synthesis and lipin-1 
accounts for all the PAP activity in skeletal muscle (Donkor et al., 2007). PAP activity 
levels are present both in the cytosol and at the ER where it catalyses the 
dephosphorylation of phosphatidic acid into DAG (Takeuchi & Reue, 2009).  Lipin-1 
is phosphorylated by insulin and dephosphorylated by epinephrine (Harris et al., 
2007). Paradoxically the increased phosphorylation by insulin results in a decreased 
fraction of lipin-1 at the ER where target substrate phosphatidic acid is produced 
(Harris et al., 2007). This unusual finding may be partly explained by lipin-1 having 
divergent roles in muscle cell cycle differentiation and autophagy (Zhang et al., 2014; 
Jiang et al., 2015), requiring different localisation and regulation. Importantly, 
overexpression of lipin-1 in mouse skeletal muscle reduces energy expenditure and 
fatty acid utilisation (Phan et al., 2004) highlighting its importance in TAG synthesis.  
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(iv) Diacylglycerol Acyltransferase (DGAT) 
DGAT is responsible for the final acylation of DAG with fatty acyl-CoA to form IMTG 
(Choi et al., 2007). DGAT1 and DGAT2 are the two isoforms that have been identified 
in human adipose tissue (Cases et al., 1998; Cases et al., 2001) and mouse skeletal 
muscle (Levin et al., 2007; Yu et al., 2015), however limited research has been 
conducted in human skeletal muscle.  Overexpression of DGAT1 in mouse skeletal 
muscle increases DGAT1 content 50% and triglyceride content 4-fold (Yang et al., 
2013). Furthermore, overexpression of DGAT1 by recombinant adenovirus in C2C12 
myotubes increased DGAT activity 4-fold and increased TAG content by 6-fold (Liu 
et al., 2007).  DGAT-1 KO mice have reduced fat pads and are resistant to weight 
gain compared to wild type mice, yet were still capable of producing TAG in adipose 
tissue (Smith et al., 2000), suggesting a compensatory role for DGAT2. DGAT activity 
increases 60-fold in differentiating adipocytes (Dircks & Sul, 1997), but mRNA 
expression for DGAT1 and DGAT2 only increases 8-fold and 30-fold, respectively, 
suggesting DGAT is regulated by post-transcriptional mechanisms (Coleman & Lee, 
2004). An early study concluded DGAT activity is a function of steady state DGAT1 
protein levels in differentiated 3T3-L1 adipocytes (Yu et al., 2002b). Despite this, 
multiple phosphorylation sites have been discovered for DGAT1 and the use of 
glutamate mutation as a phosphorylation mimetic on Ser83, Ser86 and Ser89 
increased DGAT1 activity in C2C12 cells (Yu et al., 2015), therefore suggesting it’s 
activity can be regulated post-translationally. 
(v) Monoacylglycerol acyltransferase pathway (MGAT) 
Monoacylglycerol (a substrate of DAG lipolysis) can also be re-synthesised back into 
DAG in a reaction catalysed by MGAT. Research from this pathway primarily exists 
from the small intestine where it is estimated that 75% of the TAG synthesis occurs 
via this route following ingestion of a meal (Johnston, 1977). As such, activity levels 
have been recorded higher in the small intestine and to a lesser extent in skeletal 
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muscle (Yen & Farese, 2003). There are 3 MGAT isoforms, MGAT1 and MGAT2 
which acylate both sn-2 and sn-1(3)- monoacylglycerols whereas MGAT3 has a 
higher specificity for sn-2-monoaclyglycerol (Coleman & Lee, 2004). Information 
regarding the importance and regulation of the MGAT pathway in TAG synthesis in 
skeletal muscle is limited and warrants further investigation.  
1.3.2.2 IMTG lipolysis 
In trained individuals fat oxidation rates increase approximately 10-fold when 
exercising at moderate-intensity compared to resting values (Romijn et al., 1993; van 
Loon et al., 2001). Adipose tissue has the largest TAG stores in the body and it is 
therefore unsurprising that adipose tissue derived TAG provides the largest 
contribution to fat oxidation. However, studies employing stable isotope methodology 
and indirect calorimetry have demonstrated that other fat sources (IMTG and 
lipoprotein-TAG) also provide a substantial contribution (~30-50%) to total fat 
oxidation particularly during moderate-intensity exercise (40-65% VO2 max) (Romijn et 
al., 1993; van Loon et al., 2001). These findings are complemented by non-invasive 
1H magnetic resonance spectroscopy (1HMRS) technology showing that IMTG 
concentrations are consistently reduced (~20-40%) during moderate-intensity 
exercise lasting between 1-3 hours (van Loon, 2004). More recently, using 
immunofluorescence microscopy studies have shown that IMTG stores are 2-4 fold 
higher in type I fibres compared to type II (van Loon et al., 2003a; Shepherd et al., 
2013) and IMTG utilisation is specific to type I fibres during moderate-intensity 
exercise (van Loon et al., 2003a; Van Proeyen et al., 2011a; Shepherd et al., 2013). 
This is unsurprising considering type I fibres are characterised by a greater 
mitochondrial content and oxidative capacity (Essen et al., 1975).  
IMTG hydrolysis occurs from 3 sequential cleavages of a FA from the glycerol 
backbone and is catalysed by 3 lipases; adipose triglyceride lipase (ATGL), hormone 
sensitive lipase (HSL) and monoacylgycerol lipase (MGL) (Figure 1.2). Historically, 
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HSL was considered to be the rate-limiting enzyme in lipolysis. At rest, HSL accounts 
for ~60% of total neutral hydrolase activity and the exercise-induced increase in 
skeletal muscle lipase activity was attributable to HSL (Watt et al., 2004). Immuno-
inhibition of HSL with an anti-HSL antibody has also been shown to eradicate 
contraction-induced increase in TAG lipase activity (Langfort et al., 2000). However, 
the existence of other important lipases became apparent in an experiment where an 
antiserum against HSL was applied to an assay medium measuring TAG hydrolysis 
in human skeletal muscle, and this only reduced neutral lipase activity by ~25% 
(Roepstorff et al., 2004). Additionally, only 50% of TAG hydrolase activity was 
reduced in adipose tissue in HSL-deficient mice compared to wild type mice 
(Haemmerle et al., 2002b), adding to the suggestion that other lipases are present.  
A lipase with high-affinity for TAG named ATGL was subsequently discovered, 
predominantly expressed in adipose tissue and to a lesser extent in skeletal muscle 
(Villena et al., 2004; Zimmermann et al., 2004). Overexpression of ATGL in human 
primary myotubes resulted in reduced TAG content and increased FA release and 
oxidation (Badin et al., 2011), whilst ATGL-KO mice accumulate excessive TAG in 
skeletal muscle (Haemmerle et al., 2006). On the other hand in vitro assay systems 
have demonstrated that HSL has a higher specificity for substrate DAG in comparison 
to TAG (Fredrikson et al., 1981b), and HSL-KO mice accumulate DAG in skeletal 
muscle (Haemmerle et al., 2002a). The existing evidence therefore suggests that 
ATGL and HSL preferentially hydrolyse IMTG in a sequential process (Figure 1.2) 
whereby ATGL cleaves the initial FA from IMTG to produce DAG.  HSL is likely to 
then be crucial for DAG hydrolysis to monoacylglycerol (Figure 1.2). Evidence from 
adipose tissue suggests the final FA liberation is conducted by MGL (Taschler et al., 
2011). Considering ATGL and HSL collectively account for at least 98% of 
contraction-induced TAG lipase activity in rat skeletal muscle (Alsted et al., 2013), 
little research has been conducted exploring the regulation and activation of MGL. 
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(i) Hormone Sensitive Lipase 
Similar to IMTG, HSL also appears to have a higher abundance in type I fibres 
compared to type II fibres (Langfort et al., 1999). HSL activity during exercise is 
regulated allosterically, by multiple contraction and adrenergic phosphorylation sites. 
Under lipolytic stimuli such as exercise, rising catecholamine levels activate HSL by 
cAMP-dependent protein kinase (PKA) phosphorylation on Ser563 and Ser660 (Watt 
et al., 2003c; Watt et al., 2006). Conversely, postprandial increases in insulin exert 
an inhibitory effect on skeletal muscle HSL activity by activating a phosphodiesterase 
which converts cAMP to inactive 5‘-AMP so that less HSL is phosphorylated 
(Enoksson et al., 1998).  Muscle contraction observed during exercise also activates 
HSL via protein kinase C and extracellular signal-related kinase (Donsmark et al., 
2003), most probably through phosphorylation at Ser600 (Greenberg et al., 2001). 
Due to the increase in AMP-activated protein kinase (AMPK) activity seen during 
higher intensities of exercise, phosphorylation and inhibition of HSL on Ser565 results 
in an anti-lipolytic effect (Watt et al., 2004; Watt et al., 2006). Additionally, 
accumulation of fatty acyl-CoA also exhibited at higher exercise intensities (Kiens et 
al., 1999) may allosterically inhibit HSL activity. HSL activity is therefore upregulated 
for longer at lower (30% and 60% V̇o2peak) in comparison to higher (90% V̇o2peak) 
exercise intensities (Watt et al., 2003b). In agreement, Achten and Jeukendrup (2003) 
established that maximal fat oxidation rates in males occurs at 63% V̇o2 max. In 
addition to the regulation of HSL via phosphorylation, an insightful study by Prats et 
al. (2006) demonstrated that HSL translocates to LD in isolated rat skeletal muscle 
following adrenaline or electrical stimulation. The translocation of HSL from the 
cytosol to the LD was already well established in adipocytes following adrenergic 
stimulation (Brasaemle et al., 2000), but this was the first study in skeletal muscle to 
demonstrate this effect. Transmission electron microscopy also confirmed that HSL 
penetrated the phospholipid monolayer of the LD thus enabling access to the 
substrates within the LD core (Prats et al., 2006). The use of isolated rat skeletal 
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muscle in the study elegantly eliminated the interference of plasma-derived FA on 
substrate use and IMTG synthesis allowing for IMTG hydrolysis to be studied in 
isolation. Substrate and hormone levels can however influence lipolytic rates and 
contraction of muscle during exercise induces a host of regulatory mechanisms that 
are not observed in vitro or ex vivo. Whether HSL redistribution to LDs occurs in 
human skeletal muscle in vivo still needs to be investigated.  
(ii) Adipose Triglyceride Lipase 
As ATGL is a comparatively new lipase, research examining its regulation particularly 
in skeletal muscle is relatively limited. Similar to HSL, ATGL is found in a higher 
abundance in type I compared to type II muscle fibres (Jocken et al., 2008). ATGL 
interacts with its co-activator, comparative gene-identification-58 (CGI-58), to 
increase lipase activity up to 20-fold in cultured kidney cells (Lass et al., 2006). CGI-
58 appears particularly important because individuals with a CGI-58 mutation have 
increased IMTG content (Lass et al., 2006) likely due to diminished IMTG hydrolysis 
capabilities. ATGL activity is inhibited and ATGL-mediated lipolysis is reduced if the 
patatin-like domain of ATGL interacts with the hydrophobic domain of the G(0)/G(1) 
switch gene 2 (G0S2) protein (Yang et al., 2010). In adipocytes, under resting 
conditions CGI-58 is prevented from activating ATGL because it is associated with 
the LD protein perilipin 1 (PLIN1) (Yamaguchi et al., 2004). Upon beta-adrenergic 
stimulation, PKA phosphorylates PLIN1 thus releasing CGI-58 so it can bind to and 
activate ATGL (Granneman et al., 2009). PLIN1 however, is not expressed in skeletal 
muscle (Greenberg et al., 1991) and research regarding ATGL regulation in skeletal 
muscle is limited. It has been demonstrated however, that following contraction there 
is an increase in CGI-58/ATGL protein interaction in rat soleus muscle (MacPherson 
et al., 2012), suggesting a similar mechanism may exist in skeletal muscle.  
In humans, subcutaneous adipose tissue phosphorylation of Ser404 on ATGL is 
increased by β-adrenergic stimulation and is correlated with increased lipolysis rates 
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(Pagnon et al., 2012). ATGL phosphorylation on Ser404 in human skeletal muscle is 
not however altered following moderate-intensity exercise (Mason et al., 2012), 
suggesting it is not vital for ATGL activation.  Phosphorylation of the Thr372 residue 
on the hydrophobic region in the C-terminus of ATGL prevents LD colocalisation to 
ATGL and ATGL mediated TAG hydrolysis (Xie et al., 2014). This mechanism would 
serve to reduce lipolysis under non-stimulated basal conditions. Several other 
phosphorylation sites of ATGL have been identified including Ser87 and Thr210 in 
the NH2- terminus patatin-like domain, and Ser430, Thr372, Tyr378 and Ser393   in 
the C-terminus (Xie et al., 2014), but their function and regulation still requires further 
investigation. In contrast to HSL which translocates to the LD, it is suggested that 
ATGL is already localised to LD in skeletal muscle under basal conditions and its 
positioning is unaltered following moderate-intensity exercise (Mason et al., 2014a). 
This was investigated using wide-field microscopy, which does not permit a detailed 
assessment of ATGL distribution and location relative to IMTG stores due to the 
limitations resulting from the refraction of light (compared to a laser) and the resolving 
power of the microscope. The use of higher resolution confocal microscopy is 
warranted to investigate in greater detail the location of ATGL before and after 




Figure 1.2. IMTG synthesis and hydrolysis in skeletal muscle. AGPAT, 1-
acylglycerol-3-phosphate acyltransferase; ATGL adipose triglyceride lipase, ACS, 
acyl-CoA synthetase; DAG, diacylglycerol; DGAT, diacylglycerol transferase; FA, 
fatty acid; FA-CoA, fatty acyl-CoA; CD36,  cluster of differentiation 36; G-3-P, 
glycerol-3- phosphate; GPAT, glycerol-3-phosphate acyltransferase; HSL, hormone 
sensitive lipase; IMTG, intramuscular triglyceride; LPA, lysophosphatidic acid; MAG 
























1.4 Lipid Droplets 
Previously considered an inert storage depot, LD are now recognised as functional 
and dynamic organelles implicated in various biological processes (Walther & Farese, 
2009). Having a core of neutral lipids (TAG and cholesterol esters) and surrounded 
by a phospholipid monolayer, LD are primarily abundant in adipocytes however they 
are also present in myocytes, hepatocytes and other cells to a lesser extent. As the 
primary role of LD is to store TAG, dysregulation of LD homeostasis is proposed to 
be implicated in the pathogenesis of insulin resistance and T2D (Greenberg et al., 
2011). 
1.4.1 LD formation and growth 
It is extensively accepted that LD are formed by or in close proximity to the ER, but 
the exact mechanism is still under debate.  It is commonly proposed that TAG and 
cholesterol esters accumulate between the leaflets of the ER bilayer forming a lens 
type structure before the LD buds off towards the cytoplasm (Bersuker & Olzmann, 
2017).  Evidence from cultured human macrophages analysed using freeze-fracture 
high resolution electron microscopy showed that ER membranes lie external to and 
follow the LD contour similar to an egg held by an egg cup  (Robenek et al., 2006). 
Furthermore immunogold labelling indicated that protein perilipin-2 enriched domains 
of the cytoplasmic leaflet of the ER are where LD are located, suggesting this protein 
is important for LD biogenesis (Robenek et al., 2006). Data from yeast cells also 
indicate new LD may form from fission of pre-existing LDs (Long et al., 2012). Newly-
synthesised LD are typically small in diameter (0.5 < μm) and referred to as primordial 
droplets. 
LD can increase in size by a number of mechanisms; 1) coalescence of fusion of two 
LDs via pores in the phospholipid monolayer, 2) ripening of one LD through transfer 
of molecules from a LD decreasing in size and  3) expansion of LD due to increased 
synthesis of IMTG from FA (Gemmink et al., 2017b). Experiments in NIH 3T3 cells 
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demonstrated that LD growth through fusion was independent of TAG synthesis but 
required the presence of microtubules and motor protein dynein (Bostrom et al., 
2005). Freeze-fracture electron microscopy images of macrophages show close 
contact between LDs and amalgamation of smaller LD in a larger LD, indicative of 
homotypic fusion (Robenek et al., 2006). Microtubules provide a pathway in cells for 
LD to move to different organelles or to other LD (Welte, 2009). Interestingly, 
knockdown of SNARE fusion machinery; SNAP23, synataxin-5 and VAMP4, reduced 
the rate of fusion and LD size in NIH-3T3 cells (Bostrom et al., 2007).  
LD can decrease in size through a fission or fragmentation process. ADP ribosylation 
factor (ARF) – COPI, which coats Golgi vesicles and endosomal membranes, has 
been implicated in this process. RNAi knockdown of ARF1-COPI results in larger and 
more dispersed LD in Drosophila S2 cells (Guo et al., 2008). Lipolysis of IMTG in the 
central core of LD by ATGL and HSL is also expected to reduce LD size, but whether 
fission of LD and TAG lipolysis occur in sequence or independent of one another is 
still unknown. It is generally accepted that a large number of small-sized LD is 
metabolically advantageous as this will provide a greater surface area for lipases to 
access and may increase phospholipid availability for regulatory proteins to associate 
with.  
1.4.2 LD proteome 
Decorating the phospholipid monolayer of LD are various proteins. The composition 
of this LD coat can impact the function and biological fate of each LD. The 
hydrophobic core of LD is an unfavourable environment for hydrophilic protein 
domains and therefore proteins are normally attached to or overspanning the outer 
membrane sometimes with multiple hydrophilic and hydrophobic protein domains. It 
has been proposed that the two primary ways that LD proteins associate with the 
phospholipid monolayer are; by hydrophobic domains (Class I) or amphipathic helices 
(Class II) (Kory et al., 2016). Class I proteins such as DGAT2 (Stone et al., 2006) and 
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GPAT4 (Wilfling et al., 2013) possess a hydrophobic segment embedded in the LD 
membrane and a cytosolic hydrophilic N- and C- terminus. Dually found in the ER and 
LD, class I proteins are believed to be initially inserted into the ER before being 
trafficked to nascent LD. Class II proteins, such as perilipin (PLIN) proteins (Kory et 
al., 2016),  are proposed to sense physiochemical properties of the LD membrane 
and insert their amphipathic helix into the LD membrane (Rowe et al., 2016). There 
is evidence to suggest that PLINs compete with each other for LD localisation, 
suggesting sites for amphipathic helix insertion may be limited (Rowe et al., 2016). 
Some PLINs also contain a C-terminal helical bundle which contains a hydrophobic 
cleft capable of binding to lipids (Rowe et al., 2016) which may provide another 
avenue of PLIN binding to LD. SNAP23 is neither a class I or II protein and instead is 
anchored to LD through a palmitate group (Bostrom et al., 2007). ATGL co-activator 
CGI-58 also binds to LD unusually by a unique membrane embedded motif which 
forms a hydrophobic core allowing it to anchor to the LD (Boeszoermenyi et al., 2015). 
Class I and II proteins bound to LD are also capable of recruiting other proteins to the 
LD, classically exemplified by HSL translocation to the phosphorylated N-terminus of 
PLIN1 (Wang et al., 2009). Similar to other skeletal muscle proteomes, LD proteins 
are also subject to degradation processes to aptly remove damaged and 
dysfunctional proteins. Several LD associated proteins are degraded by the ubiquitin-
proteasome system (Bersuker & Olzmann, 2017), however the regulation of this is 
still relatively unknown. The constant flux of class I proteins associating to nascent 
LD, attachment of class II proteins, further recruitment of other proteins to the LD and 
degradation of proteins is suggestive that a proteome of a singular LD is dynamic and 
likely influenced by location, maturity and metabolic state. The fact LD are 
heterogeneous in size, characteristic and function amongst different tissues and cell 
types further complicates the understanding of the LD proteome.  
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The discovery of proteins on the LD surface or within the LD has prompted various 
studies aiming to determine the LD proteome. Due to LD having a close association 
to mitochondria (Hoppeler et al., 1999) and the endoplasmic reticulum (Jacquier et 
al., 2011), it is unsurprising that proteomic analysis of the LD fraction has yielded 
proteins from both of these organelles. It may be argued that the purity of the LD sub-
fraction is compromised in this instance, as it does not reflect a completely isolated 
LD proteome. Given that class I LD proteins are inserted at the ER and LD can form 
LD-mitochondrial complexes, this finding should not be overlooked and may be 
indicative of the current metabolic state of the LD within the muscle homogenate at a 
particular time. For example, an abundance of mitochondrial protein found in the LD 
proteome (Zhang et al., 2011) may suggest a significant portion of LD are 
metabolically linked to mitochondria. This can often be classified as a metabolic 
advantage as it would allow FA sequestered from IMTG hydrolysis to be shuttled to 
mitochondria more efficiently (Aon et al., 2014). Indeed, endurance training has 
shown to increase the spatial interaction between LD and mitochondria (Tarnopolsky 
et al., 2007) which likely underpins the increased IMTG utilisation during an acute 
exercise bout (Shepherd et al., 2013).  Alternatively, a high abundance of ER proteins 
from the LD fraction may indicate that a substantial portion of LD within a muscle 
homogenate are newly-formed at the ER.  Nevertheless, there is still a desire by many 
researchers to identify the proteome of an isolated LD fraction. Very stringent studies 
to this effect have used quantitative protein correlation profiling to identify high 
confidence LD proteins (111) in Drosphila S2 cells (Krahmer et al., 2013) and in yeast 
cells (35) (Currie et al., 2014). 
Amongst the various LD proteome studies, several groups of proteins are commonly 
identified including; PLIN proteins (section 1.5) TAG biosynthetic enzymes (section 
1.3.1) TAG lipolytic machinery (section 1.3.2), ubiquitination factors and Ras-related 
proteins (Bersuker & Olzmann, 2017). Rab GTPases identified in the LD proteome of 
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Chinese hamster ovary (CHO) cells (Liu et al., 2004) may be responsible for 
mediating reactions with endosomes or with the ER. Most of these findings originate 
from non-myocyte cell lines or from tissues other than skeletal muscle. Zhang and 
colleagues (2011) identified 324 LD-associated proteins following ultracentrifugation 
of mouse skeletal muscle. An abundance of these proteins was associated to the 
mitochondria and the majority was part of the electron transport chain within the inner 
mitochondrial membrane. This shows that there is a tight association of LD with the 
mitochondria and an inability to separate the two organelles through 
ultracentrifugation. Although there were over 300 proteins identified, it still needs to 
be investigated how these proteins work together to regulate LD homeostasis and if 
there is a heterogeneity to LD proteome composition which may be related to the 
metabolic state and determine the regulation of each LD. 
1.5 Perilipin proteins regulating IMTG turnover 
Of the proteins associated with the LD, PAT/perilipin (PLIN) proteins have been the 
most extensively researched. Perilipin 1 was the first to be identified and its regulation 
in adipocytes is well characterised, but it is exclusively expressed in adipose tissue 
and steroidogenic cells (Londos et al., 1995). Consequently, research in skeletal 
muscle has focused on the four remaining perilipin proteins namely; adipose 
differentiation related protein/adipophilin (PLIN2), tail interacting protein of 47kDA 
(PLIN3), S3-12 (PLIN4) and OXPAT (PLIN5). The following section will focus on the 
role of each perilipin protein on IMTG turnover and LD regulation.  
1.5.1 Perilipin 2 
PLIN2 was the second perilipin protein to be identified and was originally implicated 
in LD biosynthesis because it was present in 3T3-L1 adipocytes and in early 
differentiated adipocytes, but absent from maturing adipocytes (Brasaemle et al., 
1997). Cultured cells exposed to oleic acid demonstrate increased PLIN2 protein 
expression concomitant to an increase in TAG stores, studied in CHO fibroblast cells 
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(Xu et al., 2005) and in J774 murine macrophages (Masuda et al., 2006). In COS-7 
cells, oleate treatment results in PLIN2 and DGAT2 colocalising at the LD surface 
(Stone et al., 2009). Knockdown of PLIN2 in vitro in C2C12 cells results in reduced 
formation of LD following oleate treatment (Bosma et al., 2012a). Together the data 
from cell culture studies suggests PLIN2 is important for expanding intracellular TAG 
stores following exposure to lipids.  
Cross-sectionally, in humans where IMTG content is elevated such as in; endurance 
trained individuals, females or specifically in type I skeletal muscle fibres, PLIN2 
protein expression is also elevated (Shaw et al., 2009; Peters et al., 2012; Shepherd 
et al., 2013). Furthermore, endurance training increases IMTG content concomitant 
with an increase of PLIN2 protein expression (Shaw et al., 2012; Shepherd et al., 
2013). Immunohistochemistry analyses in human skeletal muscle has revealed that 
approximately 60% of LD are colocalised with PLIN2 (Shaw et al., 2009; Shepherd et 
al., 2013) which has allowed the identification of LD associated with PLIN2 (PLIN2+ 
LD) and LD without PLIN2 association (PLIN2- LD) and demonstrates a 
heterogeneous LD pool. When IMTG content increases following 6 h lipid infusion 
during a HE clamp, the amount of PLIN2+ LD increases without any changes in PLIN2 
protein expression (Shepherd et al., 2017b), indicating PLIN2 has the capacity to be 
redistributed when the LD pool expands. Together, the research suggests PLIN2 is 
important for the formation of new LD which would support an increase in IMTG 
storage.   
PLIN2 co-immunoprecipitates with ATGL in isolated rat skeletal muscle at rest but 
this interaction is decreased by 21% following electrically-stimulated muscle 
contraction (MacPherson et al., 2013a). It has therefore been proposed that PLIN2 
promotes lipid accumulation by sequestering ATGL and preventing lipolysis in basal 
conditions but releases ATGL so it can interact with its co-activator CGI-58 following 
lipolytic stimulation (MacPherson et al., 2013a). Researchers from the same lab, 
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however, were unable to identify serine phosphorylation of PLIN2 following 
adrenaline or electrically stimulated muscle contraction of isolated rat muscle 
(Macpherson et al., 2013b) and therefore how PLIN2 is regulated to assist in IMTG 
lipolysis still needs further investigation. In isolated rat skeletal muscle, both 
adrenaline and electrically-stimulated muscle contraction results in an increase in 
HSL colocalisation to PLIN2 (Prats et al., 2006), illustrating one mechanism by which 
PLIN2 may directly support IMTG hydrolysis. In human skeletal muscle, PLIN2+ LD 
are preferentially utilised during 1 hour of moderate–intensity exercise in lean 
untrained men (Shepherd et al., 2012). Interestingly though, following endurance or 
sprint interval training there are no differences in the use of PLIN2+ LD or PLIN2- LD 
utilised during 1 hour of moderate-intensity exercise (Shepherd et al., 2013). This 
indicates that other perilipins may be more important in regulating IMTG lipolysis 
following endurance training.   
1.5.2 Perilipin 3 
Perilipin 3 was the third perilipin family member to be identified and research from 
non-skeletal muscle cell lines has implicated PLIN3 to play a role in lipid synthesis. 
Following oleate treatment, PLIN3 associates with smaller nascent peripherally 
located LD in 3T3-L1 adipocytes and resulted in an increase of PLIN3 in the LD 
fraction compared to cytosolic fraction (Wolins et al., 2005). In HeLa cells suppression 
of PLIN3 reduced LD maturation and decreased incorporation of TAG into LD 
(Bulankina et al., 2009). Together these studies suggest that PLIN3 plays a 
supportive role in the formation and maturation of LD.  
Although it is not known if PLIN3 plays a similar role in skeletal muscle, 
pharmacological activation of AMPK in mouse skeletal muscle is reported to increase 
PLIN3 gene expression resulting in elevated IMTG content (Kleinert et al., 2016). In 
human skeletal muscle PLIN3 protein expression is higher in type I fibres (Shepherd 
et al., 2017b) and in females (Peters et al., 2012) where IMTG content is elevated. At 
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present there is confounding data if PLIN3 increases following endurance training. 
PLIN3 protein expression does not increase following either 12 weeks of endurance 
training in lean or obese males and females (Peters et al., 2012) or 12 weeks of 
combined strength and endurance training in T2D individuals (Daemen et al., 2018). 
PLIN3 protein expression however does increase after 4 weeks of endurance training 
in sedentary obese males (Shepherd et al., 2017a). Cross-sectionally endurance-
trained in comparison to lean sedentary individuals show higher PLIN3 protein 
expression (Shepherd et al., 2017b) or comparative levels (Daemen et al., 2018). 
Following 6 h lipid infusion during a HE clamp, IMTG content increases with a 
concomitant increase in PLIN3+ LD in type I fibres without alterations in PLIN3 protein 
expression (Shepherd et al., 2017). Together the data suggests PLIN3 could play a 
role in increasing IMTG stores but the exact role requires much more investigation.  
Until recently, little evidence existed to suggest that PLIN3 assisted in IMTG lipolysis. 
Lipolytic stimulation (palmitate, forskolin, and ionomycin treatment) of myotubes from 
lean individuals increased PLIN3 protein expression, whilst knockdown of PLIN3 in 
these myotubes reduced lipid oxidation (Covington et al., 2015). A prolonged acute 
exercise bout at 50% VO2max results in an increase in PLIN3 protein expression in 
human skeletal muscle (Covington et al., 2014), but how this is related to IMTG 
lipolysis is unknown. Co-immunoprecipitation confirms that PLIN3 also interacts with 
lipases ATGL and HSL in rat skeletal muscle however this interaction is unchanged 
following lipolytic stimulation (Macpherson et al., 2013b).  At present the evidence 
indicates PLIN3 may support the expansion of IMTG stores, but there is still little 
evidence to suggest PLIN3 has a functional role in IMTG lipolysis.  
1.5.3 Perilipin 4 
PLIN4 is apparently the most abundant PLIN in skeletal muscle (Deshmukh et al., 
2015a) and has the highest mRNA expression (Pourteymour et al., 2015), yet is the 
least researched. This is partly due to the importance of PLIN4 in regulating IMTG 
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being questioned by the finding that PLIN4-KO mice show no major alterations in 
skeletal muscle lipid levels (Chen et al., 2013). Adding to this PLIN4 mRNA 
expression and protein content remains the same or are reduced following endurance 
training (Peters et al., 2012; Pourteymour et al., 2015). Nevertheless, new evidence 
has emerged that trained individuals tend to have a higher PLIN4 protein expression 
compared to sedentary individuals (Shepherd et al., 2017b). In a similar fashion to 
PLIN3, PLIN4 was also found to coat smaller peripherally located LD in 3T3-L1 
adipocytes following oleate treatment (Wolins et al., 2005). Incubation of cultured 
myotubes with oleic acid increases PLIN4 mRNA expression whereas in vivo a low 
fat diet reduces PLIN4 mRNA expression in human skeletal muscle (Gjelstad et al., 
2012). Although PLIN4 is the most abundant PLIN in skeletal muscle there is still 
limited and confounding data on the importance of PLIN4 in regulating IMTG stores. 
1.5.4 Perilipin 5 
PLIN5 was the last perilipin discovered and is highly expressed in oxidative tissues 
that exhibit high rates of lipolysis and β-oxidation (Wolins et al., 2006; Peters et al., 
2012; Shepherd et al., 2013). PLIN5 is present at the LD surface, within the cytosol 
and at the mitochondria in skeletal muscle (Bosma et al., 2012b; Shepherd et al., 
2013). Similar to PLIN2, PLIN5 protein expression is positively correlated in cases 
with elevated IMTG stores, for example in females (Peters et al., 2012), in type I fibres 
(Shepherd et al., 2013; Shepherd et al., 2017b), in endurance trained individuals 
(Shepherd et al., 2017b; Daemen et al., 2018) or following endurance training (Peters 
et al., 2012; Shepherd et al., 2013). When PLIN5 is overexpressed there is an 
increase in TAG stores in CHO cells (Dalen et al., 2007), COS-7 cells (Wolins et al., 
2006) and rat skeletal muscle (Bosma et al., 2013). In human skeletal muscle when 
IMTG increases following 6 h lipid infusion with HE clamp, PLIN5+ LD also increased 
in type I fibres (Shepherd et al., 2017b). Following a longer exposure to lipid excess 
with a 5-day high-fat high calorie diet PLIN5 protein expression of whole muscle 
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homogenate increases (Gemmink et al., 2017a). The increase in IMTG observed 
following acute elevation of FFA from prolonged fasting, is completely attributable to 
PLIN5+ LD (Gemmink et al., 2016). 
Although PLIN5 protein expression is upregulated or PLIN5 colocalisation to LD 
increases in cases of augmented IMTG content, there is more evidence to suggest 
PLIN5 has a more functional role of a scaffold protein regulating levels of lipolysis 
rather than regulating IMTG synthesis. PLIN5 has a conserved N-terminus sequence 
that can bind to HSL (Anthonsen et al., 1998) and a C-terminus region that can bind 
to either ATGL or CGI-58 (Granneman et al., 2011; Wang et al., 2011a). PLIN5 binds 
to either CGI-58 or ATGL in CHO cells reducing TAG hydrolysis in basal conditions 
(Wang et al., 2011a). CGI-58 is the known co-activator of ATGL evidenced by an 
increased lipolysis rate when there is increased interaction of ATGL with CGI-58 
(Wang et al., 2011a). PKA stimulation results in PLIN5 phosphorylation and when 
PKA activation occurs with ectopic overexpression of PLIN5 and ATGL, lipolysis 
increases (Wang et al., 2011a).  These data have generated the hypothesis that 
PLIN5 serves to limit lipolysis in basal conditions by preventing the interaction of 
ATGL with CGI-58, and promotes lipolysis by releasing and allowing the interaction 
of ATGL and CGI-58 following lipolytic stimuli. In rat skeletal muscle PLIN5 co-
immunoprecipitates with both ATGL and CGI-58 however this interaction remains 
unchanged following electrical or epinephrine stimulation (MacPherson et al., 2013a). 
The importance of PLIN5 in regulating IMTG lipolysis has been highlighted by the 
finding that following endurance training PLIN5+ LD are preferentially used during 1 
h of moderate-intensity exercise in human skeletal muscle compared to PLIN5- LD 
(Shepherd et al., 2013). Despite PLIN5’s proposed role of regulating IMTG, there has 
been limited research investigating PLIN5’s interaction with HSL and ATGL in human 
skeletal muscle during moderate-intensity exercise. PLIN5 was shown to colocalise 
with ATGL in human skeletal muscle using wide-field microscopy and this did not 
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change with 60 min of moderate-intensity exercise. (Mason et al., 2014a). As 
previously explained (section 1.3.2.2 (ii)) the use of wide-field microscopy does not 
permit a detailed assessment of distribution and colocalisation of IMTG stores and 
lipolytic proteins. The use of higher resolution confocal microscopy is therefore 
needed to investigate PLIN5 colocalisation with ATGL and HSL in human skeletal 
muscle. 
Immunogold electron microscopy and western blot of isolated mitochondria revealed 
that PLIN5 has a strong association to mitochondria (Bosma et al., 2012b). 
Overexpression of PLIN5 enhances the interaction of LDs and mitochondria (Bosma 
et al., 2012b) and increases fatty acid oxidation (Wolins et al., 2006; Bosma et al., 
2012b). The metabolic linkage between PLIN5 and mitochondria may assist in 
directing IMTG-derived FA to the mitochondria for subsequent β-oxidation. PLIN5-KO 
mice results in decreased whole body fatty acid oxidation however the interaction 
between LDs and mitochondria is unaltered when PLIN5 is absent (Mason et al., 
2014b). The role of PLIN5 in enhanced IMTG-derived fatty-acid oxidation therefore 
still warrants further investigation.  
1.6 Insulin resistance and Type 2 Diabetes 
In contrast to our predecessors, we expose our genotype to energy-dense western 
diets and reduced levels of physical activity. As such, an increased amount of time is 
spent in the postprandial period exposing the human tissues to excessive surplus of 
FA and glucose.  The following sections explain the mechanisms by which chronic 
intake of energy-dense foods and low activity levels contribute to the development of 
insulin resistance with specific focus on skeletal muscle insulin resistance.  
Insulin sensitive tissues can mal-adapt due to different stressors such are reduced 
physical activity, increased sedentary time and overfeeding. This results in tissues 
becoming less responsive to the effects of insulin, a condition termed insulin 
resistance. Reduced insulin sensitivity in peripheral tissues (adipose tissue and 
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skeletal muscle) can result in reduced uptake of glucose from the blood for a given 
concentration of insulin. Whereas, hepatic insulin resistance is characterised as 
impaired suppression of hepatic glucose production. In the face of insulin resistance, 
normal glucose tolerance can be maintained by an increased secretion of insulin by 
pancreatic beta β-cells (Festa et al., 2006). A failure to increase insulin secretion 
results in impaired glucose tolerance (Festa et al., 2006). T2D ensues with a decline 
in β-cell function, resulting in reduced insulin secretion, leading to chronic 
hyperglycaemia (Kasuga, 2006). Reduced insulin sensitivity of tissues is therefore a 
primary aberration in the progression of T2D. As discussed in section 1.1.1.1 skeletal 
muscle is one of the largest blood glucose disposal sites post-prandial (Capaldo et 
al., 1999). Results from a HE clamp comparing T2D to controls determined that 
peripheral rather than splanchnic tissues were the predominant site of insulin 
resistance (DeFronzo et al., 1985), with skeletal muscle considered the primary tissue 
accounting for peripheral tissues. Maintaining skeletal muscle insulin sensitivity is 
therefore important in preserving whole body insulin sensitivity and preventing T2D.   
Clinically, T2D is categorised as fasting blood glucose levels above 7 mmol.L-1, an 
inability to reduce blood glucose levels below 11.1 mmol.L-1 following a 2 h 75g oral 
glucose tolerance test (OGTT), or a glycated haemoglobin (HbA1c) level above 6.5% 
(American Diabetes, 2015). T2D is associated with an increased risk of 
cardiovascular complications (Laakso, 2010). Persistent hyperglycaemia can cause 
endothelial dysfunction at the microvasculature leading to complications such as 
retinopathy or neuropathy (Remuzzi et al., 2002; Watkins, 2003). Microvascular 
dysfunction at the skeletal muscle can further exacerbate reductions in insulin and 
glucose delivery to skeletal muscle furthering reducing glucose uptake (Stehouwer, 
2018). Importantly, hyperglycaemia at the macrovasculature level can increase a 
person’s risk of heart attack, stroke or peripheral vascular disease (Fowler, 2008).  
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1.6.1 Lipid induced insulin resistance 
1.6.1.2 FFA storage and lipid overflow hypothesis  
This postprandial clearance of chylomicron-TAG into adipose tissue (explained in 
section 1.3.1) serves as an important mechanism to protect the vascular wall from 
exposure to FA and TAG which can impair endothelial function and increase risk of 
atherosclerotic plaques. If this lipid buffering mechanism becomes impaired, there is 
a ‘spill over’ of FA and TAG in the circulation. The excess lipids are then deposited in 
non-adipose tissues such as liver, pancreatic beta cells and skeletal muscle (Frayn, 
2002).  Accumulation of TAG in insulin-responsive tissues such as skeletal muscle 
(Goodpaster et al., 1997; Forouhi et al., 1999) and liver (Goto et al., 1995; Ryysy et 
al., 2000) is associated with insulin resistance. Furthermore, prolonged exposure of 
FA to human pancreatic islets results in impaired insulin secretion (Paolisso et al., 
1995; Zhou & Grill, 1995). Accumulation of FA and TAG in non-adipose tissues is, 
therefore, detrimental to insulin sensitivity.  
The importance of adipose tissue as a buffer for FA flux is exemplified by the condition 
of lipodystrophy or lipoatrophy which is characterised by partial or complete loss of 
adipose tissue, presented with exacerbated insulin resistance (Ganda, 2000). Mice 
without adipose tissue (A-ZIP/F-1) have been created to mimic lipodystrophy or 
lipoatrophy (Kim et al., 2000a). These mice develop accumulation of TAG in skeletal 
muscle and liver which are associated with defects in insulin signalling in both tissues 
(Kim et al., 2000a). Interestingly fat transplantation from WT mice into A-ZIP/F-1 mice 
results in reversal of hyperglycaemia, hyperinsulinemia and insulin resistance with 
modest reductions of TAG content in liver and skeletal muscle (Gavrilova et al., 2000; 
Kim et al., 2000a). Additional evidence of the importance of buffering adipose tissue 
stems from treatment with thiazolidinedione in obese Zucker rats which results in 
adipocyte differentiation from the activation of peroxisome proliferator receptors 
(PPARƴ) (Hallakou et al., 1997). This increase in adipocytes results in an enhanced 
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capacity to store TAG in adipose tissue resulting in a reduction in liver and skeletal 
muscle TAG concomitant to an improvement in insulin sensitivity (Hallakou et al., 
1997). Adipose tissue’s ability to buffer FA flux therefore proves important in reducing 
ectopic lipid accumulation in liver and skeletal muscle and maintaining insulin 
sensitivity and euglycaemia. 
The size of adipocytes in adipose tissue appears to be an important factor in adipose 
tissue buffering. Historical evidence has shown that larger adipocytes are less 
responsive to insulin stimulation (Olefsky, 1977). Furthermore, the accumulation of 
larger adipocytes in the subcutaneous area is a risk for developing T2D (Weyer et al., 
2000). Thiazolidinedione stimulates adipocyte differentiation via nuclear receptor 
PPAR resulting in smaller adipocytes and alleviated insulin resistance (Okuno et al., 
1998). It is therefore hypothesised that smaller adipocytes are more efficient at 
buffering FA flux in the post-prandial period and an inability to differentiate new 
adipocytes required for excess TAG storage may result in ectopic lipid accumulation 
and subsequent insulin resistance. Adipocytes from different regions in the body also 
display different properties. For example visceral adipose tissue (VAT) are 
characterised by high rates of lipolysis (Ostman et al., 1979) which to maintain levels 
must be matched by high rates of fat deposition (Frayn, 2000). Enlargement of VAT 
is associated with insulin resistance (Kelley et al., 2000) and is more commonly 
associated with males than females (Janjic, 1996). VAT is unique in being the only 
adipose tissue depot which has an anatomical position capable of draining FA to the 
liver via the portal vein (Bjorndal et al., 2011). Impairments of FA buffering in VAT 
may therefore augment ectopic lipid accumulation to the liver. However, it has been 
demonstrated that VAT only contributes a small proportion of total FA release, and 
VAT lipolysis directed to the portal vein is only elevated when there are increases in 
VAT stores (Nielsen et al., 2004). 
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Fasting FA concentrations are unchanged with increasing fat mass (Karpe et al., 
2011), suggesting that basal lipolysis per kilogram of fat mass is reduced in obesity. 
This is supported by adipocytes from obese people showing reduced lipolysis in vitro 
and reduced expression of the key lipolytic enzyme HSL (Large et al., 1999). This 
downregulation of basal lipolysis per kg of mass normalises FA appearance in the 
face of elevated adipose tissue. Reduced basal lipolysis of expanding adipose stores 
however will ultimately increases adipose tissue accumulation, which may impact 
overall adipose buffering capability. The obese state is characterised by an impaired 
insulin-mediated suppression of adipose tissue lipolysis resulting in greater 
appearance of FA from adipocytes into the circulation (Coppack et al., 1992; Hickner 
et al., 1999). This relationship does not exist however when FA appearance is 
normalised to total fat mass (Bickerton et al., 2008; McQuaid et al., 2011). 
Hyperinsulinemia observed in insulin resistant states therefore may be sufficient to 
suppress FA release following meal ingestion when normalised to total adipose tissue 
mass. Exacerbation of reduced lipid flux and consequent lipid spill over is therefore 
likely to be due to a reduced capacity of adipose tissue to hydrolyse and store plasma-
derived TAG (McQuaid et al., 2011).  
In lean individuals it is estimated that LPL activity measured in adipose tissue biopsies 
increases by 124% following a meal, but it only increases by 27% in obese subjects 
(Ong & Kern, 1989). Another study demonstrated that whilst LPL activity increased in 
obese subjects following insulin stimulation this increase was delayed (6 h compared 
to 3 h) in comparison to lean subjects (Sadur et al., 1984). This could lead to 
prolonged exposure of elevated plasma TAG levels, which is more closely related to 
insulin resistance in comparison to plasma FA (Bickerton et al., 2008). It is postulated 
that to maintain lipid homeostasis, plasma TAG will remain in the circulation until it 
has been hydrolysed on the capillary bed and transported into nearby tissue. The 
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longer plasma TAG remains in circulation the increased likelihood that this will be a 
non-adipose tissue such as skeletal muscle or liver.   
1.6.2 Athlete’s Paradox 
Accumulation of TAG in skeletal muscle was previously associated with reduced 
insulin sensitivity particularly in obese, sedentary and type 2 diabetic individuals (Pan 
et al., 1997; Kelley et al., 2001; van Loon, 2004) . Paradoxically, endurance trained 
athletes also display high levels of IMTG content yet remain very insulin sensitive 
(Goodpaster et al., 2001; van Loon et al., 2004). This phenomenon is termed the 
athletes paradox and has resulted in important research investigating why endurance 
trained individuals can remain insulin sensitive whilst having elevated IMTG stores. 
IMTG has no mechanistic link towards skeletal muscle insulin resistance per se; 
however, accumulation of lipid metabolites including fatty-acyl CoA, ceramides and 
certain DAG species in the muscle have been shown to contribute to skeletal muscle 
insulin resistance (Yu et al., 2002a; Gual et al., 2005; Samuel et al., 2010). As such 
lipid metabolites are often elevated in obese or type 2 diabetic individuals compared 
to lean or endurance trained controls  (Hulver et al., 2003; Adams et al., 2004; 
Straczkowski et al., 2007; Coen et al., 2010; Bergman et al., 2012). The lipid 
metabolite species and mechanisms underpinning lipid metabolite-induced skeletal 
muscle insulin resistance are discussed in more detail in the following section (section 
1.6.3). Work from Jensen and colleagues has established that healthy individuals 
have high IMTG turnover at rest (Kanaley et al., 2009) and during submaximal 
exercise (Guo et al., 2000).  Conversely, obese pre-diabetic individuals showed 
impaired IMTG turnover leading to subsequent IMTG accumulation (Perreault et al., 
2010). The efficient regulation of FA uptake, esterification, hydrolysis and oxidation 
appears paramount in minimising the accumulation of lipid metabolites. This section 
will discuss differences in the size and turnover of IMTG stores between endurance 
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trained individuals and sedentary people, who are more susceptible to develop insulin 
resistance that is likely to result in the accumulation of lipid metabolites.  
1.6.2.1 Dysregulation of FA transporters 
In addition to delivery of FA to skeletal muscle, FA uptake is regulated by FA 
transporters namely fatty acid translocase (FAT/CD36), fatty acid transport protein1-
5 (FATP1-5) and plasma membrane fatty-acid binding protein (FABPm). These FA 
transporters are located in skeletal muscle and/or capillary endothelial cells. Whilst 
this section focuses on dysregulation of FA transporters in skeletal muscle, it is 
important to note that endothelial cells on skeletal muscle microvasculature present 
the first main barrier to transport of FA into the muscle (Wagenmakers et al., 2016).  
In whole muscle homogenates CD36 and FATP1 protein content is similar between 
obese/ type 2 diabetic groups in comparison to lean or endurance trained controls 
(Bonen et al., 2004; Holloway et al., 2007; Pelsers et al., 2007; Aguer et al., 2010). 
FABPm mRNA expression and protein content was higher in endurance trained 
individuals compared to individuals with T2D and sedentary controls, likely reflecting 
greater FA uptake and oxidation rates during increased energy expenditure of 
exercise bouts (Pelsers et al., 2007). Although protein content of CD36 and FATP1 
is not altered in insulin resistant states, evidence is accumulating that the location of 
these proteins has an influence on FA uptake. In particular, CD36 was shown to 
permanently relocate from the intracellular compartment to the sarcolemma region to 
increase FA uptake in the face of elevated plasma FA observed in obese populations 
(Bonen et al., 2004; Aguer et al., 2010). The increase uptake of FA transport proteins 
and uptake of FA observed in endurance trained individuals appears to be an 
adaptation to allow greater utilisation of adipose tissue derived fatty acids during 
exercise bouts. Comparatively in insulin-resistant states, a permanent relocation of 
CD36 to the plasma membrane can increase the flux of FA entering the muscle from 
44 
elevated plasma FA level. If FA entering the muscle is not directed to IMTG for storage 
or mitochondria for β-oxidation, it could contribute to an increase lipid metabolites.  
1.6.2.2 Dysregulation of IMTG synthesis 
Long chain acyl-CoA synthases are responsible for activation and partitioning of FA 
in skeletal muscle to synthesis into IMTG or to the mitochondria for β-oxidation. 
Studies using stable isotope tracers have confirmed that a significant portion of FA 
entering skeletal muscle are directed to IMTG storage prior to entering long-chain 
acyl-carnitine oxidative pools (Sacchetti et al., 2004; Kanaley et al., 2009). Fractional 
synthesis rates of IMTG tend to be lower in obese people with pre-diabetes (0.21/h) 
compared to obese people with normal glucose tolerance (0.42/h) (Perreault et al., 
2010). Compared to sedentary individuals (0.61/h), endurance trained cyclists display 
greater (1.56/h) IMTG fractional synthesis rates (Bergman et al., 2018). Endurance 
cyclists are also capable of fully replenishing IMTG stores 48 hours after a 3 hour 
moderate-intensity (55% Wmax) cycling protocol whilst consuming a normal fat diet 
(39% energy) (van Loon et al., 2003b). Following moderate-intensity exercise, the 
content of TAG synthesis enzymes DGAT1 and GPAT1 (Schenk & Horowitz, 2007) 
or GPAT1 activity (Newsom et al., 2011) increase, which likely aids in the 
replenishment of IMTG stores. The increase in DGAT1 and GPAT1 content prevented 
lipid-induced insulin resistance following lipid-heparin infusion by reducing the content 
of DAG, ceramides and FA metabolites (Schenk & Horowitz, 2007). Overexpression 
of DGAT1 by recombinant adenovirus in C2C12 myotubes increases TAG content 
and reduces DAG content (Liu et al., 2007). Cross-sectionally there are no differences 
in expression of GPAT1 or DGAT1 between obese and lean individuals (Thrush et 
al., 2009; Li et al., 2011) or DGAT1 mRNA or protein expression between trained 
athletes and sedentary controls (Schmitt et al., 2003; Bergman et al., 2010; Amati et 
al., 2011). Furthermore, 8-16 weeks of endurance training does not alter DGAT1 
protein expression in lean (Alsted et al., 2009) or obese individuals (Dube et al., 
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2011). It is therefore evident that whilst DGAT and GPAT are vital for IMTG synthesis, 
there is little evidence to show that DGAT or GPAT protein expression or activity is 
impaired in insulin resistant states. A recent study has confirmed that greater IMTG 
synthesis rates observed in endurance-trained athletes compared to obese controls 
and people with T2D was not due to alterations in FA delivery, DGAT1 mRNA 
expression or protein content (Bergman et al., 2018). Basal IMTG synthesis rates 
were greater in athletes and were positively correlated to insulin sensitivity and also 
cytosolic DAG accumulation whilst being inversely correlated to C18:0 ceramide and 
glucosylceramide (Bergman et al., 2018). Clearly, IMTG synthesis rates are 
important, but the differences between endurance trained in comparison to insulin 
resistant individuals is likely due to the favourable partitioning of incoming FA away 
from ceramides and glucosylceramide and towards IMTG.  
1.6.2.3 LD size and location 
Although IMTG content has no mechanistic link towards insulin resistance recent 
advances in microscopy techniques have added to our current understanding of how 
the location and size of LD storing IMTG may impact skeletal muscle insulin 
sensitivity. Transmission electron microscopy (TEM) can be used to accurately 
decipher between the intermyofibrillar (nearer to contractile elements) and 
subsarcolemmal region (near vicinity of plasma membrane) in skeletal muscle cells. 
Using TEM, Nielsen and colleagues (2017) found the diameter but not the number of 
individual subsarcolemmal LD was negatively associated with insulin sensitivity, as 
measured by HE clamp in healthy young untrained males. Despite having similar 
IMTG content, older individuals that have reduced insulin sensitivity have larger LD 
and a higher IMTG content in the subsarcolemmal region in comparison to BMI 
matched younger individuals (Crane et al., 2010). Using confocal 
immunofluorescence microscopy it was demonstrated that T2D individuals primarily 
store larger LD in the subsarcolemmal region of type II fibres whereas endurance 
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trained individuals stored smaller LD in the intermyofibrillar region of type I fibres 
(Daemen et al., 2018). Increase in LD size rather than total LD content following 8 
weeks of a high-fat high-calorie diet in sedentary males is related to reduced insulin 
sensitivity (Covington et al., 2017) whilst a decrease in LD size following weight loss 
or exercise training was associated with improved insulin sensitivity (He et al., 2004).  
TEM and confocal immunofluorescence microscopy have confirmed that LDs are 
located in close proximity to mitochondria in skeletal muscle (Hoppeler et al., 1999; 
Shaw et al., 2008). Younger more insulin sensitive individuals have a greater fraction 
of LD in contact to mitochondria (Crane et al., 2010). The preferential location of LD 
to the mitochondria would assist in trafficking IMTG-derived FA from the LD to the 
mitochondria for subsequent β-oxidation. The evidence thus far suggests that LD that 
are smaller, located in the intermyofibrillar region and in contact to mitochondria are 
more metabolically advantageous and are associated with the healthy insulin-
sensitive phenotype. Larger LD observed in insulin-resistant states, that have a lower 
surface area to volume ratio, are proposed to result in lower IMTG turnover and 
subsequent accumulation of lipid metabolites. The accumulation of these lipid 
metabolites in subsarcolemmal region near to insulin signalling cascades are 
proposed to contribute to skeletal muscle insulin resistance. 
1.6.2.3 Impairments in IMTG lipolysis and substrate use 
A key discrepancy between endurance trained athletes and sedentary, obese 
individuals or individuals with T2D is their capability to utilise IMTG as a fuel source 
during exercise. Longitudinal exercise training interventions (Phillips et al., 1996; 
Schrauwen et al., 2002; De Bock et al., 2008; Van Proeyen et al., 2011b) and cross-
sectional comparisons between trained and untrained individuals (Klein et al., 1994; 
Coggan et al., 2000) have demonstrated that endurance training leads to an 
increased use of IMTG as a substrate during exercise. In contrast sedentary, obese 
individuals or individuals with T2D display little or no IMTG use during exercise 
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(Schrauwen et al., 2002; van Loon, 2004). This may be a consequence of elevated 
plasma FA observed in obese/ type 2 diabetic individuals taking precedence over 
IMTG as substrate to minimise circulatory FA (van Loon et al., 2005b). Indeed, when 
adipose tissue lipolysis and FA release is inhibited with administration of Acipimox, 
IMTG utilisation during exercise increases in both lean and T2D individuals  (van Loon 
et al., 2005a).  
The reduced capacity to utilise IMTG stores may also be the result of impaired IMTG 
lipolysis and the location of IMTG substrates within the muscle. In obese individuals 
there is impaired β2-adrenergic-mediated stimulation of muscle lipolysis compared to 
lean participants (Blaak et al., 2004). In vitro assays in conjunction with ATGL or HSL 
knockout mice models have suggested that ATGL and HSL have a higher specificity 
for TAG and DAG, respectively (Fredrikson et al., 1981a; Haemmerle et al., 2002b; 
Haemmerle et al., 2006). An undesirable DAG to TAG hydrolysis activity stemming 
from an imbalance between HSL and ATGL protein content and activity may lead to 
accumulation of DAG. Males diagnosed with T2D have lower skeletal muscle HSL 
protein content in comparison to normal glucose tolerant controls, and HSL activity in 
people with T2D shows signs of dysregulation at rest and following insulin stimulation 
(Jocken et al., 2013). ATGL protein content increases following endurance training 
(Alsted et al., 2009) whereas HSL protein remains unchanged following endurance 
training in rats (Enevoldsen et al., 2001) and is not different between untrained and 
trained skeletal muscle (Helge et al., 2006). Rats with low intrinsic exercise capacity 
have a decreased ability to activate HSL by epinephrine stimulated phosphorylation 
of Ser660 (Lessard et al., 2009). Contrasting data has shown that there is no 
difference in HSL activity and IMTG net hydrolysis before and after 180 min of 
exercise at 60% VO2 max between trained and untrained participants (Helge et al., 
2006). Although the imbalance between ATGL and HSL hydrolysis gives an appealing 
explanation for the accumulation of DAG and subsequent skeletal muscle insulin 
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resistance, there is controversy whether ATGL-derived DAG can contribute to insulin 
resistance. For example, ATGL cannot produce signalling sn-1, 2-DAG capable of 
activating PKC and disrupting the insulin signalling cascade (Eichmann et al., 2012). 
The ability to oxidise FA in skeletal muscle can also limit the use of IMTG as a 
substrate. It has been reported that skeletal muscle from obese and T2D individuals 
have lower fatty acid oxidation in post-absorptive conditions (Kim et al., 2000b; Blaak 
& Wagenmakers, 2002). Decreases in fatty acid oxidation may be explained by 
reduced mitochondrial content and increased mitochondrial dysfunction observed in 
muscle from obese and type 2 diabetic populations. Muscle from obese and type 2 
diabetic individuals have smaller, less dense mitochondria in the intermyofibrillar and 
subsarcolemmal region (Kelley et al., 2002) and lower electron transport chain (ETC) 
activity (Ritov et al., 2005). Greater spatial contact between LD and mitochondria is 
proposed to be physiologically advantageous by reducing the distance IMTG-derived 
FA have to travel to undergo β-oxidation. Confocal immunofluorescence microscopy 
have confirmed that in lean physically active individuals LD stores are mainly located 
in spaces between mitochondria (Shaw et al., 2008). When comparing lean and 
obese insulin-resistant females however there are no differences in the amount of 
contact between LD and mitochondria (Devries et al., 2013). Endurance training 
which is associated with improvements in insulin sensitivity has been shown to 
improve mitochondrial function and contact to LD. For example, Sixteen weeks of 
combined weight loss and endurance training in obese individuals resulted in an 
increase in ETC activity in the intermyofibrillar and subsarcolemmal regions, with 
increases in subsarcolemmal ETC correlated to improvements in insulin sensitivity 
even when adjusted for changes in aerobic capacity (Menshikova et al., 2005). 
Importantly following 7-weeks of endurance training in previously sedentary 
individuals there is an increase in IMTG and mitochondria content concurrent to an 
increase in the number of LD in contact with mitochondria (Tarnopolsky et al., 2007). 
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Similarly 12-weeks of endurance training increases mitochondrial oxidative and -
oxidation capacity with an increase contact between LD and mitochondrial in both 
obese and lean females (Devries et al., 2013). Mitochondrial oxidative capacity and 
location to LD are important factors in enabling IMTG to be substrate and therefore 
preventing the accumulation of lipid metabolites known to contribute to skeletal 
muscle insulin resistance. 
1.6.2.4 Difference in proteins regulating IMTG turnover 
As discussed more thoroughly in section 1.5, PLINs are likely to play a regulatory role 
in IMTG turnover and therefore maintaining skeletal muscle insulin sensitivity. PLIN2-
5 protein expression is higher in endurance trained compared to sedentary individuals 
(Shepherd et al., 2017b). Furthermore PLIN2, PLIN3 and PLIN5 protein expression 
have all been shown to be upregulated following endurance training (Peters et al., 
2012; Shaw et al., 2012; Shepherd et al., 2013; Shepherd et al., 2017a; Daemen et 
al., 2018) which is typically associated with improvements in insulin sensitivity.  
Previous studies have reported PLIN2 protein expression is correlated positively with 
insulin sensitivity (Phillips et al., 2005; Coen et al., 2010). Additionally, overexpression 
of PLIN2 in rat skeletal muscle increases IMTG content and improves insulin 
sensitivity (Bosma et al., 2012a). Recently however PLIN2 was elevated more in 
obese and T2D in comparison to endurance-trained individuals resulting in a negative 
correlation with insulin sensitivity (Daemen et al., 2018). The reason for this 
discrepancy is unknown and clearly shows that the influence of PLIN2 on regulating 
IMTG turnover and maintaining insulin sensitivity requires further investigation. 
Overexpression of PLIN5 in rat skeletal muscle also increases also IMTG content 
without compromising insulin sensitivity (Bosma et al., 2013). PLIN5 overexpression 
in human primary myotubes also been shown to protect against lipid-induced 
lipotoxicity (Laurens et al., 2016). Deletion of PLIN5 in mice decreases TAG stores, 
increases lipid metabolites and leads to the development of skeletal muscle insulin 
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resistance (Mason et al., 2014b). The accumulating evidence therefore suggests 
PLIN5 is important in regulating IMTG turnover and maintaining skeletal muscle 
insulin sensitivity. Gemmink et al., (2018)  explored therefore whether the fraction of 
PLIN5+ LD was a determinant of skeletal muscle insulin sensitivity when IMTG 
content was matched in; endurance trained athletes, untrained controls, obese and 
T2D individuals. It was discovered that whilst PLIN5 protein expression was almost 
double in endurance trained athletes compared to T2D, PLIN5 protein content or 
PLIN5+ LD did not correlate with insulin sensitivity (Gemmink et al., 2018). PLIN5 
protein expression and PLIN5+ LD was correlated with VO2 max indicating its 
importance in oxidative capacity. PLIN proteins have been widely implicated in 
regulation of IMTG stores and lipolysis (section 1.5), however how this directly 
impacts skeletal muscle insulin sensitivity is still unknown.   
The SNARE protein SNAP23 may also assist in regulating IMTG turnover. Ablation 
of SNAP23 in fibroblasts reduces the formation of LD-mitochondria complexes and 
results in a decreased mitochondrial -oxidation (Jagerstrom et al., 2009). This has 
led to the suggestion that SNAP23 also aids the formation of LD-mitochondria 
complexes and assists in the shuttling of IMTG-derived FA to the mitochondria. This 
is important because incomplete oxidation of IMTG-derived FA can also be a source 
of lipid metabolites disruptive to the insulin signalling cascade (Koves et al., 2008). 
To date however, no research has been conducted to investigate differences in 
SNAP23 content and localisation in endurance trained insulin sensitive individuals 
compared to insulin resistant individuals who show impaired IMTG turnover. 
Together the evidence presented suggests reduced oxidative capacity mirrored with 
impaired IMTG turnover can generate lipid metabolites; ceramides and DAG which 
can impair the insulin signalling cascade (Moro et al., 2008).  
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1.6.3 Skeletal muscle insulin resistance 
1.6.3.1 The Randle cycle 
Accumulation of certain lipid metabolites in skeletal muscle is critical in the aetiology 
of insulin resistance. Initially Randle and colleagues (1963) proposed that increased 
FA availability within cardiac and diaphragm muscle would result in increased acetyl-
CoA and citrate. Acetyl-CoA was thought to inhibit PDH by activating PDH kinase 
which phosphorylates PDH to its less active form. In vitro work established that citrate 
was an inhibitor of PFK. Together it was proposed that these lead to an accumulation 
of G6P which inhibits hexokinase activity thus resulting in a rise in intracellular 
glucose concentrations causing a negative feedback for glucose uptake from the 
blood. In 1996, Roden and colleagues (1996) combined lipid infusion with HE clamp 
in healthy individuals to show that muscle G6P levels were actually reduced. 
Furthermore a HE clamp with glycerol infusion protocol resulted in a four-fold increase 
in PI3-K activity from basal levels whereas this increase was completely abolished 
during a HE clamp with lipid infusion protocol suggesting elevations in intracellular FA 
negatively impacts insulin signalling (Dresner et al., 1999). The evidence therefore 
suggests that accumulating lipid metabolites can impair glucose uptake but this is 












































Figure 1.3. Lipid induced skeletal muscle insulin resistance. aPKC, atypical protein kinase C; AS160, Akt substrate of 160 kD; DAG, 
diacylglycerol; FA, fatty acid; fatty acyl-CoA; GLUT4, glucose transporter-4; IMTG, intramuscular triglyceride; IR, insulin receptor; IRS-1, insulin 
receptor substrate-1; nPKC, novel protein kinase C, PDK, phosphoinositide-dependent kinase 1; PI3-K phosphoinositide 3-kinase; Rab-GDP, Rab 
guanosine disphosphate; Rab-GTP, Rab guanosine triphosphate. 
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1.6.3.2 Lipid metabolites 
Accumulations in fatty acyl-CoA, ceramides and certain DAG species have all been 
linked to skeletal muscle insulin resistance (Yu et al., 2002a; Gual et al., 2005; 
Samuel et al., 2010). Primarily lipid metabolites can impair skeletal muscle insulin 
signalling through increased serine phosphorylation of IRS-1 or through reduced 
serine phosphorylation of Akt (Summers & Nelson, 2005; Morino et al., 2006) (Figure 
1.3). Amati et al. (2011) highlighted the complexity of DAG’s role in contributing to 
skeletal muscle insulin resistance when they demonstrated elevated DAG content 
was observed in endurance trained insulin sensitive athletes compared to sedentary 
insulin resistant controls. It has been proposed that subcellular location, saturation 
and FA positioning on the glycerol backbone are all influential factors in DAGs 
contribution to insulin resistance, however controversy still exists in this area. Athletes 
with higher insulin sensitivity had lower saturated DAG levels in muscle compared to 
sedentary subjects (Bergman et al., 2010). In addition to lower saturated DAG an 
endurance trained athletic group also displayed lower membrane fraction of DAG 
compared to obese and type 2 diabetic individuals  (Bergman et al., 2012). A more 
thorough examination of DAG species revealed however that DAG containing two 
unsaturated FA was higher in obese muscle compared to lean athletic and sedentary 
controls (Amati et al., 2011). Historical work has also suggested that the sn-1, 2 
stereoisomer is the only DAG stereoisomer capable of being an active signalling 
molecule (Rando & Young, 1984) thus suggesting that positioning of FA on the 
glycerol backbone is important for activating PKC. It is clear future research is needed 
to identify which DAG specific species are directly linked to skeletal muscle insulin 
resistance and at what quantities they have a lipotoxic effect.  
It appears that when DAG does contribute to skeletal muscle insulin resistance it is 
via the activation of novel protein kinase c (nPKCs) isoforms (δ, ε, η, and θ). The 
nPKCs have two tandem C1 domains that have a high affinity for DAG-containing 
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membranes and unlike other PKCs are able to be activated by DAG alone (Dries et 
al., 2007). The translocation of a PKC to the plasma membrane is a mark of its 
activation. Elevated DAG concentrations following high-fat feeding or lipid infusion is 
associated with increased PKC translocation to the plasma membrane and reduced 
glucose disposal rate (Schmitz-Peiffer et al., 1997; Itani et al., 2002). Increased PKC-
θ is observed in the muscle plasma membrane fraction of obese individuals (Itani et 
al., 2000) and type 2 diabetic patients (Itani et al., 2001). PKC-θ-KO mice are 
protected from lipid infusion induced insulin resistance (Kim et al., 2004). PKC-ε 
activation is positively associated with membrane DAG and insulin resistance 
(Bergman et al., 2012). The translocation of novel PKC isoforms to the plasma 
membrane is likely to be a detrimental factor by increasing its proximity to 
intermediates of the insulin signalling cascade. Here, it is proposed that PKC targets 
IRS-1 directly or indirectly through upstream activation of stress kinases IκBα kinaseβ 
(IKKβ) and c-Jun NN-terminus kinase (JNK). In addition to tyrosine phosphorylation 
sites, multiple serine/threonine phosphorylation sites have been identified on IRS-1 
(White & Kahn, 1994a). It is now well established that nPKCs or the aforementioned 
stress kinases are capable of phosphorylating IRS-1 on serine residues 307, 636/639 
and 1101 (Gual et al., 2005; Boura-Halfon & Zick, 2009). Recently it was shown that 
increased DAG species (C16:0, C18:0, C18:1, C18:2, and C20:4) following lipid 
infusion was temporally associated with PKC-θ activation, increased Ser1101 and 
impairments in PI3-K activation and Akt phosphorylation in healthy, obese and type 
2 diabetic individuals which occurred without increases in ceramide (Szendroedi et 
al., 2014). Increased serine phosphorylation of IRS-1 via PKC-θ activation is 
associated with reduced tyrosine phosphorylation (Yu et al., 2002a). Reduced insulin 
stimulated tyrosine phosphorylation will result in decreased subsequent activation of 
PI3-K and Akt/PKB therefore reducing activation and translocation of GLUT-4 and 
glucose uptake (Figure 1.3). 
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Ceramides are composed of a sphingosine base and a fatty acid moiety. It is evident 
that ceramides are elevated in obese insulin resistant individuals compared to lean 
insulin sensitive controls (Adams et al., 2004) and this appears apparent across 
saturated and unsaturated ceramide species in addition to ceramides of varying FA 
chain length (Amati et al., 2011). When a HE clamp was performed with 
intralipid/heparin infusion in normal glucose tolerant males, ceramide content 
increased and was negatively associated with decreases in insulin sensitivity 
(Straczkowski et al., 2004). There are two proposed mechanisms by which ceramides 
can disrupt the insulin signalling pathway which are both centred around the inhibition 
of Akt. Ceramides have been shown to activate atypical PKCζ which can 
phosphorylate Akt on a Thr34 located on the enzyme’s PH domain lowering affinity 
to PIP3 (Powell et al., 2003). Ceramides can also activate protein phosphatase 2A 
(PP2A) which is a serine/threonine phosphatase capable of dephosphorylating Akt 
on its active Ser473 and Thr308 residues thus blocking recruitment of Akt to the 
plasma membrane by PIP3 (Stratford et al., 2004). Both of these mechanisms have 
been expertly reviewed in more detail (Lipina & Hundal, 2011; Chavez & Summers, 
2012). Ultimately, both mechanisms can reduce necessary recruitment of Akt to the 
plasma membrane by PIP3, which is required for downstream activation of AS160 and 
GLUT4 activation and translocation to the plasma membrane (Fig 1.3). 
Prior to storage or oxidation FA entering the muscle requires activation to fatty acyl-
CoA. Elevations in fatty acyl-CoA skeletal muscle content have also been have also 
been inversely correlated to whole body insulin action (Ellis et al., 2000). High-fat 
high-calorie diets induce insulin resistance with rats and is positively correlated with 
fatty acyl-CoA (Oakes et al., 1997a; Oakes et al., 1997b; Ellis et al., 2000). Elevations 
in fatty acyl-CoA are associated with increased PKC activity and reduced insulin 
sensitivity (Yu et al., 2002a) however this is likely a result of increased ceramide and 
DAG formation from increased fatty acyl-CoA substrate availability. To date, there 
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has been no evidence to show that fatty acyl-CoA directly activate PKCs known to 
disrupt insulin signalling.  Fatty acyl-CoA also has a regulatory role in inhibiting 
enzymes necessary to maintaining normal glucose and lipid homeostasis. There is 
evidence to suggest that fatty acyl-CoA can inhibit hexokinase in rat and human 
skeletal muscle which was additive to its inhibition by glucose-6-phosphate 
(discussed earlier in the Randle cycle, section 1.6.1.3) (Thompson & Cooney, 2000) 
thus reducing glycolytic flux into the muscle. Fatty acyl-CoA can also downregulate 
hormone sensitive lipase (Jepson & Yeaman, 1992) and reduce IMTG utilisation 
(Watt et al., 2003a). Without this regular turnover of IMTG stores, it is likely that less 
FA will be directed to IMTG stores resulting in even higher concentration of fatty acyl-
CoA. This elevation is likely to disrupt the insulin signalling pathway indirectly by 
providing more substrate for DAG and ceramide formation.  
Lipid induced skeletal muscle insulin resistance may also occur via lipid peroxidation 
and lipid-induced inflammation. When the IMTG turnover is reduced as observed in 
sedentary populations, the IMTG pool is prone to more oxidative stress which can 
generate lipid peroxidation products with the potential to inhibit insulin signalling 
(Russell et al., 2003; Russell, 2004). In particular, formation of TNFα can increase 
suppression of suppressor of cytokine signalling proteins (SOCS) which can increase 
tyrosine phosphorylation of IRS-1. Additionally disruptions in lipid homeostasis can 
activate inflammation and ER stress pathways which can disrupt IRS-1 and Akt 
activation (reviewed in Ye et al., 2007). 
1.6.3.3 SNAP23 role in lipid induced insulin resistance 
SNAP23 is a t-SNARE found in non-neural tissues that shares a similar homology 
and function to neural exclusive tissue SNAP25 (Ravichandran et al., 1996). SNAP23 
binds to multiple syntaxins and VAMPs to assist in membrane fusion (exocytosis).  
Most notably found at the plasma membrane (Jahn & Scheller, 2006) the primary 
function of SNAP23 was to mediate the docking of GLUT-4 to the plasma membrane 
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during insulin stimulated conditions (Foster et al., 1999; Kawanishi et al., 2000) 
(section 1.2.4). There is accumulating evidence that SNAP23 also aids in the 
formation of LD-mitochondrial complexes (section 1.6.2.4) and assists in LD fusion 
Knockdown of the SNAP23 gene in NIH-3T3 fibroblast cells decreased the rate of 
fusion and size of LD (Bostrom et al., 2007). Treatment of cardiomyocytes with oleic 
acid increased intracellular LD volume resulting in an increase in LD associated pool 
of SNAP23 and a simultaneous reduction in plasma membrane SNAP23 pool 
(Bostrom et al., 2007). This resulted in a decrease in insulin-stimulated uptake of 
glucose through reduced SNAP23 mediated GLUT-4 vesicle exocytosis.  
Transfection of SNAP23 in cardiomyocytes incubated in oleic acid restored insulin-
stimulated glucose uptake  (Bostrom et al., 2007), most likely from restoration of 
SNAP23 content at the plasma membrane. The findings from this paper lead to the 
SNAP23 highjacking hypothesis (Sollner, 2007). In response to lipid excess SNAP23 
is sequestered away from the plasma membrane to cytosolic compartments to assist 
with the demand for fusion of LD. Whilst this will assist in minimising the accumulation 
of lipid metabolites, a reduction of SNAP23 at the plasma membrane may reduce the 
fusion and docking of GLUT-4 storage vesicles which can lead to a decreased insulin-
stimulated glucose uptake (Figure 1.4). 
Ablation of SNAP23 in fibroblasts reduces the formation of LD-mitochondria 
complexes (Jagerstrom et al., 2009). SNAP23s putative role in the formation of LD-
mitochondria complexes may serve as an additional means to minimise skeletal 
muscle lipid metabolites however this may again occur at the expense of reduced 
plasma membrane SNAP23 pool. Our current knowledge of SNAP23 is largely 
restricted to adipocytes or in vitro systems. More recently, our lab has established a 
validated confocal immunofluorescence microscopy technique to confirm that 
SNAP23 has a high colocalisation to the plasma membrane and mitochondria and a 
weaker colocalisation to LD in lean healthy trained males (Strauss et al., 2016). There 
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is a now a need to investigate whether LD acutely hijack SNAP23 in human skeletal 
























Insulin sensitive muscle Lipid excess 
Figure 1.4. LD hijacking SNAP23 hypothesis. In insulin sensitive muscle, GLUT-4 translocates to the plasma membrane following 
insulin stimulation. SNAP23 assists in the docking of GLUT-4 to the plasma membrane allowing glucose uptake into muscle. During 
lipid excess, lipid droplets hijack SNAP23 to assist in LD fusion reducing the amount of SNAP23 at the plasma membrane and 
therefore minimising GLUT-4 docking and glucose uptake. Image adapted from Sollner (2007).  
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1.7 Investigating lipid-induced skeletal muscle insulin resistance  
1.7.1 Lipid infusion  
Due to the low solubility of NEFA, lipid (TAG) with heparin infusion protocols have 
been established to elucidate the mechanisms underpinning the relationship between 
short-term increases in FA availability and insulin resistance. Heparin is important 
because it releases LPL from its endothelial binding sites and increases the activity 
of LPL thus stimulating plasma TAG hydrolysis and an elevation of FA concentrations. 
Lipid infusion studies are effective in reducing peripheral glucose uptake (Boden et 
al., 1994; Shah et al., 2002) and increasing hepatic gluconeogenesis (Roden et al., 
2000). Importantly as discussed in section 1.6.3.2, lipid infusion studies have been 
paramount in elucidating the mechanisms by which increased FA availability results 
in increased lipid signalling metabolites known to activate PKC isoforms that disrupt 
insulin signalling (Itani et al., 2002; Yu et al., 2002a; Szendroedi et al., 2014).  
IMTG content also increases with lipid infusion and is associated with insulin 
resistance (Bachmann et al., 2001). It is now established that IMTG per se is not 
causative of insulin resistance and therefore lipid infusion-induced insulin resistance 
is more likely due to an increase in lipid metabolites with benign simultaneous 
increase in IMTG. Recently Chow et al. (2014) demonstrated that both trained and 
untrained individuals have similar reductions in insulin sensitivity following 6 h of lipid 
infusion during a HE clamp. Interestingly, trained individuals showed a preferential 
accumulation of IMTG whereas the untrained controls accumulated both IMTG and 
DAG (Chow et al., 2014).  Immunohistochemistry analysis on the same muscle 
samples from this study revealed that trained individuals increased the number of LD 
associated with PLIN2, PLIN3 and PLIN5 whereas untrained individuals only 
increased LD not associated with any PLIN protein (Shepherd et al., 2017b). As both 
populations experienced similar reductions in insulin sensitivity yet clearly divergent 
lipid storage pathways, it is important to employ more chronic lipid excess models to 
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reveal how manifestations of lipid accumulation contribute to skeletal muscle insulin 
resistance.  
1.7.2 High-fat diets 
The high palatability and energy density of high-fat foods observed in western 
countries has prompted a rise in studies using high-fat and often high-calorie diets as 
a method to induce whole-body insulin resistance and mimic the metabolic effects 
observed in obesity and T2D. The following section will review the effects of high-fat 
diets on parameters of insulin sensitivity and lipid metabolism.  
1.7.2.1 Insulin sensitivity 
In healthy lean individuals short-term high-fat high-calorie (HFHC) diets of only 5-14 
days are able to reduce hepatic insulin sensitivity (Brons et al., 2009) or peripheral 
insulin sensitivity (Bakker et al., 2014) measured with HE clamp, or whole-body insulin 
sensitivity measured with an oral glucose or mixed meal tolerance test  (Hulston et 
al., 2015; Parry et al., 2017). Peripheral insulin sensitivity measured from HE clamp 
becomes more impaired in low birth weight individuals who have a higher pre-
disposed risk of T2D compared to normal birth weight controls following a five day 
HFHC diet (Brons et al., 2012). There were similar reductions however in insulin 
sensitivity measured with oral glucose sensitivity index in Caucasian and south-Asian 
populations following a four day HFHC diet (Wulan et al., 2014). Following 5 days of 
high-fat (40%) high calorie (40%+ energy) diet there were no decrements in insulin 
sensitivity measured with HE clamp in healthy lean individuals however muscle 
biopsies revealed impairments in skeletal muscle insulin signalling (Adochio et al., 
2009). Namely there was an increased serine phosphorylation of IRS-1 and increased 
content of P85α which expression is inversely correlated with PI3-K activity (Adochio 
et al., 2009). Interestingly when the same participants were fed a high-carbohydrate 
high-calorie diet, insulin signalling intermediates IRS-1 and PI3-K were upregulated 
(Adochio et al., 2009). 
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Together the data suggests that high-fat high-calorie diets can impair aspects of 
insulin sensitivity however, this is not homogenous amongst all participant cohorts. 
Despite the known sex differences in insulin sensitivity and prevalence of T2D 
(section 1.1.2) no studies have investigated whether males are more susceptible to 
high-fat high-calorie diet induced insulin resistance and metabolic complications in 
comparison to females.  
1.7.2.2 IMTG content 
Very short-term (48 hr) high-fat (60%) diet increases IMTG content by 36% in 
endurance-trained cyclists when measured by biochemical extraction (Zderic et al., 
2004). Similar increases (45%) were observed following 60 h of isocaloric high 
saturated fat diet (45% energy of fat, 60% saturated fat) measured in healthy male 
participants by 1HMRS (Stettler et al., 2005). When high-fat (60%) feeding was 
administered for 7 days there was an increase in IMTG content by 54% measured by 
1HMRS in young healthy males (Schrauwen-Hinderling et al., 2005). When high-fat 
(53%- 62% energy) feeding is extended to longer period of 5-7 weeks IMTG content 
increases are more elevated (Helge et al., 2001; Vogt et al., 2003). Both of these 
longer duration high-fat diets were done in conjunction with regular endurance 
exercise training and therefore indicative of regular IMTG turnover which may have 
affected the results. Bachmann et al., (2001) aimed to decipher changes in IMTG 
content in different muscle types (soleus and tibilias anterior) using 1HMRS following 
a 3 day high-fat (55-60% energy) high-calorie (~80%) diet. The more oxidative soleus 
muscle displayed a greater increase in IMTG content (50%) in comparison to the 
tibilias anterior (14%) (Bachmann et al., 2001) indicating increase in IMTG stores may 
be dependent on fibre type. Most of the studies investigating the effects of high-fat 
diets on IMTG content have been isocaloric. Recently Gemmink et al., (2017a) 
showed IMTG content measured by biochemical extraction increased by 30% 
following 5 days high-fat high-calorie diet (normal diet plus 1275 kcal/day of 94% fat 
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surplus) in Caucasian and south Asian populations. Notable this study was the first 
to measure markers of lipid metabolism (ATGL, CGI-58, PLIN2, PLIN3 and PLIN5) 
following the high-fat high-calorie diet and showed that PLIN5 increased with a more 
profound increase in the south Asian group that is more prone to decrements in insulin 
sensitivity (Gemmink et al., 2017a).  Considering type I fibres are capable of storing 
2-4 fold greater IMTG than type II fibres (van Loon et al., 2003a; Shepherd et al., 
2013), there is a need to decipher fibre-type specific changes in IMTG and perilipin 
stores following high-fat high-calorie diets. 
1.8 Thesis overview 
Chapter 1 has established normal regulation of insulin-dependent glucose uptake 
and IMTG metabolism in healthy insulin-sensitive individuals. It identified that 
impairments in IMTG metabolism and lipid excess following dietary interventions can 
lead to accumulations in lipid metabolites known to disrupt the insulin-signalling 
cascade. The introductory chapter also identified several gaps in our knowledge 
regarding the regulation of IMTG metabolism and the effects of high-fat high-calorie 
diets on measurements of metabolic health. Consequently, studies in this thesis were 
designed to further our knowledge and understanding in these areas. 
Section 1.7.2.1 highlighted that short-term a high-fat high-calorie diets can impair 
components of insulin sensitivity in healthy individuals, however to date no studies 
have compared sex-differences. In Chapter 2 a pilot study was conducted to 
investigate sex-differences in metabolic and cardiovascular responses to a 7 day 
HFHC diet in young healthy males and females matched for age, BMI, cardio-
respiratory fitness and habitual activity levels.  
Chapter 3 was designed to gain further insight to the molecular consequences of 7 
days of high-fat, high-calorie diets. The athlete’s paradox (section 1.6.3) established 
that IMTG does not directly contribute to skeletal muscle insulin resistance and 
directing FA to IMTG stores might minimise the accumulation of lipid metabolites 
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known to contribute to skeletal muscle insulin resistance. Chapter 3 aimed to test the 
hypothesis that increases in IMTG stores following 7-days of high-fat, high-calorie in 
lean healthy individuals would minimise disruptions in skeletal muscle insulin 
signalling. Section (1.5) highlighted that PLINs promote TAG storage in cell culture 
models following lipid excess however how PLINs regulate IMTG synthesis in skeletal 
muscle is still understudied. Chapter 3 used novel confocal immunofluorescence 
microscopy techniques to investigate; fibre-type and region-specific changes on 
IMTG content (LD number and morphology), PLIN protein expression and the 
colocalisation of these PLIN to LD following a 7- day HFHC diet . Section 1.6.3.3 
explained the hypothesis that SNAP23 may be hijacked by LD from the plasma 
membrane following lipid excess. Chapter 3 also investigated whether there are fibre-
type specific changes in SNAP23 distribution within muscle fibres following a 7- day 
HFHC diet. 
Section 1.3.2.2 explained that HSL translocates to LD in isolated rat skeletal muscle 
and LD associated with PLIN2 and PLIN5 are utilised during an hour of moderate 
intensity exercise in human skeletal muscle. On the other hand, ATGL distribution 
appears to be unchanged following exercise. Chapter 4 used novel confocal 
immunofluorescence microscopy techniques to test the hypothesis that HSL 
redistributes in human skeletal muscle in response to moderate-intensity exercise 
and investigated the preferential colocalisation of HSL and ATGL to LD associated 
with either PLIN2 or PLIN5.  
Chapter 3 and 4 established novel mechanisms by which PLINs regulate IMTG 
metabolism. Section 1.4.2 highlighted that over 300 proteins are associated to LD in 
mouse skeletal muscle however how these proteins interact together on the LD 
surface still needs much further investigation. Chapter 5 aimed to develop a new 
immunoprecipitation- mass spectrometry method to identify proteins associated to 
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PLIN5 in human skeletal muscle that would generate new hypotheses to investigate 




Chapter 2. A pilot study investigating sex 
differences in the effects of a 7-day high-fat high-
calorie diet on metabolic and cardiovascular 




High-fat high-calorie diets (HFHC) diets have been used as a model to investigate 
lipid-induced insulin resistance.  Acute HFHC diets reduce insulin sensitivity in young 
healthy males, but to date no study has directly compared males and females to 
elucidate sex-specific differences in the effects of a HFHC diet on measurements of 
cardio-metabolic health. Eleven males (24 ± 4 years; BMI 23 ± 2 kg.m-2; V̇O2 peak 
62.3 ± 8.7 ml.min-1.kg-1FFM) were matched to 10 females (25 ± 4 years; BMI 25 ± 4 
kg.m-2; V̇O2 peak 58.2 ± 8.2 ml.min-1.kg-1FFM). Insulin sensitivity from an oral glucose 
tolerance test, metabolic flexibility, arterial stiffness, body composition and blood lipid 
and liver enzymes were measured before and after 7 days of a high-fat (65%) high-
calorie (+50%) diet. The HFHC diet did not have an effect on measures of insulin 
sensitivity, metabolic flexibility or arterial stiffness in either sex. There was a trend 
towards increased total body fat (kg) after the HFHC diet (P = 0.056) (+1.8% and 
+2.3% for males and females respectively; P = 0.056). In contrast to females, males 
had a significant increase in trunk to leg fat mass ratio (+5.1%; P = 0.005). Lean, 
healthy young males and females appear to be protected from the negative cardio-
metabolic effects of a 7 day HFHC diet. Future research should aim to determine 
whether low levels of cardiorespiratory fitness or ageing exacerbates the detrimental 
effects of a 7 day HFHC diet observed in other studies but not in this current study.    
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2.2. Introduction 
A western lifestyle is characterised by regular consumption of readily available 
energy-dense foods (Kearney, 2010), often paired with sedentary behaviour 
throughout the day (Townsend et al., 2012) and minimal exercise (British Heart 
Foundation, 2017). These western behavioural patterns are associated with 
increased risk of obesity, type 2 diabetes (T2D) and cardiovascular disease 
(Tuomilehto et al., 2001; Katzmarzyk, 2010; Naja et al., 2015). At present, 
cardiovascular disease is established as the leading cause of mortality in western 
countries (Groban et al., 2016) and T2D vastly increases the risk of cardiovascular 
complications (Laakso, 2010). 
T2D is characterised by hyperglycaemia which often manifests as a result of insulin 
resistance. Insulin resistance can be defined as impaired insulin-stimulated glucose 
uptake in skeletal muscle and adipose tissue stores and/or impaired insulin-induced 
suppression of hepatic glucose production. Skeletal muscle is the largest disposal 
site of blood glucose following insulin stimulation (DeFronzo et al., 1981), and 
therefore skeletal muscle insulin resistance is a primary aberration in the progression 
of T2D (DeFronzo, 2004). Metabolic flexibility is closely linked with skeletal muscle 
insulin sensitivity (Galgani et al., 2008a), and is defined as the capacity to switch from 
high rates of lipid oxidation in the fasted state to an increased rate of carbohydrate 
oxidation under insulin-stimulated conditions (Kelley & Mandarino, 2000). Metabolic 
flexibility is therefore diminished in obese insulin-resistant individuals in comparison 
to the lean insulin-sensitive state (Kelley et al., 1999).  
Hepatic insulin resistance is also crucially important in the development of T2D (Perry 
et al., 2014) and is closely associated with non-alcoholic fatty liver disease (NAFLD) 
(Sanyal et al., 2015; Brouwers et al., 2017). Both of these metabolic impairments are 
associated with ectopic lipid accumulation in the liver, which is proposed to manifest 
from adipose tissue lipolysis (Perry et al., 2014). Visceral fat and in particular 
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mesenteric fat depots are expected to be the primary sources leading to lipid 
accumulation in the liver (Liu et al., 2006a), due to the full drainage of these depots 
reaching the liver via the portal vein (Montague & O'Rahilly, 2000). In addition, the 
release of free fatty acids FA from these abdominal fat depots is higher than from the 
subcutaneous depots (Wajchenberg et al., 2002). Although obesity has been linked 
to T2D and cardiovascular disease (Abdullah et al., 2010), increases in subcutaneous 
fat away from visceral stores initially serve as a protective mechanism to store FFA, 
reducing daily lipid flux and therefore preventing ectopic lipid accumulation (Frayn, 
2002). Abdominal adiposity is characterised by both abdominal subcutaneous fat 
depots and visceral fat and is commonly measured with waist circumference or waist-
to-hip ratios. Although this is not a direct measure of visceral fat and mesenteric fat 
depots, studies have shown a strong association of abdominal obesity with insulin 
resistance and T2D (Racette et al., 2006; Huang et al., 2015). Abdominal adiposity is 
a primary feature of male rather than female fat accumulation, with females generally 
observing any increases in adipose tissue to lower body (femoral and gluteal) 
subcutaneous depots (Janjic, 1996).  
In addition to differential adipose tissue storage, sex differences are also apparent in 
the risk of developing metabolic diseases. For example epidemiological studies have 
shown that the incidence of T2D, NAFLD and cardiovascular disease is lower in 
females compared to males (Montague & O'Rahilly, 2000; Wild et al., 2004; Pan & 
Fallon, 2014; Groban et al., 2016). Large cross-sectional studies have also shown 
that males (35-65 years) have a higher prevalence (+1.3-1.9%) of elevated fasting 
glucose in comparison to females (Kuhl et al., 2005; Munguia-Miranda et al., 2009). 
In another cross-sectional study, males (18-32 years) also showed reduced blood 
glucose clearance capacity (-15%) following an intravenous glucose tolerance test 
compared to females (Clausen et al., 1996). Smaller clinical trials investigating insulin 
sensitivity in BMI and age-matched males and pre-menopausal females (20-45 years) 
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using a hyperinsulinaemic euglycaemic (HE) clamp have established that females 
exhibit a similar or higher glucose infusion rate per kilogram of body weight (+36-
47%) when compared to males  (Yki-Jarvinen, 1984; Nuutila et al., 1995; Donahue et 
al., 1996; Rattarasarn et al., 2004; Borissova et al., 2005), and a markedly higher 
glucose infusion rate when adjusted per kilogram of lean mass (45-98%) (Yki-
Jarvinen, 1984; Donahue et al., 1996). Aerobic capacity and habitual activity levels 
are also positively related to insulin sensitivity (Balkau et al., 2008; Nojima et al., 
2017). However, of the studies comparing insulin sensitivity between sexes only two 
studies matched for VO2 peak levels (Yki-Jarvinen, 1984; Nuutila et al., 1995) and 
none measured habitual activity levels.    
Despite females being at a reduced risk of developing insulin resistance and cardio-
metabolic disease, there is little research investigating the differences in the 
progression of insulin resistance between the sexes. One approach to investigate this 
is to provide excess lipid through an acute lipid infusion during a HE clamp, and it has 
been shown that a 7 h lipid infusion caused less reduction in glucose infusion in 
females (26%) in comparison to males (38%) (Hoeg et al., 2011). Excess lipid 
exposure from infusion studies may only illustrate acute physiological responses, 
whereas more prolonged HFHC diets provide a chronic stimulus to investigate the 
influence of increased energy intake (creating a positive energy balance) on adipose 
tissue stores and early abnormalities in metabolic and cardiovascular regulation. In 
healthy individuals short-term HFHC diets of 5-7 days have been demonstrated to 
reduce HE clamp derived indices of hepatic insulin sensitivity (-65%) (Brons et al., 
2009) and peripheral insulin sensitivity (-20%) (Bakker et al., 2014), or whole-body 
insulin sensitivity (-27%) measured with an oral glucose tolerance test (Hulston et al., 
2015) or glucose tolerance (-11%) measured with a mixed meal (112g carbohydrate 
in a 771 kcal meal) tolerance test (Parry et al., 2017). Although some of these studies 
have included female participants (Cornford et al., 2013; Hulston et al., 2015; Parry 
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et al., 2017), to date no study has directly compared sexes to clarify the sex-specific 
cardiovascular and metabolic responses to a short-term HFHC diet.  This is a 
considerable oversight considering pre-menopausal women with normal levels of the 
female hormones (oestrogen and progesterone) appear to be better protected against 
metabolic diseases compared to males. Establishing whether females are better 
equipped to handle lipid overload from a 7 day HFHC diet will be beneficial in 
underpinning the pathology of T2D in this understudied cohort.  
The aim of this study was to identify the sex-specific differences in metabolic and 
cardiovascular responses to a 7 day HFHC diet in young healthy males and females 
matched for age, BMI, cardio-respiratory fitness and habitual activity levels.  
2.3 Methods 
2.3.1 Subjects and ethical approval  
A cohort of young healthy males (n=11) and females (n=11) were matched for BMI 
(kg.m-2), age and cardiorespiratory fitness (ml.min-1.kg (FFM)-1) (see Table 2.1 for 
characteristics).  The sample size for this experiment was estimated based on 
previous literature that showed a reduction in glucose tolerance or insulin sensitivity 
following 7-days of high-fat (65% energy) high-calorie diet (+50%) (Hulston et al., 
2015; Parry et al., 2017). Written informed consent was obtained from all participants. 
The study protocol adhered to the Declaration of Helsinki and was approved by NHS 
West Midlands, Black Country Research Ethics Committee. All participants were free 
from cardiovascular or metabolic disorders, physically active (exercising at least 3 
times per week for more than 30 minutes at a time) and non-smokers. Additionally, 
females were required to have a regular menstrual cycle, not be pregnant or breast-
feeding during the study and only using the following contraceptive methods; 
condoms, diaphragm, IUD (intrauterine device), combined pill. Due to the nature of 
the dietary intervention, vegetarians and vegans were excluded from participation.  
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Table 2.1 Participants characteristics 
 
Males  Females 
N 11 10 
Age (years) 24 ± 4 25 ± 4 
Body mass (kg)* 72.6 ± 5.3 63.9 ± 9.5 
BMI (kg m-2) 23 ± 2 23.1 ± 2 
V̇O2peak (L.min-1)* 3.60 ± 0.59 2.51 ± 0.48 
V̇O2 peak (ml.min-1.kgFFM-1) 62.3 ± 8.7 58.2 ± 8.2 
Matsuda ISI  11.6 ± 10.5 9.22 ± 3.38 
Data provided as means ± SD. BMI, body mass index; FM, fat mass; FFM, fat free 
mass; ISI, insulin sensitivity index. * Significant difference between sexes P < 0.05. 
2.3.2 Pre-experimental procedures 
Prior to the start of the study participants attended the laboratory following an 
overnight fast (≥10 h) for baseline assessments of body composition, resting energy 
expenditure (REE) and VO2 peak. Body composition was measured using whole-body 
fan beam dual-energy X-ray absorptiometry (DEXA) (Hologic QDR Series, Discovery 
A, Bedford, MA, USA). Following removal of jewellery and metal objects participants 
were scanned (~180 seconds) in a supine position. Each scan was automatically 
analysed with the QDR software; however, the operator manually corrected the trunk 
and limb regions and an area identifying visceral adipose tissue (VAT). Percentage 
body fat (%), total body fat (kg) and lean body mass (kg) are presented as subtotal 
values excluding head measurements in order to reduce measurement error.  
Following the DEXA scan, participants REE was measured using a Moxus Modular 
Metabolic system (AEI Technologies, IL, USA). Participants were required to lay in a 
supine position in dark room for 10 minutes before the Moxus ventilation hood was 
placed over their head and shoulders for a further 20 minutes. Volume flow rate was 
maintained above 25 L.min-1. The first five minutes of data was discarded according 
to best practice methods (Compher et al., 2006). REE was calculated towards the 
end of the 20 minute period, averaged over a 5 minute stable period where coefficient 
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of variation for VO2 and VCO2 was ≤ 10 %.  REE (kcal/min) was calculated using the 
Weir equation where REE (kcal/min) = (3.94 x VO2 (L.min-1))  +(1.11 x VCO2 (L.min-
1)) (Weir, 1949). This number was then used to calculate REE (Kcal/day) over an 
entire day.  
Participants also performed a progressive exercise test to exhaustion on an 
electronically-braked cycle ergometer (Lode Corival, Lode B.V, Groningen, Holland) 
in order to determine VO2 peak using the Moxus Modular Metabolic system (AEI 
Technologies, IL, USA). The test consisted of cycling initially at 60W, followed by 
sequential increments of 35 W every 3 minutes until cadence was reduced to <50 
rpm, at which point the test was terminated. VO2 peak (L.min-1) was taken as the highest 
value obtained in the last 30 seconds of the test. This value was then expressed 
relative to fat free mass (FFM) (kg) obtained from the DEXA scan to give a VO2 peak 
(ml.min-1. kg (FFM)-1) normalised for fat free mass body weight allowing sexes to be 
compared directly.  
Following pre-experimental testing, participants were provided with a 3-axis activity 
monitor (wGT3X-BT, ActiGraph, Pensacola, FL, USA) and a food diary to record 
habitual activity levels and food intake, respectively. Participants were advised to 
continue habitual activity levels whilst wearing the activity monitor on their right waist 
for a duration of 3 days (2 weekdays and 1 weekend day). Participants were provided 
with detailed written and verbal instructions on how to complete the 3-day food diary 
(2 weekdays and 1 weekend day), including information on quantity, food preparation, 
brand information and cooking methods. Habitual diets were later analysed manually 
for total daily intake (kcal) and macronutrient breakdown (Table 2.2) 
2.3.3 Experimental design 
Participants were advised to consume their habitual diet 7 days prior to pre-testing. 
Experimental testing was conducted pre and post 7-days HFHC diet. Pre-testing for 
female participants occurred between days 1-6 of the follicular phase of the menstrual 
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cycle to minimise the impact of fluctuations of sex hormones on the results. 
Participants attended the laboratory following an overnight fast (≥10 h) after 
abstaining from caffeine, alcohol and vigorous exercise the day before testing. The 
following measurements were conducted pre and post-HFHC diet intervention in 
addition to a DEXA scan, as previously described.  
2.3.3.1 Arterial stiffness 
Participants rested in a supine position for 15 minutes before 3 brachial artery blood 
pressure measurements were conducted using an automated sphygmomanometer 
(GE CARESCAPE V100-1 Patient monitor, GE Healthcare, Chicago, USA). Arterial 
stiffness was measured using central (carotid- femoral) pulse wave velocity (PWV) 
using a semi-automated device and software (SphygmoCor, AtCor Medical, Sydney, 
Australia) as previously described (Cocks et al., 2013). Systemic wave reflection was 
investigated using pulse wave analysis to produce an augmentation index with the 
semi-automated device and software (SphymoCor; (Cocks et al., 2013)). The 
augmentation index was normalised to a heart rate of 75bpm (AIx@75bpm) to account 
for confounding influence of heart rate. All measurements were made in triplicate.  
2.3.3.2 Oral Glucose Tolerance Test 
A 20G cannula (BD VenflonTM, BD, Oxford, England) was inserted into an antecubital 
vein to allow for repeated blood sampling during the oral glucose tolerance test 
(OGTT). A 10 ml blood sample was obtained at baseline before participants 
consumed a 75g glucose drink made with 225ml of water. Subsequent blood samples 
(10 ml) were obtained at 15, 30, 45, 60, 90 and 120 min following glucose ingestion. 
Blood samples were divided equally between vacutainers containing EDTA or a 
clotting agent (BD, Oxford, England) to allow for the separation of plasma and serum, 
respectively. Prior to centrifugation EDTA tubes were stored on ice, whereas serum 
tubes were left at room temperature until clotting had occurred.  Blood tubes were 
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centrifuged at 1000g for 10 min at 4oC before being stored at -80 oC for subsequent 
analysis.  
2.3.3.3 Metabolic Flexibility 
Prior to the OGTT, participants rested in a supine position for 20 minutes in a dark 
room with a ventilation hood placed over their head and shoulders (Moxus Modular 
Metabolic System, AEI Technologies, IL, USA). VO2 and VCO2 was measured from 
the collected expired air and used to calculate the respiratory exchange ratio (RER). 
The first five minutes of data was discarded according to best practice methods 
(Compher et al., 2006). Fasting RER was averaged over a 5 minute stable period 
where coefficient of variation for VO2 and VCO2 was ≤ 10 %. The Moxus ventilation 
hood was removed for a brief period (≤ 2 min) to allow participants to consume the 
glucose beverage before being returned over their head and shoulders for the 
remainder of the OGTT. The Moxus volume flow rate was maintained at >25 L.min-1. 
For the remaining OGTT, RER was averaged over 5 minute intervals. Peak RER 
following glucose ingestion was identified as the maximum RER obtained at any 5 
minute interval during the 120 min OGTT. The time that peak RER was obtained was 
recorded and used in the following equation to calculate metabolic flexibility.  
Metabolic flexibility =
Peak RER − Fasting RER
Time to reach peak RER
 
 
2.3.4 Blood Analyses 
Serum samples were analysed for glucose (all time points during OGTT) and fasting; 
Non-esterified fatty-acids (NEFA), triglycerides, cholesterol, AST, ALT and GGT 
concentrations using a commercially available spectrophotometric assays (Randox) 
with a semi-automatic analyser (Randox Daytona RX, Randox, Crumlin, UK). Plasma 
samples from the OGTT were analysed for insulin concentrations with a commercially 
available direct insulin ELISA kit (Fisher Scientific, Loughborough, UK).   
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2.3.5 Calculations 
Glucose area under the curve (AUC) and insulin AUC during the OGTT was 
calculated using the trapezoidal rule with zero as baseline.  
Whole-body insulin sensitivity was calculated using the Matsuda insulin sensitivity 
index (ISI) (Matsuda & DeFronzo, 1999) with the following equation.  
Matsuda ISI =
10,000
√(FPG x FPI) x (MPG x MPI)
 
Hepatic and muscle insulin resistance indexes were estimated using the following 
equations from Abdul-Ghani et al. (2007);   
Hepatic insulin resistance = PG AUC0 – 30 min  x PI AUC0 – 30 min 
Muscle insulin resistance = dG/dt ÷ MPI 
Where FGP is fasting plasma glucose, FPI is fasting plasma insulin, MPG is mean 
plasma glucose during the OGTT, MPI is mean plasma insulin during the OGTT, PG 
AUC0 – 30 min is plasma glucose area under the curve from 0 to 30 min, PI AUC0 – 30 min 
is plasma insulin area under the curve from 0 to 30 min and dG/ dt is rate of change 
in plasma glucose from its peak to its nadir.  
2.3.6 Seven day high-fat high-calorie diet  
Although habitual dietary intake was assessed (Table 2.2), there are known issues 
with participants under-reporting food intake, and therefore the energy value of the 
HFHC was determined based on REE. The participants were highly active, as 
measured objectively by accelerometry and subjectively by the International Physical 
Activity Questionnaire (IPAQ) (Craig et al., 2003). As fitness and activity levels were 
similar between sexes, the same activity factor of 1.7 was multiplied by REE for both 
males and females to calculate total energy expenditure (TEE), before being 
multiplied by 1.5 to calculate each individual’s energy intake required during the 
HFHC diet (Table 2.2). The diets were designed so that fat contributed 65% of total 
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energy intake, with approximately 37% of fat intake derived from saturated fat. The 
remaining energy was provided from carbohydrate (~17%) and protein (~18%). All 
food was purchased and provided by the research team, in addition to a set of scales 
provided to the participants so all food items could be weighed correctly. Food for the 
diet was selected such that it would require minimal preparation and cooking by each 
participant. Where cooking was required, participants were given strict instructions on 
how to cook the food and were provided with the quantity of cooking oil/butter where 
necessary.  
To increase compliance to the diet, all participants were provided with a HFHC diet 
plan prior to the intervention to ensure palatability with all foods. Participants were 
instructed of the importance to consume all food on their HFHC dietary plan and to 
not consume any other food products. Participants were advised to report and return 
any food items that they could not consume during the diet so that energy intake and 
macronutrient percentage could be adjusted as necessary. All participants were 
required to record the food items and note the time they consumed them in an 
individual food diary. Each participant was instructed to continue their habitual 
physical activity (PA) levels and wore the 3-axis activity monitor (wGT3X-BT, 
ActiGraph, Pensacola, FL, USA) to ensure habitual PA levels remained constant.  
Table 2.2 Estimated energy requirements and actual HFHC energy intakes  
  Males Females 
Self-reported habitual intake (kcal)  2639 ± 453 2193 ± 407 
Self-reported diet fat intake (%) 33 ± 2 34 ± 7 
Estimated TEE (kcal) 2653 ± 407 2259 ± 349 
Required HFHC intake (kcal) 3979 ± 610 3389 ± 523 
Actual HFHC intake (kcal) 4063 ± 669 3464 ± 357 
HFHC diet fat intake (%) 65 ± 1  65 ± 1 
HFHC diet saturated fat intake (% of overall fat) 37 ± 3 37 ± 2  
   
Data provided as means ± SD. TEE, total energy expenditure.  
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2.3.7 Statistics  
An independent t-test was used to confirm equal matching of male and female 
participants for age, BMI and VO2 peak (ml min-1 kg (FFM)-1). All metabolic and 
cardiovascular parameters were analysed using a two-factor repeated measures 
ANOVA, with the between subjects factor ‘sex’ (males vs. females) and within-
subjects factor ‘HFHC diet’ (pre- vs.  post-diet). Significant main effects and 
interactions were assessed post-hoc using Bonferroni adjustment analysis.  
2.4 Results 
2.4.1 Subject Characteristics 
At baseline there was no significant difference between males and females for age, 
BMI and VO2 peak (ml.min-1.kgFFM-1) (P > 0.05; Table 2.1). Of the females who 
completed the HFHC diet, 4 were using the combined pill contraceptive method. 
During the dietary intervention one female participant withdrew from participation due 
to gastro-intestinal discomfort and therefore her data was withdrawn from the 
analyses. Withdrawal of this participant did not affect the group matching of sexes.  
2.4.2 Energy Intake and macronutrient composition during the HFHC diet 
All participants returned their HFHC diet plan with confirmation of times that they had 
consumed the food throughout the 7 days. Any food that was not consumed by the 
participants was notified to the researchers and returned to the lab to allow HFHC 
diet calculations to be adjusted.  All participants adhered to the HFHC diet and 
consumed 153  8 % and 155  19% of their habitual energy intake for males and 
females, respectively, following adjustment for any food that was returned. Both sexes 
consumed an equal proportion of dietary fat as saturated fat (Table 2.2). Average 
daily physical activity energy expenditure calculated from the 3-axis activity monitor 
(wGT3X-BT, ActiGraph, Pensacola, FL, USA) revealed no significant differences 
between habitual levels (535 ± 224 kcal) and during the HFHC (510 ± 229 kcal) for 
either sex (P = 0.552).  
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2.4.3 Body Composition 
At baseline males had significantly higher body mass than females (P < 0.009), but 
there was no effect of the HFHC diet for either sex (P = 0.121). Although matched for 
BMI, at baseline females had a significantly higher body fat percentage (P < 0.001) 
and total fat mass (P = 0.003; Table 2.3). Conversely at baseline, males had 
significantly higher FFM (P < 0.001), visceral fat (P < 0.001) and a higher trunk to leg 
fat mass ratio (P < 0.001), whereas trunk fat mass was not different between sexes 
(P = 0.101; Table 2.3). Following the HFHC diet, body mass did not increase (P = 
0.121), but there was a trend towards an increase in total fat mass (P = 0.056) which 
was similar for males (+1.8%) and females (+2.3%; Table 2.3). Following the HFHC 
diet there was a significant increase in trunk to leg fat mass ratio in males only (+5.1%; 
HFHC diet x sex interaction, P = 0.039, Table 2.3). After the HFHC there were no 
alterations in FFM, body fat percentage, visceral fat or trunk fat mass in either sex.  
2.4.4 OGTT 
At baseline, fasting glucose levels were similar between males (4.3  0.6 mmol.L-1) 
and females (4.2  0.4 mmol.L-1 L; P = 0.766) and after the HFHC diet fasting glucose 
did not change in either sex. There were no differences between fasting insulin levels 
between males (7.1  3.9 l U.mL-1) and females (7.5  4 l U.mL-1; P > 0.05) and 
this did not change following the HFHC diet in either sex.  Serum glucose AUC and 
plasma insulin AUC during the OGTT were not significantly different between sexes 
(P > 0.05) and not altered following the HFHC diet in either sex (P > 0.05; Figure 2.1).  
2.4.4.1 Insulin Sensitivity 
In an attempt to decipher changes in insulin sensitivity dependent on origin (liver or 
muscle), glucose and insulin values from the OGTT were also used to predict hepatic 
and muscle insulin resistance using the calculations proposed by Abdul-Ghani et al. 
(2007), in addition to the Matsuda ISI measure of whole-body insulin sensitivity. At 
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baseline there were no significant differences between sexes for the Matsuda ISI (P 
= 0.844), hepatic insulin resistance (P = 0.211) or muscle insulin resistance (P = 
0.584; Figure 2.2). After the HFHC diet there were no significant changes in any of 
the aforementioned measures of insulin sensitivity in males or females (Figure 2.2). 
2.4.4.2 Metabolic Flexibility 
At baseline there was no significant differences in fasting RER between males (0.81 
 0.07) and females (0.76  0.08; P = 0.189). Following the HFHC diet there was a 
trend towards a reduction in fasting RER, which was reduced similarly between males 
and females (0.78  0.08 and 0.74  0.07 post-HFHC diet for males and females, 
respectively; P = 0.052). At baseline, peak RER during OGTT was similar between 
males (0.94  0.07) and females (0.91  0.16; P = 0.629). Following the HFHC diet 
there was a trend towards a reduction in peak RER for males (0.91   0.07) and 
females (0.86  0.08; P = 0.070). The time it took to reach peak RER during the OGTT 
was similar between males (88  6 min) and females (90  7 min; P = 0.644) and this 
did not change after the HFHC diet.  
Metabolic flexibility was determined as the rate of change from fasting RER to peak 
RER during the OGTT. At baseline there was no significant difference between males 
and females for metabolic flexibility (P = 0.877) and this was unaltered following the 
HFHC diet in both sexes (P > 0.05; Figure 2.3A). 
2.4.5 Arterial Stiffness 
AIx@75bpm was not significantly different at baseline between sexes (P = 0.162) and 
was unaltered following the HFHC diet (P = 0.318; Figure 2.3B). PWV was also not 
significantly different at baseline between sexes (P = 0.826) and was unaltered after 
the HFHC diet (P = 0.307; Figure 2.3C). 
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2.4.6 Lipid and Liver Blood Profile 
At baseline, there was no significant differences between sexes for NEFA (P = 0.912), 
cholesterol (P = 0.878) and triglycerides (P = 0.315; Table 2.4). After the HFHC diet 
there was a significant increase in cholesterol (P = 0.049) which was similar between 
males (+8.1%) and females (+6.3%; Table 2.4). Triglyceride levels and NEFA levels 
remained unchanged following the HFHC diet for both sexes (P = 0.685; Table 2.4). 
At baseline, there was no significant difference in AST level between sexes (P = 
0.152), however males had significantly higher ALT levels (P = 0.006) and a trend 
towards higher GGT levels (P = 0.059; Table 2.4). After the HFHC diet there was no 
significant changes in levels of AST, ALT or GGT in either sex (P > 0.05; Table 2.4). 
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Table 2.3. Effect of 7-days HFHC diet on body composition 
 
Males Females 
  Pre Post Pre Post 
Body mass (kg)  72.9 ± 4.9* 73.2 ± 5.2 63.7 ± 9.3 63.9 ± 2.9 
BMI (kg m-2) 23.2 ± 1.4 23.3 ± 1.4 22.7 ± 2.3 22.8 ± 2.4 
FM (kg) 11.7 ± 3.1* 11.9 ± 3 17.3 ± 4.1 17.7 ± 4 
FFM (kg) 58.6 ± 5.5* 57.9 ± 1.2 43.2 ± 5.9 40.3 ± 10.0 
Body fat (%)  16.8 ± 4.0* 16.9 ± 3.8 28.4 ± 3.6 29 ± 3.3 
Trunk fat mass (kg) 5.4 ± 1.4 5.6 ± 1.4 6.7 ± 2.0 6.6 ± 2.0 
Trunk/leg fat ratio †  ‡ 0.87 ± 0.13* 0.92 ± 0.17 0.63 ± 0.09 0.63 ± 0.09 
VAT (g)  308 ± 45* 295 ± 47 174 ± 71 177 ± 22 
     
Data are provided as means ± SD. BMI, body mass index; FM, fat mass; FFM, fat 
free mass; VAT, visceral adipose tissue. * Significant difference vs females at 
baseline P < 0.05. † Significant main effect for the HFHC diet P < 0.05.  ‡ Significant 
interaction effect P < 0.05.  
 
Table 2.4 . Effect of 7-days HFHC diet on lipid and liver blood profile 
 
Males Females 
  Pre Post Pre Post 
Lipid profile  
    
NEFA (mmol.L-1) 1.16 ± 0.43 1.05 ± 0.25 1.17 ± 0.26 1.37 ± 0.46 
Cholesterol (mmol.L-1) † 3.56 ± 0.86 3.85 ± 0.63 3.95 ± 0.59 4.20 ± 0.58 
Triglycerides (mmol.L-1) 0.81 ± 0.92 0.70 ± 0.45 0.51 ± 0.17 0.59 ± 0.25 
Liver profile 
    
AST (U/L -1) 35.82 ± 7.86 34.64 ± 13.66 28.10 ± 4.52 28.25 ± 17.77 
ALT (U/L-1)  35.36 ± 19.80* 35.05 ± 16.77 16.15 ± 7.35 16.80 ± 7.30 
GGT (U/L-1) 21.65 ± 11.87 21.13 ± 8.41 15.28 ± 12.15 11.56 ± 5.39 
 
Data are provided as means ± SD. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT Gamma-glutamyltransferase. * Significant difference vs 
females at baseline P < 0.05. † Significant main effect for the HFHC diet P < 0.05.   
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Figure 2.1. Effect of 7-days HFHC diet on glucose and insulin values during an 
OGTT in males and females. No sex differences or effects of HFHC diet on OGTT 
serum glucose levels (A) or plasma insulin values (B). OGTT AUC shows no 
differences between sexes or effects of the HFHC diet for glucose (C) or insulin (D). 
Solid black line in graphs C & D represents mean value whereas dashed lines show 








































































































































Figure 2.2. Effect of 7-days HFHC diet on parameters of insulin sensitivity measured 
with OGTT. No sex differences or effects of the HFHC diet on the Matsuda index (A), 
hepatic insulin resistance (B) and muscle insulin resistance (C) in males and females, 
however results show varied individual responses for both males and females. Solid black 
line represents mean value whereas dashed lines show individual responses. Matsuda 
index was derived from Matsuda & DeFronzo (1999) whilst hepatic and muscle insulin 

























































































Figure 2.3. Effect of 7-days HFHC diet on metabolic and cardiovascular parameters 
of health. No sex differences or effects of HFHC diet on metabolic flexibility (A), arterial 
stiffness (B) and augmentation index (@ 75bpm) (C) in males and females, however results 
show varied individual responses for both males and females. Solid black line represents 















































































The was the first study to investigate sex differences in measurements of metabolic 
and cardiovascular health in response to a 7 day HFHC diet. Our results show there 
was no effect of the HFHC diet on outcomes related to metabolic and cardiovascular 
health in either sex, highlighting that a HFHC diet does not always impede aspects of 
health in a young, physically active cohort who have good levels of cardio-respiratory 
fitness. 
Overall, 7 days of HFHC diet did not induce changes in whole-body insulin sensitivity 
(Matsuda ISI), or indices of hepatic or muscle insulin resistance. This was a surprising 
finding considering previous studies have reported a reduction in Matsuda ISI in 
young lean, healthy individuals (males and females combined) using the same 7-day 
HFHC diet protocol (65% energy from fat, +50% calories) as the current study 
(Hulston et al., 2015; Parry et al., 2017). However, consistent with our finding, there 
are also studies that report no effect of a HFHC diet on lean healthy individuals on 
indices of insulin sensitivity (Adochio et al., 2009; Brons et al., 2009), however only 
one of these studies included female participants (Adochio et al., 2009). Specifically, 
when peripheral insulin sensitivity quantified by glucose disposal rate and M-value 
during a hyperinsulinaemic clamp was not altered in studies using a similar HFHC 
diet protocol for five days in lean healthy individuals (Adochio et al., 2009; Brons et 
al., 2009). However, it should be noted that Brons (2009) did observe reductions in 
hepatic insulin sensitivity. These findings were later extended to demonstrate that 
reductions in peripheral insulin sensitivity following a HFHC diet only existed in low 
birth weight individuals (males only) who have a predisposed risk of developing T2D 
in comparison to matched normal birth weight individuals (Brons et al., 2012). It is 
apparent from this study and others that short-term HFHC diets do not always induce 
insulin resistance in lean healthy individuals of both sexes. Importantly this current 
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study was unique in comparing sexes and measuring cardio-respiratory fitness and 
physical activity levels of participants.  
There was a trend towards a decrease in fasting RER by 0.03 following the HFHC 
diet with no differences between sexes. There was a large variability between 
participants and given the large reduction observed in RER, significance would have 
likely been observed if a larger cohort was studied. A decrease in RER has also been 
observed following 3-days eucaloric high-fat (50%) diet in young males when 
measured using a 24 h metabolic chamber (Ukropcova et al., 2007). Obese insulin-
resistant individuals exhibit lower metabolic flexibility in comparison to lean insulin 
sensitive individuals (Kelley et al., 1999). In the current study, metabolic flexibility was 
measured as the rate of change from fasting RER to peak RER during the OGTT and 
this was not altered following the HFHC diet in either sex. This current study is the 
only study to investigate sex differences in metabolic flexibility following a HFHC diet 
in young healthy active individuals. Similar findings have however been observed 
following 28-days of HFHC diet in older (~ 37 years) participants (males and females) 
with and without a family history of type 2 diabetes (Samocha-Bonet et al., 2010). 
Impairments in metabolic flexibility have been observed in the presence of normal 
peripheral insulin sensitivity in older individuals (Faerch & Vaag, 2011) suggesting 
metabolic inflexibility is an early aberration in the progression of insulin resistance 
and T2D. However, we and others (Samocha-Bonet et al., 2010) have been unable 
to detect changes in metabolic flexibility without changes in peripheral insulin 
sensitivity.  
There was a small but significant increase in body fat following the HFHC diet in both 
sexes which is comparable to previous studies showing an increase in body mass 
following HFHC diet over 7-days (Hulston et al., 2015; Parry et al., 2017). Abdominal 
adiposity, and in particular elevated visceral fat are more closely associated with 
insulin resistance and T2D (Montague & O'Rahilly, 2000; Huang et al., 2015). This is 
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due to visceral fat contributing excess FFA to the liver via the portal vein (Liu et al., 
2006a) and as a consequence of visceral fat being a source of systemic inflammation 
through increased adipocytokines that can contribute to insulin resistance (Yudkin, 
2007). In line with previous findings (Ludescher et al., 2007; Haupt et al., 2010; 
Staiano & Katzmarzyk, 2012) at baseline visceral fat stores were higher in males 
compared to females, but this did not change following the HFHC diet. Trunk fat 
measured by the DEXA scan represents overall abdominal adiposity rather than 
specific visceral fat. There were no differences between males and females at 
baseline for trunk fat and following the HFHC diet trunk fat was not changed, but there 
was an increase in trunk to leg fat mass ratio which increased only in males. This 
change in unfavourable fat accumulation ratio occurred after only 7 days of a HFHC 
diet. It is likely that more chronic overfeeding would exacerbate this fat accumulation 
and start to contribute to the development of metabolic disorders.  
An obesogenic environment is often associated with reduced PA levels in addition to 
HFHC diets. A recent systematic review concluded that HFHC diet studies can often 
influence participant’s PA levels, which may impact changes in weight gain (Giroux 
et al., 2018). In the current study, all participants exhibited high habitual PA levels as 
measured by the IPAQ and this was largely due to participants participating in regular 
structured exercise. During the HFHC diet period participants were instructed to 
maintain their PA and exercise regimes. This was confirmed by examining energy 
expenditure predicted by the accelerometer and revealing that it remained the same 
during habitual measures and the HFHC diet period.  Although this minimised the 
influence of activity levels on the effects of the HFHC diet, the pre-existing high PA 
levels may have helped compensate for the negative effects of a HFHC diet in some 
participants. Indeed, increased PA levels through daily vigorous-intensity exercise 
has been shown to counteract the detrimental metabolic effects of a HFHC diet and 
reduced habitual PA in healthy young males (Walhin et al., 2013). Reduced PA is 
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therefore likely to be a more potent stimulus to reduce insulin sensitivity. The 
combination of both reduced PA and HFHC have shown more clear reductions in 
insulin sensitivity in healthy young males (Knudsen et al., 2012). 
In this study self-reported habitual energy intake closely matched estimates of TEE 
derived from measurements of RMR with indirect calorimetry and physical activity 
levels with IPAQ. These values were also very close to the recommended energy 
intakes for males (2500 kcal) and females (2000kcal). It was therefore assumed that 
the HFHC diet did indeed provide a 50% energy surplus of relative to habitual energy 
levels although there was no distinct change in any metabolic parameters. Although 
PA maintenance was confirmed with accelerometer a limitation of this measurement 
is it might not always accurately measure high-intensity exercise bouts particularly if 
performed by modes other than running e.g. cycling or swimming. Future research 
would benefit from controlling participant’s physical activity levels or quantifying them 
more accurately with the use of combined heart rate/accelerometry measures.  
Longitudinal studies have shown that high cardio-respiratory fitness can reduce the 
risk of T2D (Nojima et al., 2017) and all-cause mortality (Blair et al., 1989). A further 
analysis of the Aerobic Centre Longitudinal Study involving over 20,000 males 
between the ages of 30-83 years were assessed for cardio-respiratory fitness in 
different BMI categories (19.0 to <25.0, 25.0 to <27.8, ≥27.8) and followed for 8 years 
(Lee et al., 1998). The results from this analysis showed that the group with the lowest 
cardio-respiratory fitness had a higher risk of all-cause mortality than their higher 
fitness level counterparts. Interestingly, males who were in the highest two BMI 
categories but had high cardio-respiratory fitness were at a lower risk of all-cause 
mortality than normal BMI but low fit counterparts (Lee et al., 1998). When a more 
diverse longitudinal study (2,506 females and 2,860 males) was conducted with 
different ethnicities and socio-economic status, high BMI and low cardio-respiratory 
fitness both presented as risk factors for cardiovascular disease and all-cause 
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mortality (Stevens et al., 2002). When a female only cohort (116,564 females) were 
followed for 24 years, both obesity and low activity levels were strong and 
independent risk factors for all-cause mortality (Hu et al., 2004), however in this study 
there was no direct measurement of cardiorespiratory fitness. Together, the evidence 
suggests that low cardio-respiratory fitness is an independent risk factor for 
cardiovascular disease and all-cause mortality and in certain populations is a stronger 
risk factor than increased adiposity. The male and female groups in the current study 
displayed high cardio-respiratory fitness associated with a reduced risk of all-cause 
mortality (Blair et al., 1989). It is possible, therefore, that the benefits of having a high 
cardio-respiratory fitness leading to a lower risk of all-cause mortality may have also 
counteracted the negative effects imposed from a HFHC diet in this study. Future 
research should compare low and high cardio-respiratory fitness individuals to 
determine if cardio-respiratory fitness can protect against short-term HFHC diets.  
In summary, this study aimed to determine sex differences in the response to a short-
term HFHC diet. Although no sex differences were observed we now highlight that 
there are large inter-individual responses to a HFHC diet in both sexes. Although 
there is a reduced prevalence of T2D in women, the pathophysiology of this metabolic 
disorder in this sex is still understudied and not understood. There is a very clear need 
to explore and understand the mechanisms of how lipid induced insulin resistance 




Chapter 3. A 7 day high-fat high-calorie diet 
induces fibre-specific increases in intramuscular 
triglyceride content and perilipin protein expression 
in human skeletal muscle. 
  
92 
3.1 Abstract  
High-fat high-calorie (HFHC) diets can induce whole body insulin resistance (IR) 
whilst increasing stores of intramuscular triglyceride (IMTG) contained within lipid 
droplets (LD). Perilipin (PLIN) proteins assist in IMTG storage. Synaptosomal-
associated protein (SNAP23) may support LD growth and also direct IMTG-derived 
fatty acids (FA) to mitochondria for β-oxidation. The objectives of this study were: 1) 
to test the hypothesis that 7 days HFHC diet increases IMTG content to prevent lipid 
induced impairments in skeletal muscle insulin signalling and 2) identify changes in 
expression and subcellular distribution of key proteins related to lipid metabolism. 
Muscle biopsies were obtained from the vastus lateralis of thirteen (n=11 male, n=2 
female) healthy individuals (age: 23±1 years, body mass index:24.4±0.7 kg.m-2) 
before (0min), during (30min) and at the end (120 min) of an oral glucose challenge, 
pre and post 7-days consuming a high-fat (65% energy) high-calorie (+50% kcal) diet. 
IMTG, PLIN2, PLIN3, PLIN5, SNAP23 and mitochondria content were measured 
using (semi)-quantitative confocal immunofluorescence microscopy. PLIN2, PLIN3 
and PLIN5 colocalisation to LD was measured using object based colocalisation 
analyses. Pearson’s correlation coefficient quantified colocalisation between SNAP23 
and; plasma membrane, mitochondria and LD. Phosphorylation of intermediates of 
the insulin-signalling cascade (Akt and AS160) were measured with western blot at 
0, 30 and 120 min of an oral glucose challenge pre and post the diet. Following the 
HFHC diet phosphorylation of Akt and AS160 were not impaired during the oral 
glucose challenge, however whole body glucose tolerance (P = 0.007) was 
significantly reduced. IMTG content increased in type I fibres (+100%; P < 0.001) after 
the diet due to both an increase in LD number (+43%; P < 0.001) and size (+44%; P 
< 0.001). Of the PLINs investigated, only PLIN3 content increased (+50%; P < 0.01) 
which occurred solely in type I fibres. PLIN2+ LD increased (80%; P < 0.01) in type I 
fibres only whereas PLIN3+ LD and PLIN5+ LD were unaltered. SNAP23 and 
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mitochondria content did not change with the diet, nor did the colocalisation of 
SNAP23 with the plasma membrane, mitochondria or LD. Seven days of HFHC diet 
increased IMTG stores without impairments of the insulin signalling cascade. This 
increase in IMTG number and size is likely aided by a concurrent increase in PLIN3 
content and a redistribution of existing stores of PLIN2 to LD in type I fibres. These 
adaptations may protect skeletal muscle insulin signalling by channelling meal-




The development of insulin resistance and type 2 diabetes is initiated by a reduction 
in peripheral insulin sensitivity (DeFronzo & Tripathy, 2009). Skeletal muscle serves 
as a large depot for insulin-stimulated glucose uptake (Katz et al., 1983; Ferrannini et 
al., 1985) and therefore impairments in skeletal muscle insulin sensitivity are a 
contributing factor to hyperglycemia. Elevated intramuscular triglyceride (IMTG) 
stores were initially associated with insulin resistance in sedentary, obese and/or type 
2 diabetes individuals (Kelley et al., 1999; Goodpaster et al., 2001). This association 
disappeared when endurance trained individuals were introduced into the comparison 
because they also had elevated IMTG stores but combined with high insulin sensitivity 
in a phenomenon termed ‘the athlete’s paradox’ (Goodpaster et al., 2001; van Loon 
et al., 2004). IMTG has no mechanistic link to impairments of skeletal muscle insulin 
signalling. Conversely, acute (4-6h) elevation of lipid metabolites, diacylglycerol 
(DAG) and ceramides have resulted in skeletal muscle insulin signalling concomitant 
to a reduction in insulin-stimulated glucose uptake  (Itani et al., 2002; Yu et al., 2002a; 
Straczkowski et al., 2004). Cross-sectionally insulin resistant states have also 
demonstrated elevated ceramide levels correlated with impairments in insulin 
signalling and glucose uptake in skeletal muscle (Adams et al., 2004). 
Directing an influx of lipid from the diet to IMTG storage would, therefore, be of benefit 
because this would reduce the risk of generating lipid metabolites.  High-fat, high-
calorie (HFHC) diets provide a model of dietary lipid excess, comparable to that 
observed when consuming a typical western diet. Several studies have shown that 
short-term HFHC diets reduce insulin sensitivity or glucose disposal in healthy 
individuals (Bakker et al., 2014; Hulston et al., 2015; Gemmink et al., 2017a; Parry et 
al., 2017). However, the mechanisms underpinning the development of insulin 
resistance are still not fully understood.  
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IMTG is stored within lipid droplets (LD) which are coated by a phospholipid 
monolayer, decorated with numerous proteins. The most extensively studied of these 
proteins is the perilipin (PLIN) family of proteins. PLIN2 and PLIN5 protein content 
increases in response to exercise training concomitant with an increase in IMTG 
content (Shaw et al., 2012; Shepherd et al., 2013; Shepherd et al., 2014), suggesting 
that PLIN proteins play a role in IMTG storage. In support, myotubes overexpressing 
PLIN3 accumulate IMTG (Kleinert et al., 2016), and  primary human myotubes 
overexpressing PLIN5 promote IMTG storage by restricting basal lipolysis (Laurens 
et al., 2016). To date, only one study has investigated the effect of a HFHC diet on 
PLIN protein expression. Using biochemical extraction to determine IMTG 
concentration and western blotting of whole muscle homogenates to investigate PLIN 
protein expression, Gemmink et al., (2017a) were the first to show that a short-term 
HFHC diet led to increased IMTG concentration and PLIN5 protein content in human 
skeletal muscle, without alterations in PLIN2 or PLIN3. Type I fibres have an 
enhanced capacity to store IMTG (Shepherd et al., 2013), and therefore it is important 
to consider fibre-type specific changes in IMTG content and PLIN protein expression 
that may not be detected using whole muscle homogenates. Another important 
consideration is the distribution of PLIN proteins relative to LDs within the muscle. In 
support, elevating free fatty acid availability in trained individuals through a lipid 
infusion augments IMTG content in type I fibres and increases the number of LD 
associated with PLIN2, PLIN3 and PLIN5, without any changes in PLIN protein 
expression (Shepherd et al., 2017b). Our first aim was therefore to investigate fibre-
type and region-specific changes in IMTG content (LD number and morphology) and 
PLIN protein expression in response to 7 days of HFHC diet. By using our previously 
validated immunofluorescence microscopy techniques (Shepherd et al., 2012, 2013; 
Shepherd et al., 2017b), we also aimed to investigate fibre-type and region-specific 
changes in the redistribution of perilipins with LD. 
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Synaptosomal-associated protein (SNAP23) is a t-SNARE (target- Soluble N 
Ethylmaleimide Sensitive Factor Attachment Protein Receptor) found at the plasma 
membrane (Jahn & Scheller, 2006) that mediates the docking of GLUT-4 to the 
plasma membrane under insulin-stimulated conditions (Foster et al., 1999; Kawanishi 
et al., 2000). Notably though, the subcellular distribution of SNAP23 is sensitive to 
changes in lipid availability.  For example, treatment of cardiomyocytes with oleic acid 
increased intracellular LD volume resulting in an increase in the LD-associated pool 
of SNAP23, with a concomitant reduction in SNAP23 associated to the plasma 
membrane (Bostrom et al., 2007). This has led to the hypothesis that in response to 
lipid excess, LD ‘highjack’ SNAP23 from the plasma membrane to assist in LD fusion 
(Sollner, 2007). Although this may assist in minimising the accumulation of lipid 
metabolites, the removal of SNAP23 from the plasma membrane may reduce GLUT-
4 docking, resulting in a reduced capacity for glucose uptake. Ablation of SNAP23 in 
fibroblasts reduces the formation of LD-mitochondria complexes and results in a 
decreased mitochondrial -oxidation (Jagerstrom et al., 2009). This suggests 
SNAP23 may also have a putative role in minimising accumulation of lipid metabolites 
by assisting IMTG-derived FA -oxidation. We have recently confirmed using confocal 
immunofluorescence microscopy that SNAP23 has a high colocalisation to the 
plasma membrane and mitochondria and a weaker colocalisation to LD in lean 
healthy trained males (Strauss et al., 2016). We now aim to extend these findings to 
determine if SNAP23 colocalisation to the plasma membrane, mitochondria or LD is 
altered following lipid excess induced by 7 days HFHC diet. 
3.3 Methods 
3.3.1 Participants and ethical approval  
The samples used in this study were collected as part of a larger study investigating 
the effect of 7 days HFHC on glucose kinetics and insulin sensitivity, in collaboration 
with Loughborough University. The study adhered to the Declaration of Helsinki and 
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was approved by Loughborough University Subcommittee Ethical Committee for 
Human Participants. Fifteen healthy individuals (n = 13 males and n = 2 females, 24 
± 1 y, body mass index (BMI) 24.8 ± 0.6 kg.m-2) participated in the study following 
written informed consent. Of these participants, thirteen consented to muscle 
biopsies, which were used for western blot and immunohistochemistry analysis. All 
participants were physically active (taking part in at least 3 x 30 min of moderate-
intensity physical activity each week), non-smokers, with no diagnosis of 
cardiovascular or metabolic disease, not taking any medication known to interfere 
with the study outcomes, and weight stable for at least 3 months. 
3.3.2 Pre-testing 
Prior to the start of the study, participants attended the laboratory for an initial 
assessment of their baseline anthropometric characteristics (height, body mass and 
BMI). This information was then used to estimate resting energy expenditure (REE) 
(Mifflin et al., 1990). A standard correction for physical activity (1.6 and 1.7 times REE 
for females and males, respectively) was applied in order to estimate total daily 
energy requirements. This information was then used to determine individual energy 
intakes for the experimental diet intervention (Parry et al., 2017). 
3.3.3 Experimental protocol 
The experimental protocol, as well as the analysis of glycaemic control and skeletal 
muscle insulin signalling, were conducted at Loughborough University, whilst all 
immunohistochemical analyses were conducted as part of this PhD experimental 
chapter. For contextualisation of the immunohistochemical analyses and better 
scientific understanding of the effects of 7 days HFHC diet, the methodology and 
results from the oral glucose challenge (whole-body glycaemic control and skeletal 
muscle insulin signalling) are reported and discussed briefly in this chapter.   
Participants consumed a high-fat (65% energy), high-calorie (+50% kcal) diet for 7 
days.  On experimental days (before and after the HFHC diet) subjects arrived at the 
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laboratory following an overnight fast (>12 h), to undergo muscle biopsies and an oral 
glucose challenge (50 g glucose plus 15 g whey protein dissolved in 400 mL plain 
water). Fasting and postprandial venous blood samples were obtained at 0, 15, 30, 
45, 60, 90 and 120 min after beverage ingestion. Plasma and serum samples were 
used to measure glucose and insulin levels, respectively. These measurements were 
then use to predict whole-body insulin sensitivity using the Matsuda Index (Matsuda 
& DeFronzo, 1999).  
Muscle biopsies from the m. vastus lateralis were obtained at 0, 30 and 120 min time 
points of the oral glucose challenge under local anaesthesia using the Bergstrom 
needle biopsy technique with suction (Bergstrӧm, 1975). Following removal of excess 
blood, fat and connective tissue a portion of muscle (10-30 mg) was mounted in 
Tissue-Tek OCT (Sakura Finetek UK Ltd) and frozen in liquid nitrogen-cooled 
isopentane for subsequent immunohistochemical analyses. An additional two 
portions of muscle tissue (30-50 mg each) were snap-frozen in liquid nitrogen. Each 
biopsy during the oral glucose challenge was obtained from a separate incision on 
the same leg (~3-4 cm proximal to the initial biopsy site). Following 7 days of HFHC 
diet, biopsies were obtained from the opposite leg.  
3.3.4 Western blot 
Commercially available antibodies were used to determine the phosphorylation of key 
insulin signalling proteins (Akt Ser473 [Cell Signalling #4060], Akt Thr308 [Cell 
Signalling #13038], AS160 Ser588 [Cell Signalling #8730], AS160 Thr642 [Cell 
Signalling #8881], by SDS-PAGE and Western blotting as previously described 
(Hulston et al., 2018).  
3.3.5 Immunohistochemistry analysis  
Serial cryosections (5 μm) were cut at -30oC onto ethanol-cleaned glass slides. 
Cryosections of samples obtained pre and post 7 days HFHC diet from one participant 
were placed on a single slide to account for any variation in staining intensity between 
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sections. Sections were fixed for 1 h in 3.7% formaldehyde, rinsed 3 x 30 s in doubly 
distilled water (dd H2O) and permeabilised in 0.5% Triton X-100 for 5 min, before 
being washed 3 x 5 min in Phosphate Buffered Saline (PBS, 137mM sodium chloride, 
3 mM potassium chloride, 8 mM sodium phosphate dibasic and 3mM potassium 
phosphate monobasic, pH of 7.4). Slides were incubated for 1 h with primary 
antibodies, washed 3 x 5 min in PBS, incubated with complementary secondary 
fluorescence-conjugated antibodies for 30 min, followed by a further 3 x 5 min PBS 
washes. To visualise IMTG, sections were incubated with BODIPY 493/503 
(Invitrogen, Paisley, UK, D3922) for 20 min followed by a single 5 min PBS wash. 
Coverslips were mounted with Vectashield (H-1000, Vector Laboratories, 
Burlingame, CA, USA) and sealed with nail varnish.  
3.3.5.1 Antibodies and staining combinations  
The primary antibodies used were guinea pig anti-adipophilin (PLIN2) and guinea pig 
anti-OXPAT (PLIN5: both Progen, GP40 & GP31 respectively, Biotechnik, 
Heidelberg, Germany), rabbit anti-perilipin 3/TIP-47 (PLIN3: NB110-40764 Novus 
Biologicals, Cambridge, UK), rabbit anti-SNAP23 (SNAP23: 111202, Synaptic 
Systems, Goettingen, Germany), mouse anti-OxPhos Complex IV subunit I (COX; 
used as a marker of muscle oxidative capacity: 459600, ThermoFisher Scientific, 
Paisley, UK), mouse anti-dystrophin (used as a plasma membrane marker: D8168, 
Sigma-Aldrich, Dorset UK). Cell border visualisation was achieved with either rabbit 
anti-laminin (L9393, Sigma-Aldrich, Dorset, UK) or with wheat germ agglutinin (WGA) 
Alexa Fluor 633 conjugate (ThermoFisher Scientific, Paisley, UK). Muscle fibre type 
was determined using mouse anti-myosin heavy chain I (MHCI) (A4.840c) and mouse 
anti-myosin heavy chain IIa (MHCIIa) (N2.261c; both DSHB, University of Iowa, USA 
developed by Dr. Blau). Appropriate Alexa Fluor secondary antibodies were obtained 
from ThermoFisher Scientific (Paisley, UK). 
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To determine fibre type-specific protein expression, primary antibodies targeting 
PLIN2, PLIN3, PLIN5 or COX, or BODIPY 493/503 to stain for IMTG, were used in 
combination with antibodies targeting MHCI, MHCIIa and the cell border, either 
laminin or WGA Alexa Fluor 633 conjugate. SNAP23 is also located at the plasma 
membrane, and therefore SNAP23 protein expression was investigated using 
antibodies targeting SNAP23 (followed by goat anti-rabbit IgG 488), MHCI and 
MHCIIA in combination with an antibody targeting dystrophin as previously described 
(Strauss et al., 2016). To investigate colocalisation between PLIN proteins and LD, 
PLIN2, PLIN3 or PLIN5 were stained in combination with BODIPY 493/503, and 
antibodies targeting MHCI and MHCIIa.  To investigate the localisation of SNAP23 to 
the plasma membrane, LD and mitochondria, respectively, SNAP23 was stained in 
combination with either dystrophin, BODIPY 493/503 or COX, as well as antibodies 
targeting MHCI and MHCIIa. 
3.3.5.2 Image capture, processing and data analysis 
All images were captured using an inverted confocal microscope (Zeiss LSM710; Carl 
Zeiss AG, Oberkochen, Germany) with a 63x 1.4 NA oil immersion objective. A diode 
laser was used to excite the Alexa Fluor 405 fluorophore, an argon laser for the Alexa 
Fluor 488 fluorophore and BODIPY 493/503 and a helium-neon laser for the Alexa 
Fluor 546 and 633 fluorophores.   
To assess IMTG content, and the protein expression of the PLIN proteins, COX and 
SNAP23, cross-sectional images were obtained at 1.1x digital zoom. Type I and type 
IIa fibres were identified through positive staining, and any fibres without positive 
staining for either MHCI or MHCIIa were assumed to be type IIx fibres. For type I and 
IIa fibres 10 images per fibre-type per participant pre and post the HFHC diet for each 
assay was obtained (equating to a total of 260 images per assay). This was not 
possible for type IIx fibres due to a low number of these fibres in muscle sections in 
a number of participants. Type IIx fibres were included in the analyses if it was 
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possible to obtain 4 or more images of type IIx fibres per time point for a participant. 
This equated to an average of 71 ± 11 images of type IIx fibres being used in 5 assays 
that were able to acquire sufficient amount of type IIx fibres to be used in statistical 
analyses.  Image analysis was undertaken using Image-Pro Plus, version 5.1 (Media 
Cybernetics, Bethesda, MD, USA). To assess IMTG and PLIN protein content within 
each muscle fibre, the fibre was first separated into a peripheral region (first 5 μm 
from the cell border) and the central region (remainder of the cell; Figure 3.1). A 
selected intensity threshold was used to represent a positive signal for IMTG and 
each PLIN protein. IMTG and PLIN protein content was expressed as the positively 
stained area fraction relative to the total area of the peripheral region or central region 
of each muscle fibre. Data was also extracted to examine LD density (number of LDs 
expressed relative to area) and LD size (mean area of individual LDs) SNAP23 and 
COX fluorescence intensity was calculated using optical density in the peripheral and 
central regions of the cell and normalised to each individual peripheral and central 
area. The peripheral region of the cell does not include the plasma membrane of the 
muscle fibre. As SNAP23 is also present in the plasma membrane of muscle fibres a 
dilation mask of 1 μm was set from the inside of the plasma membrane outwards to 
account for the area occupied by the plasma membrane. This mask was then used 
to quantify the FI of SNAP23 in the plasma membrane area by measuring optical 
density and normalised to the area covered by the plasma membrane.  


























Figure 3.1. Image analysis method for assessing IMTG and protein expression 
in cross-sectional muscle fibres. Images for content analysis were obtained at 1.1x 
zoom on a 63x 1.4NA confocal microscope. Grey scale images of the cell border 
identified with laminin (A) and of LD stained with BODIPY 493/503 (D). Erosion mask 
of 5 μm applied from the cell border to produce a peripheral region mask (B). 
Peripheral erosion mask inverted to create a mask for the central region of the cell 
(C). Masks B and C were applied to greyscale image of LD to produce extracted 
images of LD in the peripheral region of the cell (E) and the central region of the cell 
(F). Freehand ROI (green line) was manually drawn around central region of the cell 
to exclude LD from neighbouring cells (F). A selected intensity threshold was then 
applied to extracted images to represent positive signal for LD or PLIN proteins and 
the data was extracted to reveal percentage of area stained (IMTG and PLINs) as 
well as LD density (number of LDs expressed relative to area) and LD size (mean 
area of individual LDs). White bar = 25μm. For SNAP23 and mitochondria, 
fluorescence intensity measurement was applied to extracted peripheral and central 
images of SNAP23 and COX stain.  
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As previously described (Shepherd et al., 2012, 2013; Strauss et al., 2016), before 
any colocalisation analysis was undertaken controls were included to confirm 
absence of 1) bleed through of fluorophores in opposing channels when single 
staining was performed, 2) non-specific secondary antibody binding, and 3) sample 
autofluorescence. For colocalisation analysis of PLIN proteins with LD, images were 
obtained at 4x digital zoom applied to both the centre region and the peripheral region 
of type I and type IIa muscle fibres pre and post the HFHC diet (n=10 images per 
region, per fibre-type, pre and post HFHC diet, per participant, equating to a total of 
80 images for each participant for each staining protocol; Figure 3.2). Object-based 
colocalisation analysis was performed separately for PLIN2, PLIN3 and PLIN5 with 
LD, as previously described (Shepherd et al., 2012, 2013; Shepherd et al., 2017b). 
Briefly, a selected intensity threshold was used to denote a positive signal for each 
PLIN protein of interest and LD. These thresholds were used to produce binary 
images of the PLIN protein and LD used for the colocalisation analysis (Figure 3.2B 
and C). Binary images were merged to produce a colocalisation map and overlapping 
regions extracted to a separate image (Figure 3.2D and E). The number of extracted 
objects was calculated and expressed relative to area to represent the number of 
PLIN-associated LD (PLIN+ LD). The number of extracted objects was subtracted 
from the total number of LD and expressed relative to area to represent the number 
of LD not associated with PLIN (PLIN- LD). Additionally, the number of extracted 
objects was subtracted from the total number of PLIN objects and expressed relative 
to area to identify the amount of free PLIN protein not associated with LD. The fraction 
of PLIN protein colocalising to LD was also reported. When conducting the 
colocalisation analysis, if there were multiple PLIN objects localised to a single LD 
this was classified as one colocalisation count, in order to avoid over estimation of 









Figure 3.2. Colocalisation analysis between LD and PLIN5. Images for 
colocalisation analysis were obtained using a 63x 1.4NA confocal microscope at 4x 
digital zoom at the central and peripheral region of the cell indicated by the two white 
boxes (A). LD were stained with BODIPY 493/503 (green; B), PLIN5 was stained red 
(C) and subsequent merged images (D) were used to calculate colocalisation. The 
overlapping area of LD and PLIN5 was extracted (E) to calculate the number of 
PLIN5+ LD and PLIN5- LD relative to the area of interest. White box in images B-E 
represent the peripheral area that was analysed when images at the periphery were 
obtained. White bar = 25μm (A) and 5 μm (B-E). The same method was repeated for 




Cross-sectional images at 1.1x digital zoom of type I and type IIa muscle fibres pre 
and post the HFHC diet were obtained for SNAP23 colocalisation analysis with; 
plasma membrane, mitochondria and LD (n=10 per fibre-type, pre and post diet, per 
participant, equating to a total of 40 images for each participant for each separate 
staining protocol; Figure 3.3). For SNAP23 colocalisation analysis, individual type I or 
type IIa fibres were first isolated from the rest of the image (Figure 3.3) to avoid 
interference of data from non-type I or non-type IIa fibres respectively. Pearson 
colocalisation correlation coefficient (PCC) analysis were then performed on SNAP23 
with; plasma membrane, mitochondria or LD in a series of separate analysis as 
previously described (Strauss et al., 2016). At present, it is unclear whether SNAP23 
colocalisation to the plasma membrane is homogenous throughout the muscle fibre. 
PCC analyses allow for proteins of interest to be analysed within the entirety of the 
cross-sectional area of the imaged muscle fibre. These analyses are consequently 
more suitable when analysing colocalisation of SNAP23 to the plasma membrane 
that surrounds the entire cell.  The SNAP23 channel was overlapped with either a 
channel of; plasma membrane, mitochondria or LD and PCC was assessed of the 
whole cell (Figure 3.3A-C) using Image Pro Plus 5.1 Software (Media Cybernetics). 
To confirm SNAP23 colocalisation to each of the variables during image analysis 
SNAP23 stain was paired with non-matched images of either the plasma membrane, 














Figure 3.3. Colocalisation analysis between SNAP23 and LD. Images for 
colocalisation analysis were obtained at 1.1x zoom on a 63x 1.4NA confocal 
microscope. Cells of interest was isolated so that type I and IIa fibres could be studied 
separately. SNAP23 stained red (A) and LD stained with BODIPY 493/503 (green; 
B). Raw images of SNAP23 and LD were merged (C) and Pearson’s correlation 
coefficient was calculated to reveal the degree of colocalisation between SNAP23 
and LD. White bar = 25μm. The same process was repeated for SNAP23 with the 
plasma membrane (dystrophin stain) and mitochondria (COX stain).  
  




All data is reported as the mean ± SEM. Significance was set at P < 0.05. A linear 
mixed-effects model with fixed effects for fibre-type (type I vs type IIa vs type IIx), 
region (central vs peripheral) and time (pre vs post HFHC diet) and random effects to 
account for repeated measurements within subjects was used. Significant main 
effects or interaction effects were assessed using Bonferroni adjustment post hoc 
analysis.  
3.4 Results 
3.4.1 Body Mass 
The 7 day HFHC diet caused a significant increase in body mass from pre (76.4 ± 3.3 
kg) to post diet (77.7 ± 3.4 kg; P < 0.001). Each participant experienced an increase 
in body weight demonstrating the diet was effective in being hypercaloric.  
3.4.2 Insulin sensitivity and insulin signalling  
3.4.2.1 Oral glucose challenge 
Following 7 days HFHC diet glucose AUC significantly increased (+10%; P = 0.007) 
and there was a trend towards an increased insulin AUC (+17%; P = 0.086; Table 
3.1). Whole-body insulin sensitivity as measured by the Matsuda index significantly 
decreased (-23%; P = 0.006; Table 3.1).  
Data provided as means ± SEM. AUC, area under the curve; ISI, insulin sensitivity 
index. * Significant difference from pre to post diet P < 0.05.  
 
Table 3.1 Effect of a 7 day high-fat high-calorie diet on an oral glucose challenge 
  Pre Post 
Glucose AUC (mmol.L−1 (120 min)−1)* 648 ± 23 712 ± 24 
Insulin AUC  (μIU.mL−1 (120 min−1) 4979 ± 690 5834 ± 17 
Matsuda ISI* 6.25 ± 0.75 4.82 ± 2.54 
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3.4.2.2 Insulin signalling  
Phosphorylation of AS160 ser588 and thr642, and Akt ser473 and thr308 increased 
from 0 to 30 minutes during the oral glucose challenge (Figure 3.4) (P < 0.05), 
however this was not impaired following 7 days HFHC diet. Phosphorylation of AS160 
thr642 remained elevated 120 minutes into the oral glucose challenge whereas 
phosphorylation of Akt ser473 and thr308 significantly decreased from 30 to 120 
minutes (P < 0.001). There was a significant interaction effect for HFHC diet and oral 
glucose challenge for phosphorylation of AS160 ser588 (P = 0.035). Pre HFHC diet 
phosphorylation of AS160 ser588 remained elevated from 30 to 120 min into the oral 
glucose challenge whereas after the HFHC diet phosphorylation of AS160 ser588 
returned to baseline after 120 min (P = 0.011).  
3.4.3 IMTG analysis 
At baseline, type I fibres had greater IMTG content (expressed as percentage of fibre 
stained) in comparison to type IIa (P = 0.006) and type IIx fibres (P < 0.001), although 
there was no difference between type IIa and type IIx fibres (P = 0.467; Figure 3.5A). 
There was also no significant differences in IMTG content at baseline between the 
peripheral and central region of the cell (P = 0.399). Following HFHC diet there was 
an increase in IMTG content that was exclusive to type I fibres only (+101%; P < 
0.001), and this occurred in both the peripheral (+89%; P < 0.001) and central regions 
(+103; P < 0.001). Although overall IMTG content did not increase in type IIa or IIx 
fibres, IMTG content did increase in the peripheral region of both fibres following 
HFHC diet (type IIa fibres +117%; P = 0.016; and type IIx fibres +134%; P =0.016). 
Consequently, following HFHC diet IMTG content was greater in the peripheral region 
of muscle fibres compared to the central region (P = 0.022). 
The increase in IMTG content in type I fibres was due to an increase in both LD size 
(+44%; P < 0.001; Figure 3.5B) and LD density (+43%; P < 0.001; Figure 3.5C) in 
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both muscle fibre regions. Although overall IMTG content was not augmented by 
HFHC diet in type IIa and type IIx fibres, we did observe an increase in LD size in 
both the peripheral (+36% and +30% for type IIa and IIx respectively; P < 0.01) and 
central region (+47% and +46% for type IIa and IIx fibres respectively; P < 0.001) of 
these fibres. LD density increased in the peripheral region of type IIa fibres (+57%; P 
=0.014) and there was a trend towards an increase in the peripheral region of type IIx 
fibres (+48%; P = 0.074). There were no changes in LD density in the central region 
of type IIa fibres (P = 0.376) and type IIx fibres (P =0.140) after HFHC diet.  
3.4.4 PLIN protein expression 
3.4.4.1 PLIN2 
At baseline PLIN2 protein expression (expressed as percentage of fibre stained) was 
significantly greater in type I fibres in comparison to type IIa (P = 0.048) and type IIx 
fibres (P = 0.019), however, there was no difference between type IIa and type IIx 
fibres (P = 0.112; Figure 3.6A). There was a trend towards PLIN2 protein expression 
being greater in the peripheral region compared to the central region at baseline (P = 
0.060; Figure 3.6A). Following the HFHC diet there was no significant increase in 
PLIN2 protein expression in any fibre types or any region. 
3.4.4.2 PLIN3 
In type I fibres PLIN3 protein expression tended to be higher in comparison to type 
IIa fibres (P = 0.077) and was higher compared to type IIx fibres (P = 0.021; Figure 
3.6B). There were no differences in PLIN3 protein expression between type IIa and 
IIx fibres (P = 0.099).  There was a trend towards more PLIN3 in the peripheral region 
of the muscle fibres compared to the central region (P = 0.062; Figure 3.6B). 
Following HFHC diet there was an increase in PLIN3 protein expression in type I 
fibres only (+50%; P = 0.010), which tended to occur in both the peripheral (+35%; P 
= 0.081) and central region of the muscle fibre (+58%; P = 0.095). The increase in 
type I fibres resulted in a significantly higher PLIN3 protein expression in type I fibres 
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compared to type IIa (P = 0.001) and IIx (P < 0.001) after the HFHC diet. Although 
overall PLIN3 protein expression in type IIa fibres did not change there was an 
increase in PLIN3 protein expression in the peripheral region of type IIa fibres (+58%; 
P = 0.043). 
3.4.4.3 PLIN5 
At baseline there was significantly more PLIN5 protein expression in type I fibres 
compared to type IIa (P = 0.001) and type IIx (P = 0.001), although there were no 
differences between type IIa and IIx fibres (P = 1.000; Figure 3.6C). PLIN5 protein 
expression was also greater in the peripheral region of the muscle fibres compared 
to the central region (P = 0.001). Overall PLIN5 protein expression did not increase 
with HFHC diet (P = 0.342), although there was a trend towards an increase in type I 
fibres (+28%; P = 0.099). 
3.4.4 Lipid droplet and PLIN protein colocalisation 
Colocalisation analysis was only conducted on type I and IIa fibres due to insufficient 
type IIx fibres being acquired during image capture.   
3.4.4.1 PLIN2 
At baseline the fraction of PLIN2 colocalising to LD was higher in type I fibres (0.41 ± 
0.04) compared to type IIa (0.31 ± 0.04; P = 0.001), with no differences between the 
central region (0.36 ± 0.04) and the peripheral region (0.36 ± 0.04; P = 0.918). 
Following the HFHC diet there was an increase in the fraction of PLIN2 colocalising 
to LD in type I fibres only (+26%; P =0.001), due to increases in both the peripheral 
(32%; P = 0.006) and central regions (+25%; P = 0.031). At baseline type I fibres had 
significantly more PLIN2+ LD in comparison to type IIa fibres (P = 0.001) and there 
was more PLIN2+ LD in the peripheral region of muscle fibres compared to the central 
region (P < 0.001; Figure 3.7A). Following the HFHC diet there was an increase in 
PLIN2+ LD in type I fibres only (+80%; P = 0.005; Figure 3.7A), due to increases in 
both the peripheral (+78%; P = 0.002) and the central regions (+83%; P = 0.017; 
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Figure 3.6A). There were more PLIN2- LD in type I compared to type IIa fibres (P < 
0.001), but no difference in the proportion of PLIN2- LD in the peripheral and central 
region of muscle fibres at baseline (P = 0.446; Figure 3.7B), and this relationship did 
not change with the HFHC diet. At baseline the peripheral region of muscle fibres had 
higher amounts of free PLIN2 (0.065 ± 0.005 μm-2) compared to central (0.041 ± 0.004 
μm-2; P < 0.001), however there were no differences between fibre types and this was 
unaltered after the HFHC diet.  
3.4.4.2 PLIN3 
At baseline the fraction of PLIN3 colocalising to LD was higher in type I fibres (0.32 ± 
0.03) compared to type IIa (0.22 ± 0.04; P < 0.001), with no differences between the 
central region (0.26 ± 0.04) and the peripheral region (0.28 ± 0.04; P = 0.628). 
Following the HFHC diet there was an increase in the fraction of PLIN3 colocalising 
to LD in both type I fibres (+44%; P < 0.001) and type IIa fibres (+39%; P = 0.002). In 
type I fibres this was due to increases in both the peripheral (60%; P < 0.001) and 
central regions (29%; P = 0.012). In type IIa fibres however only the central region 
observed a significant increase (66%; P = 0.001). Type I fibres had significantly more 
PLIN3+ and PLIN3- LD in comparison to type IIa fibres (P < 0.001), but the proportion 
of PLIN3+ and PLIN3- LD in the peripheral and central region of muscle fibres was 
not different (P = 0.219; Figure 3.7C-D). The HFHC diet did not change the number 
of PLIN3+ LD.  However, following the HFHC diet there was a significant increase in 
PLIN3- LD in both type I (+58%; P < 0.001) and type IIa fibres (+43%; P = 0.017; 
Figure 3.7D). In type I fibres the increase was observed in both the peripheral (+69%; 
P < 0.001) and central regions (+47%; P = 0.001), whereas in type IIa fibres there 
was an increase in the peripheral region (+40%; P = 0.026) and a strong trend towards 
an increase in the central region (+48%; P = 0.050; Figure 3.7D). There was no 
difference in free PLIN3 in any fibre type or any region at baseline. The HFHC diet 
reduced free PLIN3 in type I fibres (0.071 ± 0.006 to 0.050 ± 0.008 μm-2; P = 0.010) 
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in the peripheral region (-36%; P = 0.002), and free PLIN3 tended to be lower in the 
central region (-23%; P = 0.093). There was also a trend towards a decrease in free 
PLIN3 in type IIa fibres (0.064 ± 0.007 to 0.051 ± 0.008 μm-2; P = 0.098).  
3.4.4.3 PLIN5 
At baseline the fraction of PLIN5 colocalising to LD was similar between type I fibres 
(0.56 ± 0.04) and type IIa (0.49 ± 0.04; P = 0.095), with no differences between the 
central region (0.54 ± 0.04) and the peripheral region (0.50 ± 0.04; P = 0.416). 
Following the HFHC diet there was an increase in the fraction of PLIN5 colocalising 
to LD in both type I fibres (+27%; P = 0.001) and type IIa fibres (+19%; P = 0.027), 
due to similar increases in central and peripheral region for both fibre types. There 
was more PLIN5+ LD in type I compared to type IIa fibres (P < 0.001) and in the 
peripheral region compared to the central region (P < 0.001), but this relationship was 
unchanged with the HFHC diet (Figure 3.7E). The number of PLIN5- LD was not 
different between fibre types, although there was a trend towards more PLIN5- LD in 
the peripheral compared to the central region of muscle fibres (P = 0.097; Figure 
3.7F). Following the HFHC diet there was no change in PLIN5- LD however there was 
a trend towards an interaction effect (P = 0.054) due to a trend towards an increase 
in PLIN5- LD in type I fibres only (+22%; P = 0.069; Figure 3.7F).  Free PLIN5 was 
significantly higher in type I (0.037 ± 0.003 µm-2) in comparison to type IIa fibres 
(0.028 ± 0.003 µm-2; P = 0.003) and in the peripheral region across fibre types (0.040 
± 0.003 µm-2) compared to the central region (0.025 ± 0.003 µm-2; P < 0.001) and this 
was unaltered with the HFHC diet.  
  
113 
Figure 3.4 Phosphorylation of key insulin signaling intermediates is not impaired 
following 7 days HFHC diet. Representative western blots of Akt ser473 (A), Akt thr308 
(B), AS160 ser588 (C) and AS160 thr642 (D) with coomassie blue stain to show equal 
loading of proteins. Phosphorylation of Akt ser473 (A), Akt thr308 (B), AS160 ser588 (C) 
and AS160 thr642 (D) increased from 0 to 30 minutes during the oral glucose challenge 
and this response was not impaired following 7 days HFHC diet. * Significant increase in 
phosphorylation from 0 to 30 min (P < 0.05). † Significant decrease in phosphorylation from 
30 min to 120 min (P < 0.05). ‡ Significant interaction effect for HFHC diet and time point 
























































































































































Figure 3.5. 7-days HFHC diet induces increases in IMTG content in type I fibres due 
to increases in LD density and size. 7 days HFHC diet increases type I fibre IMTG content 
(A), LD density (B) and LD size (C). Representative images of IMTG content pre and post 
HFHC diet in different fibre types obtained from confocal microscope with a 63x oil 
immersion objective and 1.1 digital zoom (D). Corresponding images of myosin heavy chain 
(MHC I) (stained red for type I fibres) and myosin heavy chain (MHC IIa) (stained blue for 
type IIa fibres), any fibres without a positive red or blue stain were assumed to be type IIx 
fibres (E). White bars represent 25 µm.* Significant difference for type I fibres vs type IIa 
and IIx fibres (P < 0.001). ‡ Significant difference for HFHC diet (P < 0.01). † Significant 
difference for central vs  peripheral region (P < 0.01). †† Significant difference for central vs 
peripheral region after HFHC diet only (P < 0.05). # Significant interaction between fibre 




















































































































































































































Figure 3.6. PLIN protein expression after pre and post 7 days HFHC diet. 7 days HFHC 
diet does not alter PLIN2 (A) or PLIN5 (C) protein expression but increases PLIN3 protein 
expression in type I fibres only (B). Representative images of PLIN2, PLIN3 and PLIN5 
protein expression pre and post the HFHC diet in type I fibres obtained from confocal 
microscope with a 63x oil immersion objective and 1.1 digital zoom (D). White bars 
represent 25 µm. * Significant difference for type I fibres vs type IIa and IIx fibres (P < 0.05). 
# Significant difference for type I fibres vs IIx fibres (P < 0.05).  †Significant difference for 









































































































































































Figure 3.7. HFHC diet increases PLIN2+ LD in type I fibres only. 7 days HFHC diet 
increased PLIN2+ LD in type I fibres (A), whilst there were no changes in PLIN3+ LD (C) or 
PLIN5+ LD (E). PLIN2- LD (B) and PLIN5- LD (F) were not altered with the HFHC diet, 
whereas PLIN3- LD significant increased (D).* Significant difference for type I fibres vs type 
IIa (P < 0.01). ‡ Significant difference for peripheral region vs central region (P < 0.001). ‡ 
Significant difference for the HFHC diet (P < 0.05). # Significant interaction effect between 










































































































































































































































3.4.5 SNAP23 and COX fluorescence intensity 
3.4.5.1 Mitochondria 
COXIV protein expression, representing mitochondrial density, displayed a 
hierarchical fibre type distribution such that type I fibres (64 ± 8 AU) was significantly 
higher in comparison to type IIa (55 ± 7 AU; P = 0.034), and type IIa fibres was 
significantly higher than type IIx fibres (52 ± 8; P = 0.030).  There was also greater 
COXIV protein expression in the peripheral region (70 ± 4 AU) compared to the central 
region across fibres (55 ± 3 AU; P < 0.001). Following the HFHC diet there was no 
change in COXIV protein expression in any fibre type or any region. 
3.4.5.2 SNAP23 
SNAP23 protein expression was only conducted on type I and IIa fibres due to 
insufficient type IIx fibres being acquired during image capture. SNAP23 protein 
expression was similar between type I (24 ± 6 AU) and type IIa fibres (23 ± 5 AU; P 
= 0.469). There was greater SNAP23 protein expression in the plasma membrane 
(35 ± 4 AU) region (P < 0.001; in comparison to both peripheral (27 ± 3 AU) and 
central region (21 ± 2 AU) and in the peripheral compared to the central region (P = 
0.004) and this was unaltered after HFHC diet.  
3.4.6 SNAP23 colocalisation 
Colocalisation data was reported as PCC (the degree of colocalisation between the 
intensities of images representing SNAP23 and either; plasma membrane LD and 
mitochondria; Figure 3.8) 
3.4.6.1 SNAP23 and the plasma membrane  
At baseline there was no significant difference between fibre types for the 
colocalisation of SNAP23 with the plasma membrane for PCC (P = 0.850; Table 3.2) 
and this relationship was unchanged after the HFHC diet.  
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3.4.6.2 SNAP23 and LD 
 At baseline there was no significant difference between fibre types for the 
colocalisation of SNAP23 with LD as measured by PCC (P = 0.172; Table 3.2) and 
this was unaltered after the HFHC diet. 
3.4.6.3 SNAP23 and Mitochondria 
 At baseline type I fibres in comparison to type IIa fibres had significantly more 
colocalisation between SNAP23 and mitochondria measured by PCC (P = 0.024; 
















Data provided as means ± SEM (n = 10 per fibre type per time point per participant). 
PCC, Pearson’s correlation coefficient. * indicates difference in fibre type (P  < 0.05). 
† indicates non-matched pairs significantly different from matched pairs.  
 
Table 3.2.  Pearson’s Correlation coefficients of 
SNAP23 colocalisation to; the plasma membrane, 
lipid droplets and mitochondria 
    




Type I 0.27 ± 0.01 
Type IIa 0.27 ± 0.02 
Post 
Type I 0.26 ± 0.02 
Type IIa 0.25 ± 0.02 




Type I 0.38 ± 0.02 
Type IIa 0.40 ± 0.03 
Post 
Type I 0.36 ± 0.03 
Type IIa 0.38 ± 0.04 
Non-matched pairs  0.21 ± 0.02† 
Mitochondria  
Pre 
Type I 0.66 ± 0.03 
Type IIa 0.62 ± 0.03* 
Post 
Type I 0.65 ± 0.03 
Type IIa 0.61 ± 0.03* 






























Figure 3.8 Representative images of SNAP23 distribution pre and post 7 days HFHC 
diet. Representative images of SNAP23 distribution with plasma membrane (A), LD (B) and 
mitochondria (C) pre and post 7 days HFHC diet in type I fibres obtained from confocal 
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The aim of the present study was to examine the effects of 7 days HFHC diet in 
healthy individuals on IMTG content (LD number and morphology) and the expression 
and subcellular distribution of key proteins related to lipid metabolism. To add context 
to the findings the effects of 7 days HFHC diet on whole body insulin-sensitivity and 
skeletal muscle insulin resistance are also discussed. The first major finding was that 
the HFHC diet increased IMTG content exclusively in type I fibres, due to an increase 
in both LD size and density. PLIN3 was the only PLIN protein to exhibit increased 
expression after 7 days HFHC diet, but this was not mirrored by an increase in PLIN3+ 
LD. Rather, we observed an increased number of PLIN2+ LD in type I fibres. SNAP23 
colocalisation to LD, mitochondria or the plasma membrane was not altered following 
7 days HFHC diet. We examined these adaptations in the context of decreased 
whole-body insulin sensitivity (as measured by the Matsuda ISI), but this occurred 
without impairments in the activation of key intermediates of the skeletal muscle 
insulin signalling cascade. Together, the data shows that following high-fat, high-
calorie feeding IMTG storage is enhanced most likely due to increases in PLIN3 
protein expression and PLIN2+ LD, and these adaptations may contribute to the 
maintenance of the skeletal muscle insulin signalling cascade. 
Following the HFHC diet glucose tolerance and whole body insulin sensitivity as 
measured by the Matsuda index was significantly reduced. The Matsuda index was 
originally designed to be implemented with results derived from a 75g oral glucose 
tolerance test (Matsuda & DeFronzo, 1999), however in the current study the results 
were derived from a 50g glucose load with 15 g whey protein. Tracer-derived 
measurements of insulin sensitivity from the oral glucose challenge analysed in a 
parallel study (Parry et al., in preparation) shows a reduced metabolic clearance rate 
(-15%) likely due to reduced uptake in skeletal muscle.  These findings of reduced 
glucose clearance and insulin sensitivity are contradictory to chapter 2 where no 
122 
reductions in insulin sensitivity were observed following the same HFHC diet protocol, 
thus highlighting different a heterogeneous response to the diet protocol. During the 
current study there were no impairments in phosphorylation of key insulin signalling 
intermediates (AS160 and Akt) during the oral glucose challenge following the HFHC 
diet. This suggests that the reduction in insulin sensitivity observed in this current 
study were not due to lipid metabolite induced disruption of skeletal muscle insulin 
signalling. 
The influx of FA from the diet appear to be instead directed to IMTG stores. The 
finding that IMTG content increases following high-fat high-calorie feeding is in line 
with previous studies investigating the short-term effects of a eucaloric or hypercaloric 
high-fat diet (Schrauwen-Hinderling et al., 2005; Gemmink et al., 2017a). 
Furthermore, we demonstrate for the first time that IMTG content is augmented 
exclusively in type I fibres. IMTG accumulation following 6 h lipid infusion during a 
hyperinsulinaemic-euglycaemic clamp is also specific to type I fibres (Shepherd et al., 
2017b), and it is now evident from the current results that this pattern of  fibre-type 
specific accretion continues following more chronic lipid excess (7-days HFHC diet). 
Type I fibres are characterised by a higher mitochondrial content, higher abundance 
of lipolytic regulatory proteins and an enhanced ability to utilise IMTG stores during a 
bout of moderate-intensity exercise (Shepherd et al., 2013; Watt & Cheng, 2017). 
Therefore, type I fibres are appreciably more equipped to store an influx of dietary FA 
as IMTG.  
We also examined changes in IMTG content on a subcellular-specific basis, as well 
as exploring adaptations to LD morphology. In this respect, increased IMTG content 
in type I fibres following the HFHC diet occurred in both the peripheral and central 
region, and was due to an increase in both LD size and number. Seven days HFHC 
diet also augmented IMTG content specifically in the peripheral region of type IIa and 
IIx fibres which was again due to elevations in both LD size and number. Interestingly, 
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LD size was also greater following the HFHC diet in the central region of type IIa and 
IIx fibres, although this did not result in increased IMTG content. These distinct 
patterns of fibre and region-specific IMTG accumulation and changes in LD 
morphology are the first of their kind in the literature. Moreover, they are indicative of 
the progression of IMTG accumulation in muscle, whereby lipid accumulates in type 
I fibres prior to type IIa or IIx fibres, changes in LD size precede an increase in LD 
density, and this occurs in the peripheral region of the cell before the central region.  
Increased IMTG content near the plasma membrane of muscle fibres has been 
associated with insulin resistance (Chee et al., 2016) particularly if these IMTG stores 
are characterised by larger LD (Nielsen et al., 2017; Daemen et al., 2018). The 
accumulation of IMTG near the plasma membrane appears to be of detriment due to 
the close proximity of insulin signalling cascades. In particular, increases in LD size 
rather than number near the plasma membrane will be less favourable because larger 
LD have a lower surface area to volume ratio which is proposed to result in lower 
IMTG turnover and subsequent accumulation of lipid metabolites. In this study the 
peripheral region was defined to identify an area within the muscle fibres that was 
distinct from the central region of the cell but in close proximity to the plasma 
membrane and therefore near to insulin signalling and trafficking of FA into the 
myocyte. The predominant increase in IMTG stores occurred in type I fibres and this 
was accountable to an increase in LD size and number in both the peripheral and 
central regions. We propose that the beneficial increase in LD number observed in 
the peripheral region would help to maintain IMTG turnover and minimise the 
accumulation of lipid metabolites near the insulin signalling cascades located at the 
plasma membrane.  
LD can increase in size by the following mechanisms: 1) coalescence of fusion of two 
LDs via pores in the phospholipid monolayer, 2) ripening of one LD through transfer 
of molecules from a LD decreasing in size, and 3) expansion of LD due to increased 
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synthesis of IMTG from FA (Gemmink et al., 2017b). Increased IMTG synthesis has 
been hypothesised to increase LD size in such a way that increases distance between 
phospholipid molecules on the LD membrane thus permitting the binding of regulatory 
proteins such as PLIN proteins (Hesselink et al., 2017). Recently Gemmink et al., 
(2016) found that LD size and number increased following acute elevation of FFA 
from prolonged fasting; however, this was entirely due to an increase in PLIN5+ LD. 
More importantly, the individuals in this study who had the highest increase in IMTG 
content also exhibited the smallest reduction in insulin sensitivity (Gemmink et al., 
2016). Therefore, larger LDs may not necessarily impede insulin sensitivity if they are 
decorated with PLINs. 
In the present study PLIN3 protein expression increased in type I fibres only. PLIN3 
has been linked to formation of new LD following lipid loading in cultured differentiated 
adipocytes (Wolins et al., 2005). If a similar role exists in skeletal muscle we might 
have expected to see an increase in PLIN3+ LD following the HFHC diet; however, 
only an increase in PLIN3- LD was observed. There was however a reduction in free 
PLIN3 in type I fibres with an increase in the fraction of PLIN3 colocalising to LD. This 
indicates that PLIN3 is targeted to LD that already have PLIN3 associated and 
therefore suggests that PLIN3 supports LD growth and stability, rather than increase 
in LD density in skeletal muscle. PLIN3 has also been observed in the mitochondria 
in skeletal muscle (Ramos et al., 2014) and PLIN3 knockdown in primary myotubes 
strongly reduces FA oxidation (Covington et al., 2015). We therefore cannot exclude 
the possibility that the increase in PLIN3 was related to mitochondrial adaptations.  
Despite there not being an increase in PLIN2 protein content there was an increase 
in PLIN2+ LD in type I fibres. This occurred without a change in free PLIN2 but with 
an increase in the fraction of PLIN2 colocalising to LD in type I fibres. Together this 
data suggests that the proportion of PLIN2 that is already localised to LD is 
redistributed to newly formed LD. Previous research has shown an increase in 
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PLIN2+ LD without increases in PLIN2 protein expression in trained individuals 
following lipid infusion (Shepherd et al., 2017b), highlighting that when there is 
sufficient PLIN2 in muscle fibres it can be redistributed to the expanded LD pool.  
PLIN2 is associated with LD biogenesis primarily in adipocytes (Wolins et al., 2005) 
and cell culture studies (Imamura et al., 2002). PLIN2 is localised at clusters in the 
cytoplasmic leaflet of the endoplasmic reticulum where LD biogenesis occurs 
(Robenek et al., 2006). Muscle-specific overexpression of PLIN2 increases IMTG 
storage in rats fed a high-fat diet without accumulation of lipid metabolite DAG 
(Bosma et al., 2012a). Newly-formed LD may therefore become associated with 
PLIN2 leading to an increase in PLIN2+ LD, and theoretically this may support IMTG 
storage rather than accumulation of lipid metabolites such as DAG.  
There was a trend towards an increase in PLIN5 protein expression in type I fibres 
only. This is similar to finding of an increase in PLIN5 protein expression in whole 
muscle homogenates after 5 days HFHC diet (Gemmink et al., 2017a). This increase 
in PLIN5 protein expression existed without an increase in PLIN5+ LD but with an 
increase in the fraction of PLIN5 colocalising to LD in type I fibres. This suggests that 
any increase in PLIN5 protein expression is directed to LD already associated with 
PLIN5. PLIN5 has been primarily associated with oxidative capacity (Koves et al., 
2013) and IMTG oxidation. For example PLIN5 protein expression is upregulated 
following endurance training (Louche et al., 2013; Shepherd et al., 2013) and during 
a moderate-intensity bout of exercise PLIN5+ LD are preferentially used (Shepherd 
et al., 2013). Recent findings suggest that PLIN5 protein expression and lipid area 
fraction covered by PLIN5+ LD correlated positively with VO2max and ex vivo fatty acid 
oxidation but not insulin sensitivity (Gemmink et al., 2018). Increased LD content due 
to increases in PLIN5+ LD are associated with blunted reductions in insulin sensitivity 
following acute FFA elevation from prolonged fasting (Gemmink et al., 2016). Given 
PLIN5’s proposed role in regulating IMTG lipolysis, in the current study the increased 
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faction of PLIN5 to LD may function to support the consistent turnover of PLIN5+ LD 
pool and thus help to minimise accumulation of lipid metabolites.  
The use of previously validated immunofluorescence microscopy techniques 
(Shepherd et al., 2012, 2013; Shepherd et al., 2017b) to examine fibre-type and 
region specific changes in IMTG content and perilipin protein expression in addition 
to colocalisation of PLIN proteins to LD following HFHC diet is a novel strength of this 
study. A limitation of this method however is that colocalisation analysis could only be 
conducted on a single PLIN protein with LD. We cannot exclude the possibility 
therefore that LD have multiple perilipin proteins colocalised to them. The increases 
observed in PLIN3- LD and PLIN5- LD could be due increases in LD coated with 
PLIN2. PLIN- LDs may also be newly formed LD that did not have sufficient PLIN 
associated to them to be detected by the lower detection limit of the microscope. 
Whether PLIN proteins work together or in isolation in regulating LD dynamics remain 
an avenue for future research.  
Contrary to our hypothesis SNAP23 colocalisation to LD, mitochondria or the plasma 
membrane did not change with the HFHC diet. Treatment of cardiomyocytes with 
oleic acid increases the LD associated pool of SNAP23 and reduces SNAP23 content 
at the plasma membrane (Bostrom et al., 2007), leading to the hypothesis that LD 
highjack SNAP23 from the plasma membrane to assist in LD fusion following lipid 
excess (Sollner, 2007).  As 7 days of HFHC diet did not alter the distribution or 
localisation of SNAP23 it is likely that LD highjacking of SNAP23 in skeletal muscle 
occurs over longer time periods of lipid excess such as in obesity and the 
development of type 2 diabetes. Nevertheless we did observe an increase in LD size 
and therefore it is also plausible that there was sufficient SNAP23 within muscle fibres 
to regulate LD fusion if it occurred without the need to ‘highjack’ SNAP23 from the 
plasma membrane. 
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In conclusion, the present study has generated novel evidence that 7 days HFHC diet 
induces fibre type specific increases in IMTG stores primarily aided by an increase in 
PLIN3 protein expression and a redistribution of PLIN2 to LD. We propose that these 
adaptations prevent accumulation of lipid metabolites (FA-CoA, DAG and ceramides) 
known to disrupt the skeletal muscle insulin-signalling cascade and contribute to the 




Chapter 4. Hormone sensitive lipase preferentially 
redistributes to lipid droplets associated with 





Hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) control 
skeletal muscle lipolysis. ATGL is present on the surface of lipid droplets (LD) 
containing intramuscular triglyceride (IMTG) in both the basal state and during 
exercise. HSL translocates to LD in ex vivo electrically stimulated rat skeletal muscle. 
Perilipin-2 and perilipin-5 associated lipid droplets (PLIN2+ and PLIN5+ LD) are 
preferentially depleted during exercise in humans indicating these PLINs may control 
muscle lipolysis. We aimed to test the hypothesis that in human skeletal muscle in 
vivo HSL (but not ATGL) is redistributed to PLIN2+ and PLIN5+ LD during moderate-
intensity exercise. Muscle biopsies from 8 lean trained males (age 21±1 years, BMI 
22.6±1.2 kg.m-2 and V̇o2peak 48.2±5.0 ml.min-1.kg-1) were obtained before and 
immediately following 60 min of cycling exercise at ~59% V̇o2peak. Cryosections were 
stained using antibodies targeting ATGL, HSL, PLIN2 and PLIN5. LD were stained 
using BODIPY 493/503. Images were obtained using confocal immunofluorescence 
microscopy and object based colocalisation analyses were performed. Following 
exercise, HSL colocalisation to LD increased (P<0.05), and was significantly larger to 
PLIN5+LD (+53%) than to PLIN5-LD (+34%) (P<0.05), while the increases in HSL 
colocalisation to PLIN2+LD (+16%) and PLIN2-LD (+28%) were not significantly 
different. Following exercise the fraction of LD colocalised with ATGL (0.53  0.04) 
did not significantly change (P<0.05) and was not affected by PLIN association to the 
LD. This study presents the first evidence of exercise-induced HSL redistribution to 




Intramuscular triglyceride (IMTG) stores provide a readily available source of energy 
during moderate-intensity exercise in healthy individuals.  IMTG are stored within lipid 
droplets (LD) which are located in close proximity to mitochondria (Shaw et al., 2008), 
which is believed to enable fatty acids (FA) liberated from IMTG to be efficiently 
shuttled to mitochondria to produce energy. Previously there was some debate as to 
whether IMTG was used during exercise because the presence of extramyocellular 
lipid deposits in muscle samples confounded measures of net changes in IMTG 
content in response to exercise (Watt et al., 2002). Recent developments in confocal 
immunofluorescence microscopy have enabled the exclusion of extramyocellular lipid 
deposits and also permit fibre type-specific analyses to be performed.  Using this 
approach, it is now well-established that IMTG stores are preferentially used from 
type I fibres in endurance-trained individuals during moderate-intensity exercise (van 
Loon et al., 2003a; Shepherd et al., 2013). 
Hormone sensitive lipase (HSL) was previously believed to be the only rate-limiting 
enzyme responsible for triacylglycerol (TAG) lipolysis (Zechner et al., 2009).  
However, it was shown that mice deficient in HSL accumulated diacylglycerol (DAG) 
in muscle and other tissues in response to fasting (Haemmerle et al., 2002a), 
suggesting that other lipases must exist.  Adipose triglyceride lipase (ATGL) was 
subsequently identified as a novel lipase which preferentially hydrolyses TAG 
(Zimmermann et al., 2004).  Moreover, overexpression of ATGL in human primary 
myotubes results in reduced TAG content and increased FA release and oxidation 
(Badin et al., 2011), whilst ATGL-KO mice accumulate TAG in skeletal muscle 
(Haemmerle et al., 2006). A pertinent role for ATGL in IMTG hydrolysis stems from 
the finding that IMTG breakdown still occurs in electrically stimulated rat muscle 
following acute pharmacological inhibition of HSL or in muscle of HSL-KO mice 
(Alsted et al., 2013). Conversely, impairment of IMTG lipolysis during exercise in mice 
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with muscle specific deletion of ATGL was not profound enough to impact on 
submaximal or maximal exercise performance which may be due to a compensatory 
increase in HSL mediated TAG hydrolysis (Dube et al., 2015).  Together these data 
suggest that both ATGL and HSL mediate IMTG hydrolysis and both can compensate 
functionally when the other is absent. Muscle TAG and DAG accumulate in ATGL-KO 
and HSL-KO mice respectively (Haemmerle et al., 2002a; Haemmerle et al., 2006). 
This, in addition to HSL having a higher specificity for DAG as a substrate in 
comparison to TAG (Fredrikson et al., 1981a), has led to the suggestion that ATGL 
and HSL hydrolyse IMTG in a sequential process in skeletal muscle. Importantly, 
ATGL and HSL together account for ~98% of contraction-induced TAG lipase activity 
in rat skeletal muscle (Alsted et al., 2013).  
HSL activity in skeletal muscle is increased during moderate-intensity exercise 
through protein phosphorylation induced by contraction and adrenergic signalling 
mechanisms (Watt et al., 2003c; Watt et al., 2006). In addition to regulation of HSL 
via phosphorylation, Prats et al. (2006) elegantly demonstrated using confocal 
immunofluorescence microscopy that HSL translocates to LD in rat skeletal muscle 
ex vivo following stimulation with adrenaline or during electrically-induced muscle 
contractions. Additional examination using immunogold transmission electron 
microscopy on single rat muscle fibres also generated images evidencing HSL 
accumulation beneath the LD phospholipid monolayer suggesting that once HSL 
translocates to the LD it subsequently penetrates the phospholipid monolayer to 
access IMTG (Prats et al., 2006). Moreover, in this study the colocalisation of HSL to 
the LD-associated protein perilipin-2 (PLIN2) increased in response to both stimuli, 
implicating PLIN2 in the regulation of HSL translocation to the LD (Prats et al., 2006). 
This was the first study to generate evidence of HSL translocation in muscle in 
response to lipolytic stimuli. It is yet to be determined, however, if a similar mechanism 
occurs in human skeletal muscle within an in vivo environment where the regulation 
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of HSL activity is under the control of multiple regulatory signalling factors that cannot 
be replicated ex vivo.    
Under resting conditions a proportion of ATGL localizes to LDs in human skeletal 
muscle, and this relationship is unaltered by moderate-intensity exercise (Mason et 
al., 2014a). It is therefore reasonable to postulate that ATGL is regulated on the LD 
surface by its co-activator protein, CGI-58 (Lass et al., 2006).  Indeed, electrical 
stimulation of rat skeletal muscle ex vivo augments the co-immunoprecipitation of 
ATGL and CGI-58 (MacPherson et al., 2013a). The PLIN proteins are also believed 
to play a key regulatory role in controlling IMTG breakdown.  Notably, the only 
member of the PLIN protein family that can bind ATGL is PLIN5, and in cells 
expressing PLIN5 both ATGL and CGI-58 are recruited to the LD under basal 
conditions (Wang et al., 2011a) suggesting that PLIN5 plays an important role in 
determining the activity of ATGL. Although the majority of the available evidence from 
cell culture studies suggests that PLIN5 (and the other PLIN proteins) facilitate the 
storage of TAG under basal conditions (Listenberger et al., 2007; Wang et al., 2011a; 
Laurens et al., 2016), PLIN5 has also been shown to promote TAG hydrolysis under 
conditions stimulating lipolysis in cultured cells (Wang et al., 2011a).  Furthermore, 
we previously reported that LD associated with PLIN2 or PLIN5 are preferentially 
utilised during 1 hour of moderate-intensity exercise (Shepherd et al., 2012, 2013).  
Whether ATGL localises to those LDs with PLIN5 associated and therefore facilitate 
their preferential use during exercise is yet to be investigated. 
Using confocal immunofluorescence microscopy we have previously developed 
methods to identify LD with (PLIN+ LD) or without PLIN associated (PLIN- LD) 
(Shepherd et al., 2012, 2013). The aim of the present study was to extend these 
methods and investigate the localisation of the key lipolytic enzymes ATGL and HSL, 
with PLIN2 and PLIN5 associated LD under resting conditions and in response to an 
acute bout of exercise in trained human skeletal muscle.  We hypothesised that 
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exercise would lead to an increase in HSL colocalisation to LDs, and that these LDs 
would have PLIN2 or PLIN5 associated.  We also hypothesised that ATGL would 
already be colocalised to LD and these LD would be PLIN5 associated.  
4.3 Methods 
4.3.1 Participants and ethical approval 
Archived muscle samples from a prior study of our laboratory comparing the effects 
of sprint interval and endurance training on IMTG utilisation during exercise 
(Shepherd et al., 2013) were utilised in the present study. Specifically, muscle 
samples from 8 lean, healthy male volunteers (see Table 4.1 for brief subject 
characteristics) were analysed in the present study and the informed consent 
provided originally covered this subsequent use. The study was approved by the 
Black Country NHS research ethics committee (West Midlands, UK) and conformed 








Data provided are means ± SEM (n = 8).  BMI, body mass index; FM, fat mass; FFM, 
fat-free mass; Wmax, maximum workload; ISI, insulin sensitivity index. Data obtained 
from post endurance training intervention from (Shepherd et al., 2013). 
Table 4.1 Subject characteristics 
Age (years) 21 ± 1 
Height (m)  1.77 ± 0.03 
Body mass (kg) 70.8 ± 4.5 
BMI (kg m-2) 22.6 ± 1.2 
V̇o2peak (l min-1) 3.40 ± 0.38 
V̇o2peak (l min-1 kg-1) 48.2 ± 5.0 
Wmax (W) 253 ± 16 
FFM (kg) 51.1 ± 2.7 
FM (kg) 12.2 ± 1.9 
ISI-Matsuda 4.7 ± 0.7 
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4.3.2 Experimental procedures 
Following completion of 6 weeks endurance training (cycling at 65% VO2peak for 40-
60 mins 5 days per week; see Shepherd et al., 2013 for further details), participants 
rested for >72 h and consumed a controlled diet (50%, carbohydrate, 35% fat and 
15% protein) matched to habitual caloric intake for 24 h prior to the experimental trial. 
Following an overnight fast (>10 h), participants performed 60 min cycling on a 
stationary ergometer at 50 ± 2% Wmax (equating to 59% V̇o2peak achieved post-
training intervention). Expired air was collected (5 min collection period) at 15 min 
intervals (t = 15, 30, 45, 60 min), using an online gas system (Oxycon Pro, Jaeger, 
Germany) in order to calculate rates of carbohydrate and lipid oxidation (Table 4.2). 
Additionally, heart rate was recorded every 5 min (Table 4.2).   
Muscle biopsies were obtained from the m. vastus lateralis of one leg before (0 min) 
and immediately after exercise (60 min). The biopsied leg was randomised to avoid 
any bias of dominant leg. Initially local anaesthetic (1% lidocaine; B Braun, Sheffield, 
UK) was injected into the skin and fascia of the muscle before two small incisions 
were made approximately 2 cm apart.  Prior to exercise, a muscle biopsy (~100 mg) 
was extracted from the distal incision using the Bergstrӧm needle technique 
(Bergstrӧm, 1975). The muscle biopsy was first dissected from any fat or connective 
tissue. A portion (60mg) of muscle was immediately embedded in Tissue-Tek OCT 
compound (Sakura Finetek Europe, The Netherlands) and frozen in liquid nitrogen-
cooled isopentane for subsequent immunohistochemical analyses. Following 
exercise, the second muscle biopsy was taken from the proximal incision using the 
method described above.  
4.3.3 Analysis of muscle samples 
4.3.3.1 Immunofluorescence staining 
Cryosections (5 μm) were cut at -25oC onto ethanol-cleaned glass slides. 
Cryosections of both pre-and post-exercise samples from one participant were placed 
135 
on a single slide to account for any variation in staining intensity between sections. 
Sections were fixed for 1 h in 3.7% formaldehyde, rinsed 3 x 30 s in doubly distilled 
water (dd H2O) and permeabilised in 0.5% Triton X-100 for 5 min, before being 
washed 3 x 5 min in Phosphate Buffered Saline (PBS, 137mM sodium chloride, 3 mM 
potassium chloride, 8 mM sodium phosphate dibasic and 3mM potassium phosphate 
monobasic, pH of 7.4). Subsequently, slides were incubated with primary antibodies 
(overnight for HSL analysis, 1 hr for ATGL analysis) before being washed again 3 x 
5 min in PBS. Sections were then incubated with complementary secondary 
fluorescence-conjugated antibodies for 30 min, followed by a further 3 x 5 min PBS 
washes. To visualise LD, sections were incubated with BODIPY 493/503 (Invitrogen, 
Paisley, UK, D3922, dilution 1:50) for 20 min followed by a further 1 x 5 min PBS 
wash. After the final wash, coverslips were mounted with Vectashield (H-1000, Vector 
Laboratories, Burlingame, CA, USA) and sealed. HSL and ATGL visualisation was 
achieved using rabbit polyclonal anti-HSL (Abcam, Cambridge, UK, ab 63492, dilution 
1:50) or rabbit polyclonal anti-ATGL (Abcam, Cambridge, UK, Ab109251, dilution 
1:50) respectively, followed by application of Alexa Fluor goat anti-rabbit IgG 546 
secondary antibody (Invitrogen, Paisley, UK, A-11035, dilution 1:100). PLIN2 was 
visualised with mouse monoclonal anti-adipophilin (PLIN2) (American Research 
Products, MA, USA, Cat. #03-610102, dilution 1:50) and Alexa Fluor goat anti-mouse 
IgG1 633 secondary antibody (Invitrogen, Paisley, UK, A-21126, dilution 1:100).  
PLIN5 was visualised with guinea pig polyclonal anti-OXPAT (PLIN5) (Progen 
Biotechnik, Germany, GP31, dilution 1:100) and Alexa Fluor goat anti-guinea pig IgG 
633 secondary antibody (Invitrogen, Paisley, UK, A-21105, dilution 1:100). All 
antibodies were previously validated in our lab except the rabbit polyclonal anti-HSL 
(see supplementary material 1 for validation results).  Initially, sections were co-
stained for HSL and LD to investigate HSL localisation to LD. HSL and LD were then 
co-stained with either PLIN2 or PLIN5 in order to determine HSL localisation to LD 
either associated (PLIN+ LDs) or not associated with each PLIN protein (PLIN- LDs). 
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This process was then repeated with ATGL and LD being co-stained with either PLIN2 
or PLIN5 to establish ATGL localisation to LD either associated (PLIN+ LDs) or not 
associated with each PLIN protein (PLIN- LDs). As described previously (Shepherd 
et al., 2012, 2013; Strauss et al., 2016; Shepherd et al., 2017b), before any 
colocalisation analysis was undertaken controls were included to confirm absence of 
1) bleed through of fluorophores in opposing channels when single staining was 
performed, 2) non-specific secondary antibody binding, and 3) sample 
autofluorescence. 
4.3.3.2 Image capture, processing and data analysis  
An inverted confocal microscope (Zeiss LSM710; Oberkochen, Germany) was used 
to obtain digital images of cross-sectionally orientated muscle sections. An argon 
laser was used to excite the Alexa Fluor 488 fluorophore whilst a helium-neon laser 
excited the Alexa Fluor 546 and 633 fluorophores. Images were initially acquired with 
a 40x 0.7 NA oil immersion objective to examine the cellular distribution of HSL and 
LDs.  The same system was used but with a 16x digital magnification to acquire 
images that were used to investigate HSL and LD colocalisation. A more powerful oil 
immersion objective of 63x 1.4 NA combined with 16x digital magnification was then 
used to identify LD that were coated with PLIN and assess the localisation of HSL to 
these LD. ATGL appeared punctate and dispersed throughout the cell and to capture 
its distribution more representatively, images were acquired using the 63X 1.4 NA 
objective at a wider 8x digital magnification. We were unable to stain for and identify 
type I fibres during the immunohistochemical analysis in the current study due to 
limitations on the number of fluorophores that could be used simultaneously. Instead, 
only muscle fibres that had the highest lipid content were imaged. Type I fibres 
typically have a high IMTG content alongside a large oxidative capacity (Shaw et al., 
2008; Shepherd et al., 2013), and we have previously shown that IMTG utilisation 
during exercise occurs specifically in type I fibres (Shepherd et al., 2012, 2013). 
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Results from our previous study also clearly demonstrated that ‘in comparison to type 
IIa fibres, type I fibres had 3-4 fold and  2-3 fold greater IMTG stores pre and post-
exercise, respectively (Shepherd et al., 2013). Therefore, by selecting fibres with the 
highest lipid content we are assuming those fibres would also have the highest 
oxidative capacity and rates of IMTG utilisation during exercise. We expect that this 
approach would consequently detect changes in lipase association with LD if they 
existed. For each participant, images were obtained of pre-exercise muscle fibres 
(n=15) and post-exercise muscle fibres (n=15) with the central region of the fibre 
imaged for each staining combination. Due to insufficient sample being available, 
ATGL immunohistochemical analysis was only performed on 7 participants.  
Image analysis was undertaken using Image-Pro Plus 5.1 software (Media 
Cybernetics, Bethesda, MD, USA).  For colocalisation analysis, an intensity threshold 
was selected to denote the positive signal for HSL or ATGL, LD (Figure 4.1) and 
PLIN2 or PLIN5. These thresholds were then used to produce binary images of HSL 
or ATGL, LD, PLIN2 or PLIN5 that were subsequently used for colocalisation analysis 
(Figure 4.1). A co-localisation map displaying the merged images was generated, and 
the overlapping regions extracted to a separate image. Initially colocalisation between 
LD and HSL was measured by expressing the total number of extracted objects as a 
proportion of the total number of LDs. To determine HSL colocalisation to LDs with or 
without PLIN associated the following analysis was conducted. LD that colocalised 
with PLIN were first characterised as PLIN+ and PLIN- LDs (Shepherd et al., 2013). 
The number of PLIN+ LDs and PLIN- LDs that overlapped with HSL was then counted 
per image pre and post-exercise.  The number of PLIN+ and PLIN- LDs colocalised 
with HSL was then expressed relative to area, thereby enabling us to quantify the 
density of each LD subgroup to be colocalised with HSL. HSL colocalisation to PLIN2 
or PLIN5 was also quantified irrespective of LD presence. The same process was 
then repeated for ATGL instead of HSL. Additional analysis on the size and number 
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of HSL or ATGL objects per image was conducted to generate a clear understanding 
of HSL and ATGL distribution pre- and post-exercise. 
4.3.4 Statistics 
All data are expressed as means ± SEM. Significance was set at P < 0.05. A student’s 
paired t test was used to measure differences from pre- to post-exercise in variables 
relating to HSL or ATGL colocalisation to LD. A Wilcoxon signed rank test was used 
to measure the differences in HSL average area from pre- to post-exercise due to 
non-normally distributed data. A two-way within-subjects ANOVA was used to 
measure the differences in HSL colocalisation with LD pre and post-exercise, where 
within subjects factors were identified as ‘time’ (pre vs post-exercise) and ‘HSL-
colocalisation’ (HSL+ LD vs. HSL- LD). A two-way within-subjects ANOVA was also 
used to measure the differences in HSL or ATGL colocalisation to PLIN+ and PLIN- 
LDs, pre- and post-exercise. Here, the within-subject factors were identified as ‘time’ 
(pre- vs. post-exercise) and ‘PLIN-association’ (PLIN+ LD vs. PLIN- LD). Significant 
main effects or interaction effects were assessed using Bonferroni adjustment post 




4.4.1 Substrate utilisation  
The RER remained stable during the 60 min of cycling at 59 ± 2% V̇o2peak. Fat 
oxidation rates increased throughout the exercise bout and averaged 45 ± 3% of total 
substrate oxidation (Table 4.2).  
 
Data provided are means ± SEM (n = 8). CHO, carbohydrate; RER, respiratory 
exchange ratio. Data obtained from Shepherd et al. (2013). 
4.4.2 Increased HSL localisation to LDs following exercise 
Images of immunofluorescence staining of HSL showed large storage clusters 
dispersed throughout the cell (Figure 4.2A). Fibres that exhibited a high lipid content 
were selected and images of HSL and BODIPY 493/503 were obtained from the 
central part of each fibre at 16x digital magnification.  Using this approach, it became 
clear that in response to exercise there was a shift in the distribution of HSL from 
large clusters to a greater number of smaller, discrete clusters (representative images 
shown in Figure 4.2B).  Accordingly, there was a significant increase in the number 
Table 4.2. Substrate utilisation during 60 min cycling at 60%  V̇o2peak 
 15 min 30 min 45 min 60 min Overall 
Heart rate  
(beats.min-1) 
134 ± 3 139  ± 5 139 ± 4 139 ± 6 138 ± 4 
% of V̇o2peak 58 ± 2 59 ± 2 60 ± 2 58 ± 2 59 ± 2 
RER 0.88 ± 0.01 0.86 ± 0.01 0.86 ± 0.01 0.85 ± 0.01 0.86 ± 0.01 
CHO oxidation  
(g.min-1) 
1.48 ± 0.08 1.38 ± 0.08 1.36 ± 0.1 1.26 ± 0.09 1.37 ± 0.07 
(% of total oxidation) 61.7 ± 3.4 57.2 ± 3.6 54.7 ± 3.2 52.8 ± 4.2 56.6 ± 3.1 
Fat oxidation  
(g.min-1) 
0.43 ± 0.05 0.49 ± 0.06 0.52 ± 0.05 0.54 ± 0.07 0.49 ± 0.05 
(% of total oxidation) 40.1 ± 3.3 44.5  ± 3.5 47.0 ± 3.2 48.9 ± 4.1 45.1 ± 3.1 
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of HSL clusters from pre (0.0919 ± 0.0068 µm-2) to post-exercise (0.1250 ± 0.0082 
µm-2; P = 0.001) whilst the size of each HSL cluster significantly decreased from pre 
(Mdn = 44.20) to post-exercise (Mdn = 38.04; Z = 2.4; P = 0.025). Importantly, HSL 
protein content as measured by fluorescence intensity did not change from pre- (39 
± 3 AU) to post-exercise (42 ± 4 AU; P = 0.107).  The fraction of LD colocalised with 
HSL clusters significantly increased (19%; P = 0.014; Figure 4.3A). At baseline, there 
were significantly more LD that were colocalised to HSL than LD without HSL 
colocalisation (P = 0.033; Figure 4.3B). Following exercise there was a significant 
interaction effect (P = 0.014), the number of LD that were colocalised to HSL 
significantly increased from pre to post-exercise (+21%, P = 0.014) whereas the 
number of LD without HSL colocalisation showed a trend towards a decrease pre to 
post-exercise (- 22%, P = 0.063; Figure 4.3B). 
4.4.3 ATGL and LD analysis 
Immunofluorescence staining of ATGL showed a distinct punctate pattern throughout 
the cytosol which was unaltered following exercise (Figure 4.4). ATGL protein content 
as measured by fluorescence intensity was not significantly different from pre (7  1 
AU) to post-exercise (8  1 AU; P = 0.354).  The average area of each ATGL object 
per image was unchanged from pre (40.61  8.72 µm-2) to post-exercise (41.35  9.66 
µm-2, P = 0.733). The number of ATGL objects was also unchanged from pre (0.044 
 0.004 µm-2) to post-exercise (0.044  0.002 µm-2; P = 0.925). The fraction of LD 
colocalised with ATGL was not significant differently from pre (0.53  0.04) to post-
exercise (0.43  0.05, P = 0.069).  As such, the number of LD colocalised with ATGL 
was not different from pre (0.0331  0.0035 µm-2) to post-exercise (0.0285  0.0040 
µm-2; P = 0.326). Similarly, the number of LD without ATGL colocalisation was not 
different from pre (0.0304  0.0028 µm-2) to post-exercise (0.0350  0.0021 µm-2; P = 
0.253). 
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4.4.4 Relationship between HSL, PLIN2 or PLIN5 and LD  
To quantify colocalisation between HSL and PLIN2+ LD or PLIN2- LD, images of 
HSL, PLIN2 and LD were acquired pre and post-exercise at 16x magnification using 
a 63x 1.4 NA objective (Figure 4.5A). This process was then repeated for HSL, PLIN5 
and LD (Figure 4.5B). The number of HSL objects colocalised to PLIN2 increased 
from pre (0.0688 ± 0.0030 µm-2) to post-exercise (0.0773 ± 0.0020 µm-2; P = 0.049). 
However, not all LDs have PLIN2 bound to them, and therefore we investigated the 
colocalisation of HSL with PLIN2+ and PLIN2- LDs.  Pre-exercise, the number of 
PLIN2+ LD colocalised to HSL was greater (0.0565 ± 0.0043 µm2) than the number 
of PLIN2- LD not colocalised with HSL (0.0205 ± 0.0019 µm-2; P < 0.001; Figure 4.6A). 
Exercise led to an increase in HSL colocalisation to both PLIN2+ LD (+16%) and 
PLIN2- LD (+28%; Fig. 6A, P = 0.047) post-exercise. There was however, no 
interaction effect for exercise and PLIN2 presence on the LD (P = 0.611).  
The number of HSL objects colocalised to PLIN5 also increased from pre (0.0573 ± 
0.0043 µm-2) to post-exercise (0.0772 ± 0.0056 µm-2; P = 0.002). Pre-exercise, the 
number of PLIN5+ LD colocalised with HSL was greater (0.0406 ± 0.0043 µm-2) 
compared to the number of PLIN5- LD without HSL colocalisation (0.0149 ± 0.0015 
µm-2; P = 0.001; Figure 4.6B). There was a main effect for exercise on HSL 
colocalisation to LD (P < 0.001; Figure 4.6B), such that HSL colocalisation to LD 
increased. Moreover, there was a significant interaction effect for exercise and PLIN5 
presence on the LD. The increase in HSL colocalisation to PLIN5+ LD (+53%) was 
greater than the increase to PLIN5- LD (+34%; P = 0.006; Figure 4.6B).  
4.4.5 Relationship between ATGL, PLIN2 or PLIN5 and LD 
To quantify colocalisation between ATGL and PLIN2+ LD or PLIN2- LD, 16x 
magnification images on a 63x 1.4 NA objective were acquired pre- and post-exercise 
of ATGL, PLIN2 and LD (Figure 4.4B). This process was then repeated for ATGL, 
PLIN5 and LD. Pre-exercise, there was greater ATGL colocalised to PLIN2+ LD 
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(0.0224  0.0029 µm-2) compared to PLIN2- LD (0.0057  0.001 µm-2, P < 0.001; 
Figure 4.7A) and this was unaltered with exercise (P = 0.187). Pre-exercise, more 
ATGL was colocalised to PLIN5+ LD (0.0222  0.0017 µm-2) compared to PLIN5- LD 
(0.0109  0.0019 µm-2, P < 0.001; Figure 4.7B) and this was also not altered with 
exercise (P = 0.287). There was no significant difference in the amount of ATGL 
colocalised to PLIN2 from pre (0.037  0.0033 µm-2) to post- exercise (0.037  0.0023 
µm-2; P = 0.985). There was also no significant difference in the amount of ATGL 
colocalised to PLIN5 from pre (0.0305  0.0018 µm-2) to post-exercise (0.0311  
0.0023; P = 0.877). 
 
Figure 4.1.  Method of colocalisation analysis. Binary images of objects 
representing HSL (A) and LD (B) identified by a selected intensity threshold to signify 
a positive signal for HSL or LD, respectively. Colocalisation of HSL objects and LD 
was investigated by merging the images (C), and the extracted objects (D) represents 
positive colocalisation between HSL and LD. Any LD that overlapped with a HSL 
object was counted as colocalisation event. If the same HSL object over-lapped more 
than once with a LD then this was counted as a dual colocalisation event and omitted 
from the analysis, allowing for only one colocalisation event to be counted. The same 
procedure was used to obtain colocalisation analysis for ATGL objects and LD, PLIN2 
or PLIN5 and LD. White bars represent 3 µm. 



















Figure 4.2. HSL redistributes to LD following from pre to post-exercise as visualised 
through confocal immunofluorescence microscopy. Representative images of HSL and 
LD pre and post-exercise were initially obtained using a 40x oil objective on a confocal 
microscope (A). White bars represent 50 µm. LD were visualised using BODIPY 493/503 and 
represent IMTG stores within the cell. Muscle fibres that had the highest lipid droplet content 
were selected for analysis. A 16x digital magnification was then applied to the centre of these 
muscle fibres and images were obtained to identify and quantify distribution and colocalisation 
between HSL and LD (B). White bars represent 2 µm. Image B shows that in the pre-exercise  
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state HSL appeared as large storage clusters throughout the cell, whereas post-exercise HSL 
was visualised as a greater number of smaller, discrete clusters centred on LDs as observed 






















Figure 4.3. HSL redistributes from larger storage clusters to smaller more frequent 
clusters from pre to post exercise resulting in an increase in LD colocalisation to 
HSL. Quantification derived from confocal immunofluorescence microscopy images. 
Colocalisation analysis was performed to determine the fraction of LD overlapping with HSL 
objects pre- and post-exercise (A). Subsequently, the number of LD colocalised with HSL 
(HSL+ LD) or not colocalised with HSL (HSL- LD) was calculated and compared from pre 
to post-exercise (B). Data collected are averages of 15 fibres per participant per time point. 
Values are given as means ± SEM (n = 8 per group). †Main effect for HSL colocalisation to 
LD (P < 0.05 vs. HSL- LD). ‡ Main interaction effect for HSL colocalisation to LD from pre 
to post-exercise (P < 0.05). Post-hoc analysis revealed an increase in HSL+ LD (* P < 0.05 


















































































Figure 4.4. ATGL distribution does not change from pre to post-exercise as 
visualised through immunofluorescence microscopy. Representative images of ATGL, 
PLIN2 and LD pre and post-exercise obtained using a 63x oil objective of a confocal 
microscope (A). White bars represent 50 µm. LD were visualised using BODIPY 493/503 
and represent IMTG stores within the cell. Muscle fibres that had the highest lipid droplet 
content were selected and analysed. An 8x digital magnification was then applied to the 
centre of these muscle fibres and images were obtained to identify and quantify distribution 
and colocalisation between ATGL and LD associated with either PLIN2 (B) or PLIN5. White 
bars represent 2 µm. Images A and B show that pre-exercise ATGL had punctate staining 
throughout the cell and this was unaltered post-exercise.   









Figure 4.5. Immunofluorescence microscopy images of HSL, PLIN2/PLIN5 and LD pre 
and post-exercise. Colocalisation between HSL, PLIN2 (A) or PLIN5 (B) and LD as 
visualised through immunofluorescence microscopy and quantified pre and post exercise. 
Images captured on a 63x oil objective of a confocal microscope at 16x digital magnification 
in the central region of fibres that had the highest lipid droplet content. White bars represent 
2 µm. PLIN2 (A) and PLIN5 (B) were associated with LD or located in the cytosol. HSL 
redistributes from larger storage clusters to a greater number of smaller, discrete clusters 
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Figure 4.6 HSL preferentially redistributes to PLIN5+ LD from pre to post-exercise. 
HSL colocalisation with different LD pools (PLIN+ or PLIN- LDs) was quantified from 
immunofluorescence microscopy images of HSL, LD and PLIN2 (A) or PLIN5 (B) pre and 
post- exercise. Data were collected as averages of 15 fibres per participant per time point. 
Values are presented as means ± SEM (n = 8 per group). * Main effect for exercise (P < 
0.05 vs. pre-exercise). †Main effect for PLIN association to LD (P < 0.05 vs. PLIN- LD). ‡ 






































































Figure 4.7. ATGL colocalisation with different pools of LD does not change from pre 
to post-exercise. ATGL colocalisation with different LD pools (PLIN+ or PLIN- LDs) was 
quantified from immunofluorescence microscopy images of ATGL, LD and PLIN2 (A) or 
PLIN5 (B) pre and post- exercise. Data were collected as averages of 15 fibres per 
participant per time point. Values are presented as means ± SEM (n = 7 per group). †Main 










































This study examined the localisation of the two key lipases in human skeletal muscle, 
ATGL and HSL, with LDs and the associated PLIN proteins at rest and in response 
to moderate-intensity exercise. The major novel observation is that HSL redistributes 
to LD in human skeletal muscle following 1 h moderate-intensity cycling exercise, with 
HSL preferentially translocating to LDs with PLIN5 associated. Furthermore, we 
confirm for the first time that ATGL was colocalised more to PLIN5+ LD in comparison 
to PLIN5- LD in agreement with our hypothesis. Additionally, the data shows that 
ATGL is also colocalised more to PLIN2+ LD in comparison to PLIN2- LD and the 
distribution of ATGL does not alter during the exercise bout. Together, these data 
demonstrate different distribution patterns of key lipases and their localisation to LD-
associated PLIN proteins in skeletal muscle, which may be important in the regulation 
of IMTG utilisation during moderate-intensity exercise. 
In the basal state HSL was observed as large storage clusters throughout the cell, 
whereas after exercise HSL was visualised as a greater number of smaller, discrete 
clusters typically centred on LD (Figure 4.2). As a result, we observed an increase in 
the fraction of LD colocalising with HSL from pre to post-exercise, demonstrating HSL 
redistributes to LD in response to exercise in human skeletal muscle. A number of 
studies in cultured adipocytes have demonstrated that HSL translocates from the 
cytosol to LD in response to lipolytic stimuli (Su et al., 2003; Sztalryd et al., 2003; 
Wang et al., 2009), whereas studies investigating the localisation of HSL in skeletal 
muscle are limited. Most notably, Prats et al. (2006) in line with our findings using 
confocal immunofluorescence microscopy and isolated rat skeletal muscle fibres 
observed that HSL in the basal state was accumulating either as storage clusters or 
colocalising with LD, whilst ex vivo electrical or adrenaline stimulation increased the 
translocation of HSL to LD. In addition transmission electron microscopy using 
immunogold labelled HSL antibodies was used in the study of Prats et al. (2006) to 
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show that the HSL translocation led to HSL passing the phospholipid monolayer of 
the LD into the TAG core (Prats et al., 2006) allowing HSL (the enzyme) greater 
access to IMTG (the substrate). The ex vivo protocol adopted by Prats et al. (2006) 
elegantly eliminates the interference of plasma-derived FA on substrate use and 
IMTG synthesis allowing for IMTG hydrolysis to be studied in isolation. We now 
extend these findings to demonstrate that HSL redistribution occurs in human skeletal 
muscle in response to moderate-intensity exercise in vivo.   
Overall we observed an increase in HSL colocalisation to PLIN2 and PLIN5 following 
exercise. This finding is in agreement with Prats et al. (2006) who demonstrated an 
increased colocalisation of HSL with PLIN2, but did not investigate PLIN5. In addition, 
by staining HSL, LD and either PLIN2 or PLIN5, we were able to determine specific 
colocalisation between HSL and different sub-groups of LD (PLIN2+ LD and PLIN2- 
LD or PLIN5+ LD and PLIN5- LD). The most important and novel finding of the present 
study was that HSL preferentially redistributed to LDs with associated PLIN5. 
Although PLIN5 is implicated in protecting intracellular TAG stores from hydrolysis 
under basal conditions (Wang et al., 2011a; Laurens et al., 2016), evidence is 
accumulating that PLIN5 also facilitates TAG breakdown when energy demand 
increases.  PLIN5 is phosphorylated in response to PKA stimulation leading to TAG 
hydrolysis in cultured cells (Wang et al., 2011a). In addition, we have previously 
shown that LDs with PLIN5 associated are preferentially used during a bout of 
moderate-intensity exercise in lean, healthy individuals (Shepherd et al., 2013).  We 
now propose that PLIN5+ LDs are targeted for breakdown during exercise because 
PLIN5 facilitates the interaction of HSL with the TGs stored in the LD core.  
Immunofluorescence staining of ATGL displayed a punctate pattern throughout the 
cytosol which was not altered in response to moderate-intensity exercise (Figure 4.4). 
At baseline the fraction of LD colocalising with ATGL was 0.53 and this was not 
altered following exercise. Mason et al., (2014a) recently reported no significant 
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changes in the percentage of ATGL colocalising with LD (stained using Oil Red O) in 
human skeletal muscle of recreationally active males following moderate-intensity 
exercise. Together these results suggest that a proportion of LD already is 
colocalising with ATGL under basal conditions and that the activity of ATGL is instead 
regulated by its co-activator CGI-58. In line with this suggestion, studies in cultured 
COS-7 cells have shown that overexpression of GGI-58 led to an increase in ATGL 
activity (Lass et al., 2006). The fraction of LD colocalising with ATGL showed a trend 
towards a decrease after exercise, which is likely explained by a decrease in LD 
number post-exercise (Shepherd et al., 2013). Interestingly the results show there is 
a substantial fraction of LD (0.47) that do not have any colocalisation with ATGL. As 
HSL acts both on TAG and DAG (Lass et al., 2011) it is plausible that LD not 
colocalised with ATGL are instead subject to HSL-mediated hydrolysis. 
Evidence from cultured cells suggests PLIN5 recruits and binds ATGL and CGI-58 at 
the LD surface under basal conditions but releases ATGL and CGI-58 following PKA 
induced phosphorylation (Granneman et al., 2011; Wang et al., 2011a). The release 
of ATGL and CGI-58 from PLIN5 allows ATGL to bind to its co-activator CGI-58 to 
increase ATGL activity (Granneman et al., 2011; Wang et al., 2011a). In the current 
study at baseline, ATGL colocalisation was higher to PLIN2+ LD and PLIN5+ LD in 
comparison to PLIN2- LD and PLIN5- LD respectively. As ATGL distribution did not 
change during exercise, the amount of ATGL colocalised with PLIN2+ LD and PLIN5+ 
LD was also not altered after the exercise bout. There was also no change in ATGL 
colocalisation with PLIN2 or PLIN5 irrespective of LD presence following exercise.  In 
line with our findings, MacPherson et al. (2013a) also reported that PLIN2 and PLIN5 
both co-immunoprecipitated with ATGL under basal conditions, but this did not 
increase in response to lipolytic stimuli (adrenaline, contraction or both) in rat skeletal 
muscle. Our data therefore suggests that PLIN2 and PLIN5 may support the 
positioning of ATGL to LD during fasted, non-exercised conditions. Immunogold 
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labelling of HSL with transmission electron microscopy has confirmed that HSL 
penetrates the phospholipid monolayer of the LD to access IMTG in response to 
epinephrine or electrical stimulation in isolated rat skeletal muscle (Prats et al., 2006). 
Whether PLIN2 or PLIN5 localises ATGL to the outside of the LD phospholipid 
monolayer during basal conditions but then releases ATGL so it can penetrate the 
phospholipid monolayer and access IMTG stores clearly warrants further 
investigation but can only accurately deciphered using immunogold transmission 
electron microscopy. 
IMTG utilisation during 60 min of moderate-intensity cycling exercise in these muscle 
samples was quantified previously, where it was confirmed that IMTG content 
decreased from pre to post-exercise (-43 ± 5%) in type I fibres only (Shepherd et al., 
2013). Due to constraints with the number of fluorophores that could be used 
simultaneously we were unable to stain and identify type I fibres as part of the analysis 
in this study. Instead, fibres with the highest lipid content were selected for analysis. 
Type I fibres are characterised by high mitochondrial content and elevated IMTG 
stores (Shaw et al., 2008; Shepherd et al., 2013). It is well documented that IMTG 
utilisation is strongly associated with pre-exercise IMTG content (van Loon et al., 
2003a; van Loon et al., 2003b) and it is therefore likely that the fibres selected in the 
current study also exhibited net IMTG breakdown. Moreover, despite being unable to 
identify fibre type in the current study we can conclude that redistribution of HSL 
occurs in fibres that have a high LD content.   
By extending our validated immunofluorescence microscopy techniques, we have 
been able to generate further insight into the role of the PLIN proteins in the regulation 
of lipolysis in skeletal muscle during endurance exercise. Our assays, however, only 
permit the analysis of ATGL or HSL colocalisation with LDs with a single PLIN protein. 
It is possible, therefore, that PLIN2+ LD or PLIN2- LD may have PLIN5 associated 
and similarly PLIN5+ LD and PLIN5- LD may have PLIN2 associated. Nevertheless, 
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the results indicate that whilst there were similar increases in HSL colocalisation to 
PLIN2+ LD and PLIN2- LD post-exercise, there was a significantly greater increase 
in HSL colocalisation to PLIN5+ LD in comparison to PLIN5- LD after the exercise 
bout. It is also possible, that PLIN5 was also present on the surface of PLIN2+ LD or 
PLIN2- LDs colocalised with ATGL. Despite this limitation we can still conclude that 
ATGL was present on PLIN5- LDs and therefore PLIN5 is not a prerequisite for ATGL 
colocalisation to the LD. 
In conclusion, this study has generated novel evidence that HSL redistributes to LD 
in skeletal muscle of endurance-trained men in response to moderate-intensity 
exercise, whereas ATGL colocalisation with LDs is unaltered by exercise. 
Furthermore, this is the first study to demonstrate that HSL preferentially redistributes 
to PLIN5+ LDs following moderate intensity exercise, demonstrating a novel 
mechanism by which PLIN5 regulates HSL recruitment to LD which could aid in 
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Perilipin-5 (PLIN5) has emerged as an important protein for regulating intramuscular 
triglyceride (IMTG) lipolysis and providing metabolic linkage to mitochondria. 
Dysregulation of IMTG turnover and incomplete fatty acid oxidation is proposed to be 
a contributing factor to the progression of skeletal muscle insulin resistance. 
Understanding the proteins that PLIN5 associates with is crucial in gaining a more 
comprehensive understanding of how IMTG turnover is regulated and how this is 
altered in insulin-resistant states such as obesity and type 2 diabetes (T2D). The aim 
of this study was to develop a PLIN5 immunoprecipitation (IP)-mass spectrometry 
protocol that would identify PLIN5 and its protein-protein interaction partners in 
human skeletal muscle. The secondary aim was to identify differences in PLIN5-IP 
associated proteins between the different metabolic environments present in lean 
sedentary, obese and T2D individuals. Gel electrophoresis prior to ultra-performance 
liquid chromatography tandem mass spectrometry (GeLC-MS/MS) was used to 
separate proteins by size (1D SDS-PAGE) and subsequent digested peptides by 
hydrophobicity (Liquid Chromatography) allowing for a deeper insight into the muscle 
proteome following IP. A control-IP was used to account for non-specific binding of 
contaminant proteins. The developed PLIN5-IP protocol successfully and 
reproducibly immunoprecipitated PLIN5 vastus lateralis muscle from lean sedentary 
individuals. This, however, could not be replicated in vastus lateralis muscle from 
obese and T2D individuals. A list of proteins from the PLIN5-IP obtained from the 
vastus lateralis muscle of lean sedentary individuals muscle, that did not appear in 
the control-IPs, established phospholipase A2 group II, subgroup A (PA2GA) as a 
unique protein associated with PLIN5. As phospholipase A2 proteins are found at the 
lipid droplet surface and have been implicated in lipid metabolism, future research is 
warranted to investigate how PA2GA interacts with PLIN5. IP of PLIN5 was not 
consistent in vastus lateralis muscle samples from obese and T2D patients. This may 
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be due to contamination from extramyocellular adipocytes or a lesser content 
(number and/or size) of type I fibres, thereby reducing PLIN5 expression and 
availability for immunoprecipitation. Future research could be advanced by using 
peptide separation by iso-electric focusing combined with using high-definition mass 
spectrometry which can increase the number of proteins detected in muscle and, 
therefore, increase the chances of detecting PLIN5 with associated protein(s) in 
obese and T2D muscle. 
5.2 Introduction 
Skeletal muscle is essential for maintenance of energy and substrate homeostasis. 
Within skeletal muscle protein-protein interactions are fundamental for various 
cellular processes. This is exemplified by the insulin-signalling cascade explained in 
section 1.2.1, whereby a cascade of proteins interacts in synchronisation to stimulate 
the activation and translocation of GLUT-4 to the plasma membrane. Identification of 
further protein interactions and potential disruptions to these interactions is, therefore, 
crucial in advancing our understanding of molecular physiology and development of 
diseases (Phizicky & Fields, 1995; Oti et al., 2006). Ectopic lipid accumulation in 
skeletal muscle has been a major focus in the pathology of skeletal muscle insulin 
resistance and progression to type 2 diabetes (T2D). Particular emphasis has been 
placed on underpinning the regulation of proteins involved in intramuscular 
triglyceride (IMTG) turnover and mitochondrial oxidation. This is due to the working 
hypothesis that dysregulation of IMTG turnover and/or incomplete fatty acid oxidation 
results in the accumulation of lipid metabolites known to disrupt the insulin signalling 
pathway and contribute to skeletal muscle insulin resistance (Moro et al., 2008). 
Over the past decade, perilipin-5 (PLIN5) has emerged as an important lipolytic 
protein that helps to regulate turnover of IMTG stores (Shepherd et al., 2013; Mason 
et al., 2014b) and provides metabolic linkage to mitochondria (Wang & Sztalryd, 
2011). Evidence from different cell lines have demonstrated that PLIN5 can regulate 
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lipolysis by binding to either; lipolytic enzyme ATGL or its co-activator CGI-58 (but not 
at the same time) (Granneman et al., 2011; Wang et al., 2011a). PKA stimulation 
results in PLIN5 phosphorylation and when PKA activation occurs with ectopic 
overexpression of PLIN5 and ATGL, lipolysis increases (Wang et al., 2011a). These 
data have generated the hypothesis that PLIN5 serves to limit lipolysis in basal 
conditions by preventing the interaction of ATGL with CGI-58, and promotes lipolysis 
by releasing and allowing the interaction of ATGL and CGI-58 following lipolytic 
stimuli. PLIN5 also has a conserved N-terminal sequence capable of binding to the 
other key lipase HSL (Anthonsen et al., 1998). Confocal immunofluorescence 
microscopy has confirmed that ~60% PLIN5 is colocalised to lipid droplets (LD) 
storing IMTG (Shepherd et al., 2013). Following an acute bout of moderate intensity 
exercise HSL in human skeletal muscle preferentially redistributes to LD associated 
with PLIN5 (PLIN5+ LD) (Whytock et al., 2018) and PLIN5+ LD are favourably utilised 
during the exercise bout  compared to LD that are not associated with PLIN5 
(Shepherd et al., 2013).  
Western blotting in isolated mitochondria and immunogold electron microscopy of rat 
soleus muscle have revealed that PLIN5 has a strong association to mitochondria 
(Bosma et al., 2012b). Evidence from heart muscle has demonstrated that PLIN5 is 
the only perilipin capable of recruiting mitochondria to the LD surface (Wang et al., 
2011b). Furthermore, overexpression of PLIN5 enhances the interaction of lipid 
droplets and mitochondria (Bosma et al., 2012b) and increases fatty acid oxidation 
(Wolins et al., 2006; Bosma et al., 2012b). The current evidence suggests that PLIN5 
supports IMTG hydrolysis following lipolytic stimuli and then assists in the trafficking 
of FA to the mitochondria for subsequent β-oxidation.  
This proposed role of PLIN5 in skeletal muscle makes it important to identify the 
proteins that it works in concert with.  Hypothesis-driven techniques such as 
immunohistochemistry or co-immunoprecipitation followed by immunoblotting of 
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PLIN5 with suspected lipolytic interacting proteins is commonly used to detect PLIN5 
protein interactions. For example co-immunoprecipitation with immunoblotting has 
identified that PLIN5 binds to HSL  (Wang et al., 2009; Macpherson et al., 2013b), 
ATGL (Wang et al., 2011a; MacPherson et al., 2013a; Macpherson et al., 2013b) and 
CGI-58 (Wang et al., 2011a; MacPherson et al., 2013a). Protein binding quantified by 
colocalisation of fluorescent fusion proteins intensities reveals that PLIN5 interacts 
with both CGI-58 and ATGL (Granneman et al., 2011). More recently in our lab we 
have identified with colocalisation analysis from confocal immunofluorescence 
microscopy that PLIN5 colocalises with HSL and ATGL in human skeletal muscle 
(Whytock et al., 2018). This spatial colocalisation being a pre-requisite for functional 
protein interaction.  
In recent years, the use of immunoprecipitation (IP) combined with mass 
spectrometry has emerged as a novel avenue to explore non-targeted protein-protein 
interactions. In contrast to targeted approaches, IP-mass spectrometry provides an 
unbiased approach so identifying protein interaction partners that would not otherwise 
be apparent from the current literature. There is currently a wide variation with 
immunoprecipitation (IP)-mass spectrometry protocols due to differences in tissue, 
species, target protein abundance, pH and location within the cell. Commonly 
research has sought to identify protein interactions in cultured cells using stable 
isotope labelling with amino acids (SILAC) techniques (Kaake et al., 2010) combined 
with affinity purification with tag proteins such as green fluorescent protein (GFP) or 
FLAG-tag (Berggard et al., 2007; Trinkle-Mulcahy et al., 2008). Whilst fusion tags 
such as GFP are benefited by near complete extraction of targeted proteins in cell 
culture, the use of GFP in vivo may not be as efficient. Cytoplasmic in vivo 
fluorescence recovery after photobleaching (FRAP) measurements have shown that 
photobleaching GFP in live cells results in rapid recovery (Trinkle-Mulcahy et al., 
2008) suggesting that GFP diffuses as a free protein in vivo which may result in weak 
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binding of cellular proteins. Fusion tagging can also alter the functionality and 
expression of the target protein which questions the characteristics of the protein-
interactions identified. Whilst cell culture studies utilising fusion tagging with SILAC 
and mass spectrometry have advanced our knowledge of protein interactions it is now 
important to develop a technique that can be used to characterise functional protein 
interactions that exist in human skeletal muscle in vivo. Development of such a 
technique would allow tissues to be extracted and protein interactions to be analysed 
in different complex metabolic diseases such as T2D that cannot be accurately 
replicated in cell or animal models.  
Due to PLIN5 being a LD associated protein and having a strong association to 
mitochondria, the IP of PLIN5 may not only yield binding partners but may also 
harvest other proteins associated to the LD or mitochondrial proteins. An effective 
non-targeted method to identify PLIN5-associated proteins is therefore of great 
interest to further characterise its role in skeletal muscle. The primary aim in this 
experimental chapter was to develop an antibody IP-mass spectrometry protocol that 
would effectively pull-down a low abundant protein such as PLIN5 in human skeletal 
muscle. Given the highlighted differences in IMTG turnover between lean, obese and 
T2D individuals and the proposed link to insulin resistance, the secondary aim was to 
identify differences in PLIN5-IP associated proteins between the different metabolic 
environments (lean sedentary, obese and T2D).  
5.2.1 Rationale of methodology  
Initial fractionation of sarcoplasmic and myofibrillar proteins was performed to assist 
in removing highly abundant myofibrillar proteins such as myosins, troponins, 
tropomyosins and other associated proteins from the sarcoplasmic fraction allowing 
less abundant regulatory proteins to be detected. Immunoprecipitation of PLIN5 was 
then performed on the sarcoplasmic fraction using a polyclonal guinea-pig anti-PLIN5 
antibody (GP31, Progen, Biotechnik, Heidelberg, Germany) raised against the C-
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terminal domain (aa 451-463; CPVKHTLMPELDF) of human PLIN5. This antibody 
has been extensively used and validated for numerous muscle molecular physiology 
techniques such as immunohistochemistry and immunoblotting (Ramos et al., 2015; 
Gemmink et al., 2017a; Shepherd et al., 2017a). The use of an antibody for 
immunoprecipitation is benefited by this specific targeting of the protein of interest in 
its functional state however this approach is associated with a higher level of 
contamination compared to protein-tag methods and so control conditions must also 
be included. A guinea-pig polyclonal antibody for sperm-specific protein calicin (GP-
SH3, Progen) which targets synthetic N-terminal domain (aa 1-24; 
MKLEFTEKNYNSFVLQNLNKQRKR) of bovine calicin coupled to KLH was used as 
a control IP to provide a background of contaminant proteins that bind non-specifically 
to guinea-pig immunoglobulins or the Dynabead. Furthermore, a BLAST (Basic Local 
Alignment Search Tool) search has confirmed the target immunogen for this antibody 
is not present in any skeletal muscle proteins. 
Sarcoplasmic protein fractions contain large quantities of glycolytic enzymes which 
can overshadow lower abundance proteins when analysed as whole sarcoplasmic 
fraction (Maughan et al., 2005). The IP sarcoplasmic fraction will therefore be 
separated by gel electrophoresis prior to high performance liquid chromatography 
tandem mass spectrometry (GeLC-MS/MS) as previously conducted in our lab 
(Holloway et al., 2009).  This is known to yield large numbers of skeletal muscle 
proteins (Hojlund et al., 2008), increasing the opportunity for lower abundance 
proteins to be identified. Following separation by gel electrophoresis, gel lanes are 
fractionated into equal segments (n ≈ 11) prior to digestion allowing differentiation of 
biological samples and the opportunity for less abundant proteins to be recognised 
from the digested peptides.  
Separation of the digested peptides will then be achieved with ultra-performance 
liquid chromatography. Here the peptide solution from each digested gel fraction is 
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diluted into an aqueous solution and is carried by a mobile phase which passes 
through the liquid chromatography column and into the mass spectrometer. As 
peptides reach the stationary phase of the liquid chromatography column they bind 
to a matrix of spherical silica non-polar beads (3-5 µm) in a manner proportional to 
their relative hydrophobicity. A non-linear gradient of organic non-polar solvent elutes 
the peptides from the matrix, more hydrophilic peptides elute sooner than relatively 
hydrophobic peptide and therefore the complex peptide mixture is separated in a 
reproducible manner over the duration of the chromatography gradient (typically 90 
min).  Electrospray ionization converts peptides to multiple positively charged ions 
allowing them to be filtered through a quadrupole ion guide before being propelled 
through the time-of-flight mass detector. The 5 most abundant precursor peptide ions 
(i.e. MS) of charge 2+ or 3+ detected in the survey scan are fragmented by collision-
induced dissociation to produce fragment ions (i.e. MS/MS). When positively charged 
peptide/fragment ions reach the detector secondary particles including electrons are 
emitted. These electrons are amplified through a series of dynodes creating a current 
that is equivalent to a number of peptides/fragment ions that entered the detector 
allowing for the intensity of each ion to be recorded. The acquired MS/MS data is then 
searched against the Swiss-Prot protein sequence database to assign peptides to 
known proteins. By leveraging GeLC-MS/MS it is our aim to produce a replicable 
PLIN5-IP mass spectrometry protocol that will pull-down PLIN5 and associated 
proteins in human skeletal muscle. 
5.3 Methods 
5.3.1 Muscle samples and preparation 
5.3.1.1 Lean healthy  samples- vastus lateralis 
Due to IP-MS/MS protocol requiring a large amount of tissue (500µg of protein), the 
first step in this method development was to test the protocol on surplus vastus 
lateralis muscle from lean healthy males  before applying it to the smaller muscle 
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samples obtained from lean, obese and T2D sedentary participants. Vastus lateralis 
muscle samples from lean healthy individuals (36.9 ± 1.9 y, body mass index (BMI) 
26.9 ± 1 kg.m-2) were acquired from a previous study (Camera et al., 2017), which 
was approved by the Australian Catholic University Human Research Ethics 
Committee. All participants provided written informed consent. Under local 
anaesthesia (2–3 ml of 1% xylocaine), a resting biopsy was obtained from the m. 
vastus lateralis by using a 5-mm Bergstrom needle (Bergstrom, 1975) that has been 
modified with suction. 
5.3.1.2 Lean, obese and T2D sedentary samples- gluteus maximus 
Gluteus maximus muscle samples were obtained from 5 lean, sedentary (65 ± 2 y, 
BMI 25.2 ± 0.7 kg.m-2), 6 obese (61 ± 5 y, BMI 31.6 ± 1.0 kg.m-2) and 8 diagnosed 
T2D (61 ± 3 y, BMI 35.3 ± 2.0 kg.m-2) males during elective orthopaedic surgery under 
general anaesthetic.  All participants were undergoing surgery at Russells Hall 
Hospital (Dudley Group of Hospitals) and gave their informed consent for participation 
in this study. The study was approved by the local NHS Research Ethics Committee. 
After the initial incisions for the total hip arthroplasty surgery a muscle biopsy (~200 
mg) was obtained from the m. gluteus maximus.  
5.3.1.3 Lean, obese and T2D sedentary samples- vastus lateralis  
Vastus lateralis muscle samples were obtained from 2 lean, sedentary (69 ± 7 y, BMI 
22.6 ± 1.8 kg.m-2), 4 obese (68 ± 4 y, BMI 37.1 ± 2.7 kg.m-2) and 4 diagnosed T2D 
(62 ± 6 y, BMI 42.8 ± 3.4 kg.m-2) females during elective orthopaedic surgery under 
general anaesthetic.  All participants were undergoing surgery at Russells Hall 
Hospital (Dudley Group of Hospitals) and gave their informed consent for participation 
in this study. The study was approved by the local NHS Research Ethics Committee. 
After the initial incisions for the total knee arthroplasty surgery a muscle biopsy (~ 200 
mg) was obtained from the m. vastus lateralis.  
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5.3.1.4 Muscle preparation 
All samples were initially blotted of excess blood and separated from any visible fat 
and connective tissue. Muscle was homogenised and fractionated as previously 
described (Malik et al., 2013; Burniston et al., 2014). Briefly, snap frozen muscle 
samples (~60 mg) were pulverised in liquid nitrogen and homogenized on ice in 10 
volume of homogenisation buffer (1% Triton X-100, 50 mM Tris, pH 7.4, 5mM EDTA 
including phosphatase inhibitor and complete protease inhibitor (Roche Diagnostics, 
Lewes, United Kingdom) using a PolyTron homogenizer. Samples were incubated on 
ice for 15 min before being centrifuged at 1000 g at 4oC for 10 min. Following 
centrifugation the supernatant containing the sarcoplasmic fraction was decanted and 
stored on ice. Protein concentration of the sarcoplasmic fractions were measured 
using a Bradford assay (Bradford, 1976). Bovine serum albumin (BSA) standards 
(0.125. 0.25, 0.5, 0.75 and 1 mg.ml-1) were prepared from a commercial stock solution 
(1.0 mg.ml-1; Sigma-Aldrich, Poole, Dorset) and pipetted in triplicate (5 μl per well) 
onto microtitre plate. Muscle supernatants were diluted at 1:20 to bring them within 
the standard range and pipetted (5 μg per well) in duplicate. Bradford reagent (Sigma-
Aldrich, Poole, Dorset, United Kingdom) was added (250 μl per well) and incubated 
at room temperature for 5 minutes, before reading at a wavelength of 595 nm (Tecan 
GmbH, Austria). Interpolation from the BSA standard curve was then used to 
determine the protein concentration of the sarcoplasmic muscle fraction. 
5.3.2 Immunoprecipitation 
Pooled samples containing 500 µg of protein from sarcoplasmic fractions were used 
for IP. Magnetised beads (Dynabeads, Invitrogen) were resuspended in phosphate 
buffer saline (PBS), pH 7.4, with 0.01% Tween-20 and sodium azide. Dynabead slurry 
(6.7 µl equating to 0.2 mg of protein A Dynabead) was transferred to a clean labelled 
tube. Dynabeads were magnetised and supernatant was removed. One microgram 
of PLIN5 antibody (GP31, Progen, Biotechnik, Heidelberg, Germany) or calicin 
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(control antibody) (GP-SH3, Progen, Biotechnik, Heidelberg, Germany) was diluted 
in 25 µl in PBS + 0.05 % Tween-20 and added to Dynabeads and left to incubate on 
a hula shaker for 30 min at room temperature. Following removal of supernatant, 
Dynabead-antibody solution was washed with PBS- 0.05 % Tween-20. Pooled 
muscle samples containing 500 µg protein were then added to Dynabead-antibody 
solution and left to incubate on a hula-shaker for 3 hrs at 4oC. Dynabeads were 
magnetised and muscle supernatant was transferred to a clean labelled tube. 
Dynabead-antibody-PLIN5 was then washed 3 times in PBS- 0.05 % Tween-20. 
Following the last wash, PBS- 0.05 % Tween-20 was removed and 5 µl of Laemmli 
sample buffer with DDT was added to Dynabead-antibody-PLIN5 solution and left to 
incubate at 95 ºC for 4 min. The Dynabeads were then magnetised and sample buffer 
was transferred to a clean labelled tube (extraction 1) before a further 5 µl sample 
buffer was added to Dynabead-antibody-PLIN5 solution and incubated for a further 4 
min at 95 ºC. Dynabeads were magnetised again and the second sample buffer was 
added to extraction 1.  
5.3.3 1D SDS-PAGE 
Proteins from the IP were separated with 12% denaturing SDS-PAGE. Mini-slab gels 
of the dimensions 11 x 8.5 x 0.75 cm were prepared according to the manufacturers 
instructions (Mini-VE system, GE Healthcare, Sweden). Initially glass plates (8 x 10.5 
cm) were cleaned with 70% ethanol to remove any traces of residue protein, before 
being separated by spacers (1.0 mm) places at either side. The resolving gel was 
composed of 12% (v/v) Acrylamide/ Bis-acrylamide RTU solution (Proto-gel) (37.5:1), 
1.5 M Tris-HCl (pH 8.8), 0.2 % (w/v) SDS, dd H20, SDS polymerisation was initiated 
with 0.06 % (v/v) N, N, N’,N’ –tetramethylethylenediamine (TEMED) and 0.075 % (v/v) 
ammonium persulfate (APS). The gel was left to polymerise at room temperature for 
1 hr before the stacking gel as added. The stacking gel consisted of 5% (v/v) 
Acrylamide/ Bis-acrylamide RTU solution (Proto-gel) (37.5:1), 1.0 M Tris-HCl (pH 
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6.8), 0.2 % (w/v) SDS, dd H20, SDS polymerisation was initiated with 0.008 % (v/v) 
TEMED and 0.1 % (v/v) APS. A 12-well comb was inserted into the plates before the 
stacking gel was added and left to polymerise at room temperature for 1 hr. Combs 
were removed after polymerisation and wells were washed with running buffer 0.1 % 
(w/v) SDS, 0.25 M Tris and 0.19 M glycine to remove unpolymerised acrylamide. 
Eight microliters from each immunoprecipitated sample (protein quantity unknown as 
it is dependent on quantity of protein immunoprecipitated from initial 500 µg protein 
sample). Electrophoresis occurred at 100 V for 30 min before being increased to 200 
V and left to run until the tracking dye reached the bottom edge of the resolving gel 
(~ 1 hr 30 min). The gel was then removed from the glass plates and washed 3 times 
for 5 min in ddH2O. Following removal of ddH2O from the last wash, gels were stained 
in 100 ml of colloidal Coomassie blue (Bio-safe, Bio-rad laboratories, Hercules, USA) 
for 1 hour before being de-stained overnight in ddH2O. 
5.3.4 In-gel digestion 
1D gel lanes from the resolving gel were fractioned in to 11 equal 5 mm x 7 mm 
segments. Each segment was cut using surgical blades (RS Pro carbon steel scalpel 
blades, RS Pro, Northants, UK) into 1mm3 gel plugs and dispensed into clean labelled 
lo-bind Eppendorf tubes. Gel plugs were de-stained with 50:50 acetonitrile (ACN)/ 50 
mM Ambic for 15 min at 37 oC. This process was repeated at least three times or until 
there was no visible blue stain on the gel plugs. Gel plugs were reduced with 10 mM 
DDT for 1 hr at 37 oC before being alkylated with 50 mM iodoacetamide (IAM) for 1 
hr in the dark at 4 oC. Gel plugs were then incubated in absolute ACN for 15 min at 
37 oC. Following removal of the ACN, gel plugs were dehydrated at 60 oC for 30 min. 
Gel plugs were incubated with 0.01 µg/µL of sequence grade trypsin (Promega; 
V5113) for 15 min at 4 oC. After the incubation 50 mM ambic was added to each 
Eppendorf and digestion was allowed to continue overnight at 37 oC. Digestion was 
stopped the following morning by addition of 10l 5% (v/v) formic acid for 30 min at 
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37 oC. Peptide solutions were cleared by centrifugation at 14,000g for 1 min and 
removed using a gel loading tip to a clean new labelled Eppendorf (extraction 1). The 
gel plugs were then incubated with 150μl of 0.5% (v/v) formic acid for a further 30 min 
at 37 oC, before being centrifuged again at 14,000g for 1 min. Peptides were removed 
with a gel loading tip and added to extraction 1. Peptide solutions were de-salted 
using a C-18 ziptip (Zip-tips; Millipore, Billercia, MA, USA) according to 
manufacturer’s instructions. 
5.3.5 Liquid chromatography-mass spectrometry 
Label-free liquid chromatography-mass spectrometry analysis was performed by 
using nanoscale reverse-phase ultra-performance liquid chromatography 
(NanoAcquity; Waters) and online electrospray ionization quadrupole–time-off light 
mass spectrometry (Q-TOF Premier; Waters). Samples were loaded in aqueous 0.1 
% (v/v) formic acid via a Symmetry C18 5 µm, 2 cm x 180 µm trap column (Waters). 
Separation was conducted at 35 °C via a BEH C18 1.7 µm, 25 cm x 75 µm analytical 
reverse-phase column (Waters). Peptides were eluted by using a gradient that rose 
to 37 % acetonitrile 0.1 % (v/v) formic acid over 90 min at a flow rate of 300 nl/min. 
Liquid chromatography eluent was sprayed into the mass spectrometer with a glass 
emitter tip (PictoTip, Waters) using a spray voltage of 3.0 kV in positive-ion mode. 
Full scan spectra were recorded from m/z 350 to 1600 at a resolution of >10,000 full 
width at half maximum (FWHM) using mass spectrometry survey scans of 0.45-s 
durations with an interscan delay of 0.05. Prior to analysis, the time-of-flight analyser 
was calibrated by using fragment ions of [Glu-1]-fibrinopeptide B from m/z 50 to 1990. 
MS/MS spectra of collision induced dissociation fragment ions were recorded for the 
5 most abundant precursor ions of charge 2+ or 3+ detected in the survey scan. 
Precursor fragmentation was achieved by collision-induced dissociation at an 
elevated (20–40 eV) collision energy over a duration of 0.15 s per parent ion with an 
interscan delay of 0.05 s over 50–2000 m/z. Acquisition was switched from MS to 
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MS/MS mode when the base peak intensity exceeded a threshold of 30 counts/s and 
returned to the MS mode when the total ion chromatogram (TIC) in the MS/MS 
channel exceeded 50,000 counts/s or when 1.0 s (5 scans) were acquired. To avoid 
repeated selection of peptides for MS/MS, the program used a 30-s dynamic 
exclusion window. The Lockmass reference (100 fmol/μL Glu-1-fibrinopeptide B) was 
delivered to the NanoLockSpray source of the mass spectrometer at a flow rate of 
200 nL/min, and was sampled at 60 s intervals. 
 
5.3.6 IP Protein identification 
Acquired MS/MS data was searched against the Swiss-Prot protein sequence 
database (2018.1) restricted to 20,333 sequences (human taxology) with Mascot 
(v2.3.2, Matrix Science) using Mascot Distiller (2.7.0.1) as the data input filter to 
generate peak lists. Enzyme specificity was trypsin, which allowed 1 missed 
cleavages, carbamidomethyl modification of cysteine (fixed), deamination of 
asparagine and glutamine (variable), oxidation of methionine (variable) and an m/z 
error of ± 0.3 Da. Decoy databases were employed to allow the calculation of 
identification error rates. Proteins were identified if they had at least one unique 
peptide with an identity threshold greater than 30 and false discovery rate <5%.  
5.4 Results 
5.4.1 PLIN5-IP GeLC-MS/MS on m. vastus lateralis from lean healthy 
participants 
The PLIN5-IP GeLC-MS/MS protocol was performed twice on 2 (A and B) pooled 
samples (total of 4) of vastus lateralis muscle from lean healthy participants (Figure 
5.1). Each replicate successfully immunoprecipitated PLIN5 and overall a total of 364 
proteins were identified (Table 5.1). In total 87 proteins were consistently identified in 
all 4 replicates and a substantial portion of these (32) were immunoglobulins (Ig). 
Upon removal of known contaminants i.e. keratin, trypsin, filaggrin and all Ig 41 
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proteins remained (see supplementary Table 1 in appendix for protein list). The 
positive replication of PLIN5 identification within this IP lead us to apply this technique 
to muscle samples from obese and T2D participants. 
Table 5.1 Number of proteins identified from PLIN5 IP GeLC-MS/MS of m. vastus lateralis from lean 
healthy male participants  
  Pooled sample A 
 
Pooled sample B 
 
Combined results 
  A1 A2 Overlap Total 
 
B1 B2 Overlap Total 
 
Overlap Total 
Proteins 155 177 115 214 
 
290 172 150 312 
 
87 364 
Ig 43 46 41 48 
 









Figure 5.1. 1D SDS-PAGE of PLIN5-IP in m. vastus lateralis from lean healthy 
participants.  1D SDS-PAGE was performed twice following PLIN5-IP on two 
different pooled samples (A & B) from m. vastus lateralis of lean healthy participants. 
1D SDS-PAGE also performed on Dynabeads-PLIN5 antibody combination without 
muscle tissue to highlight expected bands of Ig. MW, molecular weight; kDA, 
kilodaltons.  
  





PLIN5 Antibody  
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5.4.2 PLIN5-IP GeLC-MS/MS on m. gluteus maximus from obese and T2D 
participants  
The PLIN5-IP GeLC-MS/MS protocol was performed three times each on pooled 
samples from gluteus maximus muscle of obese and T2D individuals (Figure 5.2). 
PLIN5 was only successfully immunoprecipitated once which occurred in muscle from 
T2D. (Table 5.2). The amount of Ig identified was notably lower compared to the 
PLIN5-IP GeLC-MS/MS performed on m. vastus lateralis from lean healthy 
participants. Comparisons revealed that at least 20 Ig proteins were absent from the 
PLIN5-IP GeLC-MS/MS that did not successfully immunoprecipitate PLIN5. The third 
replicate of T2D which successfully immunoprecipitated PLIN5 contained the 
immunoglobulin heavy variable 3-7 which was not present in the other obese or T2D 
replicates but was identified in all four of the m. vastus lateralis muscle sample. 
Importantly the variable domain of an antibody is the region responsible for specific 
antigen binding. The 1D SDS-PAGE of obese and T2D replicates lacked 
characterizable Ig bands that are observed when PLIN5 antibody is subject to 1D 
SDS-PAGE without incubation with muscle (Figure 5.2). Together this suggest that 
the PLIN5 antibody may become dissociated from the Dynabeads during incubation 
with the muscle. Due to the high number of proteins identified within this extract it is 
also possible that there was a high amount of non-specific binding of proteins to the 
Dynabead-antibody complex. If non-specific binding occurs from proteins that are of 
high abundance this can result in concealing peptides from lower abundance protein 
such as PLIN5 when analysed with LC-MS/MS. A more stringent wash protocol can 
remove non-specific binding of proteins. These results led us to test the PLIN5-IP 





Table 5.2 Number of proteins measured following PLIN5 IP GeLC-MS/MS of gluteus 
maximus muscle from obese and T2D participants  
  Obese   T2D 
  1 2 3 
 
1 2 3 
Total no. proteins  236 253 176 
 
413 532 445 
Total no. of Ig 8 9 8 
 
14 18 15 
PLIN5 immunoprecipitated X X X 
 
X X √ 
No. Ig absent compared to lean healthy IP   24 24 24  20 24 19 
 
 
Figure 5.2. 1D SDS-PAGE of PLIN5-IP in m. gluteus maximus from obese and 
T2D participants.  1D SDS-PAGE was performed three times following PLIN5-IP on 
pooled samples of m. gluteus maximus from obese and T2D participants. 1D SDS-
PAGE also performed on Dynabead-PLIN5 antibody combination without muscle 
tissue to highlight expected bands of Ig.  
  





Replicate 1 Replicate 2 Replicate 3 
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5.4.3 PLIN5-IP GeLC-MS/MS on m. vastus lateralis from obese and T2D 
participants  
The PLIN5-IP GeLC-MS/MS protocol was performed twice on pooled samples from 
m. vastus lateralis from obese and T2D participants (Figure 5.3). The first samples 
consisted of the same wash technique as described in the methods (3 times in PBS- 
0.05 % Tween-20 by pipetting; washing protocol 1). The second samples were 
subject to washing protocol 2 which consisted of washing 5 times in wash buffer 
provided with the Dynabead kit (Invitrogen) by pipetting. On the last of the 5 washes 
the IP solution was placed on a hula-shaker for 1 min. All four PLIN5-IP GeLC-MS/MS 
successfully immunoprecipitated PLIN5. As anticipated, the more stringent wash 
protocol 2 reduced the amount of proteins identified in the samples (Table 5.3). 
Amongst the list of proteins identified was HSL, a known binding partner of PLIN5. 
Washing protocol 2 removed HSL from the list of proteins identified with the T2D 
muscle (Table 5.3). The bands from the 1D SDS-PAGE indicated successful elution 
of Igs comparable to when PLIN5-ab is subject to 1D SDS-PAGE without muscle 
incubation (Figure 5.3). The results from this part of the experiment demonstrate that 
the gluteus maximus muscle used previously may have disrupted the Dynabead-
antibody-PLIN5 complex resulting in unsuccessful immunoprecipitation of PLIN5. 
Furthermore, although a stringent washing protocol decreased the total amount of 
protein identified and likely reduced non-specific binding of proteins this wash protocol 
also removed a known binding partner of PLIN5, HSL.  The next part of the 
experiment aimed to apply the PLIN5-IP GeLC-MS/MS (washing protocol 1) 
technique to pooled m. vastus lateralis samples from; lean, obese and T2D 
participants. To control for the non-specific binding of proteins to the Dynabead-
PLIN5-antibody complex a control IP GeLC-MS/MS was also performed. 
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Table 5.3 Number of proteins measured following PLIN5-IP GeLC-MS/MS of vastus 
lateralis muscle from obese and T2D.  
  Obese 
 
T2D 
  WP 1 WP2 
 
WP1 WP2 
Total no. proteins 558 467 
 
484 293 
Total no. Ig 41 39 
 
8 11 
PLIN5 immunoprecipitated √ √ 
 
√ √ 












Figure 5.3. 1D SDS-PAGE of PLIN5-IP in m. vastus lateralis from obese and T2D 
participants with different wash protocols. 1D SDS-PAGE was performed twice 
following PLIN5-IP on pooled samples of m.vastus lateralis from obese and T2D 
participants. Washing protocol 1 (WP1) consisted of 3 washes with PBS- 0.05 % 
Tween-20 by pipetting. Washing protocol 2 consisted of 5 washes with wash buffer 
(Invitrogen) with last wash placed on hula-shaker for 1 min. 1D SDS-PAGE also 
performed on dynabead-PLIN5 antibody combination without muscle tissue to 










5.4.4 PLIN5-IP GeLC-MS/MS on m. vastus lateralis  from lean, obese and T2D 
sedentary participants.  
The PLIN5-IP GeLC-MS/MS protocol was performed in replicates on pooled samples 
of m. vastus lateralis from lean (2 replicates), obese (3 replicates) and T2D (3 
replicates)  participants (Figure 5.4). A control-IP GeLC-MS/MS with an antibody 
against protein calicin was also performed 3 times in pooled samples of m. vastus 
lateralis of obese and T2D participants (Figure 5.4). All IPs combined identified a total 
of 1596 proteins. PLIN5 was identified in both PLIN5-IP lean replicates but only once 
in each of the obese and T2D PLIN5-IP replicates (Table 5.4). Expectantly PLIN5 was 
not present in the control-IP (Table 5.4). A total of 306 proteins were identified in both 
the lean PLIN5-IP replicates that successfully immunoprecipitated PLIN5. Due to 
there being insufficient m. vastus lateralis tissue from lean participants to run a 
control-IP , any proteins identified in replicates of the obese and T2D control-IP were 
subtracted from the lean PLIN5-IP resulting in a total of 62 proteins. Upon removal of 
known contaminants i.e. keratin, myosins, haemoglobin, and all Ig 52 proteins 
remained (see supplementary Table 2 in appendix for protein list). Upon removal of 
known suspected contaminants i.e. ribosomal proteins, ribonucleoproteins and 
tropomodulins (Trinkle-Mulcahy et al., 2008), protein phospholipase A2- group II, 
subgroup A (PA2GA) was the only protein remaining known to associate with LD, with 
no known mitochondrial proteins remaining. PA2GA therefore will be the focus of the 
discussion. Supplementary table 3 in appendix lists proteins identified from attempted 




   
 
Figure 5.4. Representative 1D SDS-PAGE of PLIN5-IP (A) calicin-IP (B) in vastus 
lateralis muscle. 1D SDS-PAGE was performed following PLIN5-IP on pooled 
samples of m. vastus lateralis from lean, obese and T2D participants (A). 1D SDS-
PAGE was then performed following calicin-IP (control) on pooled samples of m. 
vastus lateralis from obese and T2D participants (B). Due to insufficient m. vastus 
lateralis from lean participants a control IP could not be performed on this cohort. 1D 
SDS-PAGE was also performed on Dynabead-PLIN5 antibody combination without 
muscle tissue to highlight expected bands of Ig. 








Table 5.4. Number of proteins identified from PLIN5-IP GeLC-MS/MS in m. vastus lateralis from lean, obese and T2D participants.   
  Lean   Obese   T2D 
 
1 2 Overlap Total 
 
1 2 3 Overlap Total 
 
1 2 3 Overlap Total 
Proteins 355 518 306 567 
 
558 666 841 392 1014 
 
484 616 541 321 812 
Ig 36 40 33 43 
 
41 35 37 27 48 
 
35 41 32 26 47 
PLIN5 √ √ 
   
√ X X 
   




The aim of this study was to develop an IP-mass spectrometry protocol that would 
capture PLIN5 and its associated proteins in human skeletal muscle in 3 different 
metabolic environments (lean sedentary, obese and T2D). PLIN5 was successfully 
and reproducibly immunoprecipitated in m. vastus lateralis from lean sedentary 
participants. This, however, was not replicated in m. vastus lateralis from obese and 
T2D participants. In the lean sedentary group PLIN5-IP extracted protein 
phospholipase A2- group II, subgroup A which uniquely was not present in any of the 
control-IP and is not recognised as a known contaminant of Dynabead-antibody 
immunoprecipitation.   
GeLC-MS/MS uses orthogonal separation to separate proteins by size (1D SDS-
PAGE) and subsequent digested peptides by hydrophobicity during liquid 
chromatography (LC) allowing for a deeper insight into the muscle proteome and 
allowing lower abundance proteins to be recognised following immunoprecipitation. 
PLIN5 is a low abundance protein that is below the limit of detection when the GeLC-
MS/MS protocol is performed directly in homogenates of soluble muscle proteins. The 
PLIN5-IP GeLC-MS/MS successfully and reproducibly immunoprecipitated PLIN5 in 
m. vastus lateralis from lean participants demonstrating enhanced sensitivity and 
selectivity when antibody immunoprecipitation is performed prior to mass 
spectrometry.  
Due to the lack of m. vastus lateralis from lean sedentary participants, muscle the 
control IP GeLC-MS/MS was only conducted on m. vastus lateralis from obese and 
T2D participants. Proteins identified in either the obese or T2D control IP GeLC-
MS/MS were subsequently extracted from proteins that appeared in both lean 
sedentary PLIN5-IP GeLC-MS/MS replicates, resulting in a list of proteins unique to 
a PLIN5-IP from m. vastus lateralis from lean sedentary participants. Although known 
contaminants such i.e. keratin, myosins, haemoglobin have been removed from this 
179 
list there are still a number of suspected contaminants i.e. ribosomal proteins, 
ribonucleoproteins and tropomodulins (Trinkle-Mulcahy et al., 2008) .  Within the 
unique set of proteins from the PLIN5-IP in the lean sedentary group phospholipase 
A2 group II, subgroup A (PA2GA) was identified as a distinctive potential PLIN5 
associated protein and will therefore be the focus of this discussion. Protein-protein 
interaction databases such as Struct2Net (Singh et al., 2010)) and BioGRID 3.5 
(Chatr-Aryamontri et al., 2017) revealed at present there are no known interactions 
between PLIN5 and PA2GA. 
PA2GA belongs to a family of phospholipase A2s which can be found extracellularly, 
or membrane bound and are responsible for the hydrolysis of the sn-2 position of 
glycerophospholipids producing FFA and lysophospholipids (Kramer et al., 1989). 
PA2GA has been classified as a low molecular weight calcium dependent group II 
phospholipase A2 (Dennis et al., 2011) which can be secreted but importantly is also 
found in the cell (Guijas et al., 2014). PA2GA in particular belongs to subgroup A of 
group II phospholipase A2 which is also found in snake venom (Leiguez et al., 2011). 
Isolated snake venom derived-PA2GA incubated in mice macrophages results in an 
increase in LD formation concomitant with an increased expression of PLIN2 and a 
recruitment of PLIN2 to the LD (Leiguez et al., 2011). The exact role of every 
phospholipase A2 has been made difficult by the fact that there are over 30 different 
variants and other enzymes that display related activity (Murakami et al., 2011). 
Interestingly the key IMTG lipase, ATGL, also belongs to the Ca2+-independent 
phospholipase A2 group otherwise known as patatin-like phospholipase domain-
containing lipases (Murakami et al., 2011). It has previously been established that 
PLIN5 binds to ATGL and its co-activator CGI-58 (Wang et al., 2011a). Research 
investigating the relationship between PLIN proteins and phospholipase A2s is still in 
its infancy. The results from this chapter suggest that there may be an interaction 
between PLIN5 and PA2GA.  
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As anticipated there was a high degree of protein contaminants in all muscle samples 
however in the case of m. vastus lateralis from obese and T2D participants this may 
have increased the chances of PLIN5 being overshadowed and therefore not 
identified. A preclearing protocol prior to the PLIN5-IP may reduce protein 
contaminants and increase the chances of PLIN5 recognition. A pre-clearing step 
normally involves incubating the muscle with protein A/G Dynabeads and then 
discarding these Dynabeads thus removing any contaminant proteins that non-
specifically bind to the protein A/G Dynabead complex. This presents a risk albeit low 
of removing proteins of interest that may have otherwise been bound to the target 
protein (i.e. PLIN5). Alternatively, a more stringent wash protocol can remove low 
non-specific binding to the Dynabead-antibody complex. A more stringent wash 
protocol was purposefully avoided in this protocol because during the development 
of the method we found removal of HSL (a known binding partner of PLIN5) occurred 
when a more thorough washing protocol (washing protocol 2) was used.  
Interestingly PLIN1 was identified as a contaminant in m. vastus lateralis from lean 
sedentary, obese and T2D participants as it was identified not only in the attempted 
PLIN5-IP but also in the control-IP. PLIN1 has historically only been expressed in 
adipocytes and steroidogenic cells (Londos et al., 1995). The conjecture that PLIN1 
exists primarily in adipocytes exists because upon identification of the protein by 
Greenberg and colleagues (1991) they conducted western blots in various tissues 
including muscle with an antibody targeting PLIN1 and found it to be only expressed 
in adipocytes. Since this discovery research investigating PLIN proteins in skeletal 
muscle has focused on the remaining PLINs (PLIN2-5). This however has a potential 
to be an oversight. mRNA expression of PLINs demonstrated that PLIN1 was 
expressed in human skeletal muscle although to a lower extent than the other four 
PLINs (Gjelstad et al., 2012). Additionally, deep proteomics of mouse skeletal muscle 
which quantified abundance of over 10,000 skeletal muscle proteins identified PLIN1 
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as the third most abundant PLIN protein (Deshmukh et al., 2015b). Western blotting 
of human skeletal muscle has shown the presence of low PLIN1 levels (Hagstrom-
Toft et al., 2002) or none at all  (Phillips et al., 2005) which may be explained by 
antibody specificity or infiltration of extracellular adipocytes. Immunohistochemical 
staining of PLIN1 in porcine skeletal muscle showed localisation of PLIN1 surrounding 
muscle fibres (Gandolfi et al., 2011) likely to be located on extracellular adipocyte 
depots.  In this study PLIN1 was identified in m. vastus lateralis of lean sedentary, 
obese and T2D partiicpants but not in lean healthy participants used as part of the 
method development. The identification of PLIN1 from analysis of muscle samples 
may be a reflection of heightened extramyocellular lipids that is commonly observed 
in obesity (Hattori et al., 2006) 
In addition to PLIN1 adipocytes also highly express HSL (Hagstrom-Toft et al., 2002), 
which together interact to stimulate lipolysis (Shen et al., 2009). Considering the 
contamination of PLIN1 in the lean sedentary, obese and T2D participants it is 
plausible the HSL observed during the method development experiments was bound 
to PLIN1 in extramyocellular LD rather than PLIN5. PLIN5 is predominantly expressed 
in oxidative tissues such as skeletal muscle, heart muscle and liver (Wang & Sztalryd, 
2011). Adipocytes, particularly from white adipose tissue have a lower oxidative 
capacity and therefore PLIN5 has often been undetectable in adipocytes from mice 
and rats (Wolins et al., 2006; Ramos et al., 2016). It is therefore unlikely that PLIN5 
would be expressed highly in any extramyocellular LD. The presence of 
extramyocellular adipocytes in the muscle sample presents a new challenge when 
using immunoprecipitation-mass spectrometry to investigate lipid metabolism 
proteins in human skeletal muscle but also highlights the benefits of using a non-
targeted mass spectrometry approach. For example, if a hypothesis driven approach 
was used to analyse this muscle such as PLIN5-IP followed by immunoblotting of 
HSL, the non-targeted PLIN1 discovery from mass spectrometry would not have been 
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identified and the potential contamination of adipocytes would have been 
unobserved. Through HSL bound to PLIN1 contamination, this may have misinformed 
us of a high abundance of HSL as a binding partner to PLIN5 in muscle from these 
cohorts. Together this highlights the benefits of using a non-targeted approach to 
detect PLIN5 associated proteins by critically evaluating proteins identified together 
from PLIN5-IP and control-IP. 
To overcome the lack of detection of PLIN5 and associated proteins from muscle from 
obese and T2D participants in this PLIN5-IP GeLC-MS/MS protocol it may be more 
effective to use cultured muscle cells from these populations. This would remove 
contamination by extramyocellular adipocytes and allow the use of tag proteins (i.e. 
GFP) with SILAC. Whilst this would increase the likelihood of identifying PLIN5 
binding partners it may sacrifice novel associated proteins that would only be detected 
in vivo. Notably, IMTG metabolism in vivo is subject to regulation from numerous 
factor such hormones, substrate levels and contraction (Donsmark et al., 2003; Watt 
et al., 2003c; Johnson et al., 2004) cannot be accurately replicated in vitro. To 
preserve the in vivo environment, recent advancement in proteomics of mouse 
skeletal muscle have used peptide separation by isoelectric focusing which can 
identify up to a third more proteins in contrast to typical protein separation by gel 
electrophoresis (Hubner et al., 2008). Improved sensitivity of detecting proteins can 
also be achieved by using an ion trap mass analyser (Deshmukh et al., 2015b) 
allowing for deeper investigation into skeletal muscle proteome. The combination of 
peptide separation by isoelectric focusing combined with an ion trap analyser would 
increase the likelihood of PLIN5 and associated proteins being detected in muscle 
from obese and T2D participants in vivo.   
Chapter 3 of this thesis highlighted PLIN5 is higher in oxidative type I muscle fibres 
in comparison to type II fibres in line with previous findings (Sollner, 2007; Shepherd 
et al., 2013). Fibre type composition analysis has revealed a progressive shift from 
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type I fibres to type II fibres with increased insulin resistance (Marin et al., 1994; 
Oberbach et al., 2006; Stuart et al., 2013; Albers et al., 2015). It is anticipated in this 
study that the muscle from T2D and obese participants would therefore have a lower 
composition of type I fibres. The amount of PLIN5 that can be immunoprecipitated in 
muscle from obese and T2D participants may therefore be diluted by a lack of 
oxidative fibres which may have resulted in greater difficulty in the reproducibility of 
detecting PLIN5. 
The aim of this study was to develop an immunoprecipitation-mass spectrometry 
protocol to pull-down PLIN5 and identify associated proteins in skeletal muscle with 
different metabolic environments. The PLIN5-IP GeLC-MS/MS protocol successfully 
immunoprecipitated PLIN5 and identified PA2GA as potential new protein interactor. 
Reverse immunoprecipitation of PA2GA would further validate this protein-protein 
interaction. Confocal immunofluorescence microscopy can be leveraged to 
investigate the colocalisation of these two proteins within skeletal muscle.. Obese and 
T2D muscle could not successfully replicate PLIN5-IP likely due to increased 
contaminants from extramyocellular adipocytes and/or decreased availability of 
PLIN5 due to known decreased composition of type I fibres. Future research needs 
to focus on optimising a protocol leveraging recent advancements in peptide 
separation by isoelectric focusing and high-resolution mass spectrometry (Hubner et 
al., 2008; Deshmukh et al., 2015b) to allow the investigation of PLIN5 associated 
proteins in muscle from obese and T2D  participants. 
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Chapter 6. Discussion  
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6.1 Overview  
Western lifestyle is characterised by reduced physical activity, increased sedentary 
time and over-consumption of energy dense foods. This has led to drastic increases 
in obesity and type 2 diabetes (T2D) (Diabetes UK, 2017; World Health Organisation, 
2017) and an increased risk for cardiovascular disease (Laakso, 2010). Fat is 
considered to be very palatable yet very energy dense (Rolls, 2000) and readily 
available in western culture. Due to this, several studies have used high-fat high-
calorie (HFHC) diets as a model to induce insulin resistance in humans and study the 
mechanisms behind this pathogenesis.  Most of this research has been completed in 
cohorts of young healthy males and studies that did include females did not directly 
compare sexes. This is a considerable oversight considering pre-menopausal women 
with normal levels of the female hormones (oestrogen and progesterone) appear to 
be better protected against metabolic diseases compared to males. 
Elevated intramuscular triglyceride (IMTG) content has been observed in insulin 
resistant individuals and endurance trained insulin sensitive individuals in a 
phenomenon called the athlete's paradox (Goodpaster et al., 2001). A key 
discrepancy between endurance trained individuals and insulin resistant individuals 
is the higher capacity for turnover (i.e. deplete and resynthesise) of their IMTG stores 
(Perreault et al., 2010) which is proposed to reduce the accumulation of lipid 
metabolites known to directly impair skeletal muscle insulin signalling. Research over 
the past two decades have explored the mechanisms behind IMTG re-synthesis and 
hydrolysis that help to regulate IMTG turnover. HFHC diets have also been shown to 
increase IMTG content. However, very few studies have investigated the 
mechanisms behind this increase in IMTG stores and how this relates to skeletal 
muscle insulin resistance. Perilipin (PLIN) proteins and synaptosomal-associated 
protein 23 (SNAP23) have been implicated in assisting the expansion of the IMTG 
stores following lipid excess (Bostrom et al., 2007; Bosma et al., 2012a; Bosma et al., 
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2013; Shepherd et al., 2017b). Furthermore, most research on the effects of HFHC 
diet on IMTG stores has been conducted on whole muscle homogenates (Gemmink 
et al., 2016). This does not take into consideration that different fibre-types have 
different capacities to store and utilise IMTG (Shepherd et al., 2013; Shepherd et al., 
2017b) or that larger lipid droplets (LD) storing IMTG located in subsarcolemmal 
region of muscle fibres are more associated with insulin resistance than 
intermyofibrillar LD (Crane et al., 2010; Daemen et al., 2018). The fibre-type and 
region-specific responses to a HFHC diet on IMTG content and proteins regulating 
IMTG stores have not yet been investigated. 
IMTG is now recognised as an important energy source particularly during moderate-
intensity exercise where maximal fat oxidation is elicited (van Loon et al., 2001). 
Understanding the mechanisms behind IMTG hydrolysis in healthy insulin-sensitive 
individuals is important to understand how overall IMTG turnover is regulated. 
Hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) are the main 
enzymes responsible for IMTG hydrolysis. LD associated with PLIN2 and PLIN5 are 
preferentially used during a 1 h bout of moderate intensity exercise (Shepherd et al., 
2012, 2013). PLIN2 and PLIN5 have been shown to interact or colocalise with HSL 
and ATGL (Prats et al., 2006; Wang et al., 2011a; MacPherson et al., 2013a). Prior 
to this thesis little was known about the distribution and colocalisation of HSL and 
ATGL to LD and to PLIN proteins during a bout of moderate-intensity exercise in 
human skeletal muscle.  
In recent years PLIN5 has emerged as an important PLIN in regulating IMTG 
hydrolysis (Wang et al., 2011a; Shepherd et al., 2013) and also provide metabolic 
linkage to mitochondria (Bosma et al., 2012b). Hypothesis driven techniques such as 
PLIN5 immunoprecipitation (IP) followed by immunoblotting has confirmed that PLIN5 
interacts with key lipolytic enzymes HSL (MacPherson et al., 2013a), ATGL and its 
co-activator CGI-58 (Wang et al., 2011a; MacPherson et al., 2013a). Proteomic 
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analyses has revealed that over 300 proteins are associated with LD (Zhang et al., 
2011). As PLIN5 is a LD associated protein and is linked to mitochondria it is likely 
that PLIN5 is also associated to other proteins that have not yet been identified.  Due 
to the differences in IMTG turnover between insulin sensitive and insulin resistant 
individuals (Perreault et al., 2010) whether PLIN5 is associated to different proteins 
in different metabolic disease states needs investigation. 
The overall aim of this thesis was to explore proteins that regulate skeletal muscle 
lipid metabolism in humans; focusing on the effects of a HFHC diet, an acute bout of 
moderate-intensity exercise and different metabolic disease states (lean, obese and 
T2D). Chapter 2 determined whether there were sex-specific differences in functional 
outcomes of cardio-metabolic health in response to 7 days HFHC diet. Chapter 3 
investigated the fibre-type and region-specific changes in IMTG content and proteins 
(PLINs and SNAP23) regulating IMTG accumulation following a 7-day HFHC diet. 
Chapter 4 investigated colocalisation of key lipases HSL and ATGL to LD associated 
with PLIN2 and PLIN5 in response to a moderate-intensity exercise bout. Due to 
PLIN5 being identified as an important PLIN for regulating IMTG hydrolysis, Chapter 
5 aimed to develop a novel immunoprecipitation mass-spectrometry protocol to 
identify PLIN5 associated proteins to investigate how these proteins change between 
different metabolic states (lean, obese and T2D). 
6.2 High-fat high-calorie diets as a method to induce insulin resistance 
Lipid-infusion studies have been extensively used to investigate lipid-induced insulin 
resistance particularly in skeletal muscle (Boden et al., 1994; Shah et al., 2002; Chow 
et al., 2014). Results from the studies however may only provide an overview of acute 
responses to lipid excess rather than more chronic lipid overload observed in obesity 
and T2D.  Consequently, many researches have used a more chronic lipid overload 
in the form of a HFHC diet to investigate lipid-induced insulin resistance (Brons et al., 
2009; Bakker et al., 2014; Hulston et al., 2015; Parry et al., 2017). Although some 
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studies included female participants (Hulston et al., 2015; Parry et al., 2017), to date 
no study had directly compared sexes to clarify the sex-specific cardiovascular and 
metabolic responses to a short-term HFHC diet. The aim of chapter 2 was to 
determine sex-specific differences in functional outcomes of cardiovascular and 
metabolic health in response to 7 days HFHC diet. A wide range of metabolic and 
cardiovascular outcomes were measured including; metabolic flexibility and insulin 
sensitivity derived indexes from the oral glucose tolerance test, body composition 
from dual x-ray absorptiometry (DXA), arterial stiffness from aortic pulse wave velocity 
and blood lipid profile and liver enzymes from fasting blood samples. This gave a 
comprehensive overview of any detrimental effects of the HFHC diet on metabolic 
and cardiovascular health. The results showed there was no overall effect of the 
HFHC diet on any of the functional outcomes of cardiovascular or metabolic health in 
young healthy adults of either sex. This is in line with other studies which have also 
reported no effect of a HFHC diet on indices of insulin sensitivity (Adochio et al., 2009; 
Brons et al., 2009) and indicates that some individuals may be protected against 
these diets. Reduced physical activity with a HFHC diet has shown more clear 
reductions in insulin sensitivity (Knudsen et al., 2012), whilst high cardio-respiratory 
fitness levels are protective against all-cause mortality (Blair et al., 1989). It is noted 
that the participants in chapter 2 were all very physically active and had high levels of 
cardio-respiratory fitness and this may therefore have protected them against the 
detrimental effects of a HFHC diet. When the same HFHC diet was applied to a mixed 
cohort (n=13 males, n=2 females) in chapter 3 glucose tolerance from an oral glucose 
challenge was impaired and tracer-derived measurements showed a reduction in 
metabolic clearance rate. Together the data indicates a 7-day HFHC diet can impair 
insulin sensitivity in healthy adults but certain cohorts may be protected.  
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6.3 Fibre-type and region-specific changes in LD morphology following 
HFHC diet. 
IMTG content increases following lipid infusion and/or after a high-fat diet (Bachmann 
et al., 2001; Gemmink et al., 2017a; Shepherd et al., 2017b) (section 1.7). It is now 
accepted that type I fibres exhibit higher capacity to store IMTG (Shepherd et al., 
2013; Shepherd et al., 2017b) and therefore fibre type specific approaches to 
investigate increases in IMTG need to be adopted. In addition to this transmission 
electron microscopy (TEM) has been able to identify larger LD located in the 
subsarcolemmal region are more associated with insulin resistance (Crane et al., 
2010; Daemen et al., 2018) (section 1.6.2.3). Chapter 3 therefore used a fibre-type 
(type 1 vs. type IIa vs. type IIx) and region-specific (central vs peripheral) approach 
to investigate changes in IMTG content (LD number and morphology) following a 7-
day HFHC diet.  The results showed that following the HFHC diet increases in IMTG 
content were specific to type I fibres and occurred similarly between the peripheral 
and central region of type I muscle fibres. This fibre-type specific increase in IMTG is 
similar to that observed following 6 h of lipid infusion during a hyperinsulinaemic-
euglycaemic clamp (Shepherd et al., 2017b). This further highlights the importance 
of adopting fibre-type specific approaches to investigate changes in IMTG. Although 
IMTG content did not increase in type IIa or IIx fibres, there was an increase in IMTG 
content in the peripheral region of these muscle fibres due to an increase in LD size 
and number. Whilst overall IMTG content did not increase in the central region of type 
IIa or IIx fibres there was an increase in LD size.  By leveraging a fibre-type and 
region-specific analysis of images obtained from confocal immunofluorescence 
microscopy chapter 3 was also to propose distinct patterns of IMTG accretion in 
human skeletal muscle, whereby lipid accumulates in type I fibres prior to type IIa or 
IIx fibres, changes in LD size precede an increase in LD density, and this occurs in 
the peripheral region of the cell before the central region. This preferable IMTG 
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accumulation in healthy individuals following a HFHC diet is distinct from that 
observed in insulin-resistant states which show IMTG accumulation in the 
subsarcolemmal region (Chee et al., 2016), in type II fibres (Daemen et al., 2018) and 
characterised by larger LD (Nielsen et al., 2017). As there were no impairments in 
skeletal muscle insulin signalling following the 7-day HFHC diet (Chapter 3) it is 
proposed these increases in IMTG stores are a protective mechanism preventing the 
accumulation of lipid metabolites known to contribute to skeletal muscle insulin 
signalling. 
6.4 The role of proteins in increasing IMTG content after HFHC diet. 
Although IMTG increases following HFHC diet the mechanisms underpinning this 
increase are still unknown. Recently Gemmink et al., (2017a) showed that PLIN5 
protein expression increased in whole muscle homogenates concomitant to an 
increase in IMTG. As previously explained type I fibres store higher IMTG content 
compared to type II fibres (Shepherd et al., 2013; Shepherd et al., 2017b) and 
therefore investigations of the mechanisms underpinning increased IMTG stores also 
need to be fibre type-specific. Chapter 3 demonstrated that PLIN3 was the only PLIN 
to increase in protein expression following a HFHC diet and this was exclusive to type 
I fibres. This did not however lead to an increase in PLIN3+ LD indicating that 
increases in PLIN3 are targeted to LD that already have PLIN3 associated suggesting 
that PLIN3 may support LD growth and stability.  
Chapter 3 also showed there was an increase in the fraction of PLIN2 colocalising 
with LD resulting in an increase in PLIN2+ LD in type I fibres without an increase in 
PLIN2 protein expression following the HFHC diet. This is a similar finding to increase 
in PLIN2+ LD in type I fibres following 6 h lipid infusion without increases in PLIN2 
protein expression (Shepherd et al., 2017b). Colocalisation analysis from chapter 3 
confirmed that only a fraction of PLIN2 (0.4) is colocalised to LD however this is 
lower than previously reported findings (0.60-0.65) (Shaw et al., 2009; Shepherd et 
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al., 2013; Shepherd et al., 2017b), but does indicate there is free PLIN2 within the 
muscle. Previous research from macrophages and adipocytes has indicated that 
PLIN2 has a role in supporting LD biogenesis (Brasaemle et al., 1997; Robenek et 
al., 2006), however is not associated with mature adipocytes (Brasaemle et al., 1997). 
Newly-formed LD may therefore become associated with PLIN2 leading to an 
increase in PLIN2+ LD and it could be speculated that free PLIN2 within the muscle 
may indicate disassociation from the LD once they reach maturity. In chapter 3 
colocalisation analysis also revealed that a fraction of PLIN3 and PLIN5 colocalise 
with LD in skeletal muscle and only a fraction of LD are colocalised to either PLIN2, 
PLIN3 or PLIN5 further confirming a heterogenous LD pool in human skeletal muscle 
(Shepherd et al., 2013; Shepherd et al., 2017b).  
Chapter 3 also revealed that SNAP23 colocalisation to; the plasma membrane, LD 
and the mitochondria was not altered following the HFHC diet in either type I or type 
IIa fibres. Previous research in cardiomyocytes treated with oleic acid showed an 
increase in the LD-associated pool of SNAP23 with a concomitant reduction in 
SNAP23 at the plasma membrane (Bostrom et al., 2007), leading to the hypothesis 
that LD ‘hijack’ SNAP23 from the plasma membrane to assist in LD fusion following 
lipid excess (Sollner, 2007). The lipid excess provided by a 7-day HFHC diet in 
chapter 3 did not stimulate any redistribution of SNAP23 in human skeletal muscle. 
There was an increase in LD size however and therefore it may be plausible that there 
was already sufficient SNAP23 colocalised to LD to regulate LD fusion. Research into 
SNAP23 regulation in human skeletal muscle is still very much in its infancy with only 
recently SNAP23 colocalisation to the plasma membrane, LD and mitochondria being 
investigated in human skeletal muscle (Strauss et al., 2016). The evidence from 
chapter 3 further confirms the distribution of SNAP23 within skeletal muscle and in 
different fibre type which paves the way for future research investigating alterations 
in distribution as a result of metabolic changes such as T2D. 
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6.4.1. The use of confocal immunofluorescence microscopy in region specific 
analyses 
Studies using TEM can accurately distinguish between the subsarcolemmal and 
intermyofibrillar regions of muscle fibres providing valuable information on LD size 
and density in these specific areas. Counterintuitively TEM can only exam small 
fragments of muscle and is limited in its ability to co-examine LD with multiple proteins 
of interest. In Chapter 3 confocal immunofluorescence microscopy was used to 
circumvent these problems; allowing full cross-sectional analysis of different fibre 
types and permitting colocalisation analyses to be performed. We identified 5μm from 
the cell border as the peripheral region and the remainder of the cell as the central 
region. Our aim was to identify these regions as one that was near the plasma 
membrane and close to insulin signalling cascades but also large enough area to be 
able to yield information regarding LD dynamics. The central region was then 
identified as an area distinguishably away from the plasma membrane and distant 
from insulin signalling cascades. This methodology consequently allowed for the 
benefits of confocal immunofluorescence microscopy to be deployed whilst gaining 
insights into region specific changes in lipid metabolism in different muscle fibres. 
6.5 Distribution and colocalisation of lipases involved in IMTG hydrolysis  
Evidence from isolated rat skeletal muscle demonstrated that HSL translocates to LD 
ex vivo from both adrenaline and electrically stimulated contraction (Prats et al., 2006) 
(section 1.3.2.2) however whether this mechanism existed in human skeletal muscle 
in vivo was still unknown. Previously widefield microscopy was used to investigate 
the effects of moderate-intensity exercise on the localisation of ATGL to LD in human 
skeletal muscle (Mason et al., 2014b) (section 1.3.2.2). This type of microscopy is 
limited by the refraction of light (compared to a laser) and the resolving power of the 
microscope. Chapter 4 used higher resolution confocal immunofluorescence 
microscopy to show that HSL preferentially redistributes to LD following 1 h moderate-
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intensity exercise in human skeletal muscle. In contrast a proportion of ATGL was 
already colocalised to LD and this was unchanged following the exercise bout. PLIN 
proteins have also been implicated in IMTG hydrolysis (section 1.5.). Chapter 4 also 
showed that HSL preferentially redistributes to PLIN5+ LD in comparison to PLIN5- 
LD whereas PLIN2+ LD and PLIN2- LD had similar amounts of increased HSL 
colocalisation. These findings are consistent with a previous analysis of muscle 
samples used in chapter 4 showing that following endurance training PLIN5+ LD are 
preferentially used during 1 h of moderate-intensity exercise in human skeletal muscle 
compared to PLIN5-LD, whereas PLIN2+ LD and PLIN2- LD are used to a similar 
extent (Shepherd et al., 2013). These results add to the current consensus that PLIN5 
is the main PLIN involved in regulating IMTG hydrolysis. PLIN5 has also been shown 
to interact with ATGL and its co-activator CGI-58 (Wang et al., 2011a) and recruits 
LD to the surface of mitochondria (Wang et al., 2011b; Bosma et al., 2012b). Together 
chapter 4 and recent evidence suggests that PLIN5 assists in IMTG hydrolysis by 
interacting with key enzymes HSL and ATGL and then assists in directing IMTG-
derived FA to the mitochondria for subsequent -oxidation. 
6.5.1 Limitations of confocal immunofluorescence microscopy 
Chapter 3 and 4 have generated novel data of LD dynamics using confocal 
immunofluorescence microscopy. Whilst these findings are important, it is crucial to 
appreciate the limitations of using this technique. The resolution of a confocal 
microscope is 200nm, whilst this is appreciably better than a widefield microscope it 
doesn’t match the accuracy of a transmission electron microscope. When analysing 
colocalisation of a protein e.g. PLIN with a LD it is possible that a PLIN in close 
proximity to LD but not actually in contact would be counted as a PLIN+ LD due to 
this resolution power. Additionally due to microscope channel constraints PLIN+ LD 
analyses can only be conducted on a single PLIN protein with LD. We cannot exclude 
the possibility therefore that LD have multiple perilipin proteins colocalised to them. It 
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is also plausible that PLIN- LDs may also be newly formed LD that did not have 
sufficient PLIN associated to them to be detected by the lower detection limit of the 
microscope. The z plane of the confocal microscope is approximately 0.53 µm which 
means any LD within this Z field will be imaged by the microscope. PLIN proteins that 
are underneath but still associated to the LD and out of this depth will not however be 
imaged and included in the analysis. Nonetheless confocal immunofluorescence 
microscopy provides a higher resolution compared to widefield microscopy and still 
permits multiple labelling of proteins unlike TEM. Despite these limitations therefore 
confocal immunofluorescence microscopy remains a beneficial and suitable method 
for investigating skeletal muscle lipid metabolism.  
6.6 A non-targeted approach to investigating PLIN5 associated proteins 
Chapter 4 highlighted that PLIN5 is important for IMTG hydrolysis because HSL 
preferentially redistributes to PLIN5+ LD during a 1 h moderate-intensity exercise 
bout. PLIN5+ LD have also been shown to be preferentially used during 1 h of 
moderate-intensity exercise (Shepherd et al., 2013) and PLIN5 also provides 
metabolic linkage to mitochondria (Bosma et al., 2012b). Together the data suggests 
PLIN5 is important in regulating IMTG hydrolysis and directing IMTG-derived fatty 
acid to the mitochondria for subsequent -oxidation. Chapter 5 aimed to develop a 
novel immunoprecipitation (IP)-mass spectrometry approach that would identify novel 
PLIN5 associated proteins in human skeletal muscle. By following PLIN5-IP with gel 
electrophoresis prior to high performance liquid chromatography tandem mass 
spectrometry (GeLC-MS/MS), a successful reproducible protocol was established 
that immunoprecipitated PLIN5 from the muscle of lean participants. Furthermore, a 
unique protein associated with PLIN5 was identified as phospholipase A2- group II, 
subgroup A (PA2GA) from muscle lean sedentary participants. PA2GA has previously 
been linked to LD formation and recruitment of PLIN2 to LD in mice macrophages 
(Leiguez et al., 2011). This finding generates the new hypothesis that PLIN5 and 
195 
PA2GA interact at the LD surface to regulate lipid metabolism in human skeletal 
muscle. However, the PLIN5-IP GeLC-MS/MS protocol developed in chapter 5 did 
not lead to a reproducible immunoprecipitation of PLIN5 from the muscles of inactive 
males and females with obesity and T2D undergoing elective orthopaedic surgery. 
Potential reasons for this were protein contaminations from extramyocellular 
adipocytes in these muscles and a low muscle PLIN5 content in these groups due to 
a reduced composition of type I fibres in insulin-resistant states. Chapter 5 was the 
first study to apply an IP-mass spectrometry technique to human skeletal muscle and 
these results highlight the complexity of using this technique particularly in diseased 
states such as obesity and T2D. Future work is certainly needed to develop a 
replicable IP- mass spectrometry protocol that can be applied to muscle from different 
metabolic conditions (lean, obese and T2D) and direct comparisons to be made. At 
present, investigations into skeletal muscle lipid metabolism can continue to occur 
with the use of confocal immunofluorescence microscopy, which can be effectively 
used in different diseased states to generate more robust conclusions. 
6.7 Future research 
6.7.1 Understanding what protects individuals from the detrimental effects of a 
HFHC diet on functional outcomes of cardiovascular and metabolic health. 
The results from chapter 2 showed there were no impairments resulting from the 
HFHC diet on functional outcomes of cardiovascular and metabolic health. Whilst 
some studies investigating the effects of HFHC diets have shown reductions in 
measurements of whole-body insulin sensitivity (Hulston et al., 2015; Parry et al., 
2017), others have shown no reduction in peripheral insulin sensitivity (Adochio et al., 
2009; Brons et al., 2009), but have observed reductions in hepatic insulin sensitivity 
(Brons et al., 2009). It is therefore apparent that some cohorts may be protected 
against the detrimental effects of a HFHC diet that clearly warrants further 
investigation. The participants in chapter 2 were all young, had high levels of physical 
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activity (PA) and had a good levels of cardio-respiratory fitness, all of which have the 
potential to be protective against cardiovascular and metabolic diseases.  
High cardio-respiratory fitness reduces the risk of T2D and all-cause mortality (Blair 
et al., 1989; Nojima et al., 2017). In chapter 2 there were no detrimental effects 
observed following a 7-day HFHC diet in either sex and both males and females 
displayed good levels of cardio-respiratory fitness (V̇O2 peak: 62.3 ± 8.7 and 58.2 ± 8.2 
ml.min-1.kgFFM-1 for males and females respectively). A question therefore emerges 
of whether participants in chapter 2 were protected from the detrimental effects of a 
HFHC diet due to their elevated cardio-respiratory fitness. Studies using a similar 
duration HFHC diet protocol that have shown impairments in insulin sensitivity have 
not measured cardio-respiratory fitness prior to the dietary protocol (Hulston et al., 
2015; Parry et al., 2017), making it difficult to ascertain whether cardio-respiratory 
fitness was a protecting factor. Future research should therefore investigate high 
cardio-respiratory fitness vs low cardio-respiratory fitness on the effects of HFHC diet 
on functional outcomes of cardiovascular and metabolic health. Importantly to 
determine whether cardio-respiratory fitness was the unique factor protecting these 
individuals, groups should be matched for sex and age and physical activity levels 
should be controlled for each group.  
Notwithstanding, the differences in male and female responses to models that induce 
insulin resistance is still vastly understudied. It would therefore be pertinent to extend 
the findings of chapter 2 by using a more rigorous method of impairing functional 
outcomes of cardiovascular and metabolic health. This could occur in the form or 
combining a HFHC diet with reduced PA or by extending the duration of the HFHC 
diet to allow aberrations to occur. The understanding of how T2D develops in females 
still remains critical in our understanding of the pathology of this disease and how to 
develop interventions to combat it. 
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6.7.2. Quantification of lipid metabolites following a HFHC diet 
Chapter 3 concluded that increases in IMTG following HFHC diet help to maintain the 
insulin signalling pathway likely by reducing the accumulation of lipid metabolites 
known to disrupt the insulin signalling pathway. Future research should confirm this 
hypothesis and quantify changes in lipid species following a HFHC diet when there 
are increases in IMTG. Previously lipid metabolite DAG was shown to impair skeletal 
muscle insulin signalling (Schmitz-Peiffer et al., 1997; Itani et al., 2002), however 
evidence has emerged that the  subcellular location, saturation and FA positioning on 
the glycerol backbone are all influential factors in DAGs contribution to insulin 
resistance (Bergman et al., 2010; Amati et al., 2011). The identification of certain lipid 
species that increase following HFHC diet but do not result in disruption in skeletal 
muscle insulin signalling will be advantageous in recognising benign lipid stores that 
are not detrimental to skeletal muscle health. This will shed further light on the 
athlete's paradox by identifying which specific lipid moieties promote an insulin 
desensitizing effect. 
6.7.3 The need for insulin signalling immunohistochemistry assays  
In chapter 3 it was demonstrated that although whole body insulin sensitivity was 
reduced this was not due to impairments in skeletal muscle insulin signalling as 
quantified with western blot of whole muscle homogenates. The mechanisms behind 
this protective insulin signalling was investigated using fibre-type specific analyses of 
lipid metabolism. Here it was demonstrated that IMTG increased in type I fibres only, 
likely aided by a concurrent increase in PLIN3 protein expression and re-distribution 
of PLIN2 to existing LD stores. It would be useful to know if the maintenance of the 
insulin signalling pathway occurred across all fibre types or whether there was fibre-
type or cell location specific changes. Glucose uptake from the muscle is also 
dependent on increased blood flow to microvascular units in the muscle (Keske et al., 
2016), allowing the effective delivery of glucose, insulin and other substrates.  It is 
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also plausible that cell specific insulin signalling may be a result of perfusion to the 
cells from surrounding microvascular units. The development of 
immunohistochemistry assays that can measure cell-specific phosphorylation of 
insulin signalling intermediates would aid in answering these questions.  
6.7.4. Is IMTG hydrolysis impaired after HFHC diet? 
In chapter 3 it was concluded that increases in IMTG following a HFHC diet help to 
maintain the insulin signalling pathway likely by reducing the accumulation of lipid 
metabolites known to disrupt the insulin signalling pathway. Increases in IMTG are 
not correlated with decrements in skeletal muscle insulin sensitivity if an individual 
retains the capacity to turnover their IMTG stores (Perreault et al., 2010), as is often 
observed in endurance trained individuals (van Loon, 2004). An increase in IMTG 
therefore also needs to be matched with an increased capability of IMTG turnover if 
skeletal muscle insulin sensitivity is to be maintained. Following HFHC diet induced 
increases in IMTG, future research should investigate whether the capacity to 
hydrolyse IMTG is impaired or not. Development of immunohistochemistry analyses 
have revealed unique mechanisms of how IMTG hydrolysis is regulated in human 
skeletal muscle. For example, during 1 h of moderate-intensity exercise, HSL 
preferentially redistributes to PLIN5+ LD (Chapter 4) and PLIN5+ LD are favourably 
used over PLIN5- LD (Shepherd et al., 2013). Future research should specifically use 
these immunohistochemistry analyses to reveal whether these mechanisms in 
insulin-sensitive individuals are impaired or maintained following HFHC diets. 
6.7.5. Does HSL redistribution change in endurance athletes or individuals with 
T2D? 
Chapter 4 established that HSL preferentially redistributed to PLIN5+ LD in human 
skeletal muscle following moderate-intensity exercise. The study was conducted on 
lean healthy insulin sensitive individuals who typically display high IMTG turnover at 
rest (Kanaley et al., 2009) and during submaximal exercise (Guo et al., 2000).  
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Conversely, obese pre-diabetic individuals showed impaired IMTG turnover 
(Perreault et al., 2010). Men diagnosed with type 2 diabetes have a lower skeletal 
muscle HSL protein content in comparison to normal glucose tolerant controls and 
their HSL activity shows signs of dysregulation at rest and following insulin-stimulation 
(Jocken et al., 2013). Future research should investigate whether impairments in 
IMTG hydrolysis that exist in pre-diabetic and diabetic individuals is matched with 
impaired HSL distribution pre and post exercise. PLIN2+ LD are used during a 
moderate-intensity bout of exercise (Shepherd et al., 2012). Following 6-weeks of 
endurance training or sprint interval training, healthy lean individuals preferentially 
utilised PLIN5+ LD in comparison to PLIN5- LD whereas both PLIN2+ LD and PLIN2 
–LD were used to the same extent (Shepherd et al., 2013) suggesting PLIN5 plays a 
pertinent role in increasing fat oxidation capacity in skeletal muscle. To add to the 
emerging field of PLIN research, it would be beneficial to know if HSL preferentially 
redistributes to PLIN5+ LD or whether this mechanism is diminished in obese or type 
2 diabetic muscle. The participants in chapter 4 had undergone 6 weeks of endurance 
training prior to the experimental protocol but were not endurance athletes. Whether 
there is an increased distribution of HSL to PLIN5+ LD in muscle from endurance 
trained athletes that enhances their ability to utilise IMTG stores during exercise also 
warrants further investigation. 
6.7.6 Advancing the use of proteomics to understand skeletal muscle lipid 
metabolism. 
Recent developments in proteomics provide an unbiased comprehensive catalogue 
of the skeletal muscle proteome and represents an ideal analytical tool for high-
throughput discovery of protein alterations in health and disease (Hochstrasser et al., 
2002). In 2015, state of the art mass spectrometry work flow was able to quantify 
abundance values of over 10,000 proteins in mouse skeletal muscle (Deshmukh et 
al., 2015b). Mass-spectrometry based proteomics is a relatively new analytical 
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approach, developments in technology and refinements in protocols are now making 
it possible to; 1. quantify abundance values of the large data sets of the skeletal 
muscle proteome (Deshmukh et al., 2015b), 2. recognise post-translational 
modifications to large protein data sets following acute contractions (Potts et al., 
2017) and 3. with the use of IP – mass spectrometry identify novel protein binding 
partners in different disease states (Yoon et al., 2012). These advancements provide 
an exciting avenue to take a non-biased approach to explore regulation in skeletal 
muscle lipid metabolism. Chapter 5 developed an IP-mass spectrometry protocol to 
investigate proteins associated with PLIN5 and identified PA2GA as a unique protein 
associated to PLIN5 in muscle of lean sedentary participants. The difficulty of applying 
this technique to muscle of obese and T2D individuals was likely compromised by 
extramyocellular adipocytes and a potential reduction in PLIN5 protein expression 
from reduced composition of type I fibres. These difficulties can potentially be 
overcome by peptide separation by isoelectric focusing and high definition mass-
spectrometry (Deshmukh et al., 2015b). If achieved it be advantageous to investigate 
PLIN5 associated proteins in different diseases states. Given only a fraction of LD 
have a PLIN colocalised to them (Chapter 3 & 4) (Shaw et al., 2012; Shepherd et al., 
2013; Shepherd et al., 2017b), human skeletal muscle clearly has a heterogenous LD 
pool. Given the diverging roles of PLIN proteins it would be useful to take a non-
targeted approach to detect proteins associated to other PLINs to further elucidate 
their role in human skeletal muscle.  
6.8 Final conclusions  
The work conducted in this thesis has produced novel information on proteins that 
regulate lipid metabolism in human skeletal muscle. Chapter 2 demonstrated that 
HFHC diet does not always impair functional measurements of cardiovascular and 
metabolic disease in young, healthy individuals with high levels of cardio-respiratory 
fitness. Chapter 3 provided novel evidence that 7-days HFHC diet induces fibre type 
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specific increases in IMTG stores primarily aided by an increase in PLIN3 protein 
expression and a redistribution of PLIN2 to LD. It is proposed that this increase in 
IMTG assisted by PLIN2 and PLIN3 help to minimise the accumulation of lipid 
metabolites known to contribute to skeletal muscle insulin resistance Chapter 4 
demonstrated that HSL preferentially redistributed to PLIN5+ LD following 1 h of 
moderate-intensity exercise and thus added weight to the argument that PLIN5 is an 
important protein in regulating IMTG hydrolysis. Chapter 5 developed a PLIN5-IP 
mass spectrometry protocol that identified PA2GA is a unique PLIN5 associated 
protein in muscle from lean sedentary participants. Furthermore, methods and results 
generated from this thesis will assist in development of new hypotheses to investigate 









Abdul-Ghani MA, Matsuda M, Balas B & DeFronzo RA. (2007). Muscle and liver 
insulin resistance indexes derived from the oral glucose tolerance test. 
Diabetes Care 30, 89-94. 
 
Abdullah A, Peeters A, de Courten M & Stoelwinder J. (2010). The magnitude of 
association between overweight and obesity and the risk of diabetes: a meta-
analysis of prospective cohort studies. Diabetes Res Clin Pract 89, 309-319. 
 
Achten J & Jeukendrup AE. (2003). Maximal fat oxidation during exercise in trained 
men. Int J Sports Med 24, 603-608. 
 
Adams JM, 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC & 
Mandarino LJ. (2004). Ceramide content is increased in skeletal muscle from 
obese insulin-resistant humans. Diabetes 53, 25-31. 
 
Adochio RL, Leitner JW, Gray K, Draznin B & Cornier MA. (2009). Early responses 
of insulin signaling to high-carbohydrate and high-fat overfeeding. Nutr Metab 
(Lond) 6, 37. 
 
Agarwal AK, Arioglu E, de Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI & 
Garg A. (2002). AGPAT2 is mutated in congenital generalized lipodystrophy 
linked to chromosome 9q34. Nat Genet 31, 21-23. 
 
Aguer C, Mercier J, Man CY, Metz L, Bordenave S, Lambert K, Jean E, Lantier L, 
Bounoua L, Brun JF, Raynaud de Mauverger E, Andreelli F, Foretz M & 
Kitzmann M. (2010). Intramyocellular lipid accumulation is associated with 
permanent relocation ex vivo and in vitro of fatty acid translocase (FAT)/CD36 
in obese patients. Diabetologia 53, 1151-1163. 
 
Albers PH, Pedersen AJ, Birk JB, Kristensen DE, Vind BF, Baba O, Nohr J, Hojlund 
K & Wojtaszewski JF. (2015). Human muscle fiber type-specific insulin 
signaling: impact of obesity and type 2 diabetes. Diabetes 64, 485-497. 
 
Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P & Hemmings BA. 
(1996). Mechanism of activation of protein kinase B by insulin and IGF-1. 
Embo J 15, 6541-6551. 
 
Alsted TJ, Nybo L, Schweiger M, Fledelius C, Jacobsen P, Zimmermann R, Zechner 
R & Kiens B. (2009). Adipose triglyceride lipase in human skeletal muscle is 
upregulated by exercise training. Am J Physiol Endocrinol Metab 296, E445-
453. 
 
Alsted TJ, Ploug T, Prats C, Serup AK, Hoeg L, Schjerling P, Holm C, Zimmermann 
R, Fledelius C, Galbo H & Kiens B. (2013). Contraction-induced lipolysis is not 




Amati F, Dube JJ, Alvarez-Carnero E, Edreira MM, Chomentowski P, Coen PM, 
Switzer GE, Bickel PE, Stefanovic-Racic M, Toledo FG & Goodpaster BH. 
(2011). Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin 
resistance: another paradox in endurance-trained athletes? Diabetes 60, 
2588-2597. 
 
American Diabetes A. (2015). (2) Classification and diagnosis of diabetes. Diabetes 
Care 38 Suppl, S8-S16. 
 
Anthonsen MW, Ronnstrand L, Wernstedt C, Degerman E & Holm C. (1998). 
Identification of novel phosphorylation sites in hormone-sensitive lipase that 
are phosphorylated in response to isoproterenol and govern activation 
properties in vitro. J Biol Chem 273, 215-221. 
 
Aon MA, Bhatt N & Cortassa SC. (2014). Mitochondrial and cellular mechanisms for 
managing lipid excess. Front Physiol 5, 282. 
 
Bachmann OP, Dahl DB, Brechtel K, Machann J, Haap M, Maier T, Loviscach M, 
Stumvoll M, Claussen CD, Schick F, Haring HU & Jacob S. (2001). Effects of 
intravenous and dietary lipid challenge on intramyocellular lipid content and 
the relation with insulin sensitivity in humans. Diabetes 50, 2579-2584. 
 
Badin PM, Louche K, Mairal A, Liebisch G, Schmitz G, Rustan AC, Smith SR, Langin 
D & Moro C. (2011). Altered skeletal muscle lipase expression and activity 
contribute to insulin resistance in humans. Diabetes 60, 1734-1742. 
 
Bakker LE, van Schinkel LD, Guigas B, Streefland TC, Jonker JT, van Klinken JB, 
van der Zon GC, Lamb HJ, Smit JW, Pijl H, Meinders AE & Jazet IM. (2014). 
A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young 
South Asian men but not in Caucasian men. Diabetes 63, 248-258. 
 
Balkau B, Mhamdi L, Oppert JM, Nolan J, Golay A, Porcellati F, Laakso M, Ferrannini 
E & Group E-RS. (2008). Physical activity and insulin sensitivity: the RISC 
study. Diabetes 57, 2613-2618. 
 
Bao Y, Lopez JA, James DE & Hunziker W. (2008). Snapin interacts with the Exo70 
subunit of the exocyst and modulates GLUT4 trafficking. J Biol Chem 283, 
324-331. 
 
Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, Bickel PE, 
Pessin JE & Saltiel AR. (2000). CAP defines a second signalling pathway 
required for insulin-stimulated glucose transport. Nature 407, 202-207. 
 
Berggard T, Linse S & James P. (2007). Methods for the detection and analysis of 
protein-protein interactions. Proteomics 7, 2833-2842. 
 
205 
Bergman BC, Hunerdosse DM, Kerege A, Playdon MC & Perreault L. (2012). 
Localisation and composition of skeletal muscle diacylglycerol predicts insulin 
resistance in humans. Diabetologia 55, 1140-1150. 
 
Bergman BC, Perreault L, Hunerdosse DM, Koehler MC, Samek AM & Eckel RH. 
(2010). Increased intramuscular lipid synthesis and low saturation relate to 
insulin sensitivity in endurance-trained athletes. J Appl Physiol (1985) 108, 
1134-1141. 
 
Bergman BC, Perreault L, Strauss A, Bacon S, Kerege A, Harrison K, Brozinick JT, 
Hunerdosse DM, Playdon MC, Holmes W, Bui HH, Sanders P, Siddall P, Wei 
T, Thomas MK, Kuo MS & Eckel RH. (2018). Intramuscular triglyceride 
synthesis: importance in muscle lipid partitioning in humans. Am J Physiol 
Endocrinol Metab 314, E152-E164. 
 
Bergstrom J. (1975). Percutaneous needle biopsy of skeletal muscle in physiological 
and clinical research. Scand J Clin Lab Invest 35, 609-616. 
 
Bergstrӧm J. (1975). Percutaneous needle biopsy of skeletal muscle in physiological 
and clinical research. Scand J Clin Lab Invest 35, 609-616. 
 
Bersuker K & Olzmann JA. (2017). Establishing the lipid droplet proteome: 
Mechanisms of lipid droplet protein targeting and degradation. Biochim 
Biophys Acta 1862, 1166-1177. 
 
Bhagavan NV & Ha C-E. (2011). Chapter 12 - Carbohydrate Metabolism I: Glycolysis 
and the Tricarboxylic Acid Cycle. In Essentials of Medical Biochemistry, ed. 
Bhagavan NV & Ha C-E, pp. 115-133. Academic Press, San Diego. 
 
Bickerton AS, Roberts R, Fielding BA, Tornqvist H, Blaak EE, Wagenmakers AJ, 
Gilbert M, Humphreys SM, Karpe F & Frayn KN. (2008). Adipose tissue fatty 
acid metabolism in insulin-resistant men. Diabetologia 51, 1466-1474. 
 
Bingley CA, Gitau R & Lovegrove JA. (2008). Impact of menstrual cycle phase on 
insulin sensitivity measures and fasting lipids. Horm Metab Res 40, 901-906. 
 
Bjorndal B, Burri L, Staalesen V, Skorve J & Berge RK. (2011). Different adipose 
depots: their role in the development of metabolic syndrome and 
mitochondrial response to hypolipidemic agents. J Obes 2011, 490650. 
 
Blaak EE, Hul G, Verdich C, Stich V, Martinez A, Petersen M, Feskens EF, Patel K, 
Oppert JM, Barbe P, Toubro S, Anderson I, Polak J, Astrup A, Macdonald IA, 
Langin D, Holst C, Sorensen TI & Saris WH. (2006). Fat oxidation before and 
after a high fat load in the obese insulin-resistant state. J Clin Endocrinol 
Metab 91, 1462-1469. 
 
206 
Blaak EE, Schiffelers SL, Saris WH, Mensink M & Kooi ME. (2004). Impaired beta-
adrenergically mediated lipolysis in skeletal muscle of obese subjects. 
Diabetologia 47, 1462-1468. 
 
Blaak EE, van Aggel-Leijssen DP, Wagenmakers AJ, Saris WH & van Baak MA. 
(2000). Impaired oxidation of plasma-derived fatty acids in type 2 diabetic 
subjects during moderate-intensity exercise. Diabetes 49, 2102-2107. 
 
Blaak EE & Wagenmakers AJ. (2002). The fate of [U-(13)C]palmitate extracted by 
skeletal muscle in subjects with type 2 diabetes and control subjects. Diabetes 
51, 784-789. 
 
Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr., Clark DG, Cooper KH & Gibbons LW. 
(1989). Physical fitness and all-cause mortality. A prospective study of healthy 
men and women. JAMA 262, 2395-2401. 
 
Blanco A & Blanco G. (2017). Chapter 19 - Integration and Regulation of Metabolism. 
In Medical Biochemistry, ed. Blanco A & Blanco G, pp. 425-445. Academic 
Press. 
 
Boden G, Chen X, Ruiz J, White JV & Rossetti L. (1994). Mechanisms of fatty acid-
induced inhibition of glucose uptake. J Clin Invest 93, 2438-2446. 
 
Boeszoermenyi A, Nagy HM, Arthanari H, Pillip CJ, Lindermuth H, Luna RE, Wagner 
G, Zechner R, Zangger K & Oberer M. (2015). Structure of a CGI-58 motif 
provides the molecular basis of lipid droplet anchoring. J Biol Chem 290, 
26361-26372. 
 
Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JF, 
Luiken JJ, Heigenhauser GJ & Dyck DJ. (2004). Triacylglycerol accumulation 
in human obesity and type 2 diabetes is associated with increased rates of 
skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. 
Faseb J 18, 1144-1146. 
 
Booth FW, Chakravarthy MV & Spangenburg EE. (2002). Exercise and gene 
expression: physiological regulation of the human genome through physical 
activity. J Physiol 543, 399-411. 
 
Borissova AM, Tankova T, Kirilov G & Koev D. (2005). Gender-dependent effect of 
ageing on peripheral insulin action. Int J Clin Pract 59, 422-426. 
 
Bosma M, Hesselink MK, Sparks LM, Timmers S, Ferraz MJ, Mattijssen F, van 
Beurden D, Schaart G, de Baets MH, Verheyen FK, Kersten S & Schrauwen 
P. (2012a). Perilipin 2 improves insulin sensitivity in skeletal muscle despite 
elevated intramuscular lipid levels. Diabetes 61, 2679-2690. 
 
Bosma M, Minnaard R, Sparks LM, Schaart G, Losen M, de Baets MH, Duimel H, 
Kersten S, Bickel PE, Schrauwen P & Hesselink MK. (2012b). The lipid droplet 
207 
coat protein perilipin 5 also localizes to muscle mitochondria. Histochem Cell 
Biol 137, 205-216. 
 
Bosma M, Sparks LM, Hooiveld GJ, Jorgensen JA, Houten SM, Schrauwen P, 
Kersten S & Hesselink MK. (2013). Overexpression of PLIN5 in skeletal 
muscle promotes oxidative gene expression and intramyocellular lipid content 
without compromising insulin sensitivity. Biochim Biophys Acta 1831, 844-
852. 
 
Bostrom P, Andersson L, Rutberg M, Perman J, Lidberg U, Johansson BR, 
Fernandez-Rodriguez J, Ericson J, Nilsson T, Boren J & Olofsson SO. (2007). 
SNARE proteins mediate fusion between cytosolic lipid droplets and are 
implicated in insulin sensitivity. Nat Cell Biol 9, 1286-1293. 
 
Bostrom P, Rutberg M, Ericsson J, Holmdahl P, Andersson L, Frohman MA, Boren J 
& Olofsson SO. (2005). Cytosolic lipid droplets increase in size by 
microtubule-dependent complex formation. Arterioscler Thromb Vasc Biol 25, 
1945-1951. 
 
Boura-Halfon S & Zick Y. (2009). Phosphorylation of IRS proteins, insulin action, and 
insulin resistance. Am J Physiol Endocrinol Metab 296, E581-591. 
 
Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
72, 248-254. 
 
Bradley H, Shaw CS, Bendtsen C, Worthington PL, Wilson OJ, Strauss JA, Wallis 
GA, Turner AM & Wagenmakers AJ. (2015). Visualization and quantitation of 
GLUT4 translocation in human skeletal muscle following glucose ingestion 
and exercise. Physiol Rep 3. 
 
Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ & Londos C. 
(1997). Adipose differentiation-related protein is an ubiquitously expressed 
lipid storage droplet-associated protein. J Lipid Res 38, 2249-2263. 
 
Brasaemle DL, Levin DM, Adler-Wailes DC & Londos C. (2000). The lipolytic 
stimulation of 3T3-L1 adipocytes promotes the translocation of hormone-
sensitive lipase to the surfaces of lipid storage droplets. Biochim Biophys Acta 
1483, 251-262. 
 




Brons C, Jacobsen S, Hiscock N, White A, Nilsson E, Dunger D, Astrup A, Quistorff 
B & Vaag A. (2012). Effects of high-fat overfeeding on mitochondrial function, 
glucose and fat metabolism, and adipokine levels in low-birth-weight subjects. 
Am J Physiol Endocrinol Metab 302, E43-51. 
208 
 
Brons C, Jensen CB, Storgaard H, Hiscock NJ, White A, Appel JS, Jacobsen S, 
Nilsson E, Larsen CM, Astrup A, Quistorff B & Vaag A. (2009). Impact of short-
term high-fat feeding on glucose and insulin metabolism in young healthy 
men. J Physiol 587, 2387-2397. 
 
Brook MS, Wilkinson DJ, Phillips BE, Perez-Schindler J, Philp A, Smith K & Atherton 
PJ. (2016). Skeletal muscle homeostasis and plasticity in youth and ageing: 
impact of nutrition and exercise. Acta Physiol (Oxf) 216, 15-41. 
 
Brouwers B, Schrauwen-Hinderling VB, Jelenik T, Gemmink A, Havekes B, Bruls Y, 
Dahlmans D, Roden M, Hesselink MKC & Schrauwen P. (2017). Metabolic 
disturbances of non-alcoholic fatty liver resemble the alterations typical for 
type 2 diabetes. Clin Sci (Lond) 131, 1905-1917. 
 
Bulankina AV, Deggerich A, Wenzel D, Mutenda K, Wittmann JG, Rudolph MG, 
Burger KNJ & Honing S. (2009). TIP47 functions in the biogenesis of lipid 
droplets. Journal of Cell Biology 185, 641-655. 
 
Burniston JG, Connolly J, Kainulainen H, Britton SL & Koch LG. (2014). Label-free 
profiling of skeletal muscle using high-definition mass spectrometry. 
Proteomics 14, 2339-2344. 
 
Bursten SL, Harris WE, Bomsztyk K & Lovett D. (1991). Interleukin-1 rapidly 
stimulates lysophosphatidate acyltransferase and phosphatidate 
phosphohydrolase activities in human mesangial cells. J Biol Chem 266, 
20732-20743. 
 
Camera DM, Burniston JG, Pogson MA, Smiles WJ & Hawley JA. (2017). Dynamic 
proteome profiling of individual proteins in human skeletal muscle after a high-
fat diet and resistance exercise. Faseb J 31, 5478-5494. 
 
Capaldo B, Gastaldelli A, Antoniello S, Auletta M, Pardo F, Ciociaro D, Guida R, 
Ferrannini E & Sacca L. (1999). Splanchnic and leg substrate exchange after 
ingestion of a natural mixed meal in humans. Diabetes 48, 958-966. 
 
Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, 
Welch CB, Lusis AJ, Erickson SK & Farese RV. (1998). Identification of a gene 
encoding an acyl CoA : diacylglycerol acyltransferase, a key enzyme in 
triacylglycerol synthesis. P Natl Acad Sci USA 95, 13018-13023. 
 
Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T & Farese RV. 
(2001). Cloning of DGAT2, a second mammalian diacylglycerol 




Chakravarthy MV & Booth FW. (2004). Eating, exercise, and "thrifty" genotypes: 
connecting the dots toward an evolutionary understanding of modern chronic 
diseases. J Appl Physiol (1985) 96, 3-10. 
 
Chatr-Aryamontri A, Oughtred R, Boucher L, Rust J, Chang C, Kolas NK, O'Donnell 
L, Oster S, Theesfeld C, Sellam A, Stark C, Breitkreutz BJ, Dolinski K & Tyers 
M. (2017). The BioGRID interaction database: 2017 update. Nucleic Acids 
Res 45, D369-D379. 
 
Chavez JA & Summers SA. (2012). A ceramide-centric view of insulin resistance. Cell 
Metab 15, 585-594. 
 
Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J & Kahn CR. (1994). 
Phosphatidylinositol 3-Kinase Activation Is Required for Insulin Stimulation of 
Pp70 S6 Kinase, DNA-Synthesis, and Glucose-Transporter Translocation. 
Mol Cell Biol 14, 4902-4911. 
 
Chee C, Shannon CE, Burns A, Selby AL, Wilkinson D, Smith K, Greenhaff PL & 
Stephens FB. (2016). Relative Contribution of Intramyocellular Lipid to Whole-
Body Fat Oxidation Is Reduced With Age but Subsarcolemmal Lipid 
Accumulation and Insulin Resistance Are Only Associated With Overweight 
Individuals. Diabetes 65, 840-850. 
 
Chen W, Chang B, Wu X, Li L, Sleeman M & Chan L. (2013). Inactivation of Plin4 
downregulates Plin5 and reduces cardiac lipid accumulation in mice. Am J 
Physiol Endocrinol Metab 304, E770-779. 
 
Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, 
Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, 
Pandey SK, Geisler JG, Bhanot S, Monia BP & Shulman GI. (2007). 
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, 
with antisense oligonucleotides reverses diet-induced hepatic steatosis and 
insulin resistance. J Biol Chem 282, 22678-22688. 
 
Chow LS, Mashek DG, Austin E, Eberly LE, Persson XM, Mashek MT, Seaquist ER 
& Jensen MD. (2014). Training status diverges muscle diacylglycerol 
accumulation during free fatty acid elevation. Am J Physiol Endocrinol Metab 
307, E124-131. 
 
Clausen JO, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard P, Winther K & 
Pedersen O. (1996). Insulin sensitivity index, acute insulin response, and 
glucose effectiveness in a population-based sample of 380 young healthy 
Caucasians. Analysis of the impact of gender, body fat, physical fitness, and 
life-style factors. J Clin Invest 98, 1195-1209. 
 
Cocks M, Shaw CS, Shepherd SO, Fisher JP, Ranasinghe AM, Barker TA, Tipton KD 
& Wagenmakers AJ. (2013). Sprint interval and endurance training are equally 
effective in increasing muscle microvascular density and eNOS content in 
sedentary males. J Physiol 591, 641-656. 
210 
 
Coen PM, Dube JJ, Amati F, Stefanovic-Racic M, Ferrell RE, Toledo FG & 
Goodpaster BH. (2010). Insulin resistance is associated with higher 
intramyocellular triglycerides in type I but not type II myocytes concomitant 
with higher ceramide content. Diabetes 59, 80-88. 
 
Coggan AR, Raguso CA, Gastaldelli A, Sidossis LS & Yeckel CW. (2000). Fat 
metabolism during high-intensity exercise in endurance-trained and untrained 
men. Metabolism-Clinical and Experimental 49, 122-128. 
 
Cohen P. (1999). The Croonian Lecture 1998. Identification of a protein kinase 
cascade of major importance in insulin signal transduction. Philos T Roy Soc 
B 354, 485-495. 
 
Colberg SR, Simoneau JA, Thaete FL & Kelley DE. (1995). Skeletal muscle utilization 
of free fatty acids in women with visceral obesity. J Clin Invest 95, 1846-1853. 
 
Coleman RA & Lee DP. (2004). Enzymes of triacylglycerol synthesis and their 
regulation. Prog Lipid Res 43, 134-176. 
 
Coleman RA, Lewin TM & Muoio DM. (2000). Physiological and nutritional regulation 
of enzymes of triacylglycerol synthesis. Annu Rev Nutr 20, 77-103. 
 
Compher C, Frankenfield D, Keim N, Roth-Yousey L & Evidence Analysis Working 
G. (2006). Best practice methods to apply to measurement of resting 
metabolic rate in adults: a systematic review. J Am Diet Assoc 106, 881-903. 
 
Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk 
ML, Potts JL & Hockaday TD. (1992). Adipose tissue metabolism in obesity: 
lipase action in vivo before and after a mixed meal. Metabolism 41, 264-272. 
 
Cornford AS, Hinko A, Nelson RK, Barkan AL & Horowitz JF. (2013). Rapid 
development of systemic insulin resistance with overeating is not 
accompanied by robust changes in skeletal muscle glucose and lipid 
metabolism. Appl Physiol Nutr Metab 38, 512-519. 
 
Corpeleijn E, Mensink M, Kooi ME, Roekaerts PM, Saris WH & Blaak EE. (2008). 
Impaired skeletal muscle substrate oxidation in glucose-intolerant men 
improves after weight loss. Obesity (Silver Spring) 16, 1025-1032. 
 
Corpeleijn E, Saris WH & Blaak EE. (2009). Metabolic flexibility in the development 
of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev 10, 
178-193. 
 
Covington JD, Galgani JE, Moro C, LaGrange JM, Zhang Z, Rustan AC, Ravussin E 
& Bajpeyi S. (2014). Skeletal muscle perilipin 3 and coatomer proteins are 




Covington JD, Johannsen DL, Coen PM, Burk DH, Obanda DN, Ebenezer PJ, Tam 
CS, Goodpaster BH, Ravussin E & Bajpeyi S. (2017). Intramyocellular Lipid 
Droplet Size Rather Than Total Lipid Content is Related to Insulin Sensitivity 
After 8 Weeks of Overfeeding. Obesity (Silver Spring) 25, 2079-2087. 
 
Covington JD, Noland RC, Hebert RC, Masinter BS, Smith SR, Rustan AC, Ravussin 
E & Bajpeyi S. (2015). Perilipin 3 Differentially Regulates Skeletal Muscle Lipid 
Oxidation in Active, Sedentary, and Type 2 Diabetic Males. J Clin Endocrinol 
Metab 100, 3683-3692. 
 
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, 
Ekelund U, Yngve A, Sallis JF & Oja P. (2003). International physical activity 
questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35, 
1381-1395. 
 
Crane JD, Devries MC, Safdar A, Hamadeh MJ & Tarnopolsky MA. (2010). The effect 
of aging on human skeletal muscle mitochondrial and intramyocellular lipid 
ultrastructure. J Gerontol A Biol Sci Med Sci 65, 119-128. 
 
Currie E, Guo X, Christiano R, Chitraju C, Kory N, Harrison K, Haas J, Walther TC & 
Farese RV, Jr. (2014). High confidence proteomic analysis of yeast LDs 
identifies additional droplet proteins and reveals connections to dolichol 
synthesis and sterol acetylation. J Lipid Res 55, 1465-1477. 
 
Cushman SW & Wardzala LJ. (1980). Potential Mechanism of Insulin Action on 
Glucose-Transport in the Isolated Rat Adipose Cell - Apparent Translocation 
of Intracellular-Transport Systems to the Plasma-Membrane. Journal of 
Biological Chemistry 255, 4758-4762. 
 
Daemen S, Gemmink A, Brouwers B, Meex RCR, Huntjens PR, Schaart G, Moonen-
Kornips E, Jorgensen J, Hoeks J, Schrauwen P & Hesselink MKC. (2018). 
Distinct lipid droplet characteristics and distribution unmask the apparent 
contradiction of the athlete's paradox. Mol Metab. 
 
Dalen KT, Dahl T, Holter E, Arntsen B, Londos C, Sztalryd C & Nebb HI. (2007). 
LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues. 
Biochim Biophys Acta 1771, 210-227. 
 
De Bock K, Derave W, Eijnde BO, Hesselink MK, Koninckx E, Rose AJ, Schrauwen 
P, Bonen A, Richter EA & Hespel P. (2008). Effect of training in the fasted 
state on metabolic responses during exercise with carbohydrate intake. J Appl 
Physiol (1985) 104, 1045-1055. 
 
DeFronzo RA. (2004). Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 
88, 787-835, ix. 
 
212 
DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M & Wahren J. (1985). Effects of 
insulin on peripheral and splanchnic glucose metabolism in noninsulin-
dependent (type II) diabetes mellitus. J Clin Invest 76, 149-155. 
 
DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J & Felber JP. (1981). The 
effect of insulin on the disposal of intravenous glucose. Results from indirect 
calorimetry and hepatic and femoral venous catheterization. Diabetes 30, 
1000-1007. 
 
DeFronzo RA & Tripathy D. (2009). Skeletal muscle insulin resistance is the primary 
defect in type 2 diabetes. Diabetes Care 32 Suppl 2, S157-163. 
 
Dennis EA, Cao J, Hsu YH, Magrioti V & Kokotos G. (2011). Phospholipase A2 
enzymes: physical structure, biological function, disease implication, chemical 
inhibition, and therapeutic intervention. Chem Rev 111, 6130-6185. 
 
Deshmukh AS, Murgia M, Nagaraj N, Treebak JT, Cox J & Mann M. (2015a). Deep 
proteomics of mouse skeletal muscle enables quantitation of protein isoforms, 
metabolic pathways, and transcription factors. Mol Cell Proteomics 14, 841-
853. 
 
Deshmukh AS, Murgia M, Nagaraj N, Treebak JT, Cox J & Mann M. (2015b). Deep 
Proteomics of Mouse Skeletal Muscle Enables Quantitation of Protein 
Isoforms, Metabolic Pathways, and Transcription Factors. Molecular & 
Cellular Proteomics 14, 841-853. 
 
Devries MC, Samjoo IA, Hamadeh MJ, McCready C, Raha S, Watt MJ, Steinberg GR 
& Tarnopolsky MA. (2013). Endurance training modulates intramyocellular 
lipid compartmentalization and morphology in skeletal muscle of lean and 
obese women. J Clin Endocrinol Metab 98, 4852-4862. 
 




Diamond J. (2003). The double puzzle of diabetes. Nature 423, 599-602. 
 
Dircks LK & Sul HS. (1997). Mammalian mitochondrial glycerol-3-phosphate 
acyltransferase. Biochim Biophys Acta 1348, 17-26. 
 
Donahue RP, Prineas RJ, DeCarlo Donahue R, Bean JA & Skyler JS. (1996). The 
female 'insulin advantage' in a biracial cohort: results from the Miami 
Community Health Study. Int J Obes Relat Metab Disord 20, 76-82. 
 
Donkor J, Sariahmetoglu M, Dewald J, Brindley DN & Reue K. (2007). Three 
mammalian lipins act as phosphatidate phosphatases with distinct tissue 
expression patterns. Journal of Biological Chemistry 282, 3450-3457. 
213 
 
Donsmark M, Langfort J, Holm C, Ploug T & Galbo H. (2003). Contractions activate 
hormone-sensitive lipase in rat muscle by protein kinase C and mitogen-
activated protein kinase. J Physiol 550, 845-854. 
 
Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, 
Andersen DK, Hundal RS, Rothman DL, Petersen KF & Shulman GI. (1999). 
Effects of free fatty acids on glucose transport and IRS-1-associated 
phosphatidylinositol 3-kinase activity. J Clin Invest 103, 253-259. 
 
Dries DR, Gallegos LL & Newton AC. (2007). A single residue in the C1 domain 
sensitizes novel protein kinase C isoforms to cellular diacylglycerol 
production. Journal of Biological Chemistry 282, 826-830. 
 
Dube JJ, Amati F, Toledo FG, Stefanovic-Racic M, Rossi A, Coen P & Goodpaster 
BH. (2011). Effects of weight loss and exercise on insulin resistance, and 
intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia 54, 
1147-1156. 
 
Dube JJ, Sitnick MT, Schoiswohl G, Wills RC, Basantani MK, Cai L, Pulinilkunnil T & 
Kershaw EE. (2015). Adipose triglyceride lipase deletion from adipocytes, but 
not skeletal myocytes, impairs acute exercise performance in mice. Am J 
Physiol Endocrinol Metab 308, E879-890. 
 
Dyck DJ, Steinberg G & Bonen A. (2001). Insulin increases FA uptake and 
esterification but reduces lipid utilization in isolated contracting muscle. Am J 
Physiol Endocrinol Metab 281, E600-607. 
 
Eaton SB, Konner M & Shostak M. (1988). Stone agers in the fast lane: chronic 
degenerative diseases in evolutionary perspective. Am J Med 84, 739-749. 
 
Edgerton DS, Kraft G, Smith M, Farmer B, Williams PE, Coate KC, Printz RL, O'Brien 
RM & Cherrington AD. (2017). Insulin's direct hepatic effect explains the 
inhibition of glucose production caused by insulin secretion. Jci Insight 2. 
 
Egawa K, Maegawa H, Shi K, Nakamura T, Obata T, Yoshizaki T, Morino K, Shimizu 
S, Nishio Y, Suzuki E & Kashiwagi A. (2002). Membrane localization of 3-
phosphoinositide-dependent protein kinase-1 stimulates activities of Akt and 
atypical protein kinase C but does not stimulate glucose transport and 
glycogen synthesis in 3T3-L1 adipocytes. Journal of Biological Chemistry 277, 
38863-38869. 
 
Eichmann TO, Kumari M, Haas JT, Farese RV, Jr., Zimmermann R, Lass A & Zechner 
R. (2012). Studies on the substrate and stereo/regioselectivity of adipose 
triglyceride lipase, hormone-sensitive lipase, and diacylglycerol-O-
acyltransferases. J Biol Chem 287, 41446-41457. 
 
214 
Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW & Cooney GJ. 
(2000). Long-chain acyl-CoA esters as indicators of lipid metabolism and 
insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 
279, E554-560. 
 
Enevoldsen LH, Stallknecht B, Langfort J, Petersen LN, Holm C, Ploug T & Galbo H. 
(2001). The effect of exercise training on hormone-sensitive lipase in rat intra-
abdominal adipose tissue and muscle. J Physiol 536, 871-877. 
 
Enoksson S, Degerman E, Hagstrom-Toft E, Large V & Arner P. (1998). Various 
phosphodiesterase subtypes mediate the in vivo antilipolytic effect of insulin 
on adipose tissue and skeletal muscle in man. Diabetologia 41, 560-568. 
 
Escalante Pulido JM & Alpizar Salazar M. (1999). Changes in insulin sensitivity, 
secretion and glucose effectiveness during menstrual cycle. Arch Med Res 
30, 19-22. 
 
Esposito DL, Li YH, Cama A & Quon MJ. (2001). Tyr(612) and Tyr(632) in human 
insulin receptor substrate-1 are important for full activation of insulin-
stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 
in adipose cells. Endocrinology 142, 2833-2840. 
 
Essen B, Jansson E, Henriksson J, Taylor AW & Saltin B. (1975). Metabolic 
characteristics of fibre types in human skeletal muscle. Acta Physiol Scand 
95, 153-165. 
 
Faerch K & Vaag A. (2011). Metabolic inflexibility is a common feature of impaired 
fasting glycaemia and impaired glucose tolerance. Acta Diabetol 48, 349-353. 
 
Fazakerley DJ, Holman GD, Marley A, James DE, Stockli J & Coster AC. (2010). 
Kinetic evidence for unique regulation of GLUT4 trafficking by insulin and 
AMP-activated protein kinase activators in L6 myotubes. J Biol Chem 285, 
1653-1660. 
 
Ferrannini E, Smith JD, Cobelli C, Toffolo G, Pilo A & DeFronzo RA. (1985). Effect of 
insulin on the distribution and disposition of glucose in man. J Clin Invest 76, 
357-364. 
 
Festa A, Williams K, D'Agostino R, Jr., Wagenknecht LE & Haffner SM. (2006). The 
natural course of beta-cell function in nondiabetic and diabetic individuals: the 
Insulin Resistance Atherosclerosis Study. Diabetes 55, 1114-1120. 
 
Fletcher LM, Welsh GI, Oatey PB & Tavare JM. (2000). Role for the microtubule 
cytoskeleton in GLUT4 vesicle trafficking and in the regulation of insulin-
stimulated glucose uptake. Biochem J 352, 267-276. 
 
Forouhi NG, Jenkinson G, Thomas EL, Mullick S, Mierisova S, Bhonsle U, McKeigue 
PM & Bell JD. (1999). Relation of triglyceride stores in skeletal muscle cells to 
215 
central obesity and insulin sensitivity in European and South Asian men. 
Diabetologia 42, 932-935. 
 
Foster LJ, Yaworsky K, Trimble WS & Klip A. (1999). SNAP23 promotes insulin-
dependent glucose uptake in 3T3-L1 adipocytes: possible interaction with 
cytoskeleton. Am J Physiol 276, C1108-1114. 
 
Fowler MJ. (2008). Microvascular and Macrovascular Complications of Diabetes. 
Clinical Diabetes 26, 77-82. 
 
Frayn KN. (2000). Visceral fat and insulin resistance--causative or correlative? Br J 
Nutr 83 Suppl 1, S71-77. 
 
Frayn KN. (2002). Adipose tissue as a buffer for daily lipid flux. Diabetologia 45, 1201-
1210. 
 
Fredrikson G, Stralfors P, Nilsson NO & Belfrage P. (1981a). Hormone-sensitive 
lipase from adipose tissue of rat. Methods Enzymol 71 Pt C, 636-646. 
 
Fredrikson G, Stralfors P, Nilsson NO & Belfrage P. (1981b). Hormone-sensitive 
lipase of rat adipose tissue. Purification and some properties. J Biol Chem 
256, 6311-6320. 
 
Galgani JE, Heilbronn LK, Azuma K, Kelley DE, Albu JB, Pi-Sunyer X, Smith SR, 
Ravussin E & Look AARG. (2008a). Metabolic flexibility in response to glucose 
is not impaired in people with type 2 diabetes after controlling for glucose 
disposal rate. Diabetes 57, 841-845. 
 
Galgani JE, Moro C & Ravussin E. (2008b). Metabolic flexibility and insulin resistance. 
Am J Physiol Endocrinol Metab 295, E1009-1017. 
 
Ganda OP. (2000). Lipoatrophy, lipodystrophy, and insulin resistance. Ann Intern 
Med 133, 304-306. 
 
Gandolfi G, Mazzoni M, Zambonelli P, Lalatta-Costerbosa G, Tronca A, Russo V & 
Davoli R. (2011). Perilipin 1 and perilipin 2 protein localization and gene 
expression study in skeletal muscles of European cross-breed pigs with 
different intramuscular fat contents. Meat Sci 88, 631-637. 
 
Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson 
C, Eckhaus M & Reitman ML. (2000). Surgical implantation of adipose tissue 
reverses diabetes in lipoatrophic mice. J Clin Invest 105, 271-278. 
 
Gemmink A, Bakker LE, Guigas B, Kornips E, Schaart G, Meinders AE, Jazet IM & 
Hesselink MK. (2017a). Lipid droplet dynamics and insulin sensitivity upon a 
5-day high-fat diet in Caucasians and South Asians. Sci Rep 7, 42393. 
216 
 
Gemmink A, Bosma M, Kuijpers HJ, Hoeks J, Schaart G, van Zandvoort MA, 
Schrauwen P & Hesselink MK. (2016). Decoration of intramyocellular lipid 
droplets with PLIN5 modulates fasting-induced insulin resistance and 
lipotoxicity in humans. Diabetologia 59, 1040-1048. 
 
Gemmink A, Daemen S, Brouwers B, Huntjens PR, Schaart G, Moonen-Kornips E, 
Jorgensen J, Hoeks J, Schrauwen P & Hesselink MKC. (2018). Dissociation 
of intramyocellular lipid storage and insulin resistance in trained athletes and 
type 2 diabetes patients; involvement of perilipin 5? J Physiol 596, 857-868. 
 
Gemmink A, Goodpaster BH, Schrauwen P & Hesselink MKC. (2017b). 
Intramyocellular lipid droplets and insulin sensitivity, the human perspective. 
Biochim Biophys Acta 1862, 1242-1249. 
 
Gimeno RE & Cao J. (2008). Thematic review series: glycerolipids. Mammalian 
glycerol-3-phosphate acyltransferases: new genes for an old activity. J Lipid 
Res 49, 2079-2088. 
 
Giroux V, Saidj S, Simon C, Laville M, Segrestin B & Mathieu ME. (2018). Physical 
activity, energy expenditure and sedentary parameters in overfeeding studies 
- a systematic review. BMC Public Health 18, 903. 
 
Gjelstad IM, Haugen F, Gulseth HL, Norheim F, Jans A, Bakke SS, Raastad T, Tjonna 
AE, Wisloff U, Blaak EE, Riserus U, Gaster M, Roche HM, Birkeland KI & 
Drevon CA. (2012). Expression of perilipins in human skeletal muscle in vitro 
and in vivo in relation to diet, exercise and energy balance. Arch Physiol 
Biochem 118, 22-30. 
 
Gonzalez-Baro MR, Lewin TM & Coleman RA. (2007). Regulation of Triglyceride 
Metabolism. II. Function of mitochondrial GPAT1 in the regulation of 
triacylglycerol biosynthesis and insulin action. Am J Physiol Gastrointest Liver 
Physiol 292, G1195-1199. 
 
Goodpaster BH, He J, Watkins S & Kelley DE. (2001). Skeletal muscle lipid content 
and insulin resistance: evidence for a paradox in endurance-trained athletes. 
J Clin Endocrinol Metab 86, 5755-5761. 
 
Goodpaster BH, Thaete FL, Simoneau JA & Kelley DE. (1997). Subcutaneous 
abdominal fat and thigh muscle composition predict insulin sensitivity 
independently of visceral fat. Diabetes 46, 1579-1585. 
 
Goto T, Onuma T, Takebe K & Kral JG. (1995). The influence of fatty liver on insulin 
clearance and insulin resistance in non-diabetic Japanese subjects. Int J 
Obes Relat Metab Disord 19, 841-845. 
 
217 
Granneman JG, Moore HP, Krishnamoorthy R & Rathod M. (2009). Perilipin controls 
lipolysis by regulating the interactions of AB-hydrolase containing 5 (Abhd5) 
and adipose triglyceride lipase (Atgl). J Biol Chem 284, 34538-34544. 
 
Granneman JG, Moore HP, Mottillo EP, Zhu Z & Zhou L. (2011). Interactions of 
perilipin-5 (Plin5) with adipose triglyceride lipase. J Biol Chem 286, 5126-
5135. 
 
Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan 
QW, Miyoshi H & Mashek DG. (2011). The role of lipid droplets in metabolic 
disease in rodents and humans. J Clin Invest 121, 2102-2110. 
 
Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ & Londos C. 
(1991). Perilipin, a major hormonally regulated adipocyte-specific 
phosphoprotein associated with the periphery of lipid storage droplets. J Biol 
Chem 266, 11341-11346. 
 
Greenberg AS, Shen WJ, Muliro K, Patel S, Souza SC, Roth RA & Kraemer FB. 
(2001). Stimulation of lipolysis and hormone-sensitive lipase via the 
extracellular signal-regulated kinase pathway. J Biol Chem 276, 45456-
45461. 
 
Groban L, Lindsey SH, Wang H & Alencar AK. (2016). Chapter 5 - Sex and Gender 
Differences in Cardiovascular Disease. In Sex Differences in Physiology, ed. 
Neigh GN & Mitzelfelt MM, pp. 61-87. Academic Press, Boston. 
 
Gual P, Le Marchand-Brustel Y & Tanti JF. (2005). Positive and negative regulation 
of insulin signaling through IRS-1 phosphorylation. Biochimie 87, 99-109. 
 
Guijas C, Rodriguez JP, Rubio JM, Balboa MA & Balsinde J. (2014). Phospholipase 
A2 regulation of lipid droplet formation. Biochim Biophys Acta 1841, 1661-
1671. 
 
Guo Y, Walther TC, Rao M, Stuurman N, Goshima G, Terayama K, Wong JS, Vale 
RD, Walter P & Farese RV. (2008). Functional genomic screen reveals genes 
involved in lipid-droplet formation and utilization. Nature 453, 657-661. 
 
Guo Z, Burguera B & Jensen MD. (2000). Kinetics of intramuscular triglyceride fatty 
acids in exercising humans. J Appl Physiol (1985) 89, 2057-2064. 
 
Gustavsson J, Parpal S, Karlsson M, Ramsing C, Thorn H, Borg M, Lindroth M, 
Peterson KH, Magnusson K & Stralfors P. (1999). Localization of the insulin 
receptor in caveolae of adipocyte plasma membrane. Faseb J 13, 1961-1971. 
 
Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, 
Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor 
M, Hoefler G & Zechner R. (2006). Defective lipolysis and altered energy 
metabolism in mice lacking adipose triglyceride lipase. Science 312, 734-737. 
218 
 
Haemmerle G, Zimmermann R, Hayn M, Theussl C, Waeg G, Wagner E, Sattler W, 
Magin TM, Wagner EF & Zechner R. (2002a). Hormone-sensitive lipase 
deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, 
and testis. J Biol Chem 277, 4806-4815. 
 
Haemmerle G, Zimmermann R, Strauss JG, Kratky D, Riederer M, Knipping G & 
Zechner R. (2002b). Hormone-sensitive lipase deficiency in mice changes the 
plasma lipid profile by affecting the tissue-specific expression pattern of 
lipoprotein lipase in adipose tissue and muscle. J Biol Chem 277, 12946-
12952. 
 
Hagstrom-Toft E, Qvisth V, Nennesmo I, Ryden M, Bolinder H, Enoksson S, Bolinder 
J & Arner P. (2002). Marked heterogeneity of human skeletal muscle lipolysis 
at rest. Diabetes 51, 3376-3383. 
 
Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, 
Morin J, Auwerx J & Ferre P. (1997). Pioglitazone induces in vivo adipocyte 
differentiation in the obese Zucker fa/fa rat. Diabetes 46, 1393-1399. 
 
Hammond LE, Gallagher PA, Wang S, Hiller S, Kluckman KD, Posey-Marcos EL, 
Maeda N & Coleman RA. (2002). Mitochondrial glycerol-3-phosphate 
acyltransferase-deficient mice have reduced weight and liver triacylglycerol 
content and altered glycerolipid fatty acid composition. Mol Cell Biol 22, 8204-
8214. 
 
Harris TE, Huffman TA, Chi A, Shabanowitz J, Hunt DF, Kumar A & Lawrence JC, Jr. 
(2007). Insulin controls subcellular localization and multisite phosphorylation 
of the phosphatidic acid phosphatase, lipin 1. J Biol Chem 282, 277-286. 
 
Hattori M, Nakagawa Y, Harada K, Banndo M & Okano G. (2006). Characteristics of 
intramyocellular lipid content in skeletal muscles of overweight men and 
endurance-trained athletes. Jpn J Phys Fit Sport 55, 43-48. 
 
Haupt A, Thamer C, Heni M, Machicao F, Machann J, Schick F, Stefan N, Fritsche A, 
Haring HU & Staiger H. (2010). Novel obesity risk loci do not determine 
distribution of body fat depots: a whole-body MRI/MRS study. Obesity (Silver 
Spring) 18, 1212-1217. 
 
He J, Goodpaster BH & Kelley DE. (2004). Effects of weight loss and physical activity 
on muscle lipid content and droplet size. Obes Res 12, 761-769. 
 
Helge JW, Biba TO, Galbo H, Gaster M & Donsmark M. (2006). Muscle triacylglycerol 
and hormone-sensitive lipase activity in untrained and trained human 
muscles. Eur J Appl Physiol 97, 566-572. 
 
Helge JW, Watt PW, Richter EA, Rennie MJ & Kiens B. (2001). Fat utilization during 
exercise: adaptation to a fat-rich diet increases utilization of plasma fatty acids 
219 
and very low density lipoprotein-triacylglycerol in humans. J Physiol 537, 
1009-1020. 
 
Hesselink MKC, Daemen S, van Polanen N & Gemmink A. (2017). What are the 
benefits of being big? J Physiol 595, 5409-5410. 
 
Heymsfield SB, Gallagher D, Kotler DP, Wang Z, Allison DB & Heshka S. (2002). 
Body-size dependence of resting energy expenditure can be attributed to 
nonenergetic homogeneity of fat-free mass. Am J Physiol Endocrinol Metab 
282, E132-138. 
 
Hickner RC, Racette SB, Binder EF, Fisher JS & Kohrt WM. (1999). Suppression of 
whole body and regional lipolysis by insulin: effects of obesity and exercise. J 
Clin Endocrinol Metab 84, 3886-3895. 
 
Hochstrasser DF, Sanchez JC & Appel RD. (2002). Proteomics and its trends facing 
nature's complexity. Proteomics 2, 807-812. 
 
Hoeg LD, Sjoberg KA, Jeppesen J, Jensen TE, Frosig C, Birk JB, Bisiani B, Hiscock 
N, Pilegaard H, Wojtaszewski JF, Richter EA & Kiens B. (2011). Lipid-induced 
insulin resistance affects women less than men and is not accompanied by 
inflammation or impaired proximal insulin signaling. Diabetes 60, 64-73. 
 
Hojlund K, Yi Z, Hwang H, Bowen B, Lefort N, Flynn CR, Langlais P, Weintraub ST & 
Mandarino LJ. (2008). Characterization of the human skeletal muscle 
proteome by one-dimensional gel electrophoresis and HPLC-ESI-MS/MS. Mol 
Cell Proteomics 7, 257-267. 
 
Holloway GP, Thrush AB, Heigenhauser GJ, Tandon NN, Dyck DJ, Bonen A & Spriet 
LL. (2007). Skeletal muscle mitochondrial FAT/CD36 content and palmitate 
oxidation are not decreased in obese women. Am J Physiol Endocrinol Metab 
292, E1782-1789. 
 
Holloway KV, O'Gorman M, Woods P, Morton JP, Evans L, Cable NT, Goldspink DF 
& Burniston JG. (2009). Proteomic investigation of changes in human vastus 
lateralis muscle in response to interval-exercise training. Proteomics 9, 5155-
5174. 
 
Hoppeler H. (2016). Molecular networks in skeletal muscle plasticity. J Exp Biol 219, 
205-213. 
 
Hoppeler H, Billeter R, Horvath PJ, Leddy JJ & Pendergast DR. (1999). Muscle 
structure with low- and high-fat diets in well-trained male runners. Int J Sports 
Med 20, 522-526. 
 
Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA & Manson JE. (2004). Adiposity as 
compared with physical activity in predicting mortality among women. New 
Engl J Med 351, 2694-2703. 
220 
 
Huang T, Qi Q, Zheng Y, Ley SH, Manson JE, Hu FB & Qi L. (2015). Genetic 
Predisposition to Central Obesity and Risk of Type 2 Diabetes: Two 
Independent Cohort Studies. Diabetes Care 38, 1306-1311. 
 
Hubner NC, Ren S & Mann M. (2008). Peptide separation with immobilized pI strips 
is an attractive alternative to in-gel protein digestion for proteome analysis. 
Proteomics 8, 4862-4872. 
 
Hulston CJ, Churnside AA & Venables MC. (2015). Probiotic supplementation 
prevents high-fat, overfeeding-induced insulin resistance in human subjects. 
Br J Nutr 113, 596-602. 
 
Hulston CJ, Woods RM, Dewhurst-Trigg R, Parry SA, Gagnon S, Baker L, James LJ, 
Markey O, Martin NRW, Ferguson RA & van Hall G. (2018). Resistance 
exercise stimulates mixed muscle protein synthesis in lean and obese young 
adults. Physiological reports 6, e13799. 
 
Hulver MW, Berggren JR, Cortright RN, Dudek RW, Thompson RP, Pories WJ, 
MacDonald KG, Cline GW, Shulman GI, Dohm GL & Houmard JA. (2003). 
Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 
284, E741-747. 
 
Imamura M, Inoguchi T, Ikuyama S, Taniguchi S, Kobayashi K, Nakashima N & 
Nawata H. (2002). ADRP stimulates lipid accumulation and lipid droplet 
formation in murine fibroblasts. Am J Physiol Endocrinol Metab 283, E775-
783. 
 
Itani SI, Pories WJ, Macdonald KG & Dohm GL. (2001). Increased protein kinase C 
theta in skeletal muscle of diabetic patients. Metabolism 50, 553-557. 
 
Itani SI, Ruderman NB, Schmieder F & Boden G. (2002). Lipid-induced insulin 
resistance in human muscle is associated with changes in diacylglycerol, 
protein kinase C, and IkappaB-alpha. Diabetes 51, 2005-2011. 
 
Itani SI, Zhou Q, Pories WJ, MacDonald KG & Dohm GL. (2000). Involvement of 
protein kinase C in human skeletal muscle insulin resistance and obesity. 
Diabetes 49, 1353-1358. 
 
Jacquier N, Choudhary V, Mari M, Toulmay A, Reggiori F & Schneiter R. (2011). Lipid 
droplets are functionally connected to the endoplasmic reticulum in 
Saccharomyces cerevisiae. J Cell Sci 124, 2424-2437. 
 
Jagerstrom S, Polesie S, Wickstrom Y, Johansson BR, Schroder HD, Hojlund K & 
Bostrom P. (2009). Lipid droplets interact with mitochondria using SNAP23. 
Cell Biol Int 33, 934-940. 
 
221 
Jahn R & Scheller RH. (2006). SNAREs--engines for membrane fusion. Nat Rev Mol 
Cell Biol 7, 631-643. 
 
Janjic D. (1996). [Android-type obesity and gynecoid-type obesity]. Praxis (Bern 
1994) 85, 1578-1583. 
 
Jensen J & Lai YC. (2009). Regulation of muscle glycogen synthase phosphorylation 
and kinetic properties by insulin, exercise, adrenaline and role in insulin 
resistance. Arch Physiol Biochem 115, 13-21. 
 
Jepson CA & Yeaman SJ. (1992). Inhibition of hormone-sensitive lipase by 
intermediary lipid metabolites. FEBS Lett 310, 197-200. 
 
Jewell JL, Oh E, Ramalingam L, Kalwat MA, Tagliabracci VS, Tackett L, Elmendorf 
JS & Thurmond DC. (2011). Munc18c phosphorylation by the insulin receptor 
links cell signaling directly to SNARE exocytosis. J Cell Biol 193, 185-199. 
 
Jiang W, Zhu J, Zhuang X, Zhang X, Luo T, Esser KA & Ren H. (2015). Lipin1 
Regulates Skeletal Muscle Differentiation through Extracellular Signal-
regulated Kinase (ERK) Activation and Cyclin D Complex-regulated Cell Cycle 
Withdrawal. J Biol Chem 290, 23646-23655. 
 
Jocken JW, Goossens GH, Boon H, Mason RR, Essers Y, Havekes B, Watt MJ, van 
Loon LJ & Blaak EE. (2013). Insulin-mediated suppression of lipolysis in 
adipose tissue and skeletal muscle of obese type 2 diabetic men and men 
with normal glucose tolerance. Diabetologia 56, 2255-2265. 
 
Jocken JW, Smit E, Goossens GH, Essers YP, van Baak MA, Mensink M, Saris WH 
& Blaak EE. (2008). Adipose triglyceride lipase (ATGL) expression in human 
skeletal muscle is type I (oxidative) fiber specific. Histochem Cell Biol 129, 
535-538. 
 
Johnson NA, Stannard SR & Thompson MW. (2004). Muscle triglyceride and 
glycogen in endurance exercise: implications for performance. Sports Med 34, 
151-164. 
 
Johnston MJ, ed. (1977). Lipid metabolism in mammals Plenum Press, New York. 
 
Kaake RM, Wang X & Huang L. (2010). Profiling of protein interaction networks of 
protein complexes using affinity purification and quantitative mass 
spectrometry. Mol Cell Proteomics 9, 1650-1665. 
 
Kanaley JA, Shadid S, Sheehan MT, Guo Z & Jensen MD. (2009). Relationship 
between plasma free fatty acid, intramyocellular triglycerides and long-chain 
acylcarnitines in resting humans. J Physiol 587, 5939-5950. 
 
222 
Kanzaki M. (2006). Insulin receptor signals regulating GLUT4 translocation and act in 
dynamics. Endocr J 53, 267-293. 
 
Karpe F, Dickmann JR & Frayn KN. (2011). Fatty acids, obesity, and insulin 
resistance: time for a reevaluation. Diabetes 60, 2441-2449. 
 
Kasuga M. (2006). Insulin resistance and pancreatic beta cell failure. J Clin Invest 
116, 1756-1760. 
 
Katz LD, Glickman MG, Rapoport S, Ferrannini E & DeFronzo RA. (1983). Splanchnic 
and peripheral disposal of oral glucose in man. Diabetes 32, 675-679. 
 
Katzmarzyk PT. (2010). Physical activity, sedentary behavior, and health: paradigm 
paralysis or paradigm shift? Diabetes 59, 2717-2725. 
 
Kawanishi M, Tamori Y, Okazawa H, Araki S, Shinoda H & Kasuga M. (2000). Role 
of SNAP23 in insulin-induced translocation of GLUT4 in 3T3-L1 adipocytes. 
Mediation of complex formation between syntaxin4 and VAMP2. J Biol Chem 
275, 8240-8247. 
 
Kearney J. (2010). Food consumption trends and drivers. Philos Trans R Soc Lond B 
Biol Sci 365, 2793-2807. 
 
Kelley DE, Goodpaster B, Wing RR & Simoneau JA. (1999). Skeletal muscle fatty 
acid metabolism in association with insulin resistance, obesity, and weight 
loss. Am J Physiol 277, E1130-1141. 
 
Kelley DE, He J, Menshikova EV & Ritov VB. (2002). Dysfunction of mitochondria in 
human skeletal muscle in type 2 diabetes. Diabetes 51, 2944-2950. 
 
Kelley DE & Mandarino LJ. (2000). Fuel selection in human skeletal muscle in insulin 
resistance: a reexamination. Diabetes 49, 677-683. 
 
Kelley DE & Simoneau JA. (1994). Impaired free fatty acid utilization by skeletal 
muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 94, 2349-
2356. 
 
Kelley DE, Thaete FL, Troost F, Huwe T & Goodpaster BH. (2000). Subdivisions of 
subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol 
Endocrinol Metab 278, E941-948. 
 
Kelley DE, Williams KV, Price JC, McKolanis TM, Goodpaster BH & Thaete FL. 
(2001). Plasma fatty acids, adiposity, and variance of skeletal muscle insulin 
resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 86, 5412-5419. 
 
223 
Keske MA, Premilovac D, Bradley EA, Dwyer RM, Richards SM & Rattigan S. (2016). 
Muscle microvascular blood flow responses in insulin resistance and ageing. 
J Physiol 594, 2223-2231. 
 
Kiens B, Roemen TH & van der Vusse GJ. (1999). Muscular long-chain fatty acid 
content during graded exercise in humans. Am J Physiol 276, E352-357. 
 
Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos 
TJ, Cline GW, O'Brien WR, Littman DR & Shulman GI. (2004). PKC-theta 
knockout mice are protected from fat-induced insulin resistance. J Clin Invest 
114, 823-827. 
 
Kim JK, Gavrilova O, Chen Y, Reitman ML & Shulman GI. (2000a). Mechanism of 
insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275, 8456-8460. 
 
Kim JY, Hickner RC, Cortright RL, Dohm GL & Houmard JA. (2000b). Lipid oxidation 
is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 
279, E1039-1044. 
 
Klein S, Coyle EF & Wolfe RR. (1994). Fat-Metabolism during Low-Intensity Exercise 
in Endurance-Trained and Untrained Men. Am J Physiol-Endoc M 267, E934-
E940. 
 
Kleinert M, Parker BL, Chaudhuri R, Fazakerley DJ, Serup A, Thomas KC, Krycer JR, 
Sylow L, Fritzen AM, Hoffman NJ, Jeppesen J, Schjerling P, Ruegg MA, Kiens 
B, James DE & Richter EA. (2016). mTORC2 and AMPK differentially regulate 
muscle triglyceride content via Perilipin 3. Mol Metab 5, 646-655. 
 
Knudsen SH, Hansen LS, Pedersen M, Dejgaard T, Hansen J, Hall GV, Thomsen C, 
Solomon TP, Pedersen BK & Krogh-Madsen R. (2012). Changes in insulin 
sensitivity precede changes in body composition during 14 days of step 
reduction combined with overfeeding in healthy young men. J Appl Physiol 
(1985) 113, 7-15. 
 
Konrad D, Bilan PJ, Nawaz Z, Sweeney G, Niu WY, Liu Z, Antonescu CN, Rudich A 
& Klip A. (2002). Need for GLUT4 activation to reach maximum effect of 
insulin-mediated glucose uptake in brown adipocytes isolated from 
GLUT4myc-expressing mice. Diabetes 51, 2719-2726. 
 
Kory N, Farese RV, Jr. & Walther TC. (2016). Targeting Fat: Mechanisms of Protein 
Localization to Lipid Droplets. Trends Cell Biol 26, 535-546. 
 
Koves TR, Sparks LM, Kovalik JP, Mosedale M, Arumugam R, DeBalsi KL, 
Everingham K, Thorne L, Phielix E, Meex RC, Kien CL, Hesselink MK, 
Schrauwen P & Muoio DM. (2013). PPARgamma coactivator-1alpha 
contributes to exercise-induced regulation of intramuscular lipid droplet 
programming in mice and humans. J Lipid Res 54, 522-534. 
 
224 
Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens 
R, Dyck JR, Newgard CB, Lopaschuk GD & Muoio DM. (2008). Mitochondrial 
overload and incomplete fatty acid oxidation contribute to skeletal muscle 
insulin resistance. Cell Metab 7, 45-56. 
 
Krahmer N, Hilger M, Kory N, Wilfling F, Stoehr G, Mann M, Farese RV, Jr. & Walther 
TC. (2013). Protein correlation profiles identify lipid droplet proteins with high 
confidence. Mol Cell Proteomics 12, 1115-1126. 
 
Kramer RM, Hession C, Johansen B, Hayes G, McGray P, Chow EP, Tizard R & 
Pepinsky RB. (1989). Structure and properties of a human non-pancreatic 
phospholipase A2. J Biol Chem 264, 5768-5775. 
 
Kuhl J, Hilding A, Ostenson CG, Grill V, Efendic S & Bavenholm P. (2005). 
Characterisation of subjects with early abnormalities of glucose tolerance in 
the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 
diabetes heredity. Diabetologia 48, 35-40. 
 
Laakso M. (2010). Cardiovascular disease in type 2 diabetes from population to man 
to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 33, 442-
449. 
 
Lachmanovich E, Shvartsman DE, Malka Y, Botvin C, Henis YI & Weiss AM. (2003). 
Co-localization analysis of complex formation among membrane proteins by 
computerized fluorescence microscopy: application to immunofluorescence 
co-patching studies. J Microsc 212, 122-131. 
 
Langfort J, Ploug T, Ihlemann J, Holm C & Galbo H. (2000). Stimulation of hormone-
sensitive lipase activity by contractions in rat skeletal muscle. Biochem J 351, 
207-214. 
 
Langfort J, Ploug T, Ihlemann J, Saldo M, Holm C & Galbo H. (1999). Expression of 
hormone-sensitive lipase and its regulation by adrenaline in skeletal muscle. 
Biochem J 340 ( Pt 2), 459-465. 
 
Large V, Reynisdottir S, Langin D, Fredby K, Klannemark M, Holm C & Arner P. 
(1999). Decreased expression and function of adipocyte hormone-sensitive 
lipase in subcutaneous fat cells of obese subjects. J Lipid Res 40, 2059-2066. 
 
Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, 
Kienesberger P, Strauss JG, Gorkiewicz G & Zechner R. (2006). Adipose 
triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-
58 and defective in Chanarin-Dorfman Syndrome. Cell Metab 3, 309-319. 
 
Lass A, Zimmermann R, Oberer M & Zechner R. (2011). Lipolysis - a highly regulated 
multi-enzyme complex mediates the catabolism of cellular fat stores. Prog 
Lipid Res 50, 14-27. 
 
225 
Laurens C, Bourlier V, Mairal A, Louche K, Badin PM, Mouisel E, Montagner A, 
Marette A, Tremblay A, Weisnagel JS, Guillou H, Langin D, Joanisse DR & 
Moro C. (2016). Perilipin 5 fine-tunes lipid oxidation to metabolic demand and 
protects against lipotoxicity in skeletal muscle. Sci Rep 6, 38310. 
 
Lauritzen HPMM, Mug T, Prats C, Tavare JM & Galbo H. (2006). Imaging of insulin 
signaling in skeletal muscle of living mice shows major role of T-tubules. 
Diabetes 55, 1300-1306. 
 
Lee CD, Jackson AS & Blair SN. (1998). US weight guidelines: is it also important to 
consider cardiorespiratory fitness? Int J Obes Relat Metab Disord 22 Suppl 
2, S2-7. 
 
Leiguez E, Zuliani JP, Cianciarullo AM, Fernandes CM, Gutierrez JM & Teixeira C. 
(2011). A group IIA-secreted phospholipase A2 from snake venom induces 
lipid body formation in macrophages: the roles of intracellular phospholipases 
A2 and distinct signaling pathways. J Leukoc Biol 90, 155-166. 
 
Lessard SJ, Rivas DA, Chen ZP, van Denderen BJ, Watt MJ, Koch LG, Britton SL, 
Kemp BE & Hawley JA. (2009). Impaired skeletal muscle beta-adrenergic 
activation and lipolysis are associated with whole-body insulin resistance in 
rats bred for low intrinsic exercise capacity. Endocrinology 150, 4883-4891. 
 
Levin MC, Monetti M, Watt MJ, Sajan MP, Stevens RD, Bain JR, Newgard CB, Farese 
RV, Sr. & Farese RV, Jr. (2007). Increased lipid accumulation and insulin 
resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. 
Am J Physiol Endocrinol Metab 293, E1772-1781. 
 
Lewin TM, Granger DA, Kim JH & Coleman RA. (2001). Regulation of mitochondrial 
sn-glycerol-3-phosphate acyltransferase activity: response to feeding status 
is unique in various rat tissues and is discordant with protein expression. Arch 
Biochem Biophys 396, 119-127. 
 
Li M, Paran C, Wolins NE & Horowitz JF. (2011). High muscle lipid content in obesity 
is not due to enhanced activation of key triglyceride esterification enzymes or 
the suppression of lipolytic proteins. Am J Physiol Endocrinol Metab 300, 
E699-707. 
 
Linden D, William-Olsson L, Ahnmark A, Ekroos K, Hallberg C, Sjogren HP, Becker 
B, Svensson L, Clapham JC, Oscarsson J & Schreyer S. (2006). Liver-
directed overexpression of mitochondrial glycerol-3-phosphate 
acyltransferase results in hepatic steatosis, increased triacylglycerol secretion 
and reduced fatty acid oxidation. Faseb J 20, 434-443. 
 
Lipina C & Hundal HS. (2011). Sphingolipids: agents provocateurs in the 
pathogenesis of insulin resistance. Diabetologia 54, 1596-1607. 
 
226 
Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ & Brown DA. (2007). 
Adipocyte differentiation-related protein reduces the lipid droplet association 
of adipose triglyceride lipase and slows triacylglycerol turnover. J Lipid Res 
48, 2751-2761. 
 
Liu KH, Chan YL, Chan JC, Chan WB & Kong WL. (2006a). Mesenteric fat thickness 
as an independent determinant of fatty liver. Int J Obes (Lond) 30, 787-793. 
 
Liu L, Zhang Y, Chen N, Shi X, Tsang B & Yu YH. (2007). Upregulation of myocellular 
DGAT1 augments triglyceride synthesis in skeletal muscle and protects 
against fat-induced insulin resistance. J Clin Invest 117, 1679-1689. 
 
Liu LZ, Zhao HL, Zuo J, Ho SKS, Chan JCN, Meng Y, Fang FD & Tong PCY. (2006b). 
Protein kinase C xi mediates insulin-induced glucose transport through actin 
remodeling in L6 muscle cells. Molecular Biology of the Cell 17, 2322-2330. 
 
Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M & Anderson RG. (2004). Chinese hamster 
ovary K2 cell lipid droplets appear to be metabolic organelles involved in 
membrane traffic. J Biol Chem 279, 3787-3792. 
 
Londos C, Brasaemle DL, Gruia-Gray J, Servetnick DA, Schultz CJ, Levin DM & 
Kimmel AR. (1995). Perilipin: unique proteins associated with intracellular 
neutral lipid droplets in adipocytes and steroidogenic cells. Biochem Soc 
Trans 23, 611-615. 
 
Long AP, Manneschmidt AK, VerBrugge B, Dortch MR, Minkin SC, Prater KE, 
Biggerstaff JP, Dunlap JR & Dalhaimer P. (2012). Lipid droplet de novo 
formation and fission are linked to the cell cycle in fission yeast. Traffic 13, 
705-714. 
 
Lopez JA, Burchfield JG, Blair DH, Mele K, Ng Y, Vallotton P, James DE & Hughes 
WE. (2009). Identification of a distal GLUT4 trafficking event controlled by 
actin polymerization. Mol Biol Cell 20, 3918-3929. 
 
Louche K, Badin PM, Montastier E, Laurens C, Bourlier V, de Glisezinski I, Thalamas 
C, Viguerie N, Langin D & Moro C. (2013). Endurance exercise training up-
regulates lipolytic proteins and reduces triglyceride content in skeletal muscle 
of obese subjects. J Clin Endocrinol Metab 98, 4863-4871. 
 
Ludescher B, Najib A, Baar S, Machann J, Thamer C, Schick F, Buchkremer G, 
Claussen CD & Eschweiler GW. (2007). Gender specific correlations of 
adrenal gland size and body fat distribution: a whole body MRI study. Horm 
Metab Res 39, 515-518. 
 
MacPherson RE, Herbst EA, Reynolds EJ, Vandenboom R, Roy BD & Peters SJ. 
(2012). Subcellular localization of skeletal muscle lipid droplets and PLIN 
family proteins OXPAT and ADRP at rest and following contraction in rat 
soleus muscle. Am J Physiol Regul Integr Comp Physiol 302, R29-36. 
227 
 
MacPherson RE, Ramos SV, Vandenboom R, Roy BD & Peters SJ. (2013a). Skeletal 
muscle PLIN proteins, ATGL and CGI-58, interactions at rest and following 
stimulated contraction. Am J Physiol Regul Integr Comp Physiol 304, R644-
650. 
 
Macpherson RE, Vandenboom R, Roy BD & Peters SJ. (2013b). Skeletal muscle 
PLIN3 and PLIN5 are serine phosphorylated at rest and following lipolysis 
during adrenergic or contractile stimulation. Physiol Rep 1, e00084. 
 
Malik ZA, Cobley JN, Morton JP, Close GL, Edwards BJ, Koch LG, Britton SL & 
Burniston JG. (2013). Label-Free LC-MS Profiling of Skeletal Muscle Reveals 
Heart-Type Fatty Acid Binding Protein as a Candidate Biomarker of Aerobic 
Capacity. Proteomes 1, 290-308. 
 
Marin P, Andersson B, Krotkiewski M & Bjorntorp P. (1994). Muscle fiber composition 
and capillary density in women and men with NIDDM. Diabetes Care 17, 382-
386. 
 
Martin A, Hales P & Brindley DN. (1987). A rapid assay for measuring the activity and 
the Mg2+ and Ca2+ requirements of phosphatidate phosphohydrolase in 
cytosolic and microsomal fractions of rat liver. Biochem J 245, 347-355. 
 
Mason RR, Meex RC, Lee-Young R, Canny BJ & Watt MJ. (2012). Phosphorylation 
of adipose triglyceride lipase Ser(404) is not related to 5'-AMPK activation 
during moderate-intensity exercise in humans. Am J Physiol Endocrinol Metab 
303, E534-541. 
 
Mason RR, Meex RC, Russell AP, Canny BJ & Watt MJ. (2014a). Cellular localization 
and associations of the major lipolytic proteins in human skeletal muscle at 
rest and during exercise. PLoS One 9, e103062. 
 
Mason RR, Mokhtar R, Matzaris M, Selathurai A, Kowalski GM, Mokbel N, Meikle PJ, 
Bruce CR & Watt MJ. (2014b). PLIN5 deletion remodels intracellular lipid 
composition and causes insulin resistance in muscle. Mol Metab 3, 652-663. 
 
Masuda Y, Itabe H, Odaki M, Hama K, Fujimoto Y, Mori M, Sasabe N, Aoki J, Arai H 
& Takano T. (2006). ADRP/adipophilin is degraded through the proteasome-
dependent pathway during regression of lipid-storing cells. J Lipid Res 47, 87-
98. 
 
Matsuda M & DeFronzo RA. (1999). Insulin sensitivity indices obtained from oral 
glucose tolerance testing: comparison with the euglycemic insulin clamp. 
Diabetes Care 22, 1462-1470. 
 
Maughan DW, Henkin JA & Vigoreaux JO. (2005). Concentrations of glycolytic 
enzymes and other cytosolic proteins in the diffusible fraction of a vertebrate 
muscle proteome. Mol Cell Proteomics 4, 1541-1549. 
228 
 
McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM, Ruge 
T, Gilbert M, Fielding BA, Frayn KN & Karpe F. (2011). Downregulation of 
adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat 
deposition? Diabetes 60, 47-55. 
 
Meex RC, Hoy AJ, Mason RM, Martin SD, McGee SL, Bruce CR & Watt MJ. (2015). 
ATGL-mediated triglyceride turnover and the regulation of mitochondrial 
capacity in skeletal muscle. Am J Physiol Endocrinol Metab 308, E960-970. 
 
Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH & Kelley DE. 
(2005). Effects of weight loss and physical activity on skeletal muscle 
mitochondrial function in obesity. Am J Physiol Endocrinol Metab 288, E818-
825. 
 
Mensink M, Blaak EE, van Baak MA, Wagenmakers AJ & Saris WH. (2001). Plasma 
free Fatty Acid uptake and oxidation are already diminished in subjects at high 
risk for developing type 2 diabetes. Diabetes 50, 2548-2554. 
 
Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA & Koh YO. (1990). A new 
predictive equation for resting energy expenditure in healthy individuals. The 
American journal of clinical nutrition 51, 241-247. 
 
Miinea CP, Sano H, Kane S, Sano E, Fukuda M, Peranen J, Lane WS & Lienhard 
GE. (2005). AS160, the Akt substrate regulating GLUT4 translocation, has a 
functional Rab GTPase-activating protein domain. Biochem J 391, 87-93. 
 
Montague CT & O'Rahilly S. (2000). The perils of portliness: causes and 
consequences of visceral adiposity. Diabetes 49, 883-888. 
 
Moran A, Jacobs DR, Jr., Steinberger J, Steffen LM, Pankow JS, Hong CP & Sinaiko 
AR. (2008). Changes in insulin resistance and cardiovascular risk during 
adolescence: establishment of differential risk in males and females. 
Circulation 117, 2361-2368. 
 
Morino K, Petersen KF & Shulman GI. (2006). Molecular mechanisms of insulin 
resistance in humans and their potential links with mitochondrial dysfunction. 
Diabetes 55 Suppl 2, S9-S15. 
 
Moro C, Bajpeyi S & Smith SR. (2008). Determinants of intramyocellular triglyceride 
turnover: implications for insulin sensitivity. Am J Physiol Endocrinol Metab 
294, E203-213. 
 
Munguia-Miranda C, Sanchez-Barrera RG, Tuz K, Alonso-Garcia AL & Cruz M. 
(2009). [Impaired fasting glucose detection in blood donors population]. Rev 
Med Inst Mex Seguro Soc 47, 17-24. 
 
229 
Muoio DM, Dohm GL, Tapscott EB & Coleman RA. (1999). Leptin opposes insulin's 
effects on fatty acid partitioning in muscles isolated from obese ob/ob mice. 
Am J Physiol 276, E913-921. 
 
Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T & Yamamoto K. (2011). 
Recent progress in phospholipase A(2) research: from cells to animals to 
humans. Prog Lipid Res 50, 152-192. 
 
Myers MG, Backer JM, Sun XJ, Shoelson S, Hu P, Schlessinger J, Yoakim M, 
Schaffhausen B & White MF. (1992). Irs-1 Activates Phosphatidylinositol 3'-
Kinase by Associating with Src Homology-2 Domains of P85. P Natl Acad Sci 
USA 89, 10350-10354. 
 
Naja F, Hwalla N, Itani L, Karam S, Sibai AM & Nasreddine L. (2015). A Western 
dietary pattern is associated with overweight and obesity in a national sample 
of Lebanese adolescents (13-19 years): a cross-sectional study. Br J Nutr 
114, 1909-1919. 
 
Neel JV. (1962). Diabetes mellitus: a "thrifty" genotype rendered detrimental by 
"progress"? Am J Hum Genet 14, 353-362. 
 
Neel JV. (1999). The "thrifty genotype" in 1998. Nutr Rev 57, S2-9. 
 
Newsom SA, Schenk S, Li M, Everett AC & Horowitz JF. (2011). High fatty acid 
availability after exercise alters the regulation of muscle lipid metabolism. 
Metabolism 60, 852-859. 
 
Nielsen J, Christensen AE, Nellemann B & Christensen B. (2017). Lipid droplet size 
and location in human skeletal muscle fibers are associated with insulin 
sensitivity. Am J Physiol Endocrinol Metab 313, E721-E730. 
 
Nielsen S, Guo Z, Johnson CM, Hensrud DD & Jensen MD. (2004). Splanchnic 
lipolysis in human obesity. J Clin Invest 113, 1582-1588. 
 
Nojima H, Yoneda M, Watanabe H, Yamane K, Kitahara Y, Sekikawa K, Yamamoto 
H, Yokoyama A, Hattori N, Kohno N & Stud HUHP. (2017). Association 
between aerobic capacity and the improvement in glycemic control after the 
exercise training in type 2 diabetes. Diabetol Metab Syndr 9. 
 
Nuutila P, Knuuti MJ, Maki M, Laine H, Ruotsalainen U, Teras M, Haaparanta M, Solin 
O & Yki-Jarvinen H. (1995). Gender and insulin sensitivity in the heart and in 
skeletal muscles. Studies using positron emission tomography. Diabetes 44, 
31-36. 
 
Oakes ND, Bell KS, Furler SM, Camilleri S, Saha AK, Ruderman NB, Chisholm DJ & 
Kraegen EW. (1997a). Diet-induced muscle insulin resistance in rats is 
ameliorated by acute dietary lipid withdrawal or a single bout of exercise: 
230 
parallel relationship between insulin stimulation of glucose uptake and 
suppression of long-chain fatty acyl-CoA. Diabetes 46, 2022-2028. 
 
Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ & Kraegen EW. (1997b). 
Mechanisms of liver and muscle insulin resistance induced by chronic high-
fat feeding. Diabetes 46, 1768-1774. 
 
Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, Schon MR, 
Bluher M & Punkt K. (2006). Altered fiber distribution and fiber-specific 
glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 
2 diabetes. Diabetes Care 29, 895-900. 
 
Okada T, Kawano Y, Sakakibara T, Hazeki O & Ui M. (1994). Essential role of 
phosphatidylinositol 3-kinase in insulin-induced glucose transport and 
antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J 
Biol Chem 269, 3568-3573. 
 
Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma 
Y, Fujiwara T, Horikoshi H, Yazaki Y & Kadowaki T. (1998). Troglitazone 
increases the number of small adipocytes without the change of white adipose 
tissue mass in obese Zucker rats. J Clin Invest 101, 1354-1361. 
 
Olefsky JM. (1977). Insensitivity of large rat adipocytes to the antilipolytic effects of 
insulin. J Lipid Res 18, 459-464. 
 
Ong JM & Kern PA. (1989). Effect of feeding and obesity on lipoprotein lipase activity, 
immunoreactive protein, and messenger RNA levels in human adipose tissue. 
J Clin Invest 84, 305-311. 
 
Ostman J, Arner P, Engfeldt P & Kager L. (1979). Regional differences in the control 
of lipolysis in human adipose tissue. Metabolism 28, 1198-1205. 
 
Oti M, Snel B, Huynen MA & Brunner HG. (2006). Predicting disease genes using 
protein-protein interactions. J Med Genet 43. 
 
Pagnon J, Matzaris M, Stark R, Meex RC, Macaulay SL, Brown W, O'Brien PE, 
Tiganis T & Watt MJ. (2012). Identification and functional characterization of 
protein kinase A phosphorylation sites in the major lipolytic protein, adipose 
triglyceride lipase. Endocrinology 153, 4278-4289. 
 
Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB & 
Storlien LH. (1997). Skeletal muscle triglyceride levels are inversely related to 
insulin action. Diabetes 46, 983-988. 
 
Pan JJ & Fallon MB. (2014). Gender and racial differences in nonalcoholic fatty liver 
disease. World Journal of Hepatology 6, 274-283. 
 
231 
Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varricchio M & 
D'Onofrio F. (1995). Opposite effects of short- and long-term fatty acid infusion 
on insulin secretion in healthy subjects. Diabetologia 38, 1295-1299. 
 
Parry SA, Smith JR, Corbett TRB, Woods RM & Hulston CJ. (2017). Short-term, high-
fat overfeeding impairs glycaemic control but does not alter gut hormone 
responses to a mixed meal tolerance test in healthy, normal-weight 
individuals. Brit J Nutr 117, 48-55. 
 
Pelsers MM, Tsintzas K, Boon H, Jewell K, Norton L, Luiken JJ, Glatz JF & van Loon 
LJ. (2007). Skeletal muscle fatty acid transporter protein expression in type 2 
diabetes patients compared with overweight, sedentary men and age-
matched, endurance-trained cyclists. Acta Physiol (Oxf) 190, 209-219. 
 
Perreault L, Bergman BC, Hunerdosse DM & Eckel RH. (2010). Altered intramuscular 
lipid metabolism relates to diminished insulin action in men, but not women, 
in progression to diabetes. Obesity (Silver Spring) 18, 2093-2100. 
 
Perry RJ, Samuel VT, Petersen KF & Shulman GI. (2014). The role of hepatic lipids 
in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91. 
 
Pessin JE & Saltiel AR. (2000). Signaling pathways in insulin action: molecular targets 
of insulin resistance. J Clin Invest 106, 165-169. 
 
Peters SJ, Samjoo IA, Devries MC, Stevic I, Robertshaw HA & Tarnopolsky MA. 
(2012). Perilipin family (PLIN) proteins in human skeletal muscle: the effect of 
sex, obesity, and endurance training. Appl Physiol Nutr Metab 37, 724-735. 
 
Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, 
Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL & Shulman GI. 
(2007). The role of skeletal muscle insulin resistance in the pathogenesis of 
the metabolic syndrome. Proc Natl Acad Sci U S A 104, 12587-12594. 
 
Phan J, Peterfy M & Reue K. (2004). Lipin expression preceding peroxisome 
proliferator-activated receptor-gamma is critical for adipogenesis in vivo and 
in vitro. Journal of Biological Chemistry 279, 29558-29564. 
 
Phillips SA, Choe CC, Ciaraldi TP, Greenberg AS, Kong AP, Baxi SC, Christiansen 
L, Mudaliar SR & Henry RR. (2005). Adipocyte differentiation-related protein 
in human skeletal muscle: relationship to insulin sensitivity. Obes Res 13, 
1321-1329. 
 
Phillips SM, Green HJ, Tarnopolsky MA, Heigenhauser GF, Hill RE & Grant SM. 
(1996). Effects of training duration on substrate turnover and oxidation during 
exercise. J Appl Physiol (1985) 81, 2182-2191. 
 
Phizicky EM & Fields S. (1995). Protein-protein interactions: methods for detection 
and analysis. Microbiol Rev 59, 94-123. 
232 
 
Polotsky HN & Polotsky AJ. (2010). Metabolic implications of menopause. Semin 
Reprod Med 28, 426-434. 
 
Potts GK, McNally RM, Blanco R, You JS, Hebert AS, Westphall MS, Coon JJ & 
Hornberger TA. (2017). A map of the phosphoproteomic alterations that occur 
after a bout of maximal-intensity contractions. J Physiol-London 595, 5209-
5226. 
 
Pourteymour S, Lee S, Langleite TM, Eckardt K, Hjorth M, Bindesboll C, Dalen KT, 
Birkeland KI, Drevon CA, Holen T & Norheim F. (2015). Perilipin 4 in human 
skeletal muscle: localization and effect of physical activity. Physiol Rep 3. 
 
Powell DJ, Hajduch E, Kular G & Hundal HS. (2003). Ceramide disables 3-
phosphoinositide binding to the pleckstrin homology domain of protein kinase 
B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 23, 7794-
7808. 
 
Prats C, Donsmark M, Qvortrup K, Londos C, Sztalryd C, Holm C, Galbo H & Ploug 
T. (2006). Decrease in intramuscular lipid droplets and translocation of HSL 
in response to muscle contraction and epinephrine. J Lipid Res 47, 2392-
2399. 
 
Racette SB, Evans EM, Weiss EP, Hagberg JM & Holloszy JO. (2006). Abdominal 
adiposity is a stronger predictor of insulin resistance than fitness among 50-
95 year olds. Diabetes Care 29, 673-678. 
 
Ramos SV, MacPherson RE, Turnbull PC, Bott KN, LeBlanc P, Ward WE & Peters 
SJ. (2014). Higher PLIN5 but not PLIN3 content in isolated skeletal muscle 
mitochondria following acute in vivo contraction in rat hindlimb. Physiol Rep 
2. 
 
Ramos SV, Turnbull PC & MacPherson RE. (2016). Adipose tissue depot specific 
differences of PLIN protein content in endurance trained rats. Adipocyte 5, 
212-223. 
 
Ramos SV, Turnbull PC, MacPherson RE, LeBlanc PJ, Ward WE & Peters SJ. 
(2015). Changes in mitochondrial perilipin 3 and perilipin 5 protein content in 
rat skeletal muscle following endurance training and acute stimulated 
contraction. Exp Physiol 100, 450-462. 
 
Randle PJ, Garland PB, Hales CN & Newsholme EA. (1963). The glucose fatty-acid 
cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes 
mellitus. Lancet 1, 785-789. 
 
Rando RR & Young N. (1984). The Stereospecific Activation of Protein Kinase-C. 
Biochem Bioph Res Co 122, 818-823. 
 
233 
Rattarasarn C, Leelawattana R, Soonthornpun S, Setasuban W & Thamprasit A. 
(2004). Gender differences of regional abdominal fat distribution and their 
relationships with insulin sensitivity in healthy and glucose-intolerant Thais. J 
Clin Endocrinol Metab 89, 6266-6270. 
 
Ravichandran V, Chawla A & Roche PA. (1996). Identification of a novel syntaxin- 
and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-
neuronal tissues. J Biol Chem 271, 13300-13303. 
 
Remuzzi G, Schieppati A & Ruggenenti P. (2002). Clinical practice. Nephropathy in 
patients with type 2 diabetes. N Engl J Med 346, 1145-1151. 
 
Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH & Kelley DE. (2005). 
Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. 
Diabetes 54, 8-14. 
 
Robenek H, Hofnagel O, Buers I, Robenek MJ, Troyer D & Severs NJ. (2006). 
Adipophilin-enriched domains in the ER membrane are sites of lipid droplet 
biogenesis. J Cell Sci 119, 4215-4224. 
 
Roden M, Price TB, Perseghin G, Petersen KF, Cline GW, Rothman DL & Shulman 
GI. (1996). Mechanism of free fatty acid induced insulin resistance in humans. 
Diabetes 45, 33-33. 
 
Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny 
P, Waldhausl W & Shulman GI. (2000). Effects of free fatty acid elevation on 
postabsorptive endogenous glucose production and gluconeogenesis in 
humans. Diabetes 49, 701-707. 
 
Roepstorff C, Vistisen B, Donsmark M, Nielsen JN, Galbo H, Green KA, Hardie DG, 
Wojtaszewski JF, Richter EA & Kiens B. (2004). Regulation of hormone-
sensitive lipase activity and Ser563 and Ser565 phosphorylation in human 
skeletal muscle during exercise. J Physiol 560, 551-562. 
 
Rolls BJ. (2000). The role of energy density in the overconsumption of fat. J Nutr 130, 
268S-271S. 
 
Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Endert E & Wolfe RR. 
(1993). Regulation of endogenous fat and carbohydrate metabolism in relation 
to exercise intensity and duration. Am J Physiol 265, E380-391. 
 
Rowe ER, Mimmack ML, Barbosa AD, Haider A, Isaac I, Ouberai MM, Thiam AR, 
Patel S, Saudek V, Siniossoglou S & Savage DB. (2016). Conserved 
Amphipathic Helices Mediate Lipid Droplet Targeting of Perilipins 1-3. J Biol 
Chem 291, 6664-6678. 
 
234 
Ruan H & Pownall HJ. (2001). Overexpression of 1-acyl-glycerol-3-phosphate 
acyltransferase-alpha enhances lipid storage in cellular models of adipose 
tissue and skeletal muscle. Diabetes 50, 233-240. 
 
Russell AP. (2004). Lipotoxicity: the obese and endurance-trained paradox. Int J 
Obes Relat Metab Disord 28 Suppl 4, S66-71. 
 
Russell AP, Gastaldi G, Bobbioni-Harsch E, Arboit P, Gobelet C, Deriaz O, Golay A, 
Witztum JL & Giacobino JP. (2003). Lipid peroxidation in skeletal muscle of 
obese as compared to endurance-trained humans: a case of good vs. bad 
lipids? FEBS Lett 551, 104-106. 
 
Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J & Yki-
Jarvinen H. (2000). Hepatic fat content and insulin action on free fatty acids 
and glucose metabolism rather than insulin absorption are associated with 
insulin requirements during insulin therapy in type 2 diabetic patients. 
Diabetes 49, 749-758. 
 
Sacchetti M, Saltin B, Olsen DB & van Hall G. (2004). High triacylglycerol turnover 
rate in human skeletal muscle. J Physiol-London 561, 883-891. 
 
Sadur CN, Yost TJ & Eckel RH. (1984). Insulin responsiveness of adipose tissue 
lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 
59, 1176-1182. 
 
Samocha-Bonet D, Campbell LV, Viardot A, Freund J, Tam CS, Greenfield JR & 
Heilbronn LK. (2010). A family history of type 2 diabetes increases risk factors 
associated with overfeeding. Diabetologia 53, 1700-1708. 
 
Samuel VT, Petersen KF & Shulman GI. (2010). Lipid-induced insulin resistance: 
unravelling the mechanism. Lancet 375, 2267-2277. 
 
Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S & Chowdhury S. 
(2015). Profile of liver enzymes in non-alcoholic fatty liver disease in patients 
with impaired glucose tolerance and newly detected untreated type 2 
diabetes. Indian J Endocrinol Metab 19, 597-601. 
 
Schenk S & Horowitz JF. (2007). Acute exercise increases triglyceride synthesis in 
skeletal muscle and prevents fatty acid-induced insulin resistance. J Clin 
Invest 117, 1690-1698. 
 
Schmitt B, Fluck M, Decombaz J, Kreis R, Boesch C, Wittwer M, Graber F, Vogt M, 
Howald H & Hoppeler H. (2003). Transcriptional adaptations of lipid 
metabolism in tibialis anterior muscle of endurance-trained athletes. Physiol 
Genomics 15, 148-157. 
 
Schmitz-Peiffer C, Browne CL, Oakes ND, Watkinson A, Chisholm DJ, Kraegen EW 
& Biden TJ. (1997). Alterations in the expression and cellular localization of 
235 
protein kinase C isozymes epsilon and theta are associated with insulin 
resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46, 169-178. 
 
Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, Moonen-Kornips E, Schaart G, 
Mustard KJ, Hardie DG, Saris WH, Nicolay K & Schrauwen P. (2005). 
Intramyocellular lipid content and molecular adaptations in response to a 1-
week high-fat diet. Obes Res 13, 2088-2094. 
 
Schrauwen P, van Aggel-Leijssen DP, Hul G, Wagenmakers AJ, Vidal H, Saris WH 
& van Baak MA. (2002). The effect of a 3-month low-intensity endurance 
training program on fat oxidation and acetyl-CoA carboxylase-2 expression. 
Diabetes 51, 2220-2226. 
 
Schulze PC. (2009). Myocardial lipid accumulation and lipotoxicity in heart failure. J 
Lipid Res 50, 2137-2138. 
 
Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, Johnson CM, Nair KS, 
Jensen MD & Rizza RA. (2002). Effects of free fatty acids and glycerol on 
splanchnic glucose metabolism and insulin extraction in nondiabetic humans. 
Diabetes 51, 301-310. 
 
Shaw CS, Jones DA & Wagenmakers AJ. (2008). Network distribution of 
mitochondria and lipid droplets in human muscle fibres. Histochem Cell Biol 
129, 65-72. 
 
Shaw CS, Shepherd SO, Wagenmakers AJM, Hansen D, Dendale P & van Loon LJC. 
(2012). Prolonged exercise training increases intramuscular lipid content and 
perilipin 2 expression in type I muscle fibers of patients with type 2 diabetes. 
Am J Physiol-Endoc M 303, E1158-E1165. 
 
Shaw CS, Sherlock M, Stewart PM & Wagenmakers AJ. (2009). Adipophilin 
distribution and colocalization with lipid droplets in skeletal muscle. Histochem 
Cell Biol 131, 575-581. 
 
Shen WJ, Patel S, Miyoshi H, Greenberg AS & Kraemer FB. (2009). Functional 
interaction of hormone-sensitive lipase and perilipin in lipolysis. J Lipid Res 
50, 2306-2313. 
 
Shepherd SO, Cocks M, Meikle PJ, Mellett NA, Ranasinghe AM, Barker TA, 
Wagenmakers AJM & Shaw CS. (2017a). Lipid droplet remodelling and 
reduced muscle ceramides following sprint interval and moderate-intensity 
continuous exercise training in obese males. Int J Obes (Lond) 41, 1745-1754. 
 
Shepherd SO, Cocks M, Tipton KD, Ranasinghe AM, Barker TA, Burniston JG, 
Wagenmakers AJ & Shaw CS. (2012). Preferential utilization of perilipin 2-
associated intramuscular triglycerides during 1 h of moderate-intensity 
endurance-type exercise. Exp Physiol 97, 970-980. 
 
236 
Shepherd SO, Cocks M, Tipton KD, Ranasinghe AM, Barker TA, Burniston JG, 
Wagenmakers AJ & Shaw CS. (2013). Sprint interval and traditional 
endurance training increase net intramuscular triglyceride breakdown and 
expression of perilipin 2 and 5. J Physiol 591, 657-675. 
 
Shepherd SO, Cocks M, Tipton KD, Witard OC, Ranasinghe AM, Barker TA, 
Wagenmakers AJ & Shaw CS. (2014). Resistance training increases skeletal 
muscle oxidative capacity and net intramuscular triglyceride breakdown in 
type I and II fibres of sedentary males. Exp Physiol 99, 894-908. 
 
Shepherd SO, Strauss JA, Wang Q, Dube JJ, Goodpaster B, Mashek DG & Chow 
LS. (2017b). Training alters the distribution of perilipin proteins in muscle 
following acute free fatty acid exposure. J Physiol 595, 5587-5601. 
 
Shin DH, Paulauskis JD, Moustaid N & Sul HS. (1991). Transcriptional regulation of 
p90 with sequence homology to Escherichia coli glycerol-3-phosphate 
acyltransferase. J Biol Chem 266, 23834-23839. 
 
Singh R, Park D, Xu J, Hosur R & Berger B. (2010). Struct2Net: a web service to 
predict protein-protein interactions using a structure-based approach. Nucleic 
Acids Res 38, W508-515. 
 
Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, 
Eckel RH & Farese RV, Jr. (2000). Obesity resistance and multiple 
mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 25, 87-
90. 
 
Sollner T, Whitehart SW, Brunner M, Erdjumentbromage H, Geromanos S, Tempst P 
& Rothman JE. (1993). Snap Receptors Implicated in Vesicle Targeting and 
Fusion. Nature 362, 318-324. 
 
Sollner TH. (2007). Lipid droplets highjack SNAREs. Nat Cell Biol 9, 1219-1220. 
 
Staiano AE & Katzmarzyk PT. (2012). Ethnic and sex differences in body fat and 
visceral and subcutaneous adiposity in children and adolescents. Int J Obes 
(Lond) 36, 1261-1269. 
 
Stehouwer CDA. (2018). Microvascular Dysfunction and Hyperglycemia: A Vicious 
Cycle With Widespread Consequences. Diabetes 67, 1729-1741. 
 
Stettler R, Boesch C, Ith M, Tappy L, Acheson KJ, Binnert C & Decombaz J. (2005). 
Interaction between dietary lipids and physical inactivity on insulin sensitivity 
and on intramyocellular lipids in healthy men. Diabetes Care 28, 1404-1409. 
 
Stevens J, Cai JW, Evenson KR & Thomas R. (2002). Fitness and fatness as 
predictors of mortality from all causes and from cardiovascular disease in men 
and women in the Lipid Research Clinics Study. American Journal of 
Epidemiology 156, 832-841. 
237 
 
Stone SJ, Levin MC & Farese RV, Jr. (2006). Membrane topology and identification 
of key functional amino acid residues of murine acyl-CoA:diacylglycerol 
acyltransferase-2. J Biol Chem 281, 40273-40282. 
 
Stone SJ, Levin MC, Zhou P, Han J, Walther TC & Farese RV, Jr. (2009). The 
endoplasmic reticulum enzyme DGAT2 is found in mitochondria-associated 
membranes and has a mitochondrial targeting signal that promotes its 
association with mitochondria. J Biol Chem 284, 5352-5361. 
 
Straczkowski M, Kowalska I, Baranowski M, Nikolajuk A, Otziomek E, Zabielski P, 
Adamska A, Blachnio A, Gorski J & Gorska M. (2007). Increased skeletal 
muscle ceramide level in men at risk of developing type 2 diabetes. 
Diabetologia 50, 2366-2373. 
 
Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Kinalska I, 
Baranowski M, Zendzian-Piotrowska M, Brzezinska Z & Gorski J. (2004). 
Relationship between insulin sensitivity and sphingomyelin signaling pathway 
in human skeletal muscle. Diabetes 53, 1215-1221. 
 
Stratford S, Hoehn KL, Liu F & Summers SA. (2004). Regulation of insulin action by 
ceramide - Dual mechanisms linking ceramide accumulation to the inhibition 
of Akt/protein kinase B. Journal of Biological Chemistry 279, 36608-36615. 
 
Strauss JA, Shaw CS, Bradley H, Wilson OJ, Dorval T, Pilling J & Wagenmakers AJ. 
(2016). Immunofluorescence microscopy of SNAP23 in human skeletal 
muscle reveals colocalization with plasma membrane, lipid droplets, and 
mitochondria. Physiol Rep 4. 
 
Stuart CA, McCurry MP, Marino A, South MA, Howell ME, Layne AS, Ramsey MW & 
Stone MH. (2013). Slow-twitch fiber proportion in skeletal muscle correlates 
with insulin responsiveness. J Clin Endocrinol Metab 98, 2027-2036. 
 
Su CL, Sztalryd C, Contreras JA, Holm C, Kimmel AR & Londos C. (2003). Mutational 
analysis of the hormone-sensitive lipase translocation reaction in adipocytes. 
J Biol Chem 278, 43615-43619. 
 
Summers SA & Nelson DH. (2005). A role for sphingolipids in producing the common 
features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. 
Diabetes 54, 591-602. 
 
Szendroedi J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, Zhang DY, Jelenik T, 
Muller J, Herder C, Nowotny P, Shulman GI & Roden M. (2014). Role of 
diacylglycerol activation of PKC theta in lipid-induced muscle insulin 
resistance in humans. P Natl Acad Sci USA 111, 9597-9602. 
 
238 
Sztalryd C, Xu G, Dorward H, Tansey JT, Contreras JA, Kimmel AR & Londos C. 
(2003). Perilipin A is essential for the translocation of hormone-sensitive lipase 
during lipolytic activation. J Cell Biol 161, 1093-1103. 
 
Takeuchi K & Reue K. (2009). Biochemistry, physiology, and genetics of GPAT, 
AGPAT, and lipin enzymes in triglyceride synthesis. Am J Physiol Endocrinol 
Metab 296, E1195-1209. 
 
Tarnopolsky MA, Rennie CD, Robertshaw HA, Fedak-Tarnopolsky SN, Devries MC 
& Hamadeh MJ. (2007). Influence of endurance exercise training and sex on 
intramyocellular lipid and mitochondrial ultrastructure, substrate use, and 
mitochondrial enzyme activity. Am J Physiol Regul Integr Comp Physiol 292, 
R1271-1278. 
 
Taschler U, Radner FP, Heier C, Schreiber R, Schweiger M, Schoiswohl G, Preiss-
Landl K, Jaeger D, Reiter B, Koefeler HC, Wojciechowski J, Theussl C, 
Penninger JM, Lass A, Haemmerle G, Zechner R & Zimmermann R. (2011). 
Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-
induced insulin resistance. J Biol Chem 286, 17467-17477. 
 
Teodoro BG, Sampaio IH, Bomfim LH, Queiroz AL, Silveira LR, Souza AO, 
Fernandes AM, Eberlin MN, Huang TY, Zheng D, Neufer PD, Cortright RN & 
Alberici LC. (2017). Long-chain acyl-CoA synthetase 6 regulates lipid 
synthesis and mitochondrial oxidative capacity in human and rat skeletal 
muscle. J Physiol 595, 677-693. 
 
Thompson AL & Cooney GJ. (2000). Acyl-CoA inhibition of hexokinase in rat and 
human skeletal muscle is a potential mechanism of lipid-induced insulin 
resistance. Diabetes 49, 1761-1765. 
 
Thrush AB, Brindley DN, Chabowski A, Heigenhauser GJ & Dyck DJ. (2009). Skeletal 
muscle lipogenic protein expression is not different between lean and obese 
individuals: a potential factor in ceramide accumulation. J Clin Endocrinol 
Metab 94, 5053-5061. 
 
Townsend N, Bhatnagar P, Wickramasinghe K, Scarborough P, Foster C & Rayner 
M. (2012). Physical activity 
statistics 2012. British Heart Foundation: London. 
 
Trinkle-Mulcahy L, Boulon S, Lam YW, Urcia R, Boisvert FM, Vandermoere F, Morrice 
NA, Swift S, Rothbauer U, Leonhardt H & Lamond A. (2008). Identifying 
specific protein interaction partners using quantitative mass spectrometry and 
bead proteomes. J Cell Biol 183, 223-239. 
 
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, 
Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, 
Uusitupa M & Finnish Diabetes Prevention Study G. (2001). Prevention of type 
239 
2 diabetes mellitus by changes in lifestyle among subjects with impaired 
glucose tolerance. N Engl J Med 344, 1343-1350. 
 
Ukropcova B, Sereda O, de Jonge L, Bogacka I, Nguyen T, Xie H, Bray GA & Smith 
SR. (2007). Family history of diabetes links impaired substrate switching and 
reduced mitochondrial content in skeletal muscle. Diabetes 56, 720-727. 
 
Uranga AP, Levine J & Jensen M. (2005). Isotope tracer measures of meal fatty acid 
metabolism: reproducibility and effects of the menstrual cycle. Am J Physiol 
Endocrinol Metab 288, E547-555. 
 
Ureta T. (1982). The comparative isozymology of vertebrate hexokinases. Comp 
Biochem Physiol B 71, 549-555. 
 
Valdes CT & Elkind-Hirsch KE. (1991). Intravenous glucose tolerance test-derived 
insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 
72, 642-646. 
 
van Loon LJ. (2004). Use of intramuscular triacylglycerol as a substrate source during 
exercise in humans. J Appl Physiol (1985) 97, 1170-1187. 
 
van Loon LJ, Greenhaff PL, Constantin-Teodosiu D, Saris WH & Wagenmakers AJ. 
(2001). The effects of increasing exercise intensity on muscle fuel utilisation 
in humans. J Physiol 536, 295-304. 
 
van Loon LJ, Koopman R, Manders R, van der Weegen W, van Kranenburg GP & 
Keizer HA. (2004). Intramyocellular lipid content in type 2 diabetes patients 
compared with overweight sedentary men and highly trained endurance 
athletes. Am J Physiol Endocrinol Metab 287, E558-565. 
 
van Loon LJ, Koopman R, Stegen JH, Wagenmakers AJ, Keizer HA & Saris WH. 
(2003a). Intramyocellular lipids form an important substrate source during 
moderate intensity exercise in endurance-trained males in a fasted state. J 
Physiol 553, 611-625. 
 
van Loon LJ, Manders RJ, Koopman R, Kaastra B, Stegen JH, Gijsen AP, Saris WH 
& Keizer HA. (2005a). Inhibition of adipose tissue lipolysis increases 
intramuscular lipid use in type 2 diabetic patients. Diabetologia 48, 2097-2107. 
 
van Loon LJ, Schrauwen-Hinderling VB, Koopman R, Wagenmakers AJ, Hesselink 
MK, Schaart G, Kooi ME & Saris WH. (2003b). Influence of prolonged 
endurance cycling and recovery diet on intramuscular triglyceride content in 
trained males. Am J Physiol Endocrinol Metab 285, E804-811. 
 
van Loon LJ, Thomason-Hughes M, Constantin-Teodosiu D, Koopman R, Greenhaff 
PL, Hardie DG, Keizer HA, Saris WH & Wagenmakers AJ. (2005b). Inhibition 
of adipose tissue lipolysis increases intramuscular lipid and glycogen use in 
vivo in humans. Am J Physiol Endocrinol Metab 289, E482-493. 
240 
 
Van Pelt RE, Gozansky WS, Schwartz RS & Kohrt WM. (2003). Intravenous 
estrogens increase insulin clearance and action in postmenopausal women. 
Am J Physiol Endocrinol Metab 285, E311-317. 
 
Van Proeyen K, Szlufcik K, Nielens H, Deldicque L, Van Dyck R, Ramaekers M & 
Hespel P. (2011a). High-fat diet overrules the effects of training on fiber-
specific intramyocellular lipid utilization during exercise. J Appl Physiol (1985) 
111, 108-116. 
 
Van Proeyen K, Szlufcik K, Nielens H, Ramaekers M & Hespel P. (2011b). Beneficial 
metabolic adaptations due to endurance exercise training in the fasted state. 
J Appl Physiol 110, 236-245. 
 
Vancura A & Haldar D. (1994). Purification and characterization of glycerophosphate 
acyltransferase from rat liver mitochondria. J Biol Chem 269, 27209-27215. 
 
Villena JA, Roy S, Sarkadi-Nagy E, Kim KH & Sul HS. (2004). Desnutrin, an adipocyte 
gene encoding a novel patatin domain-containing protein, is induced by 
fasting and glucocorticoids: ectopic expression of desnutrin increases 
triglyceride hydrolysis. J Biol Chem 279, 47066-47075. 
 
Vogt M, Puntschart A, Howald H, Mueller B, Mannhart C, Gfeller-Tuescher L, Mullis 
P & Hoppeler H. (2003). Effects of dietary fat on muscle substrates, 
metabolism, and performance in athletes. Med Sci Sports Exerc 35, 952-960. 
 
Wagenmakers AJ, Strauss JA, Shepherd SO, Keske MA & Cocks M. (2016). 
Increased muscle blood supply and transendothelial nutrient and insulin 
transport induced by food intake and exercise: effect of obesity and ageing. J 
Physiol 594, 2207-2222. 
 
Wajchenberg BL, Giannella-Neto D, da Silva ME & Santos RF. (2002). Depot-specific 
hormonal characteristics of subcutaneous and visceral adipose tissue and 
their relation to the metabolic syndrome. Horm Metab Res 34, 616-621. 
 
Walhin JP, Richardson JD, Betts JA & Thompson D. (2013). Exercise counteracts the 
effects of short-term overfeeding and reduced physical activity independent of 
energy imbalance in healthy young men. J Physiol-London 591, 6231-6243. 
 
Walther TC & Farese RV, Jr. (2009). The life of lipid droplets. Biochim Biophys Acta 
1791, 459-466. 
 
Wang H, Bell M, Sreenivasan U, Hu H, Liu J, Dalen K, Londos C, Yamaguchi T, Rizzo 
MA, Coleman R, Gong D, Brasaemle D & Sztalryd C. (2011a). Unique 
regulation of adipose triglyceride lipase (ATGL) by perilipin 5, a lipid droplet-
associated protein. J Biol Chem 286, 15707-15715. 
 
241 
Wang H, Hu L, Dalen K, Dorward H, Marcinkiewicz A, Russell D, Gong D, Londos C, 
Yamaguchi T, Holm C, Rizzo MA, Brasaemle D & Sztalryd C. (2009). 
Activation of hormone-sensitive lipase requires two steps, protein 
phosphorylation and binding to the PAT-1 domain of lipid droplet coat proteins. 
J Biol Chem 284, 32116-32125. 
 
Wang H, Sreenivasan U, Hu H, Saladino A, Polster BM, Lund LM, Gong DW, Stanley 
WC & Sztalryd C. (2011b). Perilipin 5, a lipid droplet-associated protein, 
provides physical and metabolic linkage to mitochondria. J Lipid Res 52, 2159-
2168. 
 
Wang H & Sztalryd C. (2011). Oxidative tissue: perilipin 5 links storage with the 
furnace. Trends Endocrinol Metab 22, 197-203. 
 
Watkins PJ. (2003). ABC of diabetes - Retinopathy. Brit Med J 326, 924-926. 
 
Watson RT, Kanzaki M & Pessin JE. (2004). Regulated membrane trafficking of the 
insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev 25, 177-
204. 
 
Watt MJ & Cheng Y. (2017). Triglyceride metabolism in exercising muscle. Biochim 
Biophys Acta 1862, 1250-1259. 
 
Watt MJ, Heigenhauser GJ, O'Neill M & Spriet LL. (2003a). Hormone-sensitive lipase 
activity and fatty acyl-CoA content in human skeletal muscle during prolonged 
exercise. J Appl Physiol (1985) 95, 314-321. 
 
Watt MJ, Heigenhauser GJ & Spriet LL. (2002). Intramuscular triacylglycerol 
utilization in human skeletal muscle during exercise: is there a controversy? J 
Appl Physiol (1985) 93, 1185-1195. 
 
Watt MJ, Heigenhauser GJ & Spriet LL. (2003b). Effects of dynamic exercise intensity 
on the activation of hormone-sensitive lipase in human skeletal muscle. J 
Physiol 547, 301-308. 
 
Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, Kemp BE & 
Febbraio MA. (2006). Regulation of HSL serine phosphorylation in skeletal 
muscle and adipose tissue. Am J Physiol Endocrinol Metab 290, E500-508. 
 
Watt MJ, Steinberg GR, Chan S, Garnham A, Kemp BE & Febbraio MA. (2004). Beta-
adrenergic stimulation of skeletal muscle HSL can be overridden by AMPK 
signaling. Faseb J 18, 1445-1446. 
 
Watt MJ, Stellingwerff T, Heigenhauser GJ & Spriet LL. (2003c). Effects of plasma 
adrenaline on hormone-sensitive lipase at rest and during moderate exercise 
in human skeletal muscle. J Physiol 550, 325-332. 
 
242 
Wegener G & Krause U. (2002). Different modes of activating phosphofructokinase, 
a key regulatory enzyme of glycolysis, in working vertebrate muscle. Biochem 
Soc Trans 30, 264-270. 
 
Weir JB. (1949). New methods for calculating metabolic rate with special reference 
to protein metabolism. J Physiol 109, 1-9. 
 
Welte MA. (2009). Fat on the move: intracellular motion of lipid droplets. Biochem Soc 
Trans 37, 991-996. 
 
Weyer C, Foley JE, Bogardus C, Tataranni PA & Pratley RE. (2000). Enlarged 
subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II 
diabetes independent of insulin resistance. Diabetologia 43, 1498-1506. 
 
White MF & Kahn CR. (1994a). The insulin signaling system. Journal of Biological 
Chemistry 269, 1-4. 
 
White MF & Kahn CR. (1994b). The insulin signaling system. J Biol Chem 269, 1-4. 
 
Whytock KL, Shepherd SO, Wagenmakers AJM & Strauss JA. (2018). Hormone-
sensitive lipase preferentially redistributes to lipid droplets associated with 
perilipin-5 in human skeletal muscle during moderate-intensity exercise. J 
Physiol. 
 
Wilcox G. (2005). Insulin and insulin resistance. Clin Biochem Rev 26, 19-39. 
 
Wild S, Roglic G, Green A, Sicree R & King H. (2004). Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-
1053. 
 
Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, Cheng JX, Graham M, 
Christiano R, Frohlich F, Liu X, Buhman KK, Coleman RA, Bewersdorf J, 
Farese RV, Jr. & Walther TC. (2013). Triacylglycerol synthesis enzymes 
mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev 
Cell 24, 384-399. 
 
Wohl P, Wohl P, Girman P & Pelikanova T. (2004). Inflexibility of energy substrate 
oxidation in type 1 diabetic patients. Metabolism 53, 655-659. 
 
Wolins NE, Quaynor BK, Skinner JR, Schoenfish MJ, Tzekov A & Bickel PE. (2005). 
S3-12, Adipophilin, and TIP47 package lipid in adipocytes. J Biol Chem 280, 
19146-19155. 
 
Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Croce MA, Gropler MC, Varma V, 
Yao-Borengasser A, Rasouli N, Kern PA, Finck BN & Bickel PE. (2006). 
OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid 
utilization. Diabetes 55, 3418-3428. 
243 
 
World Health Organisation. (2017). Obesity and Overweight factsheet. 
http://new.who.int/news-room/fact-sheets/detail/obesity-and-overweight. 
 
Wulan SN, Westerterp KR & Plasqui G. (2014). Metabolic profile before and after 
short-term overfeeding with a high-fat diet: a comparison between South 
Asian and White men. Br J Nutr 111, 1853-1861. 
 
Xie X, Langlais P, Zhang X, Heckmann BL, Saarinen AM, Mandarino LJ & Liu J. 
(2014). Identification of a novel phosphorylation site in adipose triglyceride 
lipase as a regulator of lipid droplet localization. Am J Physiol Endocrinol 
Metab 306, E1449-1459. 
 
Xu GH, Sztalryd C, Lu XY, Tansey JT, Gan JW, Dorward H, Kimmel AR & Londos C. 
(2005). Post-translational regulation of adipose differentiation-related protein 
by the ubiquitin/proteasome pathway. Journal of Biological Chemistry 280, 
42841-42847. 
 
Yamaguchi T, Omatsu N, Matsushita S & Osumi T. (2004). CGI-58 interacts with 
perilipin and is localized to lipid droplets. Possible involvement of CGI-58 
mislocalization in Chanarin-Dorfman syndrome. J Biol Chem 279, 30490-
30497. 
 
Yamashita A, Hayashi Y, Matsumoto N, Nemoto-Sasaki Y, Oka S, Tanikawa T & 
Sugiura T. (2014). Glycerophosphate/Acylglycerophosphate 
acyltransferases. Biology (Basel) 3, 801-830. 
 
Yang F, Wei Z, Ding X, Liu X, Ge X, Song G, Li G & Guo H. (2013). Upregulation of 
triglyceride synthesis in skeletal muscle overexpressing DGAT1. Lipids Health 
Dis 12, 63. 
 
Yang X, Lu X, Lombes M, Rha GB, Chi YI, Guerin TM, Smart EJ & Liu J. (2010). The 
G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with 
adipose triglyceride lipase. Cell Metab 11, 194-205. 
 
Yen CL & Farese RV, Jr. (2003). MGAT2, a monoacylglycerol acyltransferase 
expressed in the small intestine. J Biol Chem 278, 18532-18537. 
 
Yki-Jarvinen H. (1984). Sex and insulin sensitivity. Metabolism 33, 1011-1015. 
 
Yoon JH, Johnson E, Xu R, Martin LT, Martin PT & Montanaro F. (2012). Comparative 
proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and 
Galgt2 transgenic mouse skeletal muscle. J Proteome Res 11, 4413-4424. 
 
Yu CL, Chen Y, Cline GW, Zhang DY, Zong HH, Wang YL, Bergeron R, Kim JK, 
Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW & Shulman 
GI. (2002a). Mechanism by which fatty acids inhibit insulin activation of insulin 
244 
receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity 
in muscle. Journal of Biological Chemistry 277, 50230-50236. 
 
Yu J, Li Y, Zou F, Xu S & Liu P. (2015). Phosphorylation and function of DGAT1 in 
skeletal muscle cells. Biophys Rep 1, 41-50. 
 
Yu YH, Zhang Y, Oelkers P, Sturley SL, Rader DJ & Ginsberg HN. (2002b). 
Posttranscriptional control of the expression and function of diacylglycerol 
acyltransferase-1 in mouse adipocytes. J Biol Chem 277, 50876-50884. 
 
Yudkin JS. (2007). Inflammation, obesity, and the metabolic syndrome. Horm Metab 
Res 39, 707-709. 
 
Zderic TW, Davidson CJ, Schenk S, Byerley LO & Coyle EF. (2004). High-fat diet 
elevates resting intramuscular triglyceride concentration and whole body 
lipolysis during exercise. Am J Physiol Endocrinol Metab 286, E217-225. 
 
Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R & Lass A. (2009). 
Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J 
Lipid Res 50, 3-21. 
 
Zhang H, Wang Y, Li J, Yu J, Pu J, Li L, Zhang H, Zhang S, Peng G, Yang F & Liu P. 
(2011). Proteome of skeletal muscle lipid droplet reveals association with 
mitochondria and apolipoprotein a-I. J Proteome Res 10, 4757-4768. 
 
Zhang P, Verity MA & Reue K. (2014). Lipin-1 regulates autophagy clearance and 
intersects with statin drug effects in skeletal muscle. Cell Metab 20, 267-279. 
 
Zhou YP & Grill V. (1995). Long term exposure to fatty acids and ketones inhibits B-
cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol 
Metab 80, 1584-1590. 
 
Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, 
Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A & Zechner R. 
(2004). Fat mobilization in adipose tissue is promoted by adipose triglyceride 







Chapter 8. Appendix 
  
246 
Supplementary Material 1. Anti-HSL antibody validation 
Basic Local Alignment Search Tool (BLAST) search confirmed the target immunogen 
for anti-HSL antibody was 100% specific to human HSL.  
Western blot method. Snap frozen muscle was powdered in liquid nitrogen before 
being transferred to Eppendorf tubes that contained lysis buffer (1x RIPA buffer, Cell 
Signalling, including 1 complete mini protease inhibitor tablet, Roche Diagnostics, 
Germany) and mixed on ice for 2 h. Samples were then homogenized on ice for ~30 
sec at slow speed (Polytron), before being centrifuged for 20 min at 4°C and 10,000 
g. The supernatant was removed and a small portion was extracted to assess protein 
concentration (Pierce BCA assay kit; Pierce, Rockford, IL, USA). Samples were then 
diluted to a concentration of 3 μgμl-1, using a homogenization buffer and Laemmli 
sample buffer (Sigma, Gillingham, UK). Samples were subsequently boiled for 5 
minutes in 5 μg.μl-1 reducing buffer (Sigma Gillingham, UK) and loaded 50 µg per 
lane in pre-cast gels in a MiniVe (GE Healthcare, Amersham, UK) electrophoresis 
tank. Electrophoresis was performed on pre-cast gels at 80 V for 20 min and at 140 
V for 40 min in order to separate equal quantities of protein. Samples were 
subsequently transferred to nitrocellulose membrane at 25 V for 2 h in transfer buffer. 
Transfer efficacy was assessed using Ponceau S staining and subsequently imaged 
on ChemiDoc XRS+ system (Bio-Rad, Hemel Hempstead, UK), in order to quantify 
the total protein stain of each line. Membranes were subsequently destained in 
sodium hydroxide 0.1 M,  before being blocked for 1 hour in 5% Non-fat dried milk 
(NFDM) in phosphate-buffered saline with 0.1% Tween (PBS-Tw) and incubated 
overnight at room temperature with anti-HSL (Abcam, Cambridge, UK) primary 
antibody diluted in 1% NFDM in PBS-Tw. The membranes were washed three times 
for 5 min in PBS-Tw and subsequently blocked in 5% NFDM in PBS-Tw for 1 h at 
room temperature before being incubated with appropriate horseradish peroxidase-
conjugated IgG secondary antibodies diluted in 1% NFDM in PBS-Tw for 1 h and 30 
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min. Membranes were washed in PBS-Tw a further two times for 5 min and once for 
15 min before being incubated with ECL Prime Reagent for 5 min in the dark. Antibody 
binding was detected using enhanced chemiluminescence HRP detection reagent 
(GE Healthcare). Following this imaging and band quantification was performed using 
ChemiDoc XRS+ system (Bio-Rad, Hemel Hempstead, UK) (Supplementary figure 
1A). 
Immunofluorescence staining. Sections were fixed for 1 h in 3.7% formaldehyde, 
rinsed 3 x 30 s in doubly distilled water (dd H2O) and permeabilised in 0.5% Triton X-
100 for 5 min, before being washed 3 x 5 min in Phosphate Buffered Saline (PBS, 
137mM sodium chloride, 3 mM potassium chloride, 8 mM sodium phosphate dibasic 
and 3mM potassium phosphate monobasic, pH of 7.4). Subsequently, slides were 
incubated with rabbit polyclonal anti-HSL overnight (supplementary figure 1B) of PBS 
control (supplementary figure 1C) before being washed again 3 x 5 min in PBS. 
Sections were then incubated with  Alexa Fluor goat anti-rabbit IgG 546 (Invitrogen, 
Paisley, UK) for 30 min, followed by a further 3 x 5 min PBS washes. After the final 
wash, coverslips were mounted with Vectashield (H-1000, Vector Laboratories, 
Burlingame, CA, USA) and sealed.  
An inverted confocal microscope (Zeiss LSM710; Oberkochen, Germany) was used 
to obtain digital images of cross-sectionally orientated muscle sections. A helium-
neon laser excited the Alexa Fluor 546 fluorophores. Images were acquired with a 
40x 0.7 NA oil immersion objective to examine the cellular distribution of HSL 
(supplementary figure 1B) and confirm omission of staining with PBS control 










Supplementary Figure 1. Antibody validation. Immunoblot using anti-HSL (Abcam) 
of human skeletal muscle from a lean male. Results show single molecular weight band 
above 75 kDa. Expected molecular weight of HSL is 84 kDa (A). Immunofluorescence 
staining of HSL reveals expected distribution pattern (B). HSL antibody omitted from 
staining protocol to confirm antibody specificity for immunohistochemistry. Results 





Supplementary table 1. List of proteins identified from PLIN5 IP GeLC-MS/MS of lean healthy male participants  
Accession Protein name  MW (Da) MOWSE score 
Sequence 
coverage (%) 
1433E 14-3-3 protein epsilon  29326 230 ± 68 (20.4 - 51.0) 
1433G 14-3-3 protein gamma  28456 137 ± 10 (17.0 - 21.1) 
ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial  47015 60 ± 11 (13.3  - 29.5) 
ACSL1 Long-chain-fatty-acid--CoA ligase 1  78919 181 ± 47 (11.6 - 36.4) 
ACTB Actin, cytoplasmic 1  42052 441 ± 102 (36.3 - 49.9) 
ACTS Actin, alpha skeletal muscle  42366 828 ± 118 (56.0 - 61.8) 
ADT1 ADP/ATP translocase 1  33271 117 ± 13 (33.2 - 38.3) 
ARHL1 [Protein ADP-ribosylarginine] hydrolase-like protein 1  40649 111 ± 21 (12.4 - 28.0) 
AT2A1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  111550 1742 ± 333 (34.4 - 48.9) 
AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  116336 1104 ± 224 (23.2 - 45.2) 
ATPA ATP synthase subunit alpha, mitochondrial  59828 666 ± 153 (40.7 - 54.8) 
ATPB ATP synthase subunit beta, mitochondrial  56525 640 ± 129 (39.5 - 67.1) 
ATPG ATP synthase subunit gamma, mitochondrial  33032 71 ± 7 (13.1 - 18.5) 
CASQ1 Calsequestrin-1  45132 195 ± 36 (16.4 - 21.7) 
CMC1 Calcium-binding mitochondrial carrier protein Aralar1  75114 98 ± 40 (13.1- 40.9) 
CRYAB Alpha-crystallin B chain  20146 194 ± 28 (34.3 - 65.7) 
ECHA Trifunctional enzyme subunit alpha, mitochondrial  83688 252 ± 100 (15.2 - 42.9) 
ECHB Trifunctional enzyme subunit beta, mitochondrial  51547 162 ± 53 (17.1 - 38.2) 
ENOB Beta-enolase  47299 668 ± 223 (31.1- 60.1) 
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Accession Protein name  MW (Da) MOWSE score 
Sequence 
coverage (%) 
G3P Glyceraldehyde-3-phosphate dehydrogenase  36201 175 ± 71 (16.0 - 41.2) 
HS90B Heat shock protein HSP 90-beta  83554 292 ± 92 (8.3 - 36.9) 
HSPB1 Heat shock protein beta-1  22826 619 ± 117 (53.7 - 80.0) 
IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  40022 100 ± 22 (12.6 - 34.4) 
IL25 Interleukin-25  20887 41 ± 2 (5.6 - 10.7) 
KCRM Creatine kinase M-type  43302 160 ± 63 (11.5 - 44.6) 
KLH41 Kelch-like protein 41  68792 54 ± 7 (4.8 - 23.9) 
LDHA L-lactate dehydrogenase A chain  36950 77 ± 19 (12.7 - 29.2) 
LMCD1 LIM and cysteine-rich domains protein 1  42004 95 ± 47 (5.2 - 44.9) 
MPCP Phosphate carrier protein, mitochondrial  40525 45 ± 5 (8.0 - 13.0) 
NB5R1 NADH-cytochrome b5 reductase 1  34244 41 ± 4 (6.2 - 21.3) 
PANK4 Pantothenate kinase 4  86621 45 ± 3 (1.8 - 12.7) 
PHKG1 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform  45280 221 ± 63 (20.4 - 64.6) 
PLIN5 Perilipin-5  51444 73 ± 21 (12.3 - 27.2) 
POTEE POTE ankyrin domain family member E  122882 295 ± 89 (8.0 - 15.2) 
QCR2 Cytochrome b-c1 complex subunit 2, mitochondrial  48584 70 ± 11 (3.5 - 22.1) 
SRCA Sarcalumenin  101069 201 ± 82 (8.5 - 25.0) 
TBA4A Tubulin alpha-4A chain  50634 160 ± 49 (12.3 - 40.8) 
TBB4B Tubulin beta-4B chain  50255 236 ± 45 (24.5 - 44.9) 
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Accession Protein name  MW (Da) MOWSE score 
Sequence 
coverage (%) 
TBB5 Tubulin beta chain  50095 254 ± 54 (20.7 - 45.5) 
THIL Acetyl-CoA acetyltransferase, mitochondrial  45456 256 ± 107 (23.9 - 55.0) 
TRI72 Tripartite motif-containing protein 72  53609 85 ± 20 (5.0 - 29.8) 
MOWSE score presented as means ± SEM. Sequence coverage (%) presented as (min-max) from the 4 replicates. MW, molecular weight; Da, daltons. 
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41 Protein 4.1  97528 226 ± 25 (25.5 - 25.9) 
ABLM2 Actin-binding LIM protein 2  69479 148 ± 46 (30.8 - 36) 
ACTG Actin, cytoplasmic 2  42108 1356 ± 1260 (72.8 - 22.4) 
AINX Alpha-internexin  55528 49 ± 8 (10.4 - 3.8) 
AP2A1 AP-2 complex subunit alpha-1  108561 122 ± 59 (15 - 21.6) 
AP2A2 AP-2 complex subunit alpha-2  104807 68 ± 5 (11.4 - 15.5) 
BAF Barrier-to-autointegration factor  10280 63 ± 18 (48.3 - 50.6) 
C4BPA C4b-binding protein alpha chain  69042 48 ± 8 (10.1 - 3.4) 
CAPZB F-actin-capping protein subunit beta  31616 74 ± 28 (15.2 - 26.4) 
CENPE Centromere-associated protein E  317588 38 ± 0 (5.8 - 6) 
DDX1 ATP-dependent RNA helicase DDX1  83349 133 ± 73 (18.5 - 25.7) 
DZIP1 Zinc finger protein DZIP1  99286 37 ± 2 (5.8 - 3.8) 
FLNC Filamin-C  293407 306 ± 220 (8.6 - 18.9) 
FXR1 Fragile X mental retardation syndrome-related protein 1  70020 55 ± 1 (6.9 - 6.3) 
H2A1B Histone H2A type 1-B/E  14127 89 ± 33 (4 - 26.9) 
H2B1C Histone H2B type 1-C/E/F/G/I  13898 92 ± 43 (26.2 - 26.2) 
HNRPC Heterogeneous nuclear ribonucleoproteins C1/C2  33707 115 ± 23 (27.1 - 27.1) 
HNRPM Heterogeneous nuclear ribonucleoprotein M  77749 150 ± 7 (19 - 28.9) 
HNRPQ Heterogeneous nuclear ribonucleoprotein Q  69788 80 ± 2 (10.6 - 11.9) 
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HSPB8 Heat shock protein beta-8  21762 46 ± 8 (10.7 - 10.7) 
KCC2D Calcium/calmodulin-dependent protein kinase type II subunit delta  56961 120 ± 52 (12.6 - 20.4) 
MFAP5 Microfibrillar-associated protein 5  20055 45 ± 2 (17.9 - 6.9) 
NEXN Nexilin  80837 63 ± 10 (7.1 - 5.9) 
NID1 Nidogen-1  139142 105 ± 64 (2.5 - 11.4) 
OPTN Optineurin  66279 132 ± 5 (8.7 - 15.4) 
PA2GA Phospholipase A2, membrane associated  16870 53 ± 3 (12.5 - 17.4) 
PABP1 Polyadenylate-binding protein 1  70854 101 ± 4 (12.4 - 13.5) 
PABP3 Polyadenylate-binding protein 3  70215 51 ± 13 (9.8 - 8.4) 
PABP4 Polyadenylate-binding protein 4  71080 166 ± 12 (32.8 - 29.5) 
PGM5 Phosphoglucomutase-like protein 5  62756 149 ± 50 (11.6 - 29.8) 
PHKG1 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform  45280 66 ± 15 (8.5 - 19.1) 
PLEC Plectin  533462 38 ± 0 (6.7 - 4.1) 
PLIN5 Perilipin-5  51444 103 ± 23 (24 - 17.3) 
PURA Transcriptional activator protein Pur-alpha  35003 122 ± 20 (17.1 - 12.4) 
RL11 60S ribosomal protein L11  20468 55 ± 2 (19.7 - 20.2) 
RL18A 60S ribosomal protein L18a  21034 49 ± 2 (21 - 15.3) 
RL30 60S ribosomal protein L30  12947 91 ± 2 (24.3 - 24.3) 
RL31 60S ribosomal protein L31  14454 65 ± 5 (18.4 - 18.4) 
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RLA0 60S acidic ribosomal protein P0  34423 73 ± 10 (25.2 - 16.7) 
ROA2 Heterogeneous nuclear ribonucleoproteins A2/B1  37464 74 ± 5 (21.2 - 24.6) 
RS11 40S ribosomal protein S11  18590 47 ± 6 (40.5 - 41.8) 
RT22 28S ribosomal protein S22, mitochondrial  41425 40 ± 2 (6.1 - 11.7) 
RTRAF RNA transcription, translation and transport factor protein  28165 88 ± 2 (19.7 - 24.6) 
SGCD Delta-sarcoglycan  32393 60 ± 14 (9 - 12.1) 
SGCG Gamma-sarcoglycan  32815 67 ± 31 (4.8 - 17.2) 
SYNCI Syncoilin  55494 54 ± 1 (8.5 - 21.8) 
TAF1 Transcription initiation factor TFIID subunit 1  213969 37 ± 1 (2.1 - 2.6) 
TBA4B Putative tubulin-like protein alpha-4B  27819 88 ± 23 (17.8 - 30.7) 
TGM2 Protein-glutamine gamma-glutamyltransferase 2  78420 109 ± 63 (15.9 - 25.9) 
TMOD1 Tropomodulin-1  40658 70 ± 32 (32.9 - 27.6) 
TMOD4 Tropomodulin-4  39653 155 ± 10 (23.2 - 23.2) 
YBOX3 Y-box-binding protein 3  40066 53 ± 8 (18.8 - 17.2) 
 














1433B 14-3-3 protein beta/alpha  √ √ √ √ 
1433E 14-3-3 protein epsilon  √ √ √ √ 
1433F 14-3-3 protein eta  √ √ √ √ 
1433G 14-3-3 protein gamma  √ √ √ √ 
1433T 14-3-3 protein theta  X X √ X 
1433Z 14-3-3 protein zeta/delta  √ √ √ √ 
2AAA Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform  √ √ √ √ 
2ABA Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform  √ √ √ √ 
41 Protein 4.1  X √ X X 
5NT1A Cytosolic 5~-nucleotidase 1A  X √ √ √ 
5NT3A Cytosolic 5~-nucleotidase 3A  X X X √ 
A1AT Alpha-1-antitrypsin  √ X √ √ 
AAMDC Mth938 domain-containing protein  √ √ √ √ 
AATM Aspartate aminotransferase, mitochondrial  √ √ √ √ 
ABEC2 C->U-editing enzyme APOBEC-2  X X √ √ 
ABHEB Protein ABHD14B  X √ √ √ 
ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial  √ √ √ √ 
ACADS Short-chain specific acyl-CoA dehydrogenase, mitochondrial  X X √ √ 
ACADV Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  √ √ √ √ 
ACDSB Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial  X X √ X 
ACO13 Acyl-coenzyme A thioesterase 13  X X √ √ 
ACOC Cytoplasmic aconitate hydratase  X X √ √ 
ACON Aconitate hydratase, mitochondrial  √ √ √ √ 
ACOT1 Acyl-coenzyme A thioesterase 1  X X √ √ 












ACSL3 Long-chain-fatty-acid--CoA ligase 3  √ X √ √ 
ACTA Actin, aortic smooth muscle  √ √ √ √ 
ACTB Actin, cytoplasmic 1  √ √ √ √ 
ACTBL Beta-actin-like protein 2  √ √ √ √ 
ACTBM Putative beta-actin-like protein 3  X √ X X 
ACTC Actin, alpha cardiac muscle 1  √ √ √ √ 
ACTN1 Alpha-actinin-1  √ X √ √ 
ACTN2 Alpha-actinin-2  √ √ √ √ 
ACTN3 Alpha-actinin-3  √ X √ √ 
ACTN4 Alpha-actinin-4  √ X √ X 
ACTS Actin, alpha skeletal muscle  √ √ √ √ 
ACTY Beta-centractin  X X X √ 
ACTZ Alpha-centractin  √ √ √ √ 
ACY1 Aminoacylase-1  X X X √ 
ADH1B Alcohol dehydrogenase 1B  √ √ √ √ 
ADH1G Alcohol dehydrogenase 1C  X X X √ 
ADT1 ADP/ATP translocase 1  √ √ √ √ 
ADT2 ADP/ATP translocase 2  √ √ √ √ 
ADT3 ADP/ATP translocase 3  √ √ √ √ 
AFG32 AFG3-like protein 2  √ X X X 
AHNK2 Protein AHNAK2  X √ X √ 
AIFM1 Apoptosis-inducing factor 1, mitochondrial  √ √ √ √ 
AIMP2 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2  √ X √ X 
AINX Alpha-internexin  √ X X X 











AL3A2 Fatty aldehyde dehydrogenase  √ X X X 
AL4A1 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial  X X √ X 
ALBU Serum albumin  √ √ √ √ 
ALDH2 Aldehyde dehydrogenase, mitochondrial  √ √ √ √ 
ALDOA Fructose-bisphosphate aldolase A  √ √ √ √ 
AMPD1 AMP deaminase 1  √ √ √ √ 
AN32A Acidic leucine-rich nuclear phosphoprotein 32 family member A  √ √ √ √ 
AN32B Acidic leucine-rich nuclear phosphoprotein 32 family member B  √ X X X 
ANM5 Protein arginine N-methyltransferase 5  X X √ X 
ANXA2 Annexin A2  X X √ √ 
ANXA7 Annexin A7  X X √ X 
AOFA Amine oxidase [flavin-containing] A  √ √ √ √ 
AOFB Amine oxidase [flavin-containing] B  √ X X X 
AP2B1 AP-2 complex subunit beta  X X X √ 
ARF1 ADP-ribosylation factor 1  X √ √ √ 
ARF4 ADP-ribosylation factor 4  √ √ √ √ 
ARF5 ADP-ribosylation factor 5  X X √ √ 
ARF6 ADP-ribosylation factor 6  X X √ √ 
ARHL1 [Protein ADP-ribosylarginine] hydrolase-like protein 1  √ √ √ √ 
ARL1 ADP-ribosylation factor-like protein 1  X X √ X 
ARL8B ADP-ribosylation factor-like protein 8B  X X √ X 
ASAP2 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2  √ X √ √ 
ASPN Asporin  √ √ √ √ 
ASPP2 Apoptosis-stimulating of p53 protein 2  √ X X √ 













AT2A1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  √ √ √ √ 
AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  √ √ √ √ 
AT5F1 ATP synthase F(0) complex subunit B1, mitochondrial  √ √ √ √ 
ATP5H ATP synthase subunit d, mitochondrial  √ √ √ √ 
ATP5I ATP synthase subunit e, mitochondrial  √ √ √ √ 
ATP5L ATP synthase subunit g, mitochondrial  √ √ √ √ 
ATP6 ATP synthase subunit a  √ √ √ X 
ATPA ATP synthase subunit alpha, mitochondrial  √ √ √ √ 
ATPB ATP synthase subunit beta, mitochondrial  √ √ √ √ 
ATPD ATP synthase subunit delta, mitochondrial  √ X √ X 
ATPG ATP synthase subunit gamma, mitochondrial  √ √ √ √ 
ATPK ATP synthase subunit f, mitochondrial  √ √ √ √ 
ATPO ATP synthase subunit O, mitochondrial  √ √ √ √ 
B3AT Band 3 anion transport protein  √ √ √ √ 
BAF Barrier-to-autointegration factor  X √ X X 
BGH3 Transforming growth factor-beta-induced protein ig-h3  √ √ √ √ 
C1QB Complement C1q subcomponent subunit B  X X √ √ 
C1S Complement C1s subcomponent  X X √ X 
C1TC C-1-tetrahydrofolate synthase, cytoplasmic  √ X √ √ 
CAH3 Carbonic anhydrase 3  √ √ √ √ 
CALM1 Calmodulin-1  X X X √ 
CALR Calreticulin  X X X √ 
CALU Calumenin  √ X X X 
CAN1 Calpain-1 catalytic subunit  √ √ √ √ 
CAN2 Calpain-2 catalytic subunit  X X √ √ 











CANB1 Calcineurin subunit B type 1  X X √ X 
CARM1 Histone-arginine methyltransferase CARM1  X X √ √ 
CASQ1 Calsequestrin-1  √ √ √ √ 
CASQ2 Calsequestrin-2  √ √ √ √ 
CAV1 Caveolin-1  √ √ X X 
CAVN1 Caveolae-associated protein 1  √ √ √ √ 
CAVN2 Caveolae-associated protein 2  √ √ √ √ 
CAVN3 Caveolae-associated protein 3  √ √ √ √ 
CAVN4 Caveolae-associated protein 4  √ √ √ √ 
CAZA2 F-actin-capping protein subunit alpha-2  √ X √ √ 
CBPA3 Mast cell carboxypeptidase A  √ X X X 
CD5L CD5 antigen-like  √ X √ X 
CH60 60 kDa heat shock protein, mitochondrial  √ √ √ √ 
CHIP E3 ubiquitin-protein ligase CHIP  X X √ X 
CISD1 CDGSH iron-sulfur domain-containing protein 1  X X √ √ 
CISY Citrate synthase, mitochondrial  X X X √ 
CLIC1 Chloride intracellular channel protein 1  X X √ √ 
CLUS Clusterin  √ √ √ √ 
CMBL Carboxymethylenebutenolidase homolog  X X X √ 
CMC1 Calcium-binding mitochondrial carrier protein Aralar1  √ √ √ √ 
CNTRL Centriolin  X √ X X 
CO3 Complement C3  X X √ X 
CO6A1 Collagen alpha-1(VI) chain  √ X √ √ 
CO6A2 Collagen alpha-2(VI) chain  √ X X √ 












COF1 Cofilin-1  X √ √ √ 
COF2 Cofilin-2  √ √ √ √ 
COMP Cartilage oligomeric matrix protein  √ √ √ √ 
COPD Coatomer subunit delta  X X X √ 
COQ5 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial  √ X √ √ 
COQ6 Ubiquinone biosynthesis monooxygenase COQ6, mitochondrial  X X √ √ 
COQ8A Atypical kinase COQ8A, mitochondrial  √ √ √ √ 
COX2 Cytochrome c oxidase subunit 2  √ √ √ √ 
CPNS1 Calpain small subunit 1  √ X √ X 
CPT1B Carnitine O-palmitoyltransferase 1, muscle isoform  √ √ √ √ 
CRIP2 Cysteine-rich protein 2  X X √ X 
CRYAB Alpha-crystallin B chain  √ √ √ √ 
CSN1 COP9 signalosome complex subunit 1  X X √ X 
CSN4 COP9 signalosome complex subunit 4  X X √ √ 
CSN8 COP9 signalosome complex subunit 8  X X √ X 
CSRP1 Cysteine and glycine-rich protein 1  √ X √ X 
CSRP3 Cysteine and glycine-rich protein 3  √ √ √ √ 
CUL5 Cullin-5  √ √ √ √ 
CWC22 Pre-mRNA-splicing factor CWC22 homolog  X X √ X 
CX7A1 Cytochrome c oxidase subunit 7A1, mitochondrial  X √ √ √ 
CY1 Cytochrome c1, heme protein, mitochondrial  √ √ √ √ 
DCD Dermcidin  X X X √ 
DCTN2 Dynactin subunit 2  √ √ √ √ 
DCTN3 Dynactin subunit 3  √ √ √ X 













DCXR L-xylulose reductase  X X √ X 
DECR 2,4-dienoyl-CoA reductase, mitochondrial  √ X √ √ 
DERM Dermatopontin  √ X √ √ 
DESM Desmin  √ √ √ √ 
DEST Destrin  √ X √ √ 
DHB12 Very-long-chain 3-oxoacyl-CoA reductase  √ √ √ √ 
DHRS7 Dehydrogenase/reductase SDR family member 7  √ X √ √ 
DLDH Dihydrolipoyl dehydrogenase, mitochondrial  √ √ √ √ 
DMXL2 DmX-like protein 2  X X X √ 
DNM1L Dynamin-1-like protein  X X √ √ 
DPYL2 Dihydropyrimidinase-related protein 2  X X √ √ 
DPYL3 Dihydropyrimidinase-related protein 3  X X √ √ 
DRS7B Dehydrogenase/reductase SDR family member 7B  √ X √ X 
DRS7C Dehydrogenase/reductase SDR family member 7C  √ X √ √ 
DTNA Dystrobrevin alpha  √ X √ X 
DUPD1 Dual specificity phosphatase DUPD1  X X X √ 
DUS23 Dual specificity protein phosphatase 23  √ X √ X 
DUS3 Dual specificity protein phosphatase 3  √ X √ X 
DX39B Spliceosome RNA helicase DDX39B  X X √ X 
ECHA Trifunctional enzyme subunit alpha, mitochondrial  √ √ √ √ 
ECHB Trifunctional enzyme subunit beta, mitochondrial  √ √ √ √ 
ECHM Enoyl-CoA hydratase, mitochondrial  √ √ √ √ 
ECI1 Enoyl-CoA delta isomerase 1, mitochondrial  X X √ √ 
EF1A1 Elongation factor 1-alpha 1  √ √ √ √ 













EF1D Elongation factor 1-delta  X X √ X 
EF1G Elongation factor 1-gamma  √ X √ √ 
EF2 Elongation factor 2  √ √ √ √ 
EFTU Elongation factor Tu, mitochondrial  √ √ √ √ 
EHD1 EH domain-containing protein 1  √ X √ √ 
EHD2 EH domain-containing protein 2  √ √ √ √ 
EHD3 EH domain-containing protein 3  √ X X X 
EHD4 EH domain-containing protein 4  √ √ √ √ 
EI2BD Translation initiation factor eIF-2B subunit delta  √ X X X 
EIF3D Eukaryotic translation initiation factor 3 subunit D  X X X √ 
EIF3L Eukaryotic translation initiation factor 3 subunit L  X √ √ X 
ENDD1 Endonuclease domain-containing 1 protein  X X X √ 
ENOA Alpha-enolase  √ √ √ √ 
ENOB Beta-enolase  √ √ √ √ 
ENPL Endoplasmin  X X √ √ 
EPB42 Erythrocyte membrane protein band 4.2  X √ √ √ 
ERAP1 Endoplasmic reticulum aminopeptidase 1  √ X X √ 
ERLN2 Erlin-2  √ √ √ √ 
ETFA Electron transfer flavoprotein subunit alpha, mitochondrial  X X √ √ 
ETFB Electron transfer flavoprotein subunit beta  X X √ X 
ETFD Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial  X X √ X 
EVPL Envoplakin  X X X √ 
F13A Coagulation factor XIII A chain  √ √ √ √ 
F16P1 Fructose-1,6-bisphosphatase 1  X X X X 












FERM2 Fermitin family homolog 2  X X √ √ 
FHL1 Four and a half LIM domains protein 1  √ √ √ √ 
FHL3 Four and a half LIM domains protein 3  √ √ √ √ 
FIBA Fibrinogen alpha chain  √ √ √ √ 
FIBB Fibrinogen beta chain  √ √ √ √ 
FIBG Fibrinogen gamma chain  √ √ √ √ 
FITM1 Fat storage-inducing transmembrane protein 1  √ X X X 
FKB1A Peptidyl-prolyl cis-trans isomerase FKBP1A  X √ X X 
G3P Glyceraldehyde-3-phosphate dehydrogenase  √ √ √ √ 
GALK1 Galactokinase  √ X √ X 
GAMT Guanidinoacetate N-methyltransferase  X X √ √ 
GANAB Neutral alpha-glucosidase AB  X X X √ 
GBB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  X X √ √ 
GELS Gelsolin  √ √ √ √ 
GLUCM D-glutamate cyclase, mitochondrial  √ √ √ √ 
GNAI2 Guanine nucleotide-binding protein G(i) subunit alpha-2  X X √ √ 
GNAS1 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas  X X X √ 
GPD1L Glycerol-3-phosphate dehydrogenase 1-like protein  √ √ √ √ 
GPDA Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic  √ √ √ √ 
GPX1 Glutathione peroxidase 1  X X √ X 
GRHPR Glyoxylate reductase/hydroxypyruvate reductase  X X X √ 
GRP75 Stress-70 protein, mitochondrial  √ √ √ X 
GRP78 78 kDa glucose-regulated protein  X √ √ X 
GSH0 Glutamate--cysteine ligase regulatory subunit  X X √ √ 











GSTM1 Glutathione S-transferase Mu 1  X X X √ 
GSTM2 Glutathione S-transferase Mu 2  X X √ √ 
GSTM3 Glutathione S-transferase Mu 3  X X √ X 
GSTO1 Glutathione S-transferase omega-1  X X √ X 
GSTP1 Glutathione S-transferase P  X X √ √ 
GSTT1 Glutathione S-transferase theta-1  X X √ √ 
GYS1 Glycogen [starch] synthase, muscle  √ √ √ √ 
H2A1B Histone H2A type 1-B/E  √ √ X X 
H2B1B Histone H2B type 1-B  X X √ √ 
H2B1C Histone H2B type 1-C/E/F/G/I  √ X X X 
H31T Histone H3.1t  X X √ X 
H4 Histone H4  √ √ √ √ 
HBA Hemoglobin subunit alpha  X √ √ √ 
HBB Hemoglobin subunit beta  √ √ √ √ 
HCDH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  X X √ √ 
HDHD5 Haloacid dehalogenase-like hydrolase domain-containing 5  X X √ √ 
HNRPK Heterogeneous nuclear ribonucleoprotein K  √ √ X √ 
HNRPU Heterogeneous nuclear ribonucleoprotein U  √ X X √ 
HS12A Heat shock 70 kDa protein 12A  X X √ X 
HS71A Heat shock 70 kDa protein 1A  √ √ √ √ 
HS90A Heat shock protein HSP 90-alpha  √ √ √ √ 
HS90B Heat shock protein HSP 90-beta  √ √ √ √ 
HSDL2 Hydroxysteroid dehydrogenase-like protein 2  X X √ √ 
HSP72 Heat shock-related 70 kDa protein 2  √ √ √ √ 













HSPB1 Heat shock protein beta-1  √ √ √ √ 
HSPB2 Heat shock protein beta-2  √ √ √ √ 
HSPB3 Heat shock protein beta-3  X X √ √ 
HSPB6 Heat shock protein beta-6  √ X √ √ 
HV307 Immunoglobulin heavy variable 3-7  √ √ X X 
HV315 Immunoglobulin heavy variable 3-15  √ √ √ √ 
HV323 Immunoglobulin heavy variable 3-23  √ √ √ √ 
HV349 Immunoglobulin heavy variable 3-49  √ √ X √ 
HV364 Immunoglobulin heavy variable 3-64  √ √ X X 
HV372 Immunoglobulin heavy variable 3-72  X √ √ X 
HV43D Immunoglobulin heavy variable 3-43D  √ X √ X 
HV64D Immunoglobulin heavy variable 3-64D  √ √ √ √ 
HV69D Immunoglobulin heavy variable 1-69D  X √ X √ 
HVC33 Immunoglobulin heavy variable 3-30-3  √ √ √ √ 
HXK1 Hexokinase-1  √ X √ √ 
ICLN Methylosome subunit pICln  X X X √ 
ICT1 Peptidyl-tRNA hydrolase ICT1, mitochondrial  √ X X X 
IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  √ X √ √ 
IDH3B Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial  √ X √ √ 
IDHC Isocitrate dehydrogenase [NADP] cytoplasmic  X X √ √ 
IDHP Isocitrate dehydrogenase [NADP], mitochondrial  √ √ √ √ 
IF2A Eukaryotic translation initiation factor 2 subunit 1  X X X √ 
IF4A1 Eukaryotic initiation factor 4A-I  √ X √ √ 
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2  √ √ √ √ 













IGG1 Immunoglobulin gamma-1 heavy chain  √ √ √ √ 
IGHA1 Immunoglobulin heavy constant alpha 1  √ √ √ √ 
IGHG2 Immunoglobulin heavy constant gamma 2  √ √ √ √ 
IGHG3 Immunoglobulin heavy constant gamma 3  √ √ √ √ 
IGHG4 Immunoglobulin heavy constant gamma 4  √ √ √ √ 
IGHM Immunoglobulin heavy constant mu  √ √ √ √ 
IGJ Immunoglobulin J chain  X X √ X 
IGK Immunoglobulin kappa light chain  √ √ √ √ 
IGKC Immunoglobulin kappa constant  √ √ √ √ 
IGL1 Immunoglobulin lambda-1 light chain  √ X X X 
IGLC2 Immunoglobulin lambda constant 2  √ √ √ √ 
IGLC7 Immunoglobulin lambda constant 7  √ X X X 
IGLL5 Immunoglobulin lambda-like polypeptide 5  √ X X √ 
IL25 Interleukin-25  √ √ √ √ 
ILK Integrin-linked protein kinase  X X √ X 
IMA4 Importin subunit alpha-4  X X √ X 
IMA5 Importin subunit alpha-5  √ X X √ 
IMA7 Importin subunit alpha-7  √ X X X 
IMB1 Importin subunit beta-1  X X √ √ 
IMDH2 Inosine-5~-monophosphate dehydrogenase 2  √ √ √ X 
IMPA1 Inositol monophosphatase 1  X X √ X 
IMPA2 Inositol monophosphatase 2  √ √ √ √ 
IPYR2 Inorganic pyrophosphatase 2, mitochondrial  X X √ √ 
K1614 Uncharacterized protein KIAA1614  X X X √ 












K1C13 Keratin, type I cytoskeletal 13  √ √ √ √ 
K1C14 Keratin, type I cytoskeletal 14  √ √ √ √ 
K1C16 Keratin, type I cytoskeletal 16  √ √ √ √ 
K1C17 Keratin, type I cytoskeletal 17  X X √ X 
K1C20 Keratin, type I cytoskeletal 20  X X √ X 
K1C24 Keratin, type I cytoskeletal 24  X X √ X 
K1C9 Keratin, type I cytoskeletal 9  √ √ √ √ 
K1H1 Keratin, type I cuticular Ha1  X X √ X 
K22E Keratin, type II cytoskeletal 2 epidermal  √ √ √ √ 
K22O Keratin, type II cytoskeletal 2 oral  X X √ X 
K2C1 Keratin, type II cytoskeletal 1  √ √ √ √ 
K2C1B Keratin, type II cytoskeletal 1b  √ X √ X 
K2C4 Keratin, type II cytoskeletal 4  X X √ √ 
K2C5 Keratin, type II cytoskeletal 5  √ √ √ √ 
K2C6A Keratin, type II cytoskeletal 6A  √ √ √ √ 
K2C6B Keratin, type II cytoskeletal 6B  √ √ √ √ 
K2C73 Keratin, type II cytoskeletal 73  X X √ X 
K2C75 Keratin, type II cytoskeletal 75  X √ X X 
K2C79 Keratin, type II cytoskeletal 79  X X √ X 
K2C8 Keratin, type II cytoskeletal 8  √ X √ X 
K2C80 Keratin, type II cytoskeletal 80  X X X √ 
KAD1 Adenylate kinase isoenzyme 1  X √ √ √ 
KAP2 cAMP-dependent protein kinase type II-alpha regulatory subunit  X X √ √ 
KAPCA cAMP-dependent protein kinase catalytic subunit alpha  X X √ √ 












KCRM Creatine kinase M-type  √ √ √ √ 
KCRS Creatine kinase S-type, mitochondrial  X √ √ √ 
KGP1 cGMP-dependent protein kinase 1  √ √ √ √ 
KLH40 Kelch-like protein 40  X X √ √ 
KLH41 Kelch-like protein 41  √ √ √ √ 
KPBB Phosphorylase b kinase regulatory subunit beta  √ X X √ 
KPYM Pyruvate kinase PKM  √ √ √ √ 
KRT34 Keratin, type I cuticular Ha4  X X √ X 
KRT85 Keratin, type II cuticular Hb5  X X √ X 
KRT86 Keratin, type II cuticular Hb6  X X √ X 
KS6A3 Ribosomal protein S6 kinase alpha-3  X X √ X 
KV108 Immunoglobulin kappa variable 1-8  X X √ √ 
KV224 Immunoglobulin kappa variable 2-24  X X √ √ 
KV315 Immunoglobulin kappa variable 3-15  √ X X X 
KV320 Immunoglobulin kappa variable 3-20  √ √ √ √ 
KV401 Immunoglobulin kappa variable 4-1  √ X √ X 
KVD07 Immunoglobulin kappa variable 3D-7  X X √ X 
KVD11 Immunoglobulin kappa variable 3D-11  X √ X X 
KVD13 Immunoglobulin kappa variable 1D-13  X X √ √ 
KVD20 Immunoglobulin kappa variable 3D-20  √ √ √ √ 
KVD26 Immunoglobulin kappa variable 2D-26  √ √ √ √ 
KVD33 Immunoglobulin kappa variable 1D-33  √ X √ X 
KVD39 Immunoglobulin kappa variable 1D-39  X √ X X 
L2HDH L-2-hydroxyglutarate dehydrogenase, mitochondrial  X X X √ 












LDB3 LIM domain-binding protein 3  √ √ √ √ 
LDHA L-lactate dehydrogenase A chain  √ √ √ √ 
LDHB L-lactate dehydrogenase B chain  X √ √ √ 
LEG1 Galectin-1  √ √ √ √ 
LIPS Hormone-sensitive lipase  √ √ √ √ 
LKHA4 Leukotriene A-4 hydrolase  X X √ √ 
LMCD1 LIM and cysteine-rich domains protein 1  √ √ √ √ 
LMNA Prelamin-A/C  √ √ √ X 
LONM Lon protease homolog, mitochondrial  X X √ √ 
LRC47 Leucine-rich repeat-containing protein 47  X X X √ 
LUM Lumican  √ √ √ √ 
LV147 Immunoglobulin lambda variable 1-47  X √ √ √ 
LV39 Immunoglobulin lambda variable 3-9  X √ √ √ 
M2OM Mitochondrial 2-oxoglutarate/malate carrier protein  √ √ √ √ 
MACD1 O-acetyl-ADP-ribose deacetylase MACROD1  X X √ √ 
MCCA Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial  √ X √ X 
MCCB Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial  X X √ X 
MCU Calcium uniporter protein, mitochondrial  X X √ √ 
MDHM Malate dehydrogenase, mitochondrial  √ √ √ √ 
MEIOC Meiosis-specific coiled-coil domain-containing protein MEIOC  X X X √ 
MELT Ventricular zone-expressed PH domain-containing protein homolog 1  X X √ X 
MET7A Methyltransferase-like protein 7A  √ √ √ √ 
MFAP4 Microfibril-associated glycoprotein 4  X X √ X 
MFAP5 Microfibrillar-associated protein 5  √ X X X 












MGST2 Microsomal glutathione S-transferase 2  X X √ X 
MGST3 Microsomal glutathione S-transferase 3  √ √ √ √ 
MIC19 MICOS complex subunit MIC19  √ √ √ √ 
MIC27 MICOS complex subunit MIC27  √ √ √ √ 
MIC60 MICOS complex subunit MIC60  √ √ √ √ 
MIME Mimecan  √ X √ X 
ML12A Myosin regulatory light chain 12A  √ √ √ X 
MLRS Myosin regulatory light chain 2, skeletal muscle isoform  √ √ √ √ 
MLRV Myosin regulatory light chain 2, ventricular/cardiac muscle isoform  √ √ √ √ 
MMSA Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial  X X √ X 
MP2K1 Dual specificity mitogen-activated protein kinase kinase 1  X X X √ 
MPC2 Mitochondrial pyruvate carrier 2  X X X √ 
MPCP Phosphate carrier protein, mitochondrial  √ √ √ √ 
MYG Myoglobin  √ √ √ √ 
MYH1 Myosin-1  √ √ √ √ 
MYH13 Myosin-13  √ X X √ 
MYH2 Myosin-2  √ √ √ √ 
MYH3 Myosin-3  X √ X X 
MYH4 Myosin-4  √ X X √ 
MYH6 Myosin-6  √ √ √ √ 
MYH7 Myosin-7  √ √ √ √ 
MYH8 Myosin-8  √ √ √ √ 
MYL1 Myosin light chain 1/3, skeletal muscle isoform  √ √ √ √ 
MYL3 Myosin light chain 3  √ √ √ √ 












MYL6B Myosin light chain 6B  X √ √ √ 
MYL9 Myosin regulatory light polypeptide 9  √ √ √ X 
MYLK2 Myosin light chain kinase 2, skeletal/cardiac muscle  X X √ X 
MYOC Myocilin  √ √ √ √ 
MYOM2 Myomesin-2  X X X √ 
MYOTI Myotilin  √ √ X √ 
MYOZ1 Myozenin-1  √ √ √ √ 
MYP0 Myelin protein P0  √ X √ X 
NB5R1 NADH-cytochrome b5 reductase 1  √ X √ √ 
NDUA2 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2  X √ √ √ 
NDUA4 Cytochrome c oxidase subunit NDUFA4  X √ √ √ 
NDUA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5  X X √ √ 
NDUA6 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6  X X √ √ 
NDUA7 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7  X X √ √ 
NDUA8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8  X √ X √ 
NDUA9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial  √ √ √ √ 
NDUAA NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial  √ X √ √ 
NDUAB NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11  X X √ √ 
NDUAC NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12  X √ √ √ 
NDUAD NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13  √ √ √ √ 
NDUB4 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4  √ √ √ √ 
NDUS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial  √ √ √ √ 
NDUS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial  √ √ √ √ 
NDUS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial  √ √ √ √ 












NDUS5 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5  √ √ √ √ 
NDUS6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial  X √ √ √ 
NDUS7 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial  √ √ √ √ 
NDUS8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial  √ √ √ √ 
NDUV1 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial  √ √ √ √ 
NDUV2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  √ √ √ √ 
NEST Nestin  X X √ X 
NFH Neurofilament heavy polypeptide  √ √ √ √ 
NID1 Nidogen-1  √ X X X 
NIPS2 Protein NipSnap homolog 2  X √ √ √ 
NLRC4 NLR family CARD domain-containing protein 4  X X X √ 
NLRX1 NLR family member X1  X X X √ 
NNTM NAD(P) transhydrogenase, mitochondrial  X X X √ 
NP1L4 Nucleosome assembly protein 1-like 4  X X √ X 
NPL4 Nuclear protein localization protein 4 homolog  X X √ X 
NSF Vesicle-fusing ATPase  X X √ √ 
NUCL Nucleolin  √ X X X 
NXN Nucleoredoxin  X X X √ 
ODO1 2-oxoglutarate dehydrogenase, mitochondrial  √ X √ √ 
ODO2 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial  X X √ √ 
ODP2 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial  √ √ √ √ 
ODPA Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial  √ √ √ √ 
ODPB Pyruvate dehydrogenase E1 component subunit beta, mitochondrial  √ √ √ √ 
ODPX Pyruvate dehydrogenase protein X component, mitochondrial  X X √ X 












OST48 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit  X X √ X 
OTUB1 Ubiquitin thioesterase OTUB1  X X √ X 
PABP4 Polyadenylate-binding protein 4  √ X X X 
PADI2 Protein-arginine deiminase type-2  √ √ √ √ 
PANK4 Pantothenate kinase 4  √ √ √ √ 
PBIP1 Pre-B-cell leukemia transcription factor-interacting protein 1  √ X X √ 
PCBP1 Poly(rC)-binding protein 1  √ √ √ √ 
PCBP2 Poly(rC)-binding protein 2  X X √ X 
PDC6I Programmed cell death 6-interacting protein  X X √ √ 
PDIA6 Protein disulfide-isomerase A6  √ √ √ √ 
PDLI3 PDZ and LIM domain protein 3  √ √ √ √ 
PDLI5 PDZ and LIM domain protein 5  √ X X √ 
PERI Peripherin  √ X X √ 
PFKAL ATP-dependent 6-phosphofructokinase, liver type  √ X √ √ 
PFKAM ATP-dependent 6-phosphofructokinase, muscle type  √ √ √ √ 
PFKAP ATP-dependent 6-phosphofructokinase, platelet type  X X √ √ 
PGAM2 Phosphoglycerate mutase 2  X √ X X 
PGM1 Phosphoglucomutase-1  X √ √ √ 
PGM2L Glucose 1,6-bisphosphate synthase  X X √ √ 
PGP Glycerol-3-phosphate phosphatase  √ √ √ √ 
PGS1 Biglycan  √ √ √ √ 
PGS2 Decorin  √ √ √ √ 
PHB Prohibitin  √ √ √ √ 
PHB2 Prohibitin-2  √ √ √ √ 












PIMT Protein-L-isoaspartate(D-aspartate) O-methyltransferase  X √ √ √ 
PLAP Phospholipase A-2-activating protein  X X √ √ 
PLIN1 Perilipin-1  √ √ √ √ 
POTEE POTE ankyrin domain family member E  √ X √ √ 
POTEF POTE ankyrin domain family member F  X X √ X 
POTEI POTE ankyrin domain family member I  √ √ X √ 
POTEJ POTE ankyrin domain family member J  X X X X 
PP1B Serine/threonine-protein phosphatase PP1-beta catalytic subunit  √ √ √ X 
PPAC Low molecular weight phosphotyrosine protein phosphatase  √ √ √ √ 
PPCE Prolyl endopeptidase  X X √ √ 
PRDX1 Peroxiredoxin-1  √ √ √ √ 
PRDX2 Peroxiredoxin-2  √ √ √ √ 
PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial  X X √ X 
PRDX5 Peroxiredoxin-5, mitochondrial  X X X X 
PRDX6 Peroxiredoxin-6  √ √ √ √ 
PRELP Prolargin  √ √ √ √ 
PROF1 Profilin-1  X X X √ 
PROF2 Profilin-2  √ X √ √ 
PRPS1 Ribose-phosphate pyrophosphokinase 1  X X √ √ 
PRS4 26S proteasome regulatory subunit 4  X X √ X 
PRS7 26S proteasome regulatory subunit 7  X X √ X 
PSA Puromycin-sensitive aminopeptidase  √ √ √ √ 
PSB5 Proteasome subunit beta type-5  X √ X X 













PSMD2 26S proteasome non-ATPase regulatory subunit 2  X X √ √ 
PSMD3 26S proteasome non-ATPase regulatory subunit 3  √ X √ √ 
PUR8 Adenylosuccinate lyase  X X √ √ 
PYGB Glycogen phosphorylase, brain form  X X √ √ 
PYGL Glycogen phosphorylase, liver form  X X √ √ 
PYGM Glycogen phosphorylase, muscle form  √ √ √ √ 
QCR1 Cytochrome b-c1 complex subunit 1, mitochondrial  √ √ √ √ 
QCR2 Cytochrome b-c1 complex subunit 2, mitochondrial  √ √ √ √ 
QCR6 Cytochrome b-c1 complex subunit 6, mitochondrial  X √ X X 
QCR8 Cytochrome b-c1 complex subunit 8  X √ √ X 
QCR9 Cytochrome b-c1 complex subunit 9  X √ √ √ 
RAB10 Ras-related protein Rab-10  X X X √ 
RAB14 Ras-related protein Rab-14  X X √ √ 
RAB1B Ras-related protein Rab-1B  X √ √ √ 
RACK1 Receptor of activated protein C kinase 1  X X √ √ 
RAN GTP-binding nuclear protein Ran  √ √ √ √ 
RETST All-trans-retinol 13,14-reductase  √ X √ √ 
RHOA Transforming protein RhoA  X X √ X 
RINI Ribonuclease inhibitor  √ √ √ √ 
RL12 60S ribosomal protein L12  X X √ X 
RL14 60S ribosomal protein L14  √ X √ X 
RL15 60S ribosomal protein L15  X X √ X 
RL18 60S ribosomal protein L18  √ X X X 
RL22 60S ribosomal protein L22  √ √ X √ 












RL27A 60S ribosomal protein L27a  X X X √ 
RL31 60S ribosomal protein L31  √ X X X 
RL40 Ubiquitin-60S ribosomal protein L40  X X X √ 
RL7 60S ribosomal protein L7  √ X √ √ 
RL7A 60S ribosomal protein L7a  √ X X X 
RLA0 60S acidic ribosomal protein P0  √ X X X 
RM49 39S ribosomal protein L49, mitochondrial  √ X X X 
RO60 60 kDa SS-A/Ro ribonucleoprotein  X √ √ X 
RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  √ √ √ √ 
RPN2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2  X X √ √ 
RS13 40S ribosomal protein S13  √ √ X X 
RS14 40S ribosomal protein S14  √ √ √ √ 
RS15A 40S ribosomal protein S15a  √ X X X 
RS16 40S ribosomal protein S16  √ X √ X 
RS18 40S ribosomal protein S18  √ √ √ X 
RS2 40S ribosomal protein S2  √ √ √ √ 
RS23 40S ribosomal protein S23  √ X √ X 
RS25 40S ribosomal protein S25  X X √ √ 
RS27A Ubiquitin-40S ribosomal protein S27a  X X √ √ 
RS3 40S ribosomal protein S3  √ X √ √ 
RS4X 40S ribosomal protein S4, X isoform  X X √ √ 
RS5 40S ribosomal protein S5  √ X X X 
RS8 40S ribosomal protein S8  √ √ √ √ 
RTN2 Reticulon-2  √ √ √ √ 












S27A1 Long-chain fatty acid transport protein 1  √ X √ √ 
SAHH Adenosylhomocysteinase  X X √ √ 
SAM50 Sorting and assembly machinery component 50 homolog  X √ √ X 
SAMH1 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1  √ X √ X 
SAMP Serum amyloid P-component  √ √ √ √ 
SC22B Vesicle-trafficking protein SEC22b  √ X √ X 
SCFD1 Sec1 family domain-containing protein 1  X X √ X 
SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial  √ √ √ √ 
SDHB Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  X √ √ √ 
SERA D-3-phosphoglycerate dehydrogenase  X X √ X 
SESN1 Sestrin-1  X X √ X 
SET Protein SET  X X √ X 
SH3BG SH3 domain-binding glutamic acid-rich protein  √ √ √ √ 
SMD3 Small nuclear ribonucleoprotein Sm D3  √ √ √ √ 
SNTA1 Alpha-1-syntrophin  √ √ √ √ 
SNTB1 Beta-1-syntrophin  √ X X X 
SNTB2 Beta-2-syntrophin  √ X X X 
SQSTM Sequestosome-1  X X X √ 
SRCA Sarcalumenin  √ √ √ √ 
SRCH Sarcoplasmic reticulum histidine-rich calcium-binding protein  √ √ X √ 
STAT1 Signal transducer and activator of transcription 1-alpha/beta  X X √ X 
STAT3 Signal transducer and activator of transcription 3  √ X √ √ 
STML2 Stomatin-like protein 2, mitochondrial  √ X X √ 
STOM Erythrocyte band 7 integral membrane protein  √ √ √ √ 












SUCB1 Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial  √ X √ √ 
SYDC Aspartate--tRNA ligase, cytoplasmic  X √ √ √ 
SYFB Phenylalanine--tRNA ligase beta subunit  X X X X 
SYIM Isoleucine--tRNA ligase, mitochondrial  √ X X √ 
SYNC Asparagine--tRNA ligase, cytoplasmic  X X √ √ 
SYPL2 Synaptophysin-like protein 2  √ √ √ √ 
SYQ Glutamine--tRNA ligase  √ √ √ √ 
SYRC Arginine--tRNA ligase, cytoplasmic  √ X √ √ 
TBA1A Tubulin alpha-1A chain  √ √ √ √ 
TBA1B Tubulin alpha-1B chain  √ √ √ √ 
TBA4A Tubulin alpha-4A chain  √ √ √ √ 
TBA8 Tubulin alpha-8 chain  √ √ √ √ 
TBAL3 Tubulin alpha chain-like 3  √ X √ √ 
TBB2A Tubulin beta-2A chain  √ √ √ √ 
TBB3 Tubulin beta-3 chain  √ X √ √ 
TBB4A Tubulin beta-4A chain  √ X X X 
TBB4B Tubulin beta-4B chain  √ √ √ √ 
TBB5 Tubulin beta chain  √ √ √ √ 
TBB6 Tubulin beta-6 chain  √ X √ X 
TBC17 TBC1 domain family member 17  X √ √ X 
TCPA T-complex protein 1 subunit alpha  √ √ √ √ 
TCPD T-complex protein 1 subunit delta  √ √ √ √ 
TCPE T-complex protein 1 subunit epsilon  √ X √ √ 
TCPG T-complex protein 1 subunit gamma  √ √ √ √ 












TCPQ T-complex protein 1 subunit theta  √ X √ √ 
TCPZ T-complex protein 1 subunit zeta  √ X X √ 
TELT Telethonin  X X √ √ 
TERA Transitional endoplasmic reticulum ATPase  √ √ √ √ 
TFR1 Transferrin receptor protein 1  X X X √ 
THIL Acetyl-CoA acetyltransferase, mitochondrial  √ √ √ √ 
THIM 3-ketoacyl-CoA thiolase, mitochondrial  √ √ √ √ 
TITIN Titin  √ √ √ √ 
TM109 Transmembrane protein 109  √ X √ X 
TM143 Transmembrane protein 143  X X X √ 
TM38A Trimeric intracellular cation channel type A  √ √ √ √ 
TM38B Trimeric intracellular cation channel type B  X X √ X 
TMM33 Transmembrane protein 33  X X √ X 
TNNC1 Troponin C, slow skeletal and cardiac muscles  √ √ √ √ 
TNNC2 Troponin C, skeletal muscle  √ √ √ √ 
TNNI1 Troponin I, slow skeletal muscle  √ √ √ √ 
TNNI2 Troponin I, fast skeletal muscle  √ √ √ √ 
TNNT1 Troponin T, slow skeletal muscle  √ √ √ √ 
TNNT3 Troponin T, fast skeletal muscle  √ √ √ √ 
TPIS Triosephosphate isomerase  X √ √ √ 
TPM1 Tropomyosin alpha-1 chain  √ √ √ √ 
TPM2 Tropomyosin beta chain  √ √ √ √ 
TPM3 Tropomyosin alpha-3 chain  √ √ √ √ 
TPM4 Tropomyosin alpha-4 chain  √ X √ √ 












TRI72 Tripartite motif-containing protein 72  √ √ √ √ 
TRY1 Trypsin-1  X X √ √ 
TRY3 Trypsin-3  √ √ √ √ 
TRY6 Putative trypsin-6  √ X √ √ 
TRYD Tryptase delta  X X X √ 
TSP4 Thrombospondin-4  √ X √ √ 
TTBK1 Tau-tubulin kinase 1  X X X X 
TTHY Transthyretin  X X √ √ 
UB2D1 Ubiquitin-conjugating enzyme E2 D1  √ X X √ 
UBE2N Ubiquitin-conjugating enzyme E2 N  X X √ X 
UBE3A Ubiquitin-protein ligase E3A  X X √ X 
UBP14 Ubiquitin carboxyl-terminal hydrolase 14  X X √ X 
UBP5 Ubiquitin carboxyl-terminal hydrolase 5  X X √ X 
UCRI Cytochrome b-c1 complex subunit Rieske, mitochondrial  √ √ √ √ 
UGDH UDP-glucose 6-dehydrogenase  X X √ X 
UN45B Protein unc-45 homolog B  √ X √ √ 
USMG5 Up-regulated during skeletal muscle growth protein 5  X √ √ √ 
USO1 General vesicular transport factor p115  √ X X √ 
VDAC1 Voltage-dependent anion-selective channel protein 1  √ X √ √ 
VDAC3 Voltage-dependent anion-selective channel protein 3  √ √ √ √ 
VIME Vimentin  √ √ √ √ 
VPS35 Vacuolar protein sorting-associated protein 35  X √ √ √ 
VTNC Vitronectin  X √ √ √ 
WDR1 WD repeat-containing protein 1  X X √ √ 












XPO2 Exportin-2  X X X √ 
XRCC5 X-ray repair cross-complementing protein 5  X X √ √ 
XRCC6 X-ray repair cross-complementing protein 6  X √ √ √ 
Z804A Zinc finger protein 804A  X X √ X 
 
